Nothing Special   »   [go: up one dir, main page]

US20130005716A1 - Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors - Google Patents

Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors Download PDF

Info

Publication number
US20130005716A1
US20130005716A1 US13/488,818 US201213488818A US2013005716A1 US 20130005716 A1 US20130005716 A1 US 20130005716A1 US 201213488818 A US201213488818 A US 201213488818A US 2013005716 A1 US2013005716 A1 US 2013005716A1
Authority
US
United States
Prior art keywords
oxide
ethyl
phenyl
carbonyloxy
difluoromethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/488,818
Inventor
Elisabetta Armani
Gabriele Amari
Laura Carzaniga
Carmelida Capaldi
Oriana Esposito
Gino Villetti
Renato De Fanti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Assigned to CHIESI FARMACEUTICI S.P.A. reassignment CHIESI FARMACEUTICI S.P.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AMARI, GABRIELE, ARMANI, ELISABETTA, CAPALDI, Carmelida, CARZANIGA, LAURA, DE FANTI, RENATO, ESPOSITO, Oriana, VILLETTI, GINO
Publication of US20130005716A1 publication Critical patent/US20130005716A1/en
Priority to US14/048,651 priority Critical patent/US20140057882A1/en
Priority to US14/863,915 priority patent/US9931327B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Definitions

  • the present invention relates to inhibitors of the phosphodiesterase 4 (PDE4) enzyme. More particularly, the present invention relates to compounds that are derivatives of 1-phenyl-2-pyridinyl alkyl alcohols, methods of preparing such compounds, compositions containing them, and therapeutic uses of such compounds and compositions.
  • PDE4 phosphodiesterase 4
  • Airway obstruction characterizes a number of severe respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD). Events leading to airway obstruction include edema of airway walls, increased mucous production and inflammation.
  • COPD chronic obstructive pulmonary disease
  • Drugs for treating respiratory diseases such as asthma and COPD are currently administered through inhalation.
  • One of the advantages of the inhalatory route over the systemic one is the possibility of delivering the drug directly at site of action, reducing systemic side-effects, thus resulting in a more rapid clinical response and a higher therapeutic ratio.
  • Inhaled corticosteroids are the current maintenance therapy of choice for asthma and together with bronchodilator beta 2 -agonists for acute symptom relief, they form the mainstay of current therapy for the disease.
  • the current management of COPD is largely symptomatic by means of bronchodilating therapy with inhaled anticholinergics and inhaled beta 2 -adrenoceptor agonists.
  • corticosteroids do not reduce the inflammatory response in COPD as they do in asthma.
  • PDEs phosphodiesterases
  • PDE4 inhibitors Various compounds acting as PDE4 inhibitors have been disclosed in the prior art. However, the usefulness of several PDE4 inhibitors of the first-generation such as rolipram and piclamilast has been limited due to their undesirable side effects. Said effects include nausea and emesis due to their action on PDE4 in the central nervous system and gastric acid secretion due to the action on PDE4 in parietal cells in the gut.
  • PDE4 exists in two distinct forms representing different conformations, that were designated as high affinity rolipram binding site or HPDE4, especially present in the central nervous system and in parietal cells, and low affinity rolipram binding site or LPDE4 (see Jacobitz, S et al., Mol. Pharmacol., 1996, 50, 891-899, which is incorporated herein by reference in its entirety), which is found in the immune and inflammatory cells. While both forms appear to exhibit catalytic activity, they differ with respect to their sensitivity to inhibitors. In particular compounds with higher affinity for LPDE4 appear less prone to induce side-effects such as nausea, emesis and increased gastric secretion.
  • roflumilast is under dosed in order to achieve an acceptable side effect profile.
  • EP 1 634 606 discloses, among others, ketone derivatives like benzofuran or 1,3-benzodioxole derivatives.
  • WO 94/02465 discloses, among others, ketone derivatives of general formula
  • R 1 is lower alkyl and R 2 may be alkyl, alkenyl, cycloalkyl, cycloalkyl, cycloalkenyl, cyclothioalkyl or cyclothioalkenyl.
  • WO 95/35281 in the name of Celltech Therapeutics relates to tri-substituted phenyl derivatives.
  • WO 2009/018909 discloses derivatives of 1-phenyl-2-pyridinyl alkyl alcohols which have general formula below reported
  • PDE4 phosphodiesterase 4
  • WO 2009/077068 discloses further derivatives of 1-phenyl-2-pyridinyl alkyl alcohols which have general formula below reported
  • PDE4 phosphodiesterase 4
  • WO 2010/089107 discloses further derivatives of 1-phenyl-2-pyridinyl alkyl alcohols which have general formula below reported
  • PDE4 phosphodiesterase 4
  • Such reduction of side effects may be achieved, by way of example, through a low systemic exposure of the drug; an appropriate profile in terms of some pharmacokinetic characteristics, especially metabolic clearance, may be thus key to this goal.
  • the present invention is directed to compounds acting as inhibitors of the phosphodiesterase 4 (PDE4) enzyme, methods of preparing said compounds, compositions containing them and therapeutic use thereof.
  • PDE4 phosphodiesterase 4
  • the present invention is directed to derivatives of 1-phenyl-2-pyridinyl alkyl alcohols of general formula (I):
  • R 19 is hydrogen or, if different from hydrogen, it forms together with R 2 a group of formula (x) wherein bonds labeled with (1) and (2) indicate the points of attachment for group (x) to atoms bearing groups R 19 and R 2 respectively
  • R 3 is one or more substituents independently selected from the group consisting of H, CN, NO 2 , CF 3 and a halogen atom;
  • Z is a group —(CH 2 ) n — wherein n is 0 or 1;
  • A is a saturated and monocyclic (C 3 -C 7 )heterocycloalkylene group;
  • K is selected from the group consisting of:
  • the invention is directed to derivatives of 1-phenyl-2-pyridinyl alkyl alcohols of general formula (IG):
  • R 1 is selected from the group consisting of:
  • R 19 is hydrogen;
  • R 3 is one or more substituents independently selected from the group consisting of H, CN, NO 2 , CF 3 and a halogen atom;
  • Z is a group —(CH 2 ) n — wherein n is 0 or 1;
  • A is a saturated and monocyclic (C 3 -C 7 )heterocycloalkyl-ene group;
  • K is selected from the group consisting of:
  • invention is directed to derivatives of 1-phenyl-2-pyridinyl alkyl alcohols of general formula (IL):
  • R 1 and R 2 are different or the same and are independently selected from the group consisting of:
  • the present invention further provides the corresponding N-oxides on the pyridine ring of compounds of formula (I).
  • the present invention also provides the pharmaceutically acceptable salts and/or solvates thereof.
  • pharmaceutically acceptable salts refers to derivatives of compounds of formula (I) or of their corresponding N-oxides on the pyridine ring wherein the parent compound is suitably modified by converting any of the free acid or basic groups, if present, into the corresponding addition salt with any base or acid conventionally intended as being pharmaceutically acceptable.
  • Suitable examples of said salts may thus include mineral or organic acid addition salts of basic residues such as amino groups, as well as mineral or organic acid residues such as carboxylic groups.
  • Cations of inorganic bases which can be suitably used to prepare salts within the invention comprise ions of alkali or alkaline earth metals such as potassium, sodium, calcium or magnesium.
  • Those obtained by reacting the main compound, functioning as a base, with an inorganic or organic acid to form a salt comprise, for example, salts of hydrochloric acid, sulfuric acid, phosphoric acid, methane sulfonic acid, camphor sulfonic acid, oxalic acid, maleic acid, succinic acid and citric acid.
  • the present invention further provides a process for the preparation of compounds of the invention.
  • the present invention also provides pharmaceutical compositions of compounds of the invention either alone or in combination, in admixture with one or more pharmaceutically acceptable carriers.
  • the present invention provides the use of the compounds of the present invention as a medicament.
  • the present invention provides the use of the compounds of the present invention for the manufacture of a medicament.
  • the present invention provides the use of the compounds of the present invention for the prevention and/or treatment of any disease characterized by phosphodiesterase 4 (PDE4) overactivity and/or wherein an inhibition of PDE4 activity is desirable.
  • PDE4 phosphodiesterase 4
  • the compounds of the present invention alone or combined with other active ingredients may be administered for the prevention and/or treatment of a disease the respiratory tract characterized by airway obstruction such as asthma and COPD.
  • the present invention provides the use of compounds of the present invention for the preparation of a medicament for the prevention and/or treatment of any disease characterized by phosphodiesterase 4 (PDE4) overactivity and/or wherein an inhibition of PDE4 activity is desirable.
  • PDE4 phosphodiesterase 4
  • the present invention provides methods for prevention and/or treatment of any disease wherein PDE4 inhibition is desiderable, said method comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of the present invention.
  • halogen atoms as used herein includes fluorine, chlorine, bromine, and iodine, preferably chlorine.
  • (C 1 -C x )alkyl where x is an integer greater than 1, refers to straight-chained and branched alkyl groups wherein the number of constituent carbon atoms is in the range 1 to x.
  • Particular alkyl groups are methyl, ethyl, n-propyl, isopropyl, and t-butyl.
  • (C 1 -C x )alkylene refers to a divalent (C 1 -C x )alkyl radical, wherein (C 1 -C x )alkyl is as above defined.
  • (C I -C x )alkoxyl where x is an integer greater than 1, refers to straight-chained and branched alkoxy groups wherein the number of constituent carbon atoms is in the range 1 to x.
  • Particular alkyl groups are methoxyl, ethoxyl, n-propoxyl, isopropoxyl, and t-butoxyl.
  • (C 1 -C x )haloalkyl refer to the above defined “(C 1 -C x )alkyl” groups wherein one or more hydrogen atoms are replaced by one or more halogen atoms, which can be the same or different from each other.
  • Examples of said (C 1 -C 6 )haloalkyl groups may thus include halogenated, poly-halogenated and fully halogenated alkyl groups wherein all of the hydrogen atoms are replaced by halogen atoms, e.g. trifluoromethyl or difluoro methyl groups.
  • (C 3 -C y )cycloalkyl refers to saturated cyclic hydrocarbon groups containing from 3 to y ring carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
  • (C 3 -C y )heterocycloalkyl refers to monocyclic (C 3 -C y )cycloalkyl groups, in which at least one ring carbon atom is replaced by a heteroatom (e.g. N, NH, S or O).
  • a heteroatom e.g. N, NH, S or O.
  • Non-limiting examples of (C 3 -C y )heterocycloalkyl are represented by: pyrrolidinyl, thiazolidinyl, piperazinyl, piperidnyl, morpholinyl, thiomorpholinyl, and azetidinyl.
  • (C 3 -C y )heterocycloalkyl-ene refers to a divalent (C 3 -C y )heterocycloalkyl radical, wherein (C 3 -C y )heterocycloalkyl is as above defined.
  • (C 3 -C y )cycloalkylcarbonyl refers to (C 3 -C y )cycloalkylCO— groups wherein the group “(C 3 -C y )cycloalkyl” has the meaning above defined.
  • (C 2 -C 6 )alkenyl refers to straight or branched, conjugated or non-conjugated, carbon chains with one or more double bonds, in cis or trans configuration, wherein the number atoms is in the range 2 to 6.
  • (C 5 -C z )cycloalkenyl refers to cyclic hydrocarbon groups containing from 5 to z ring carbon atoms and one or more double bonds.
  • (C 2 -C 6 )alkynyl refers to straight or branched carbon chains with one or more triple bonds wherein the number of atoms is in the range 2 to 6.
  • (C 3 -C y )heterocycloalkyl(C 1 -C x )alkyl refers to the above “(C r C x )alkyl” group wherein one or more hydrogen atoms are replaced by one or more “(C 3 -C y )heterocycloalkyl” groups.
  • ring system refers to mono- or bicyclic ring systems which may be saturated, partially unsaturated or unsaturated, such as aryl, (C 3 -C 8 )cycloalkyl, (C 3 -C 7 )heterocycloalkyl or heteroaryl, having 5 to 11 ring atoms in which at least one ring atom is a heteroatom (e.g. N, S or O).
  • aryl refers to mono or bi-ring systems which have 6 to 10 ring atoms, wherein at least one ring is aromatic.
  • heteroaryl refers to mono or bi-ring systems with 5 to 11 ring atoms, in which at least one ring is aromatic and in which at least one ring atom is a heteroatom (e.g. N, NH, S or O).
  • Suitable aryl or 5 or 6-membered heteroaryl monocyclic systems include, for instance, phenyl, thiophene (thiophenyl), benzene (phenyl), pyrrole (pyrrolyl), pyrazole (pyrazolyl), imidazole (imidazolyl), isoxazole (isoxazolyl), oxazole (oxazolyl), isothiazole (isothiazolyl), thiazole (thiazolyl), pyridine (pyridinyl), imidazolidine (imidazolidinyl), furan (furanyl) radicals and the like.
  • Suitable aryl or heteroaryl bicyclic systems include naphthalene (naphthyl), biphenylene (biphenylenyl), purine (purinyl), pteridine (pteridinyl), benzotriazole (benzotriazolyl), quinoline (quinolinyl), isoquinoline (isoquinolinyl), indole (indolyl), isoindole (isoindolyl), benzothiophene (benzothiophenyl), dihydrobenzo dioxin, dihydrobenzo dioxepin, benzo oxazin radicals and the like.
  • the present invention is directed to a class of compounds acting as inhibitors of the phosphodiesterase 4 (PDE4) enzyme.
  • Said class of compounds inhibits the conversion of cyclic nucleotides, in particular cyclic adenosine monophosphate (cAMP), into their inactive 5′-mononucleotide forms.
  • cAMP cyclic adenosine monophosphate
  • cyclic nucleotides in particular of cAMP, lead to the suppression of the activity of immune and pro-inflammatory cells such as mast cells, macrophages, T lymphocytes, eosinophils and neutrophils, resulting in a decrease of the release of inflammatory mediators which include cytokines such as IL-1, IL-3 and tumor necrosis factor-alpha (TNF- ⁇ ). It also leads to an airway smooth muscle relaxation and a decrease in oedema.
  • cytokines such as IL-1, IL-3 and tumor necrosis factor-alpha (TNF- ⁇ ).
  • the present invention relates to derivatives of 1-phenyl-2-pyridinyl alkyl alcohols of general formula (I), N-oxides on the pyridine ring and pharmaceutically acceptable salts or solvates thereof:
  • R 1 , R 2 , R 3 , R 19 , Z, A and K are as above defined.
  • the compounds according to the invention may accordingly exist as enantiomers.
  • they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present invention.
  • the present invention is directed to compounds of formula (I)′, which are compounds of formula (I) as above defined where the absolute configuration of carbon (1) is that shown below:
  • the absolute configuration for carbon (1) is assigned on the basis of Cahn-Ingold-Prelog nomenclature based on groups' priorities.
  • the absolute configuration at carbon (1) is (S).
  • the present invention is directed to compounds of formula (I)′′, which are compounds of formula (I)′ as above defined where the absolute configuration of carbon (2) is that shown below:
  • the present invention is directed to compounds of formula (I)′′′, which are compounds of formula (I)′ as above defined where the absolute configuration of carbon (2) is that shown below:
  • the invention provides compounds of formula (IH), which are N-oxides derivatives of the pyridine ring of compounds of formula (I), or pharmaceutically acceptable salts thereof:
  • 2-pyridinyl ring has two R 3 substituents which are halogen atom.
  • such R 3 substituents are two chlorine atoms at positions 3 and 5 of the pyridine ring.
  • R 1 is (C 1 -C 6 )haloalkyl or (C 1 -C 6 )alkyl.
  • R 2 is (C 1 -C 6 )alkyl which optionally is substituted by (C 3 -C 7 )cycloalkyl or is a (C 3 -C 7 )cycloalkyl.
  • R 1 and R 2 together with the interconnecting atoms, form a 2,2-difluoro-1,3-dioxolane ring of formula (q) fused to the phenyl moiety which bears groups OR 1 and —OR 2 , wherein asterisks indicate carbon atoms shared with such phenyl ring:
  • R 1 is (C 1 -C 6 )haloalkyl and R 2 is (C 1 -C 6 )alkyl which is substituted by (C 3 -C 7 )cycloalkyl.
  • R 1 is (C 1 -C 6 )alkyl and R 2 is (C 1 -C 6 )alkyl.
  • R 19 is hydrogen
  • R 19 is hydrogen
  • R 1 is (C 1 -C 6 )haloalkyl
  • R 2 is (C 1 -C 6 )alkyl which is substituted by (C 3 -C 7 )cycloalkyl.
  • R 19 if different from hydrogen, forms together with R 2 a group of formula (x) wherein bonds labeled with (1) and (2) indicate the points of attachment for group (x) to atoms bearing groups R 19 and R 2 respectively
  • a preferred group of compounds of general formula (I) is that wherein the 2-pyridinyl ring is substituted in positions 3 and 5 with two atoms of chlorine, according to the general formula (IA):
  • R 1 , R 2 , R 19 , K, z, and A are as defined above for compounds of formula (I); and the corresponding N-oxide on the pyridine ring, or pharmaceutically acceptable salts thereof.
  • R 3 , K, Z and A are as defined above for compounds of formula (I); and the corresponding N-oxide on the pyridine ring, or pharmaceutically acceptable salts thereof.
  • K, Z and A are as defined above for compounds of formula (I); and the corresponding N-oxide on the pyridine ring, or pharmaceutically acceptable salts thereof.
  • A is a (C 3 -C 7 )heterocycloalkyl-ene group comprising a nitrogen atom which represents the connecting point to group K as below represented:
  • A is selected in the list of di-radicals below reported:
  • A is selected in the list of di-radicals below reported:
  • A is a group
  • Z is a group —(CH 2 ) n — in which n is zero.
  • R 1 , R 2 , R 3 and K are as defined above for compounds of formula (I), R 19 is hydrogen, Z is a bond (i.e., n is zero), and A is a thiazolidine divalent radical group as above represented; and the corresponding N-oxide on the pyridine ring, or pharmaceutically acceptable salts thereof.
  • R 1 , R 2 , R 3 and K are as defined above for compounds of formula (I), R 19 is hydrogen, Z is a bond (i.e. n is zero), A is a thiazolidine divalent radical group and stereogenic center have absolute configuration as above represented; and the corresponding N-oxide on the pyridine ring, or pharmaceutically acceptable salts thereof.
  • R 1 is (C 1 -C 6 ) haloalkyl
  • R 2 is (C 1 -C 6 )alkyl which is substituted by (C 3 -C 7 )cycloalkyl
  • 2-pyridinyl ring is substituted in positions 3 and 5 with two chlorine R 3 groups
  • K is a group
  • R 1 , R 2 , R 3 and K are as defined above for compounds of formula (I), Z is a bond (i.e. n is zero), R 19 is hydrogen and A is a pyrrolidine divalent radical group as above represented; and the corresponding N-oxide on the pyridine ring, or pharmaceutically acceptable salts thereof.
  • R 1 , R 2 , R 3 and K are as defined above for compounds of formula (I), Z is a bond (i.e. n is zero), R19 is hydrogen, A is a pyrrolidine divalent radical group, and the stereogenic centers have the absolute configuration as above represented; and the corresponding N-oxide on the pyridine ring, or pharmaceutically acceptable salts thereof.
  • R 1 is (C 1 -C 6 )haloalkyl
  • R 2 is (C 1 -C 6 )alkyl which is substituted by (C 3 -C 7 )cycloalkyl
  • 2-pyridinyl ring is substituted in 3 and 5 with two chlorine R 3 groups
  • K is a group
  • K is selected in the list of groups below reported:
  • K is selected in the list of groups below reported:
  • K is selected in the list of groups below reported:
  • K is a group
  • R 4 is selected in the group consisting of: a group phenyl, a 5 or 6-membered heteroaryl group, a monocyclic (C 3 -C 7 )heterocycloalkyl and a bicyclic ring system; and each of which is optionally substituted by one or more groups R 5 .
  • R 4 is a group phenyl or a 5 or 6-membered heteroaryl group, each of which is optionally substituted by one or more groups R 5 .
  • R 4 is a group phenyl which is optionally substituted by one or more groups R 5 .
  • R 4 is a 5 or 6-membered heteroaryl group which is optionally substituted by one or more groups R 5 .
  • R 4 is a monocyclic (C 3 -C 7 )heterocycloalkyl optionally substituted by one or more groups R 5 .
  • R 4 is a bicyclic ring system optionally substituted by one or more groups R 5 .
  • the number of substituents R 5 is zero, 1, or 2. In a further preferred embodiment, such number is 1.
  • R 5 is independently selected in the group consisting of:
  • R 5 is independently selected in the group consisting of:
  • R 5 is independently selected in the group consisting of:
  • R 5 is selected in the group consisting of:
  • Z is a bond
  • R19 is hydrogen
  • A is a (C 3 -C 7 )heterocycloalkyl-ene group comprising a nitrogen atom which represents the connecting point to group K
  • K is selected in the list of groups consisting of:
  • R 4 is a group phenyl or a 5 or 6-membered heteroaryl group, each of which is optionally substituted by one or more groups R 5 : and the corresponding N-oxide on the pyridine ring, or pharmaceutically acceptable salts thereof.
  • the present invention provides the compounds reported below:
  • the compounds of the invention are selected in the group consisting of:
  • Typical reaction conditions comprise reacting a compound of formula (II) with a compound of formula (III) in a suitable dipolar solvent, such as THF, methanol, ethanol or DCM, in the presence of an appropriate reducing agent, such as sodium triacetoxy borohydride, sodium cyano borohydride or sodium borohydride, and of an appropriate acid, such as acetic acid, HCl in methanol or ammonium acetate. It could be useful to preform the imine before adding the reducing agent.
  • a suitable dipolar solvent such as THF, methanol, ethanol or DCM
  • an appropriate reducing agent such as sodium triacetoxy borohydride, sodium cyano borohydride or sodium borohydride
  • an appropriate acid such as acetic acid, HCl in methanol or ammonium acetate. It could be useful to preform the imine before adding the reducing agent.
  • the reaction proceeds smoothly at room temperature (RT) over 1 to 12 hours.
  • Typical reaction conditions comprise reacting a compound of formula (XVI), where X is a leaving group such as Cl or Br, with a compound of formula (II) in a suitable polar aprotic solvent, such as acetonitrile or DMF, in the presence of an appropriate base such as K 2 CO 3 , alkaline bicarbonate, TEA or DIPEA, at a temperature ranging from RT to 70° C.
  • a suitable polar aprotic solvent such as acetonitrile or DMF
  • Typical reaction conditions comprise reacting a compound of formula (II) with a compound of formula (IV) in a suitable dipolar aprotic solvent, such as DMF, chloroform or DCM, in the presence of an appropriate condensing agent such as EDC, DCC, HOBT, HOAT, or CDI, and, if necessary, of an appropriate agent, such as DMAP, HOBT, 4-pyrrolidinopyridine (4-PPY) or other 4-alkylamino pyridine, at room temperature.
  • a suitable dipolar aprotic solvent such as DMF, chloroform or DCM
  • Typical reaction conditions comprise reacting a compound of formula (II) with a compound of formula (XVII) in a suitable solvent such as pyridine or DCM, and in the presence, if necessary, of an appropriate base such as TEA, DIPEA, DBU, or another organic base at a temperature ranging from 0° C. to room temperature.
  • a suitable solvent such as pyridine or DCM
  • an appropriate base such as TEA, DIPEA, DBU, or another organic base at a temperature ranging from 0° C. to room temperature.
  • Typical reaction conditions comprise reacting a compound of formula (II) with a compound of formula (V) in a suitable polar aprotic solvent, such as DMF or acetonitrile, in the presence of an appropriate base such as K 2 CO 3 , alkaline bicarbonate, TEA or DIPEA, at a temperature ranging from RT to 50° C.
  • a suitable polar aprotic solvent such as DMF or acetonitrile
  • Typical reaction conditions comprise reacting a compound of formula (II) with a compound of formula (VI) in a suitable polar aprotic solvent such as DMF or acetonitrile, in the presence of an appropriate base such as K 2 CO 3 , alkaline bicarbonate, TEA, or DIPEA, at a temperature ranging from RT to 50° C.
  • a suitable polar aprotic solvent such as DMF or acetonitrile
  • Typical reaction conditions comprise reacting a compound of formula (II) with a compound of formula (XVIII) in a suitable polar aprotic solvent, such as DMF or acetonitrile, in the presence of an appropriate base such as K 2 CO 3 , alkaline bicarbonate, TEA, or DIPEA, at a temperature ranging from RT to 50° C.
  • Compound (XIX) thus obtained is successively reacted with a suitable oxidizing agent, such as MCPBA or hydrogen peroxide, in a suitable polar solvent, such as DCM, chloroform, EtOH or MeOH, at a temperature ranging from room temperature to 60° C.
  • a suitable oxidizing agent such as MCPBA or hydrogen peroxide
  • a suitable polar solvent such as DCM, chloroform, EtOH or MeOH
  • Typical reaction conditions comprise reacting a compound of formula (II) with a compound of formula (VII) in a suitable solvent such as pyridine or DCM, and in the presence, if necessary, of an appropriate base such as TEA, DIPEA, DBU, or another organic base at a temperature ranging from 0° C. to room temperature.
  • a suitable solvent such as pyridine or DCM
  • an appropriate base such as TEA, DIPEA, DBU, or another organic base at a temperature ranging from 0° C. to room temperature.
  • compounds of formula (I) may be prepared according to Scheme 7 below by reaction of a compound of formula (VIII), with an appropriate compound of formula (IX).
  • Typical reaction conditions comprise reacting a compound of formula (VIII) with a compound of formula (IX) in a suitable polar aprotic solvent, such as DMF, THF, chloroform, or DCM, in the presence of an appropriate condensing agent such as EDC, DCC, or CDI and of an appropriate agent, such as DMAP, HOBT, 4-pyrrolidinopyridine (4-PPY) or other 4-alkylamino pyridine at room temperature; removal of possibly present protecting group is performed under conditions known to the person skilled in the art or as described in ‘Protection Groups in Organic Synthesis’ by T. W. Green and P. Wutz, (Wiley-Interscience publication, 1999, which is incorporated herein by reference in its entirety).
  • a suitable polar aprotic solvent such as DMF, THF, chloroform, or DCM
  • Typical coupling reaction conditions comprise reacting a compound of formula (VIII) with a compound of formula (X) in a suitable polar aprotic solvent, such as DMF, THF, chloroform, or DCM, in the presence of an appropriate (coupling) condensing agent such as EDC, DCC, or CDI and of an appropriate agent such as DMAP, HOBT, 4-pyrrolidinopyridine (4-PPY) or other 4-alkylamino pyridine at room temperature; removal of protecting group is performed under conditions known to the person skilled in the art or as described in ‘Protection Groups in Organic Synthesis’ by T. W. Green and P.
  • a suitable polar aprotic solvent such as DMF, THF, chloroform, or DCM
  • deprotection may be conveniently performed under acidic conditions (such as HCl in dioxane or in AcOEt or TFA in CH 2 Cl 2 ).
  • acyl chloride can be preformed, by reacting compound (X) with oxalyl chloride or thionyl chloride or other reagents well known to those skilled in the art, in a suitable aprotic solvent such as DCM at 0 degrees, in presence, if necessary, of a catalytic amount of DMF, and successively adding compound (VIII) and an appropriate base such as TEA or DIPEA.
  • a suitable aprotic solvent such as DCM at 0 degrees
  • Typical reaction conditions comprise reacting a compound of formula (Ie) as above defined with a suitable acid, such as TFA or BBr 3 or BCl 3 , at a temperature ranging from room temperature to 40 degrees.
  • a suitable acid such as TFA or BBr 3 or BCl 3
  • the N-oxides on the 2-pyridinyl ring of the compounds of general formula (I) and embodiments thereof may be prepared according to methods available in the literature and well known to the skilled person. For instance, they may be prepared by dissolving the compound of general formula (I) or embodiments thereof in CH 2 Cl 2 or CHCl 3 , then adding an oxidizing agent such as m-chloro perbenzoic acid (mCPBA) to the resulting solution.
  • mCPBA m-chloro perbenzoic acid
  • Other oxidizing agents which may be used are hydrogen peroxide, perbenzoic acid, and peracetic acid.
  • the corresponding N-oxides are prepared by carrying out the oxidation step before further functional groups are introduced, for example on compounds of formula (II) or (VIII).
  • the process for preparation of compounds of formula (I) or embodiments thereof is performed starting from N-oxide on the pyridine ring of compound of formula (VIII), thus allowing the preparation of compound of formula (I) or embodiments thereof in the form of N-oxides on the pyridine ring.
  • Compounds of general formula (III), (IV), (V), (VI), (VII), (VIII), (IX), (XVI), (XVII), (XVIII), (XIX), and (X) may be commercially available, their preparation may be specifically described in the literature or they may be prepared according to methods available in the literature and known to the person skilled in the art.
  • Typical reaction conditions for the process described in Scheme 43 comprise: a) adding a solution of a compound of formula (VII) in pyridine (3-30 vol. preferably 8 vol.) to a refrigerated solution of a compound of formula (XI), in pyridine (3-30 vol.
  • compounds of formula (IDa) obtained as above reported according to Scheme 43 are crystallized by a process comprising: dissolving the compounds in EtOH (8 vol); g) vigorously stirring overnight at room temperature; h) filtering the solid formed; and, optionally, i) washing the solid obtained from step h) with EtOH (2 vol) and 1) drying the solid under vacuum.
  • step 1) of Scheme 43 is conducted by drying first the solid under vacuum at room temperature, followed by drying under vacuum at 60° C.
  • Typical reaction conditions for the process described in Scheme 44 comprise: a) adding under stirring a solution of conc. HCl (about 5M; large excess) in dry AcOEt (9 vol.) to a solution of a compound of formula (XII) in AcOEt (6 vol.) at room temperature; b) stirring; c) filtering the precipitated solid; optionally d) washing the obtained solid with AcOEt; and optionally e) drying the solid obtained under vacuum at room temperature.
  • Typical reaction conditions for the process described in Scheme 45 comprise: a) adding a compound of formula (XIV), DMAP, and EDC to a solution of a compound of formula (XV) in DMF; b) stirring the mixture, preferably overnight; c) pouring the mixture into cold water; d) filtering the precipitate; optionally e) dissolving the precipitate in DCM, washing the solution with water, drying and evaporating the solvent; and optionally f) dissolving the solid obtained from step d) or e) in boiling MTBE (3.5 vol.) adding petroleum ether (4 vol.) under stirring, stirring at room temperature, filtering the solid obtained and drying it at room temperature under vacuum.
  • a process is provided for the preparation of compounds of formula (IDaa), i.e. a compound of formula (IDa) wherein R 1 is (C 1 -C 6 ) haloalkyl, R 2 is (C 1 -C 6 )alkyl which is substituted by (C 3 -C 7 )cycloalkyl, 2-pyridinyl ring is substituted in 3 and 5 with two chlorine R 3 groups, K is a group
  • R 4 is a phenyl group which is optionally substituted by one or more groups R 5 ; which process comprises sequentially performing reactions as provided in Schemes 43, 44, and 45 above described.
  • A′ is (C 3 -C 7 )heterocycloalkyl-ene group comprising a group —NH—.
  • compounds of formula (XI) as above defined are provided as intermediates in the process of preparation of compounds of formula (IDa).
  • R 1 is (C 1 -C 6 )haloalkyl and R 2 is (C 1 -C 6 )alkyl which is substituted by (C 3 -C 7 )cycloalkyl, and the pyridine ring is substituted by two groups R 3 placed at position 3 and 5.
  • compounds of formula (II) as above defined are provided which act as inhibitors of the phosphodiesterase 4 (PDE4) enzyme, thus solving the above mentioned need of identifying further PDE4 inhibitors endowed with a high affinity for PDE4 enzyme, and possibly showing an appropriate developability profile as an inhalation treatment for example in terms of reduced side effects.
  • PDE4 phosphodiesterase 4
  • compositions containing compounds of formula (II) and therapeutic uses thereof are also provided by the present invention.
  • any of the described groups may be present as such or in any properly protected form.
  • functional groups present in the compounds of formula (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII), (XIV), (XV), (XVI), (XVII), (XVIII), and (XIX) and which could generate unwanted side reaction and by-products, need to be properly protected before the alkylation, acylation, coupling, oxidation, or sulfonylation takes place. Likewise, subsequent deprotection of those same protected groups may follow upon completion of the said reactions.
  • protecting group designates a protective group adapted to preserve the function of the group it is bound to.
  • protective groups are used to preserve amino, hydroxyl, or carboxyl functions.
  • Appropriate protecting groups may thus include, for example, benzyl, benzyloxycarbonyl, t-butoxycarbonyl, alkyl, or benzyl esters or the like, which are well known to those skilled in the art (see, for a general reference, T. W. Green; Protective Groups in Organic Synthesis (Wiley, N.Y. 1999) which is incorporated herein by reference in its entirety).
  • selective protection and deprotection of any of the said groups for instance including carbonyl, hydroxyl, or amino groups, may be accomplished according to very well known methods commonly employed in organic synthetic chemistry.
  • Optional salification of the compounds of formula (I) or N-oxides on the pyridine ring thereof may be carried out by properly converting any of the free acidic or amino groups into the corresponding pharmaceutically acceptable salts.
  • the operative conditions being employed for the optional salification of the compounds of the invention are all within the ordinary knowledge of the skilled person.
  • the present invention also provides pharmaceutical compositions of compounds of the invention or of compounds of formula (II) in admixture with one or more pharmaceutically acceptable carriers, for example those described in Remington's Pharmaceutical Sciences Handbook, XVII Ed., Mack Pub., N.Y., U.S.A., which is incorporated herein by reference in its entirety.
  • Administration of the compounds of the present invention or of compounds of formula (II) may be accomplished according to patient needs, for example, orally, nasally, parenterally (subcutaneously, intravenously, intramuscularly, intrasternally, and by infusion), by inhalation, rectally, vaginally, topically, locally, transdermally, and by ocular administration.
  • Various solid oral dosage forms may be used for administering compounds of the present invention including such solid forms as tablets, gelcaps, capsules, caplets, granules, lozenges, and bulk powders.
  • the compounds of the present invention or compounds of formula (II) may be administered alone or combined with various pharmaceutically acceptable carriers, diluents (such as sucrose, mannitol, lactose, starches) and excipients known in the art, including but not limited to suspending agents, solubilizers, buffering agents, binders, disintegrants, preservatives, colorants, flavorants, lubricants, and the like.
  • diluents such as sucrose, mannitol, lactose, starches
  • excipients known in the art, including but not limited to suspending agents, solubilizers, buffering agents, binders, disintegrants, preservatives, colorants, flavorants, lubricants, and the like.
  • Time release capsules, tablets, and gels are also advantageous in administering the compounds of the present invention or compounds of formula (II).
  • liquid oral dosage forms may also be used for administering compounds of the present invention or compounds of formula (II), including aqueous and non-aqueous solutions, emulsions, suspensions, syrups, and elixirs.
  • Such dosage forms can also contain suitable inert diluents known in the art such as water and suitable excipients known in the art such as preservatives, wetting agents, sweeteners, flavorants, as well as agents for emulsifying and/or suspending the compounds of the invention or compounds of formula (II).
  • the compounds of the present invention or compounds of formula (II) may be injected, for example, intravenously, in the form of an isotonic sterile solution. Other preparations are also possible.
  • Suppositories for rectal administration of the compounds of the present invention or of compounds of formula (II) may be prepared by mixing the compound with a suitable excipient such as cocoa butter, salicylates, and polyethylene glycols.
  • a suitable excipient such as cocoa butter, salicylates, and polyethylene glycols.
  • Formulations for vaginal administration may be in the form of cream, gel, paste, foam, or spray formula containing, in addition to the active ingredient, such suitable carriers as are known in the art.
  • the pharmaceutical composition may be in the form of creams, ointments, liniments, lotions, emulsions, suspensions, gels, solutions, pastes, powders, sprays, and drops suitable for administration to the skin, eye, ear, or nose.
  • Topical administration may also involve transdermal administration via means such as transdermal patches.
  • the compounds according to the present invention or compounds of formula (II) are preferably administered by inhalation.
  • Inhalable preparations include inhalable powders, propellant-containing metering aerosols, and propellant-free inhalable formulations.
  • the powder may be filled in gelatine, plastic, or other capsules, cartridges, or blister packs or in a reservoir.
  • a diluent or carrier generally non-toxic and chemically inert to the compounds of the invention, e.g. lactose or any other additive suitable for improving the respirable fraction may be added to the powdered compounds of the invention or compounds of formula (II).
  • Inhalation aerosols containing propellant gas such as hydrofluoroalkanes may contain the compounds of the invention or compounds of formula (II) either in solution or in dispersed form.
  • the propellant-driven formulations may also contain other ingredients such as co-solvents, stabilizers, and optionally other excipients.
  • the propellant-free inhalable formulations comprising the compounds of the present invention or compounds of formula (II) may be in form of solutions or suspensions in an aqueous, alcoholic, or hydroalcoholic medium and they may be delivered by jet or ultrasonic nebulizers known from the prior art or by soft-mist nebulizers such as Respimat®.
  • the compounds of the present invention or compounds of formula (II) may be administered as the sole active agent or in combination with other pharmaceutical active ingredients including those currently used in the treatment of respiratory disorders, e.g. beta2-agonists, antimuscarinic agents, corticosteroids, mitogen-activated protein kinases (P38 MAP kinase) inhibitors, nuclear factor kappa-B kinase subunit beta (IKK2) inhibitors, human neutrophil elastase (FINE) inhibitors, phosphodiesterase 4 (PDE4) inhibitors, leukotriene modulators, non-steroidal anti-inflammatory agents (NSAIDs), and mucus regulators.
  • beta2-agonists e.g. beta2-agonists, antimuscarinic agents, corticosteroids, mitogen-activated protein kinases (P38 MAP kinase) inhibitors, nuclear factor kappa-B kinase subunit beta (IKK2) inhibitors, human neutrophil elastase (
  • the present invention also provides combinations of a compound of the present invention or of compounds of formula (II), with a ⁇ 2-agonist selected from the group consisting of carmoterol, GSK-642444, indacaterol, milveterol, arformoterol, formoterol, salbutamol, levalbuterol, terbutaline, AZD-3199, BI-1744-CL, LAS-100977, bambuterol, isoproterenol, procaterol, clenbuterol, reproterol, fenoterol and ASF-1020, and salts thereof.
  • a ⁇ 2-agonist selected from the group consisting of carmoterol, GSK-642444, indacaterol, milveterol, arformoterol, formoterol, salbutamol, levalbuterol, terbutaline, AZD-3199, BI-1744-CL, LAS-100977, bambuterol, isoprotereno
  • the present invention also provides combinations of a compound of the present invention or of a compound of formula (II), with a corticosteroid selected from the group consisting of fluticasone propionate, fluticasone furoate, mometasone furoate, beclometasone dipropionate, ciclesonide, budesonide, GSK 685698, and GSK 870086.
  • a corticosteroid selected from the group consisting of fluticasone propionate, fluticasone furoate, mometasone furoate, beclometasone dipropionate, ciclesonide, budesonide, GSK 685698, and GSK 870086.
  • the present invention also provides combinations of a compound of the present invention or of a compound of formula (II), with an antimuscarinic agent selected from the group consisting of aclidinium, tiotropium, ipratropium, trospium, glycopyrronium, and oxitropium salts.
  • an antimuscarinic agent selected from the group consisting of aclidinium, tiotropium, ipratropium, trospium, glycopyrronium, and oxitropium salts.
  • the present invention also provides combinations of a compound of the present invention or of a compound of formula (II), with a PDE4 inhibitor selected from the group consisting of AN-2728, AN-2898, CBS-3595, apremilast, ELB-353, KF-66490, K-34, LAS-37779, IBFB-211913, AWD-12-281, cipamfylline, cilomilast, roflumilast, BAY19-8004 and SCH-351591, AN-6415, indus-82010, TP1-PD3, ELB-353, CC-11050, GSK-256066, oglemilast, OX-914, tetomilast, MEM-1414, and RPL-554.
  • a PDE4 inhibitor selected from the group consisting of AN-2728, AN-2898, CBS-3595, apremilast, ELB-353, KF-66490, K-34, LAS-377
  • the present invention also provides combinations of a compound of the present invention or of a compound of formula (II), with a P38 MAP kinase inhibitor selected from the group consisting of semapimod, talmapimod, pirfenidone, PH-797804, GSK-725, minokine, and losmapimod and salts thereof.
  • a P38 MAP kinase inhibitor selected from the group consisting of semapimod, talmapimod, pirfenidone, PH-797804, GSK-725, minokine, and losmapimod and salts thereof.
  • the present invention provides combinations of a compound of the present invention or of a compound of formula (II) with an IKK2 inhibitor.
  • the present invention also provides combinations of a compound of the present invention or of a compound of formula (II), with a HNE inhibitor selected from the group consisting of AAT, ADC-7828, Aeriva, TAPI, AE-3763, KRP-109, AX-9657, POL-6014, AER-002, AGTC-0106, respriva, AZD-9668, zemaira, AAT IV, PGX-100, elafin, SPHD-400, prolastin C, and prolastin inhaled.
  • a HNE inhibitor selected from the group consisting of AAT, ADC-7828, Aeriva, TAPI, AE-3763, KRP-109, AX-9657, POL-6014, AER-002, AGTC-0106, respriva, AZD-9668, zemaira, AAT IV, PGX-100, elafin, SPHD-400, prolastin C, and prolastin inhaled.
  • the present invention also provides combinations of a compound of the present invention or of a compound of formula (II), with a leukotriene modulator selected from the group consisting of montelukast, zafirlukast, and pranlukast.
  • the present invention also provides combinations of a compound of the present invention or of a compound of formula (II), with a NSAID selected from the group consisting of ibuprofen and ketoprofen.
  • the present invention also provides combinations of a compound of the present invention or of a compound of formula (II), with a mucus regulator selected from the group consisting of INS-37217, diquafosol, sibenadet, CS-003, talnetant, DNK-333, MSI-1956, and gefitinib.
  • a mucus regulator selected from the group consisting of INS-37217, diquafosol, sibenadet, CS-003, talnetant, DNK-333, MSI-1956, and gefitinib.
  • the dosages of the compounds of the present invention depend upon a variety of factors including the particular disease to be treated, the severity of the symptoms, the route of administration, the frequency of the dosage interval, the particular compound utilized, the efficacy, toxicology profile, and pharmacokinetic profile of the compound.
  • the compounds of the present invention or compounds of formula (II) may be administered for example, at a dosage comprised between 0.001 and 1000 mg/day, preferably between 0.1 and 500 mg/day.
  • the dosage of the compounds of the present invention or of compounds of formula (II) is advantageously comprised between 0.01 and 20 mg/day, preferably between 0.1 and 10 mg/day.
  • the compounds of the present invention or compounds of formula (II) alone or combined with other active ingredients may be administered for the prevention and/or treatment of any obstructive respiratory disease such as asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD).
  • any obstructive respiratory disease such as asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • any disease wherein PDE4 inhibition is required include: allergic disease states such as atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, eosinophilic granuloma, psoriasis, inflammatory arthritis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock, cystic fibrosis, arterial restenosis, artherosclerosis, keratosis, rheumatoid spondylitis, osteoarthritis, pyresis, diabetes mellitus, pneumoconiosis, toxic and allergic contact eczema, atopic eczema, seborrheic
  • Such diseases also include neurological and psychiatric disorders such as Alzheimer's disease, multiple sclerosis, amylolaterosclerosis (ALS), multiple systems atrophy (MSA), schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, depression, stroke, and spinal cord injury.
  • neurological and psychiatric disorders such as Alzheimer's disease, multiple sclerosis, amylolaterosclerosis (ALS), multiple systems atrophy (MSA), schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, depression, stroke, and spinal cord injury.
  • EDC 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide) hydrochloride;
  • DMAP 4-dimethylaminopyridine;
  • DMF dimethylformamide;
  • EtOAc or AcOEt Ethyl acetate;
  • RT room temperature;
  • THF tetrahydrofurane;
  • DCM dichloromethane;
  • (Ipr) 2 O diisopropylether;
  • MIK methyl isobutyl ketone;
  • MEK methyl ethyl ketone;
  • MTBE methyl tert-butyl ether;
  • AcOH acetic acid;
  • vv volumes;
  • v/w ratio volume/weight;
  • the enantiomeric purity was determined on Hewlett Packard 1050 HPLC system using Chiracel OD column (5 ⁇ 4.6 ⁇ 250 mm), eluting using isocratic mixture of hexane and isopropanol in different ratios as indicated in each specific example.
  • Trifluoroacetate Salts when stated in the Salt Name column, compounds containing one or more basic centres and purified by reverse-phase HPLC (Method 2 or 3) were obtained as 2,2,2-trifluoroacetic acid salts, once clean fractions collected from chromatography were evaporated under reduced pressure without any further basic treatment.
  • Hydrochloride Salts when stated in the Salt Name column, Compounds containing one or more basic centres which underwent Boc deprotection under acidic condition without any further basic work-up, were obtained as hydrochloride salts.
  • the salt stoichiometry was determined, if required, by NMR.
  • Diastereoisomeric ratio by LC/UV/MS when indicated, is estimated to be affected by an experimental error of ⁇ 1%.
  • diastereoisomeric ratio is determined by 1 H NMRand it is estimated to be >95:5 when a single diastereoisomer was detected using NMR analysis.
  • Step 1 4-((S)-2-((S)-2-acetoxy-2-phenylacetoxy)-2-(3-(cyclopropyl-methoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (161)
  • Step 2 4-((S)-2-((S)-2-acetoxy-2-phenylacetoxy)-2-(4-(difluoromethoxy)-3-hydroxyphenyl)ethyl)-3,5-dichloropyridine 1-oxide (162)
  • Step 3 4-((S)-2-((S)-2-acetoxy-2-phenylacetoxy)-2-(4-(difluoromethoxy)-3-methoxyphenyl)ethyl)-3,5-dichloropyridine 1-oxide (163)
  • Step 4 (S)-3,5-dichloro-4-(2-(4-(difluoromethoxy)-3-methoxyphenyl)-2-hydroxyethyl)pyridine 1-oxide (164)
  • 3,5-dichloro-4-methylpyridine (160) 54 g, 331 mmol was dissolved in dry THF (480 mL) under anargon atmosphere and it was cooled at ⁇ 78° C. in dry-ice/acetone bath.
  • LHMDS 1N THF solution (331 ml, 331 mmol) was added drop-wise by keeping the temperature at ⁇ 78°. The mixture was stirred at ⁇ 78° for 1 hour. After that, a solution of 3,4-dimethoxybenzaldehyde (50 g, 301 mmol) in dry THF (120 ml) was added drop-wise by keeping the temperature at ⁇ 78° C. When the addition was completed, the mixture was allowed to warm at RT.
  • the reaction was poured in ice and water (1 L), and the mixture was stirred until a copious precipitate formed.
  • the solid was filtered, and dissolved in ethyl acetate (500 ml), dried over Na 2 SO 4 and the solvent evaporated under vacuum.
  • the crude was crystallized in CHCl 3 /hexane.
  • the precipitate was filtered, washed with hexane and dried under vacuum at 40° C. for 8 hours to give 55 g (yield 45%).
  • the mother liquor solution was evaporated under vacuum at 40° C., dissolved in ethyl acetate (200 ml) and extracted with 200 ml of water.
  • the organic solution was dried over Na 2 SO 4 and the solvent evaporated under vacuum at 40° C.
  • the crude was crystallized in CHCl 3 /hexane, and additional 15 g of the desired product (166) were obtained (overall yield 70%).
  • Step 2 Synthesis of ((R)-2-(3,5-dichloropyridin-4-yl)-1-(3,4-dimethoxyphenyl)ethyl) 2-(6-methoxynaphthalen-2-yl)propanoate (167)
  • Step 3 Synthesis of (R)-((S)-2-(3,5-dichloropyridin-4-yl)-1-(3,4-dimethoxyphenyl)ethyl) 2-(6-methoxynaphthalen-2-yl)propanoate (168)
  • Step 1 Synthesis of 2-(3,5-dichloropyridin-4-yl)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)ethanol (171)
  • 3,5-dichloro-4-methylpyridine (166) (4.37 g, 0.016 mol) was dissolved in dry THF (40 mL) under an argon atmosphere and it was cooled at ⁇ 78° C. in dry-ice/acetone bath.
  • LHMDS IN THF solution (28 ml, 28 mmol) was added drop-wise by keeping the temperature at ⁇ 78°. The mixture was stirred at ⁇ 78° for 1 hour. After that, a solution of 2,3-difluoro-3,4-benzodioxolocarboxaldheyde (5 g, 0.026 mol) in dry THF (10 ml) was added drop-wise by keeping the temperature at ⁇ 78° C.
  • Step 1 3,5-dichloro-4-(2-(4-methoxyspiro[benzo[d][1,3]dioxole-2,1′-cyclopentane]-'7-yl)-2-oxoethyl)pyridine 1-oxide (173)
  • Step 2 3,5-dichloro-4-(2-hydroxy-2-(4-methoxyspiro[benzo[d][1,3]dioxole-2,1′-cyclopentane]-7-yl)ethyl)pyridine 1-oxide (174)
  • Step 1 4-((S)-2-((S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (2)
  • Step 2 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide hydrochloride (3) 4-((S)-2-((S)-1-(tert-butoxycarbonyppyrrolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (2) (300 mg, 0.486 mmol) was dissolved in Dioxane/HCl (4M, 2 ml) and stirred at RT for 8 hours. After that time, the solvent was removed on a rotavapour under reduced pressure and dried in a vacuum oven overnight to yield the wanted product as an hydrochloride salt (200 mg; yield 80%).
  • Compound 6, 7, 181, and 183 were obtained by reacting its appropriate Boc-protected precursor with AcOEt/HCl (5M), followed by filtration at room temperature of the hydrochloride salt, which spontaneously precipitates from the reaction mixture.
  • Compounds 177, 178, and 179 were obtained by performing Step 2 with HCl in EtOAc and removing the solvent without heating.
  • Step 1 4-((S)-2-((S)-1-(3-(N-(tert-butoxycarbonyl)methylsulfonamido)-4-(cyclopropylmethoxy)benzoyl)pyrrolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (18)
  • Step 2 3,5-dichloro-4-((S)-2-((S)-1-(4-(cyclopropylmethoxy)-3-(methylsulfonamido)benzoyl)pyrrolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)pyridine 1-oxide (19)
  • Step 3 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(4-nitrobenzoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (25)
  • Step 4 4-((2S)-2-(3-(4-aminobenzoyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (26)
  • Step 3 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoro methoxy)phenyl)-2-((S)-1-(4-methoxy-3-(methylsulfonyloxy)benzoyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (30)
  • Step 1 3-((1,3-dioxolan-2-yl)methyl)-N,N-dimethylbenzamide (196) 3-((1,3-dioxolan-2-yl)methyl)benzoic acid (250 mg, 1.201 mmol), dimethylamine hydrochloride (147 mg, 1.801 mmol), EDC (345 mg, 1.801 mmol), and DMAP (513 mg, 4.20 mmol) were dissolved in DCM (30 ml) and the solution was stirred at RT for 1 hour. The reaction mixture was washed twice with 1N HCl, and the organic layer was dried over Na 2 SO 4 . The solvent was removed under reduced pressure to give the desired product (244 mg, 1.037 mmol, 86% yield) MS/ESI + 236.18 [MH] +
  • Step 3 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoro-methoxy)phenyl)-2-((S)-3-(2-(3-(dimethylcarbamoyl)phenyl)acetyl)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (198)
  • Methyl 3-(cyclopropylmethoxy)-5-nitrobenzoate (44) (4.9 g, 19.5 mmol) was dissolved in MeOH (200 ml), and Pd/C 5 % (1.5 g, 0.7 mmol) was added. The solution was shaken under hydrogen atmosphere on a Parr apparatus at 40 psi for 1 hour. The catalyst was filtered on a Diatomaceus earth pad, and the solvent was evaporated under vacuum to give 3.67 g of the desired product (yield 85%).
  • Step 4 methyl 3-(cyclopropylmethoxy)-5-(N-(2-morpholinoethyl)methylsulfonamido)benzoate (47)
  • Step 5 3-(cyclopropylmethoxy)-5-(N-(2-morpholinoethyl)methylsulfonamido)benzoic acid (48)
  • Step 6 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(3-(cyclopropylmethoxy)-5-(N-(2-morpholinoethyl)methylsulfonamido)benzoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide formate (49)
  • Step 1 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(5-formylthiophene-2-carbonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (50) 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (5) (200 mg, 0.374 mmol), 5-formylthiophene-2-carboxylic acid (233 mg, 1.494 mmol), DMAP (100 mg, 0.822 mmol), and EDC (358 mg, 1.868 mmol) were dissolved in DMF (2 ml).
  • Step 2 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(5-((dimethylamino)methyl)thiophene-2-carbonyl)thiazolidine-2-carbonyl oxy)ethyl)pyridine 1-oxide (51)
  • Step 1 4-((2S)-2-(3-(3-carboxy-4-methoxyphenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide, (122)
  • Step 2 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(3-(dimethylcarbamoyl)-4-methoxyphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (123)
  • Step 1 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(4-nitrophenyl sulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (134)
  • Step 2 4-((2S)-2-(3-(4-aminophenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (135)
  • Step 1 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(4-(methylsulfonamido)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (142)
  • Step 2 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(4-(N-(2-morpholinoethyl)methylsulfonamido)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide formate (143)
  • Step 3 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoro-methoxy)phenyl)-2-((S)-3-(2-(3-(dimethylcarbamoyl)phenyl)-2-oxoethyl)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (261)
  • Methyl thiazolidine-2-carboxylate hydrochloride (145) (20 g; 109 mmol) was dissolved in pyridine (100 ml), then 4-nitrobenzene-1-sulfonyl chloride (27 g, 124 mmol) was added at 0° C., and the mixture was stirred for 3 hours. After that time, the reaction was quenched with HCl 1N to precipitate a solid that was filtered on a fit and washed with water several times. The orange solid was triturated in acetone, washed with acetone ( ⁇ 2) and dried under vacuum to yield 27 g (76%).
  • Step 4 4-((2S)-2-(3-(4-aminophenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (149)
  • Step 5 4-((S)-2-((S)-3-(4-aminophenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (150)
  • Step 3 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(1-methyl-1H-imidazol-2-ylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (155)
  • Step 2 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(hydroxymethyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (271)
  • Step 3 4-((2S)-2-(2-(3-benzoylthiazolidin-2-yl)acetoxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (274)
  • Step 1 ethyl 2-(3-(phenylsulfonyl)thiazolidin-2-yl)acetate (276)
  • Step 3 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(2-(3-(phenylsulfonyl)thiazolidin-2-yl)acetoxy)ethyl)pyridine 1-oxide (278)
  • Step 1 1-(3-(dimethylcarbamoyl)phenylsulfonyl)azetidine-3-carboxylic acid (280)
  • Step 2 (S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(1-(3-(dimethylcarbamoyl)phenylsulfonyl)azetidine-3-carbonyloxy)ethyl)pyridine 1-oxide (281)
  • Step 1 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(vinylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (286)
  • Step 2 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(2-morpholinoethylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (287)
  • Step 2 (S)-1-(2-(phenylsulfonyl)ethyl)pyrrolidine-2-carboxylic acid (290)
  • Step 3 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoro-methoxy)phenyl)-2-((S)-1-(2-(phenylsulfonyl)ethyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (291)
  • Step 3 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoro-methoxy)phenyl)-2-((S)-3-(3-(dimethylcarbamoyl)benzylsulfonyl)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (295)
  • Step 1 4-((S)-2-((S)-3-(tert-butoxycarbonyl)thiazolidine-2-carbonyloxy)-2-(4-(difluoromethoxy)-3-methoxyphenyl)ethyl)-3,5-dichloropyridine 1-oxide (297)
  • Step 2 3,5-dichloro-4-((S)-2-(4-(difluoromethoxy)-3-methoxyphenyl)-2-((S)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide hydrochloride (298)
  • Step 3 3,5-dichloro-4-((S)-2-(4-(difluoromethoxy)-3-methoxyphenyl)-2-((S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (299)
  • Step 2 3,5-dichloro-4-((S)-2-(4-(difluoromethoxy)-3-methoxyphenyl)-2-((S)-1-(phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (305)
  • Step 1 (S)-ethyl 3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carboxylate (318)
  • Step 2 (S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carboxylic acid (319)
  • Step 3 3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-methoxyphenyl)-2-((S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (320)
  • U937 human monocytic supernatants cells lysate were cultured, harvested and supernatant fraction prepared essentially as described in Torphy T J, et al., 1 J. Pharmacol. Exp. Ther., 1992; 263:1195-1205, which is incorporated herein by reference in its entirety.
  • U937 cells Cell Bank, Interlab Cell Line Collection, ICLC HTL94002 were grown at 37° C., 5% CO 2 in RPMI 1640 with GlutaMAXTM-I medium supplemented with 10% fetal bovine serum and 100 ⁇ g/ml Pen-strep (Gibco).
  • PDE4 activity was determined in cells supernatants by assaying cAMP disappearance from the incubation mixtures.
  • concentration of the test compounds ranged between 10 ⁇ 12 M and 10 ⁇ 6 M. Reactions were stopped by enzyme heat inactivation (2.5 minutes at 100° C.), and residual cAMP content was determined using the ‘LANCE cAMP Assay’ from PerkinElmer following the providers instructions.
  • the results of the tested compounds, representatives of the invention, expressed as mean ⁇ standard deviation of the nM concentration of the test compound producing 50% inhibition of cAMP disappearance (IC 50 ) are shown in the following Table:
  • PDE4 binding potencies are indicated as follows: >10 nM “+”; 10-1 nM “++”; 1-0.1 nM “+++”; ⁇ 0.1 nM “++++”.
  • Percentage of inhibition of PDE4 activity was calculated, assuming cAMP disappearance in the absence of inhibitors as 100% and cAMP disappearance in heat inactivated samples as 0%.
  • PDE4 binding potencies are indicated as follows: >10 nM “+”; 10-1 nM “++”; 1-0.1 nM “+++”; ⁇ 0.1 nM “++++”.
  • the assay which is based on the known inhibitory activity exerted by PDE4 inhibitors on the lipopolyshaccarides (LPS)-induced tumour necrosis factor-alpha (TNF- ⁇ release in peripheral blood mononuclear cells (PBMCs), was performed according to a method previously described (Hatzelmann A et al., J. Pharmacol. Exp. Ther., 2001; 297:267-279; and Draheim R et al., J. Pharmacol. Exp. Ther., 2004; 308:555-563, which are incorporated herein by reference in their entireties).
  • LPS lipopolyshaccarides
  • Cryopreserved human PBMCs (100 ⁇ l/well) were incubated in 96-well plates (10 5 cells/well), for 30 minutes, in the presence or absence (50 microl) of the test compounds whose concentrations ranged from 10 ⁇ 12 M to 10 ⁇ 6 M or from 10 ⁇ 13 M to 10 ⁇ 7 M. Subsequently, LPS (3 ng/ml) was added.
  • PDE4 Compound No. inhibition 239, 240, 241, 242, 206, 271, 210, 310, 250, 251, 252, ++++ 269, 287, 299, 35, 37, 38, 52, 54, 56, 59, 64, 66, 73, 74, 82, 83, 84, 85, 88, 90, 91, 92, 93, 94, 95, 96, 97, 101, 106, 107, 109, 113, 115, 116, 118, 119, 123, 124, 128, 129, 130, 131, 132, 133, 139, 140, 150, 155 238, 201, 203, 228, 207, 198, 209, 295, 243, 186, 187, +++ 185, 281, 253, 288, 200, 16, 17, 20, 22, 26, 31, 32, 34, 36, 39, 40, 41, 49, 51, 53, 55, 57, 58, 60, 61, 62, 63, 65
  • PDE4 binding potencies are indicated as follows: >10 nM “+”; 10-1 nM “++”; 1-0.1 nM “+++”; ⁇ 0.1 nM “++++”.
  • the effects of the tested compounds were calculated as percentage of inhibition of TNF- ⁇ release, assuming LPS-induced TNF- ⁇ production in the absence of inhibitor compound as 100% and basal TNF- ⁇ production of PBMCs in the absence of LPS as 0%.
  • results of tested compounds for compounds of formula (II) expressed as mean ⁇ 95% confidence limits of the molar concentration of the test compound producing 50% inhibition of LPS-induced TNF- ⁇ release (IC 50 ) are shown in the following Table:
  • PDE4 binding potencies are indicated as follows: >10 nM “+”; 10-1 nM “++”; 1-0.1 nM “+++”; ⁇ 0.1 nM “++++”.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme and the treatment of certain conditions such as COPD.

Description

    CROSS REFERENCES TO RELATED APPLICATIONS
  • This application claims priority to European Patent Application No. 11168853.7, filed on Jun. 6, 2011, which is incorporated herein by reference in its entirety.
    • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The present invention relates to inhibitors of the phosphodiesterase 4 (PDE4) enzyme. More particularly, the present invention relates to compounds that are derivatives of 1-phenyl-2-pyridinyl alkyl alcohols, methods of preparing such compounds, compositions containing them, and therapeutic uses of such compounds and compositions.
  • 2. Discussion of the Background
  • Airway obstruction characterizes a number of severe respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD). Events leading to airway obstruction include edema of airway walls, increased mucous production and inflammation.
  • Drugs for treating respiratory diseases such as asthma and COPD are currently administered through inhalation. One of the advantages of the inhalatory route over the systemic one is the possibility of delivering the drug directly at site of action, reducing systemic side-effects, thus resulting in a more rapid clinical response and a higher therapeutic ratio.
  • Inhaled corticosteroids are the current maintenance therapy of choice for asthma and together with bronchodilator beta2-agonists for acute symptom relief, they form the mainstay of current therapy for the disease. The current management of COPD is largely symptomatic by means of bronchodilating therapy with inhaled anticholinergics and inhaled beta2-adrenoceptor agonists. However, corticosteroids do not reduce the inflammatory response in COPD as they do in asthma.
  • Another class of therapeutic agents which has been widely investigated in view of its anti-inflammatory effects for the treatment of inflammatory respiratory diseases such as asthma and COPD is represented by the inhibitors of the enzymes phosphodiesterases (PDEs), in particular of the phosphodiesterase type 4 (hereinafter referred to as PDE4).
  • Various compounds acting as PDE4 inhibitors have been disclosed in the prior art. However, the usefulness of several PDE4 inhibitors of the first-generation such as rolipram and piclamilast has been limited due to their undesirable side effects. Said effects include nausea and emesis due to their action on PDE4 in the central nervous system and gastric acid secretion due to the action on PDE4 in parietal cells in the gut.
  • The cause of said side effects has been widely investigated. It has been found that PDE4 exists in two distinct forms representing different conformations, that were designated as high affinity rolipram binding site or HPDE4, especially present in the central nervous system and in parietal cells, and low affinity rolipram binding site or LPDE4 (see Jacobitz, S et al., Mol. Pharmacol., 1996, 50, 891-899, which is incorporated herein by reference in its entirety), which is found in the immune and inflammatory cells. While both forms appear to exhibit catalytic activity, they differ with respect to their sensitivity to inhibitors. In particular compounds with higher affinity for LPDE4 appear less prone to induce side-effects such as nausea, emesis and increased gastric secretion.
  • The effort of targeting LPDE4 has resulted in a slight improvement in the selectivity for the second-generation PDE4 inhibitors such as roflumilast. Nonetheless, roflumilast is under dosed in order to achieve an acceptable side effect profile.
  • Other classes of compounds acting as PDE4 inhibitors have also been disclosed. For example, EP 1 634 606 discloses, among others, ketone derivatives like benzofuran or 1,3-benzodioxole derivatives.
  • WO 94/02465 discloses, among others, ketone derivatives of general formula
  • Figure US20130005716A1-20130103-C00001
  • wherein R1 is lower alkyl and R2 may be alkyl, alkenyl, cycloalkyl, cycloalkyl, cycloalkenyl, cyclothioalkyl or cyclothioalkenyl.
  • WO 95/35281 in the name of Celltech Therapeutics relates to tri-substituted phenyl derivatives.
  • WO 2009/018909 discloses derivatives of 1-phenyl-2-pyridinyl alkyl alcohols which have general formula below reported
  • Figure US20130005716A1-20130103-C00002
  • as inhibitors of phosphodiesterase 4 (PDE4) enzyme.
  • WO 2009/077068 discloses further derivatives of 1-phenyl-2-pyridinyl alkyl alcohols which have general formula below reported
  • Figure US20130005716A1-20130103-C00003
  • as inhibitors of phosphodiesterase 4 (PDE4) enzyme.
  • WO 2010/089107 discloses further derivatives of 1-phenyl-2-pyridinyl alkyl alcohols which have general formula below reported
  • Figure US20130005716A1-20130103-C00004
  • as inhibitors of phosphodiesterase 4 (PDE4) enzyme.
  • Although several PDE4 inhibitors have been disclosed so far as above reported, there is still a need for further PDE4 inhibitors. Particularly, there is still a need for further PDE4 inhibitors endowed with a high affinity for PDE4 enzyme. Particularly advantageous would also be the identification of further PDE4 inhibitors endowed with a high affinity for PDE4 enzyme and which would show an appropriate developability profile as an inhalation treatment for example in terms of reduced side effects.
  • Such reduction of side effects may be achieved, by way of example, through a low systemic exposure of the drug; an appropriate profile in terms of some pharmacokinetic characteristics, especially metabolic clearance, may be thus key to this goal.
    • SUMMARY OF THE INVENTION
  • Accordingly, it is one object of the present invention to provide novel PDE4 inhibitors endowed with a high affinity for PDE4 enzyme.
  • It is another object of the present invention to provide novel PDE4 inhibitors endowed with a high affinity for PDE4 enzyme and which show an appropriate developability profile as an inhalation treatment for example in terms of reduced side effects.
  • It is another object of the present invention to provide novel pharmaceutical compositions which contain such PDE4 inhibitor.
  • It is another object of the present invention to provide novel combinations of such a PDE4 inhibitor and one or more other active agents.
  • It is another object of the present invention to provide novel methods of treating a condition such as COPD by administering such a PDE4 inhibitor.
  • These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery of certain new PDE4 inhibitors. Thus, the present invention addresses the above mentioned object by providing the compounds of the invention.
  • Thus, the present invention is directed to compounds acting as inhibitors of the phosphodiesterase 4 (PDE4) enzyme, methods of preparing said compounds, compositions containing them and therapeutic use thereof.
  • In particular, the present invention is directed to derivatives of 1-phenyl-2-pyridinyl alkyl alcohols of general formula (I):
  • Figure US20130005716A1-20130103-C00005
  • wherein:
    • R1 is selected from the group consisting of:
      • H;
      • (C3-C7)cycloalkylcarbonyl;
      • (C1-C6)alkyl, optionally substituted by one or more substituents selected from (C3-C7)cycloalkyl or (C5-C7)cycloalkenyl;
      • (C1-C6)haloalkyl;
      • (C3-C7)cycloalkyl;
      • (C5-C7)cycloalkenyl;
      • (C2-C6)alkenyl; and
      • (C2-C6)alkynyl;
    • R2 is selected from the group consisting of:
      • H;
      • (C3-C7)cycloalkylcarbonyl;
      • (C1-C6)alkyl, optionally substituted by one or more substituents selected from (C3-C7)cycloalkyl or (C5-C7)cycloalkenyl;
      • (C1-C6)haloalkyl;
      • (C3-C7)cycloalkyl;
      • (C5-C7)cycloalkenyl;
      • (C2-C6)alkenyl; and
      • (C2-C6)alkynyl;
      • or, when R19 is different from hydrogen, R2 forms together with R19 a group of formula (x) as below defined;
      • or R1 and R2, together with the interconnecting atoms, form a 2,2-difluoro-1,3-dioxolane ring of formula (q) fused to the phenyl moiety which bears groups —OR1 and —OR2, wherein asterisks indicate carbon atoms shared with such phenyl ring:
  • Figure US20130005716A1-20130103-C00006
  • R19 is hydrogen or, if different from hydrogen, it forms together with R2 a group of formula (x) wherein bonds labeled with (1) and (2) indicate the points of attachment for group (x) to atoms bearing groups R19 and R2 respectively
  • Figure US20130005716A1-20130103-C00007
  • in such a way that R2 and R19 together with the interconnecting atoms form a ring of formula (w) which is fused to phenyl ring which bears groups —OR2 and R19, wherein asterisks indicate carbon atoms shared with such phenyl ring:
  • Figure US20130005716A1-20130103-C00008
  • R3 is one or more substituents independently selected from the group consisting of H, CN, NO2, CF3 and a halogen atom;
    Z is a group —(CH2)n— wherein n is 0 or 1;
    A is a saturated and monocyclic (C3-C7)heterocycloalkylene group;
    K is selected from the group consisting of:
      • —(CH2)mC(O)R4 wherein m may be 0 or 1;
      • —C(O)(CH2)jR4, wherein j may be 1 or 2;
      • —SO2(CH2)pR4 wherein p may be zero, 1 or 2;
      • —(CH2)ySO2R4 wherein y may be 1 or 2;
      • —(CH2)zR4 wherein z may be 1 or 2; and
      • —C(O)(CH2)2SO2R4;
      • R4 is a ring system, that is a mono- or bicyclic ring which may be saturated, partially unsaturated or fully unsaturated, such as aryl, (C3-C8)cycloalkyl, (C3-C7)heterocycloalkyl or heteroaryl, such ring being optionally substituted by one or more groups R5 which may be the same or different, and which are independently selected from the group consisting of:
        • (C1-C6)alkyl optionally substituted by one or more groups independently selected in the list consisting of: (C3-C7)cycloalkyl, —OH and a group —NR18C(O)(C1-C4) alkyl, wherein R18 is hydrogen or (C1-C4)alkyl;
        • (C3-C7)heterocycloalkyl;
        • 5 or 6-membered heteroaryl which is optionally substituted by one or two groups (C1-C4)alkyl;
        • (C1-C6)haloalkyl;
        • (C3-C7)heterocycloalkyl(C1-C4)alkyl;
        • a group —OR6 wherein R6 is selected from the group consisting of
          • H:
          • (C1-C6)haloalkyl;
          • a group —SO2R7, wherein R7 is (C1-C4)alkyl;
          • a group —C(O)RD wherein R7 is (C1-C4)alkyl;
          • —(C1-C10)alkyl optionally substituted by one or more (C3-C7) cycloalkyl or by a group —NR8R9 as below defined; and
          • (C3-C7)cycloalkyl;
        • a group —SR20 wherein R20 is selected from the group consisting of
          • —H:
          • (C1-C6)haloalkyl;
          • a group —C(O)R7 wherein R7 is (C1-C4)alkyl;
          • (C1-C10)alkyl optionally substituted by one or more (C3-C7) cycloalkyl or by a group —NR8R9; and
          • (C3-C7)cycloalkyl;
        • halogen atoms;
        • CN;
        • NO2;
        • NR8R9 wherein R8 and R9 are different or the same and are independently selected from the group consisting of:
          • H;
          • (C1-C4)alkylene-NR13R14 wherein R13 and R14 are different or the same and are independently selected from the group consisting of: H and (C1-C6)alkyl, which is optionally substituted with (C3-C7)cycloalkyl or (C3-C7) heterocycloalkyl; or they form with the nitrogen atom to which they are linked a saturated or partially saturated (C3-C7)heterocyclic ring;
          • (C1-C6)alkyl, optionally substituted with (C3-C7)cycloalkyl, (C3-C7)heterocycloalkyl, a group —OH or (C1-C6)alkoxyl;
          • a group —SO2R15, wherein R15 is selected in the group consisting of: (C1-C4)alkyl optionally substituted by (C3-C7)cycloalkyl or (C3-C7)heterocycloalkyl; (C3-C7)heterocycloalkyl; and phenyl optionally substituted by one or more (C1-C6)alkyl, halogen or a group —OH;
          • a group —C(O)R16, wherein R16 is selected in the group consisting of: (C1-C6)alkyl optionally substituted by (C3-C7)cycloalkyl or (C3-C7)heterocycloalkyl; (C3-C7)heterocycloalkyl; phenyl optionally substituted by one or more (C1-C6)alkyl, halogen or —OH; and a group —NH2;
          • a group —C(O)OR17, wherein R17 is selected in the group consisting of: (C1-C6)alkyl optionally substituted by (C3-C7)cycloalkyl or (C3-C7)heterocycloalkyl; (C3-C7)heterocycloalkyl; phenyl optionally substituted by one or more (C1-C6)alkyl, halogen or —OH; and a group —NH2;
          • or they form with the nitrogen atom to which they are linked a saturated or partially saturated heterocyclic ring, which is optionally substituted by one or more (C1-C6)alkyl or oxo groups;
        • (C1-C4)alkylene-NR8R9 as above defined;
        • COR10 wherein R10 is phenyl or (C1-C6)alkyl;
        • oxo;
        • —SO2R11 wherein R11 is (C1-C4)alkyl, OH or NR8R9 wherein R8 and R9 are as defined above;
        • —COOR12 wherein R12 is H, (C1-C4)alkyl or (C1-C4)alkylene-NR8R9 wherein R8 and R9 are as defined above; and
        • —CONR8R9 wherein R8 and R9 are as defined above;
      • wherein groups R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19 and R20 may assume the same or different meanings at each occurrence, if present in more than one group;
        their N-oxides on the pyridine ring, and pharmaceutically acceptable salts, or solvates thereof.
  • In a preferred embodiment, the invention is directed to derivatives of 1-phenyl-2-pyridinyl alkyl alcohols of general formula (IG):
  • Figure US20130005716A1-20130103-C00009
  • wherein:
    R1 is selected from the group consisting of:
      • H;
      • (C3-C7)cycloalkylcarbonyl;
      • (C1-C6)alkyl, optionally substituted by one or more substituents selected from (C3-C7)cycloalkyl or (C5-C7)cycloalkenyl;
      • (C1-C6)haloalkyl;
      • (C3-C7)cycloalkyl;
      • (C5-C7)cycloalkenyl;
      • (C2-C6)alkenyl; and
      • (C2-C6)alkynyl;
        R2 is selected from the group consisting of:
      • H;
      • (C3-C7)cycloalkylcarbonyl;
      • (C1-C6)alkyl, optionally substituted by one or more substituents selected from (C3-C7)cycloalkyl or (C5-C7)cycloalkenyl;
      • (C1-C6)haloalkyl;
      • (C3-C7)cycloalkyl;
      • (C5-C7)cycloalkenyl;
      • (C2-C6)alkenyl; and
      • (C2-C6)alkynyl;
      • or R1 and R2, together with the interconnecting atoms, form a 2,2-difluoro-1,3-dioxolane ring of formula (q) fused to the phenyl moiety which bears groups —OR1 and —OR2, wherein asterisks indicate carbon atoms shared with such phenyl ring:
  • Figure US20130005716A1-20130103-C00010
  • R19 is hydrogen;
    R3 is one or more substituents independently selected from the group consisting of H, CN,
    NO2, CF3 and a halogen atom;
    Z is a group —(CH2)n— wherein n is 0 or 1;
    A is a saturated and monocyclic (C3-C7)heterocycloalkyl-ene group;
    K is selected from the group consisting of:
      • —(CH2)mC(O)R4 wherein m may be 0 or 1;
      • —C(O)(CH2)jR4, wherein j may be 1 or 2;
      • —SO2 (CH2)pR4 wherein p may be zero, 1 or 2;
      • —(CH2)ySO2R4 wherein y may be 1 or 2;
      • —(CH2)nR4 wherein z may be 1 or 2; and
      • —C(O)(CH2)2SO2R4;
      • R4 is a ring system, that is a mono- or bicyclic ring which may be saturated, partially unsaturated or fully unsaturated, such as aryl, (C3-C8)cycloalkyl, (C3-C7)heterocycloalkyl or heteroaryl, such ring being optionally substituted by one or more groups R5 which may be the same or different, and which are independently selected from the group consisting of:
        • (C1-C6)alkyl optionally substituted by one or more groups independently selected in the list consisting of: (C3-C7)cycloalkyl, —OH and a group —NR18C(O)(C1-C4)alkyl, wherein R18 is hydrogen or (C1-C4)alkyl;
        • (C3-C7)heterocycloalkyl;
        • 5 or 6-membered heteroaryl which is optionally substituted by one or two groups
        • (C1-C4)alkyl;
        • (C1-C6)haloalkyl;
        • (C3-C7)heterocycloalkyl(C1-C4)alkyl;
        • a group —OR6 wherein R6 is selected from the group consisting of
          • —H:
          • —(C1-C6)haloalkyl;
          • a group —SO2R7, wherein R7 is (C1-C4)alkyl;
          • a group —C(O)R7 wherein R7 is (C1-C4)alkyl;
          • (C1-C10)alkyl optionally substituted by one or more (C3-C7) cycloalkyl or by a group —NR8R9; and
          • (C3-C7)cycloalkyl;
        • a group —SR20 wherein R20 is selected from the group consisting of
          • —H:
          • (C1-C6)haloalkyl;
          • a group —C(O)RD wherein R7 is (C1-C4)alkyl;
          • (C1-C10)alkyl optionally substituted by one or more (C3-C7) cycloalkyl or by a group —NR8R9 as below defined; and
          • (C3-C7)cycloalkyl;
        • halogen atoms;
        • CN;
        • NO2;
        • NR8R9 wherein R8 and R9 are different or the same and are independently selected from the group consisting of:
          • H;
          • —(C1-C4)alkylene-NR13R14 wherein R13 and R14 are different or the same and are independently selected from the group consisting of: H and (C1-C6)alkyl, which is optionally substituted with (C3-C7)cycloalkyl or (C3-C7)heterocycloalkyl; or they form with the nitrogen atom to which they are linked a saturated or partially saturated (C3-C7)heterocyclic ring;
          • (C1-C6)alkyl, optionally substituted with (C3-C7)cycloalkyl, (C3-C7)heterocycloalkyl, a group —OH or (C1-C6)alkoxyl;
          • a group —SO2R15, wherein R15 is selected in the group consisting of: (C1-C4)alkyl optionally substituted by (C3-C7)cycloalkyl or (C3-C7)heterocycloalkyl; (C3-C7)heterocycloalkyl; and phenyl optionally substituted by one or more (C1-C6)alkyl, halogen or a group —OH;
          • a group —C(O)R16, wherein R16 is selected in the group consisting of: (C1-C6)alkyl optionally substituted by (C3-C7)cycloalkyl or (C3-C7)heterocycloalkyl; (C3-C7)heterocycloalkyl; phenyl optionally substituted by one or more (C1-C6)alkyl, halogen or —OH; and a group —NH2;
          • a group —C(O)OR17, wherein R17 is selected in the group consisting of: (C1-C6)alkyl optionally substituted by (C3-C7)cycloalkyl or (C3-C7)heterocycloalkyl; (C3-C7)heterocycloalkyl; phenyl optionally substituted by one or more (C1-C6)alkyl, halogen or —OH; and a group —NH2;
          • or they form with the nitrogen atom to which they are linked a saturated or partially saturated heterocyclic ring, which is optionally substituted by one or more (C1-C6)alkyl or oxo groups;
        • (C1-C4)alkylene-NR8R9 as above defined;
        • COR10 wherein R10 is phenyl or (C1-C6)alkyl;
        • oxo;
        • —SO2R11 wherein R11 is (C1-C4)alkyl, OH or NR8R9 wherein R8 and R9 are as defined above;
        • —COOR12 wherein R12 is H or (C1-C4)alkyl or (C1-C4)alkylene-NR8R9 wherein R8 and R9 are as defined above; and
        • —CONR8R9 wherein R8 and R9 are as defined above;
      • wherein groups R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19 and R20 may assume the same or different meanings at each occurrence, if present in more than one group;
        their N-oxides on the pyridine ring, and pharmaceutically acceptable salts, or solvates thereof.
  • In another preferred embodiment, invention is directed to derivatives of 1-phenyl-2-pyridinyl alkyl alcohols of general formula (IL):
  • Figure US20130005716A1-20130103-C00011
  • wherein:
    R1 and R2 are different or the same and are independently selected from the group consisting of:
      • H;
      • (C3-C7)cycloalkylcarbonyl;
      • (C1-C6)alkyl, optionally substituted by one or more substituents selected from (C3-C7)cycloalkyl or (C5-C7)cycloalkenyl;
      • (C1-C6)haloalkyl;
      • (C3-C7)cycloalkyl;
      • (C5-C7)cycloalkenyl;
      • (C2-C6)alkenyl; and
      • (C2-C6)alkynyl;
        R3 is one or more substituents independently selected from the group consisting of H, CN,
        NO2, CF3 and a halogen atom;
        Z is a group —(CH2)n— wherein n is 0 or 1;
        A is a saturated and monocyclic (C3-C7)heterocycloalkyl-ene group;
        K is selected from the group consisting of:
      • —(CH2)mC(O)R4 wherein m may be 0 or 1;
        • —C(O)(CH2)R4;
        • —SO2 (CH2)pR4 wherein p may be zero or 1;
        • —CH2SO2R4; and
        • —CH2R4;
      • R4 is a ring system, that is a mono- or bicyclic ring which may be saturated, partially unsaturated or fully unsaturated, such as aryl, (C3-C8)cycloalkyl, (C3-C7)heterocycloalkyl or heteroaryl, such ring being optionally substituted by one or more groups R5 which may be the same or different, and which are independently selected from the group consisting of:
        • (C1-C6)alkyl optionally substituted by one or more (C3-C7)cycloalkyl;
        • (C3-C7)heterocycloalkyl;
        • (C3-C7)heterocycloalkyl(C1-C4)alkyl;
        • a group —OR6 wherein R6 is selected from the group consisting of
          • —H:
          • (C1-C6)haloalkyl;
          • a group —SO2R7, wherein R7 is (C1-C4)alkyl;
          • a group —C(O)R7 wherein R7 is (C1-C4)alkyl;
          • (C1-C10)alkyl optionally substituted by one or more (C3-C7) cycloalkyl or by a group —NR8R9; and
          • (C3-C7)cycloalkyl;
        • a group —SR20 wherein R20 is selected from the group consisting of
          • —H:
          • —(C1-C6)haloalkyl;
          • a group —C(O)RD wherein R7 is (C1-C4)alkyl;
          • (C1-C10)alkyl optionally substituted by one or more (C3-C7)cycloalkyl or by a group —NR8R9 as below defined; and
          • (C3-C7)cycloalkyl;
        • halogen atoms;
        • CN;
        • NO2;
        • NR8R9 wherein R8 and R9 are different or the same and are independently selected from the group consisting of:
          • H;
          • (C1-C4)alkylene-NR13R14 wherein R13 and R14 are different or the same and are independently selected from the group consisting of: H and (C1-C6)alkyl, which is optionally substituted with (C3-C7)cycloalkyl or (C3-C7)heterocycloalkyl; or they form with the nitrogen atom to which they are linked a saturated or partially saturated (C3-C7)heterocyclic ring;
          • (C1-C6)alkyl, optionally substituted with (C3-C7)cycloalkyl, (C3-C7)heterocycloalkyl, a group —OH or (C1-C6)alkoxyl;
          • a group —SO2R15, wherein R15 is selected in the group consisting of: (C1-C4)alkyl optionally substituted by (C3-C7)cycloalkyl or (C3-C7)heterocycloalkyl; (C3-C7)heterocycloalkyl; and phenyl optionally substituted by one or more (C1-C6)alkyl, halogen or a group —OH;
          • a group —C(O)R16, wherein R16 is selected in the group consisting of: (C1-C6)alkyl optionally substituted by (C3-C7)cycloalkyl or (C3-C7)heterocycloalkyl; (C3-C7)heterocycloalkyl; phenyl optionally substituted by one or more (C1-C6)alkyl, halogen or —OH; and a group —NH2;
          • a group —C(O)OR17, wherein R17 is selected in the group consisting of: (C1-C6)alkyl optionally substituted by (C3-C7)cycloalkyl or (C3-C7)heterocycloalkyl; (C3-C7)heterocycloalkyl; phenyl optionally substituted by one or more (C1-C6)alkyl, halogen or —OH; and a group —NH2;
          • or they form with the nitrogen atom to which they are linked a saturated or partially saturated heterocyclic ring, which is optionally substituted by one or more (C1-C6)alkyl or oxo groups;
        • (C1-C4)alkylene-NR8R9 as above defined;
        • COR10 wherein R10 is phenyl or (C1-C6)alkyl;
        • oxo;
        • —SO2R11 wherein R11 is (C1-C4)alkyl, OH or NR8R9 wherein R8 and R9 are as defined above;
        • —COOR12 wherein R12 is H or (C1-C4)alkyl or (C1-C4)alkylene-NR8R9 wherein R8 and R9 are as defined above; and
        • —CONR8R9 wherein R8 and R9 are as defined above;
      • wherein groups R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17 and R20 may assume the same or different meanings at each occurrence, if present in more than one group; their N-oxides on the pyridine ring, and pharmaceutically acceptable salts, or solvates thereof.
  • The present invention further provides the corresponding N-oxides on the pyridine ring of compounds of formula (I).
  • The present invention also provides the pharmaceutically acceptable salts and/or solvates thereof.
  • The term “pharmaceutically acceptable salts”, as used herein, refers to derivatives of compounds of formula (I) or of their corresponding N-oxides on the pyridine ring wherein the parent compound is suitably modified by converting any of the free acid or basic groups, if present, into the corresponding addition salt with any base or acid conventionally intended as being pharmaceutically acceptable.
  • Suitable examples of said salts may thus include mineral or organic acid addition salts of basic residues such as amino groups, as well as mineral or organic acid residues such as carboxylic groups.
  • Cations of inorganic bases which can be suitably used to prepare salts within the invention comprise ions of alkali or alkaline earth metals such as potassium, sodium, calcium or magnesium.
  • Those obtained by reacting the main compound, functioning as a base, with an inorganic or organic acid to form a salt comprise, for example, salts of hydrochloric acid, sulfuric acid, phosphoric acid, methane sulfonic acid, camphor sulfonic acid, oxalic acid, maleic acid, succinic acid and citric acid.
  • Those skilled in the art of organic chemistry will appreciate that many organic compounds can form complexes with solvents in which they are reacted or from which they are precipitated or crystallized. These complexes are known as “solvates”. Pharmaceutically acceptable solvates of compound of the invention are within the scope of the invention.
  • Included within the scope of the present invention are also polymoprhs and crystalline forms of compounds of formula (I), of their N-oxides on the pyridine ring, or of pharmaceutically acceptable salts, or solvates thereof.
  • Hereinafter, compounds of formula (I), (IG), (IL), corresponding N-Oxides on the pyridine ring, embodiments, enantiomers, diastereoisomers thereof, their pharmaceutically acceptable salts and solvates, and polymorphs or crystalline forms thereof defined in any aspect of the invention (except intermediate compounds described in the chemical processes) are referred to as “compounds of the invention”.
  • The present invention further provides a process for the preparation of compounds of the invention.
  • The present invention also provides pharmaceutical compositions of compounds of the invention either alone or in combination, in admixture with one or more pharmaceutically acceptable carriers.
  • In a further aspect the present invention provides the use of the compounds of the present invention as a medicament.
  • In another aspect the present invention provides the use of the compounds of the present invention for the manufacture of a medicament.
  • In particular, the present invention provides the use of the compounds of the present invention for the prevention and/or treatment of any disease characterized by phosphodiesterase 4 (PDE4) overactivity and/or wherein an inhibition of PDE4 activity is desirable.
  • In particular, the compounds of the present invention alone or combined with other active ingredients may be administered for the prevention and/or treatment of a disease the respiratory tract characterized by airway obstruction such as asthma and COPD.
  • In a further aspect, the present invention provides the use of compounds of the present invention for the preparation of a medicament for the prevention and/or treatment of any disease characterized by phosphodiesterase 4 (PDE4) overactivity and/or wherein an inhibition of PDE4 activity is desirable.
  • Moreover, the present invention provides methods for prevention and/or treatment of any disease wherein PDE4 inhibition is desiderable, said method comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of the present invention.
    • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • The term “halogen atoms” as used herein includes fluorine, chlorine, bromine, and iodine, preferably chlorine.
  • As used herein, the term “(C1-Cx)alkyl” where x is an integer greater than 1, refers to straight-chained and branched alkyl groups wherein the number of constituent carbon atoms is in the range 1 to x. Particular alkyl groups are methyl, ethyl, n-propyl, isopropyl, and t-butyl.
  • By analogy, the term “(C1-Cx)alkylene”, refers to a divalent (C1-Cx)alkyl radical, wherein (C1-Cx)alkyl is as above defined.
  • The term “(CI-Cx)alkoxyl” where x is an integer greater than 1, refers to straight-chained and branched alkoxy groups wherein the number of constituent carbon atoms is in the range 1 to x. Particular alkyl groups are methoxyl, ethoxyl, n-propoxyl, isopropoxyl, and t-butoxyl.
  • The expressions “(C1-Cx)haloalkyl” refer to the above defined “(C1-Cx)alkyl” groups wherein one or more hydrogen atoms are replaced by one or more halogen atoms, which can be the same or different from each other.
  • Examples of said (C1-C6)haloalkyl groups may thus include halogenated, poly-halogenated and fully halogenated alkyl groups wherein all of the hydrogen atoms are replaced by halogen atoms, e.g. trifluoromethyl or difluoro methyl groups.
  • The term “(C3-Cy)cycloalkyl”, where y is an integer greater than or equal to 3, refers to saturated cyclic hydrocarbon groups containing from 3 to y ring carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
  • The derived expression “(C3-Cy)heterocycloalkyl” refers to monocyclic (C3-Cy)cycloalkyl groups, in which at least one ring carbon atom is replaced by a heteroatom (e.g. N, NH, S or O). Non-limiting examples of (C3-Cy)heterocycloalkyl are represented by: pyrrolidinyl, thiazolidinyl, piperazinyl, piperidnyl, morpholinyl, thiomorpholinyl, and azetidinyl.
  • By analogy, the term “(C3-Cy)heterocycloalkyl-ene”, refers to a divalent (C3-Cy)heterocycloalkyl radical, wherein (C3-Cy)heterocycloalkyl is as above defined.
  • The expression “(C3-Cy)cycloalkylcarbonyl” refers to (C3-Cy)cycloalkylCO— groups wherein the group “(C3-Cy)cycloalkyl” has the meaning above defined.
  • The term “(C2-C6)alkenyl” refers to straight or branched, conjugated or non-conjugated, carbon chains with one or more double bonds, in cis or trans configuration, wherein the number atoms is in the range 2 to 6.
  • The term “(C5-Cz)cycloalkenyl”, where z is an integer greater than or equal to 5, refers to cyclic hydrocarbon groups containing from 5 to z ring carbon atoms and one or more double bonds.
  • The term “(C2-C6)alkynyl” refers to straight or branched carbon chains with one or more triple bonds wherein the number of atoms is in the range 2 to 6.
  • The term “(C3-Cy)heterocycloalkyl(C1-Cx)alkyl” refers to the above “(Cr Cx)alkyl” group wherein one or more hydrogen atoms are replaced by one or more “(C3-Cy)heterocycloalkyl” groups.
  • As used herein, the expression “ring system” refers to mono- or bicyclic ring systems which may be saturated, partially unsaturated or unsaturated, such as aryl, (C3-C8)cycloalkyl, (C3-C7)heterocycloalkyl or heteroaryl, having 5 to 11 ring atoms in which at least one ring atom is a heteroatom (e.g. N, S or O).
  • The expression “aryl” refers to mono or bi-ring systems which have 6 to 10 ring atoms, wherein at least one ring is aromatic.
  • The expression “heteroaryl” refers to mono or bi-ring systems with 5 to 11 ring atoms, in which at least one ring is aromatic and in which at least one ring atom is a heteroatom (e.g. N, NH, S or O).
  • Examples of suitable aryl or 5 or 6-membered heteroaryl monocyclic systems include, for instance, phenyl, thiophene (thiophenyl), benzene (phenyl), pyrrole (pyrrolyl), pyrazole (pyrazolyl), imidazole (imidazolyl), isoxazole (isoxazolyl), oxazole (oxazolyl), isothiazole (isothiazolyl), thiazole (thiazolyl), pyridine (pyridinyl), imidazolidine (imidazolidinyl), furan (furanyl) radicals and the like.
  • Examples of suitable aryl or heteroaryl bicyclic systems include naphthalene (naphthyl), biphenylene (biphenylenyl), purine (purinyl), pteridine (pteridinyl), benzotriazole (benzotriazolyl), quinoline (quinolinyl), isoquinoline (isoquinolinyl), indole (indolyl), isoindole (isoindolyl), benzothiophene (benzothiophenyl), dihydrobenzo dioxin, dihydrobenzo dioxepin, benzo oxazin radicals and the like.
  • Thus, the present invention is directed to a class of compounds acting as inhibitors of the phosphodiesterase 4 (PDE4) enzyme. Said class of compounds inhibits the conversion of cyclic nucleotides, in particular cyclic adenosine monophosphate (cAMP), into their inactive 5′-mononucleotide forms.
  • In the airways, the physiological responses to elevated intracellular levels of cyclic nucleotides, in particular of cAMP, lead to the suppression of the activity of immune and pro-inflammatory cells such as mast cells, macrophages, T lymphocytes, eosinophils and neutrophils, resulting in a decrease of the release of inflammatory mediators which include cytokines such as IL-1, IL-3 and tumor necrosis factor-alpha (TNF-α). It also leads to an airway smooth muscle relaxation and a decrease in oedema.
  • The present invention relates to derivatives of 1-phenyl-2-pyridinyl alkyl alcohols of general formula (I), N-oxides on the pyridine ring and pharmaceutically acceptable salts or solvates thereof:
  • Figure US20130005716A1-20130103-C00012
  • wherein R1, R2, R3, R19, Z, A and K are as above defined.
  • It will be apparent to those skilled in the art that compounds of general formula (I) contain at least one stereogenic center, namely represented by the carbon atom (1) with an asterisk below, and therefore exist as optical stereoisomers.
  • Figure US20130005716A1-20130103-C00013
  • When the compounds according to the invention have at least one stereogenic center, they may accordingly exist as enantiomers. When the compounds according to the invention possess two or more stereogenic centers, they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present invention.
  • In a preferred embodiment, the present invention is directed to compounds of formula (I)′, which are compounds of formula (I) as above defined where the absolute configuration of carbon (1) is that shown below:
  • Figure US20130005716A1-20130103-C00014
  • The absolute configuration for carbon (1) is assigned on the basis of Cahn-Ingold-Prelog nomenclature based on groups' priorities.
  • In one preferred embodiment, for compounds of formula (I), the absolute configuration at carbon (1) is (S).
  • When the compounds of formula (I) possess a second stereogenic center, namely at carbon (2) represented by another asterisk herebelow, they exist as at least four diastereoisomers:
  • Figure US20130005716A1-20130103-C00015
  • The four diastereoisomers thereof are represented below:
  • Figure US20130005716A1-20130103-C00016
  • and are comprised within the scope of the present invention.
  • In a preferred embodiment, the present invention is directed to compounds of formula (I)″, which are compounds of formula (I)′ as above defined where the absolute configuration of carbon (2) is that shown below:
  • Figure US20130005716A1-20130103-C00017
  • In another preferred embodiment, the present invention is directed to compounds of formula (I)′″, which are compounds of formula (I)′ as above defined where the absolute configuration of carbon (2) is that shown below:
  • Figure US20130005716A1-20130103-C00018
  • For compounds of formula (I)″ and (I)′″, the absolute configuration of carbon (1) and (2) is assigned on the basis of Cahn-Ingold-Prelog nomenclature based on groups' priorities.
  • It is to be understood that all preferred groups or embodiments described herebelow and hereabove for compounds of formula (I) may be combined among each other and apply to compounds of formula (IG), (IL), (I)′, (I)″, (I)′″, (I)″″ and (I)′″″ as well mutatis mutandis.
  • In a preferred embodiment, the invention provides compounds of formula (IH), which are N-oxides derivatives of the pyridine ring of compounds of formula (I), or pharmaceutically acceptable salts thereof:
  • Figure US20130005716A1-20130103-C00019
  • In a preferred embodiment, 2-pyridinyl ring has two R3 substituents which are halogen atom. In a further preferred embodiment, such R3 substituents are two chlorine atoms at positions 3 and 5 of the pyridine ring.
  • In one preferred embodiment, R1 is (C1-C6)haloalkyl or (C1-C6)alkyl.
  • In one preferred embodiment, R2 is (C1-C6)alkyl which optionally is substituted by (C3-C7)cycloalkyl or is a (C3-C7)cycloalkyl.
  • In another preferred embodiment, R1 and R2, together with the interconnecting atoms, form a 2,2-difluoro-1,3-dioxolane ring of formula (q) fused to the phenyl moiety which bears groups OR1 and —OR2, wherein asterisks indicate carbon atoms shared with such phenyl ring:
  • Figure US20130005716A1-20130103-C00020
  • In a further preferred embodiment, R1 is (C1-C6)haloalkyl and R2 is (C1-C6)alkyl which is substituted by (C3-C7)cycloalkyl.
  • In another preferred embodiment, R1 is (C1-C6)alkyl and R2 is (C1-C6)alkyl.
  • In a preferred embodiment, R19 is hydrogen.
  • In a further preferred embodiment, R19 is hydrogen, R1 is (C1-C6)haloalkyl and R2 is (C1-C6)alkyl which is substituted by (C3-C7)cycloalkyl.
  • In another preferred embodiment, R19, if different from hydrogen, forms together with R2 a group of formula (x) wherein bonds labeled with (1) and (2) indicate the points of attachment for group (x) to atoms bearing groups R19 and R2 respectively
  • Figure US20130005716A1-20130103-C00021
  • in such a way that R2 and R19 together with the interconnecting atoms form a ring of formula (w) which is fused to phenyl ring which bears groups —OR2 and R19, wherein asterisks indicate carbon atoms shared with such phenyl ring:
  • Figure US20130005716A1-20130103-C00022
  • A preferred group of compounds of general formula (I) is that wherein the 2-pyridinyl ring is substituted in positions 3 and 5 with two atoms of chlorine, according to the general formula (IA):
  • Figure US20130005716A1-20130103-C00023
  • wherein R1, R2, R19, K, z, and A are as defined above for compounds of formula (I); and the corresponding N-oxide on the pyridine ring, or pharmaceutically acceptable salts thereof.
  • Another preferred group of compounds of formula (I) is that shown below according to general formula (IB):
  • Figure US20130005716A1-20130103-C00024
  • wherein R3, K, Z and A are as defined above for compounds of formula (I); and the corresponding N-oxide on the pyridine ring, or pharmaceutically acceptable salts thereof.
  • A further preferred group of compounds of formula (I) is that shown below according to general formula (IC):
  • Figure US20130005716A1-20130103-C00025
  • wherein K, Z and A are as defined above for compounds of formula (I); and the corresponding N-oxide on the pyridine ring, or pharmaceutically acceptable salts thereof.
  • In one preferred embodiment, A is a (C3-C7)heterocycloalkyl-ene group comprising a nitrogen atom which represents the connecting point to group K as below represented:
  • Figure US20130005716A1-20130103-C00026
  • In another preferred embodiment, A is selected in the list of di-radicals below reported:
  • Figure US20130005716A1-20130103-C00027
  • wherein the symbols [3] and [4] indicate the points of connection for group A with, respectively, groups Z and K.
  • In a further preferred embodiment, A is selected in the list of di-radicals below reported:
  • Figure US20130005716A1-20130103-C00028
  • wherein the symbols [3] and [4] indicate the points of connection for group A with, respectively, groups Z and K.
  • In an additional preferred embodiment, A is a group
  • Figure US20130005716A1-20130103-C00029
  • wherein the symbols [3] and [4] indicate the points of connection for group A with, respectively, groups Z and K.
  • In a preferred embodiment, Z is a group —(CH2)n— in which n is zero.
  • Another preferred group of compounds of formula (I) is that shown below according to general formula (ID):
  • Figure US20130005716A1-20130103-C00030
  • wherein R1, R2, R3 and K are as defined above for compounds of formula (I), R19 is hydrogen, Z is a bond (i.e., n is zero), and A is a thiazolidine divalent radical group as above represented; and the corresponding N-oxide on the pyridine ring, or pharmaceutically acceptable salts thereof.
  • Another preferred group of compounds of formula (I) is that shown below according to general formula (ID′″):
  • Figure US20130005716A1-20130103-C00031
  • wherein R1, R2, R3 and K are as defined above for compounds of formula (I), R19 is hydrogen, Z is a bond (i.e. n is zero), A is a thiazolidine divalent radical group and stereogenic center have absolute configuration as above represented; and the corresponding N-oxide on the pyridine ring, or pharmaceutically acceptable salts thereof.
  • In one embodiment, for compounds of formula (ID) or (ID′″), R1 is (C1-C6) haloalkyl, R2 is (C1-C6)alkyl which is substituted by (C3-C7)cycloalkyl, 2-pyridinyl ring is substituted in positions 3 and 5 with two chlorine R3 groups, and K is a group
  • Figure US20130005716A1-20130103-C00032
  • Another preferred group of compounds of formula (I) is that shown below according to general formula (IE):
  • Figure US20130005716A1-20130103-C00033
  • wherein R1, R2, R3 and K are as defined above for compounds of formula (I), Z is a bond (i.e. n is zero), R19 is hydrogen and A is a pyrrolidine divalent radical group as above represented; and the corresponding N-oxide on the pyridine ring, or pharmaceutically acceptable salts thereof.
  • Another preferred group of compounds of formula (I) is that shown below according to general formula (IE′″):
  • Figure US20130005716A1-20130103-C00034
  • wherein R1, R2, R3 and K are as defined above for compounds of formula (I), Z is a bond (i.e. n is zero), R19 is hydrogen, A is a pyrrolidine divalent radical group, and the stereogenic centers have the absolute configuration as above represented; and the corresponding N-oxide on the pyridine ring, or pharmaceutically acceptable salts thereof.
  • In one embodiment, for compounds of formula (IE) or (IE′″), R1 is (C1-C6)haloalkyl, R2 is (C1-C6)alkyl which is substituted by (C3-C7)cycloalkyl, 2-pyridinyl ring is substituted in 3 and 5 with two chlorine R3 groups, and K is a group
  • Figure US20130005716A1-20130103-C00035
  • In one preferred embodiment, K is selected in the list of groups below reported:
  • Figure US20130005716A1-20130103-C00036
  • wherein the symbol [5] indicates the point of connection for group K with group A.
  • In another preferred embodiment, K is selected in the list of groups below reported:
  • Figure US20130005716A1-20130103-C00037
  • wherein the symbol [5] indicates the point of connection for group K with group A.
  • In yet another preferred embodiment, K is selected in the list of groups below reported:
  • Figure US20130005716A1-20130103-C00038
  • wherein the symbol [5] indicates the point of connection for group K with group A.
  • In further preferred embodiment, K is a group
  • Figure US20130005716A1-20130103-C00039
  • wherein the symbol [5] indicates the point of connection for group K with group A.
  • In a preferred embodiment, R4 is selected in the group consisting of: a group phenyl, a 5 or 6-membered heteroaryl group, a monocyclic (C3-C7)heterocycloalkyl and a bicyclic ring system; and each of which is optionally substituted by one or more groups R5.
  • In one preferred embodiment, R4 is a group phenyl or a 5 or 6-membered heteroaryl group, each of which is optionally substituted by one or more groups R5.
  • In a further preferred embodiment, R4 is a group phenyl which is optionally substituted by one or more groups R5.
  • In a still preferred embodiment, R4 is a 5 or 6-membered heteroaryl group which is optionally substituted by one or more groups R5.
  • In another preferred embodiment, R4 is a monocyclic (C3-C7)heterocycloalkyl optionally substituted by one or more groups R5.
  • In a still preferred embodiment, R4 is a bicyclic ring system optionally substituted by one or more groups R5.
  • In one preferred embodiment, the number of substituents R5 is zero, 1, or 2. In a further preferred embodiment, such number is 1.
  • In one preferred embodiment, R5 is independently selected in the group consisting of:
      • —(C1-C6)alkyl optionally substituted by one or more groups independently selected in the list consisting of: (C3-C7)cycloalkyl, —OH and a group —NR18C(O)(C1-C4)alkyl, wherein R18 is hydrogen or (C1-C4)alkyl-(C3-C7)heterocycloalkyl;
      • 5 or 6-membered heteroaryl which is optionally substituted by one or two groups (C1-C4)alkyl;
      • (C1-C6)haloalkyl;
      • (C3-C7)heterocycloalkyl(C1-C4)alkyl;
      • a group —OR6 wherein R6 is selected from the group consisting of:
        • (C1-C6)haloalkyl;
        • (C1-C10)alkyl optionally substituted by one or more (C3-C7)cycloalkyl;
      • a group —SO2R7, wherein R7 is (C1-C4)alkyl;
      • halogen atoms;
      • cyano;
      • NR8R9 wherein R8 and R9 are different or the same and are independently selected from the group consisting of:
        • H;
        • (C1-C6)alkyl, optionally substituted with (C3-C7)cycloalkyl, (C3-C7)heterocycloalkyl;
        • a group —SO2R15, wherein R15 is (C1-C4)alkyl;
        • or they form with the nitrogen atom to which they are linked a saturated or partially saturated heterocyclic ring, which is optionally substituted by one or more (C1-C6)alkyl or oxo groups;
      • (C1-C4)alkylene-NR8R9;
      • COR10 wherein R10 is phenyl or (C1-C6)alkyl;
      • oxo;
      • —SO2R11 wherein R11 is NR8R9 wherein R8 and R9 are as defined above;
      • —COOR12 wherein R12 is H or (C1-C4)alkyl or (C1-C4)alkylene-NR8R9 wherein R8 and R9 are as defined above; and
      • —CONR8R9 wherein R8 and R9 are as defined above.
  • In another preferred embodiment, R5 is independently selected in the group consisting of:
      • (C1-C6)alkyl;
      • (C3-C7)heterocycloalkyl;
      • (C3-C7)heterocycloalkyl(C1-C4)alkyl;
      • a group —OR6 wherein R6 is selected from the group consisting of:
        • (C1-C6)haloalkyl;
        • —(C1-C10)alkyl optionally substituted by one or more (C3-C7)cycloalkyl;
      • a group —SO2R7, wherein R7 is (C1-C4)alkyl;
      • halogen atoms;
      • NR8R9 wherein R8 and R9 are different or the same and are independently selected from the group consisting of:
        • H;
        • (C1-C6)alkyl, optionally substituted with (C3-C7)cycloalkyl, (C3-C7)heterocycloalkyl;
        • a group —SO2R15, wherein R15 is (C1-C4)alkyl;
        • or they form with the nitrogen atom to which they are linked a saturated or partially saturated heterocyclic ring, which is optionally substituted by one or more (C1-C6)alkyl or oxo groups;
      • —(C1-C4)alkylene-NR8R9;
      • COR10 wherein R10 is phenyl or (C1-C6)alkyl;
      • oxo;
      • —SO2R11 wherein R11 is NR8R9 wherein R8 and R9 are as defined above;
      • —COOR12 wherein R12 is H or (C1-C4)alkyl or (C1-C4)alkylene-NR8R9 wherein
      • R8 and R9 are as defined above; and
      • —CONR8R9 wherein R8 and R9 are as defined above.
  • In another preferred embodiment, R5 is independently selected in the group consisting of:
      • (C1-C6)alkyl;
      • —(C3-C7)heterocycloalkyl(C1-C4)alkyl;
      • a group —OR6 wherein R6 is (C1-C10)alkyl optionally substituted by one or more (C3-C7)cycloalkyl;
      • halogen atoms;
      • NR8R9 wherein R8 and R9 are different or the same and are independently selected from the group consisting of:
        • H;
        • —(C1-C6)alkyl, optionally substituted with (C3-C7)cycloalkyl, (C3-C7)heterocycloalkyl;
        • a group —SO2R15, wherein R15 is (C1-C4)alkyl; or they form with the nitrogen atom to which they are linked a saturated or partially saturated heterocyclic ring, which is optionally substituted by (C1-C6)alkyl or oxo;
      • —COOR12 wherein R12 is H or (C1-C4)alkyl or (C1-C4)alkylene-NR8R9 wherein R8 and R9 are as defined above; and
      • —CONR8R9 wherein R8 and R9 are as defined above.
  • In a further preferred embodiment, R5 is selected in the group consisting of:
      • —(C1-C6)alkyl;
      • —NR8R9 wherein R8 and R9 are different or the same and are independently selected from the group consisting of:
        • H;
        • —(C1-C6)alkyl; and
      • CONR8R9 wherein R8 and R9 are as defined above.
  • A further preferred group of compounds of formula (I) is that shown below according to general formula (IF):
  • Figure US20130005716A1-20130103-C00040
  • wherein Z is a bond, R19 is hydrogen, A is a (C3-C7)heterocycloalkyl-ene group comprising a nitrogen atom which represents the connecting point to group K, K is selected in the list of groups consisting of:
  • Figure US20130005716A1-20130103-C00041
  • R4 is a group phenyl or a 5 or 6-membered heteroaryl group, each of which is optionally substituted by one or more groups R5: and the corresponding N-oxide on the pyridine ring, or pharmaceutically acceptable salts thereof.
  • According to a preferred embodiment, the present invention provides the compounds reported below:
  • Compound Chemical Name
    19 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(3-(cyclopropylmethoxy)-4-
    (methylsulfonamido)benzoyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    30 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(4-methoxy-3-
    (methylsulfonyloxy)benzoyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    53 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(3,4-
    dimethoxyphenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    135 4-((2S)-2-(3-(4-aminophenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-
    (cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-
    dichloropyridine 1-oxide
    142 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(4-
    (methylsulfonamido)phenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    143 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(4-(N-(2-
    morpholinoethyl)methylsulfonamido)phenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    151 4-((S)-2-((R)-3-(4-aminophenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-
    (cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-
    dichloropyridine 1-oxide
    150 4-((S)-2-((S)-3-(4-aminophenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-
    (cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-
    dichloropyridine 1-oxide
    136 4-((S)-2-((S)-1-(4-aminophenylsulfonyl)pyrrolidine-2-carbonyloxy)-2-(3-
    (cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-
    dichloropyridine 1-oxide
    15 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(1-((4-(methoxycarbonyl)-5-methylfuran-2-
    yl)methyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    124 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(3-(dimethylcarbamoyl)-4-
    methoxyphenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    77 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((R)-4-(3-
    sulfamoylphenylsulfonyl)morpholine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    or
    3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-4-(3-
    sulfamoylphenylsulfonyl)morpholine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    144 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(2-oxo-2-(thiophen-2-yl)ethyl)thiazolidine-
    2-carbonyloxy)ethyl)pyridine 1-oxide
    16 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(4-
    (dimethylcarbamoyl)benzyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    or
    3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((R)-3-(4-
    (dimethylcarbamoyl)benzyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    17 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(4-
    (dimethylcarbamoyl)benzyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    or
    3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((R)-3-(4-
    (dimethylcarbamoyl)benzyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    26 4-((2S)-2-(3-(4-aminobenzoyl)thiazolidine-2-carbonyloxy)-2-(3-
    (cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-
    dichloropyridine 1-oxide
    56 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(3-
    (dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    80 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(4-(3-
    (dimethylcarbamoyl)phenylsulfonyl)thiomorpholine-3-
    carbonyloxy)ethyl)pyridine 1-oxide
    81 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(4-(4-(N-
    methylsulfamoyl)phenylsulfonyl)thiomorpholine-3-
    carbonyloxy)ethyl)pyridine 1-oxide
    137 4-((2S)-2-(3-(3-amino-4-methoxyphenylsulfonyl)thiazolidine-2-
    carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide
    57 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(phenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    138 4-((S)-2-((R)-3-(4-aminophenylsulfonyl)thiazolidine-4-carbonyloxy)-2-(3-
    (cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-
    dichloropyridine 1-oxide
    139 4-((2S)-2-(4-(4-aminophenylsulfonyl)morpholine-2-carbonyloxy)-2-(3-
    (cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-
    dichloropyridine 1-oxide
    54 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(3-
    (dimethylcarbamoyl)phenylsulfonyl)pyrrolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    78 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(4-(3-
    (dimethylcarbamoyl)phenylsulfonyl)morpholine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    84 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((R)-3-(3-
    (dimethylcarbamoyl)phenylsulfonyl)thiazolidine-4-
    carbonyloxy)ethyl)pyridine 1-oxide
    58 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(1,3-dioxoisoindolin-5-
    ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    125 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(4-
    (dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    55 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((R)-1-(3-
    (dimethylcarbamoyl)phenylsulfonyl)pyrrolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    59 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(3-sulfamoylphenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    122 4-((2S)-2-(3-(3-carboxy-4-methoxyphenylsulfonyl)thiazolidine-2-
    carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide
    60 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(3-fluorophenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    61 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(2,4-dimethylphenylsulfonyl)thiazolidine-
    2-carbonyloxy)ethyl)pyridine 1-oxide
    62 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(thiophen-2-ylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    123 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(3-(dimethylcarbamoyl)-4-
    methoxyphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    121 (S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(2-(4-(3-
    (dimethylcarbamoyl)phenylsulfonyl)piperazin-1-yl)acetoxy)ethyl)pyridine
    1-oxide
    126 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(4-(4-methylpiperazine-1-
    carbonyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    63 3,5-dichloro-4-((2S)-2-(3-(3-chlorophenylsulfonyl)thiazolidine-2-
    carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)ethyl)pyridine 1-oxide
    64 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(1-methyl-1H-imidazol-2-
    ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    65 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(cyclopropylmethylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    66 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(pyridin-3-ylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    67 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(2,4-difluorophenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    68 3,5-dichloro-4-((2S)-2-(3-(2-chloro-4-fluorophenylsulfonyl)thiazolidine-2-
    carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)ethyl)pyridine 1-oxide
    69 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(4-fluoro-2-
    methylphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    70 3,5-dichloro-4-((2S)-2-(3-(2-chlorophenylsulfonyl)thiazolidine-2-
    carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)ethyl)pyridine 1-oxide
    71 3,5-dichloro-4-((2S)-2-(3-(cyclohexylsulfonyl)thiazolidine-2-
    carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)ethyl)pyridine 1-oxide
    72 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-
    ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    85 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(thiophen-3-ylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    52 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(3-
    (dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    82 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(3-
    (dimethylcarbamoyl)phenylsulfonyl)piperidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    83 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((R)-1-(3-
    (dimethylcarbamoyl)phenylsulfonyl)piperidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    49 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(3-(cyclopropylmethoxy)-5-(N-(2-
    morpholinoethyl)methylsulfonamido)benzoyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    73 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(3,4-
    dimethoxyphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    141 (S)-4-(2-(2-(4-(4-aminophenylsulfonyl)piperazin-1-yl)acetoxy)-2-(3-
    (cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-
    dichloropyridine 1-oxide
    129 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(3-(dimethylcarbamoyl)-4-
    methoxyphenylsulfonyl)piperidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    74 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(6-morpholinopyridin-3-
    ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    127 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(4-methoxy-3-(4-methylpiperazine-1-
    carbonyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    128 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(4-methoxy-3-(morpholine-4-
    carbonyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    31 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(4-methoxy-3-
    (morpholinomethyl)benzoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    or
    3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((R)-3-(4-methoxy-3-
    (morpholinomethyl)benzoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    32 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(3-(N,N-dimethylsulfamoyl)-4-
    methoxybenzoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    75 4-((S)-2-((S)-3-(3-carboxyphenylsulfonyl)thiazolidine-2-carbonyloxy)-2-
    (3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-
    dichloropyridine 1-oxide
    or
    4-((S)-2-((R)-3-(3-carboxyphenylsulfonyl)thiazolidine-2-carbonyloxy)-2-
    (3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-
    dichloropyridine 1-oxide
    33 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(4-
    (morpholinomethyl)benzoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    79 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(4-(phenylsulfonyl)morpholine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    76 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(3,5-dimethylisoxazol-4-
    ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    38 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(thiazole-5-carbonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    34 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(3-
    ((dimethylamino)methyl)benzoyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    35 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(oxazole-5-carbonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    130 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(3-(4-methylpiperazine-1-
    carbonyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    155 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(1-methyl-1H-imidazol-2-
    ylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    86 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(phenylsulfonyl)pyrrolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    87 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(5-(methoxycarbonyl)thiophen-2-
    ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    88 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(pyridin-3-ylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    131 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(3-(dimethylcarbamoyl)-4-
    methoxyphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    89 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(phenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    90 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(1-methyl-1H-imidazol-2-
    ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    91 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(3-
    sulfamoylphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    92 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(4-
    (methylsulfonyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine
    1-oxide
    93 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(3,4-
    dimethoxyphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    51 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(5-((dimethylamino)methyl)thiophene-2-
    carbonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    22 4-((2S)-2-(3-(4-(2-aminoethyl)benzoyl)thiazolidine-2-carbonyloxy)-2-(3-
    (cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-
    dichloropyridine 1-oxide
    94 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(4-(N-
    methylsulfamoyl)phenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    95 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(furan-2-ylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    96 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(furan-3-ylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    97 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(3-(N,N-
    dimethylsulfamoyl)phenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    98 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(3,4-
    dimethoxyphenylsulfonyl)piperidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    99 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(pyridin-3-ylsulfonyl)piperidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    100 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(4-
    (methoxycarbonyl)phenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    101 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(2-
    (methoxycarbonyl)phenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    102 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(3-
    (dimethylcarbamoyl)phenylsulfonyl)thiazolidine-4-
    carbonyloxy)ethyl)pyridine 1-oxide
    103 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(3-
    methoxyphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    104 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(3-
    (trifluoromethoxy)phenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    36 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(4-(1,1-
    dioxothiomorpholinobenzoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    37 4-((S)-2-((S)-3-(4-carbamoylbenzoyl)thiazolidine-2-carbonyloxy)-2-(3-
    (cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-
    dichloropyridine 1-oxide
    105 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(6-morpholinopyridin-3-
    ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    20 4-((S)-2-((S)-3-(4-(aminomethyl)picolinoyl)thiazolidine-2-carbonyloxy)-2-
    (3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-
    dichloropyridine 1-oxide
    or
    4-((S)-2-((R)-3-(4-(aminomethyl)picolinoyl)thiazolidine-2-carbonyloxy)-
    2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-
    dichloropyridine 1-oxide
    106 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(2-methoxy-4-
    methylphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    107 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(2,4-dimethylthiazol-5-
    ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    108 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(4-methyl-3,4-dihydro-2H-
    benzo[b][1,4]oxazin-6-ylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    42 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-picolinoylthiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    133 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(3-((2-
    morpholinoethoxy)carbonyl)phenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    or
    3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((R)-3-(3-((2-
    morpholinoethoxy)carbonyl)phenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    110 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(4-
    methoxyphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    111 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(6-morpholinopyridin-3-
    ylsulfonyl)piperidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    112 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(4-nitrophenylsulfonyl)piperidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    113 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(3-(N,N-
    dimethylsulfamoyl)phenylsulfonyl)piperidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    114 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(phenylsulfonyl)piperidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    115 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(2,5-
    dimethoxyphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    116 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(1-methyl-1H-imidazol-2-
    ylsulfonyl)piperidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    117 4-((S)-2-((S)-3-(3-acetylphenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-
    (cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-
    dichloropyridine 1-oxide
    39 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(4-
    (morpholinomethyl)benzoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    40 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(4-(1,1-dioxo
    thiomorpholinomethyl)benzoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine
    1-oxide
    21 4-((S)-2-((S)-3-(3-(aminomethyl)benzoyl)thiazolidine-2-carbonyloxy)-2-
    (3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-
    dichloropyridine 1-oxide
    41 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(3-(oxazol-5-yl)benzoyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    140 4-((S)-2-((S)-3-(3-aminophenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-
    (cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-
    dichloropyridine 1-oxide
    109 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(4-
    (methylsulfonyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine
    1-oxide
    132 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(3-(4-methylpiperazine-1-
    carbonyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    118 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(3-(3-(N-
    methylsulfamoyl)phenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    119 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(1-methyl-1H-imidazol-4-
    ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    188 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(2-phenylacetyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    189 3,5-dichloro-4-((S)-2-((S)-3-(2-cyclopropylacetyl)thiazolidine-2-
    carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)ethyl)pyridine 1-oxide
    190 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(3-
    (phenylsulfonyl)propanoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    191 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(3-morpholinopropanoyl)thiazolidine-
    2-carbonyloxy)ethyl)pyridine 1-oxide
    192 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(3-(4-methylpiperazin-1-
    yl)propanoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    193 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(3-
    (dimethylcarbamoyl)benzoyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    194 4-((S)-2-(2-((S)-1-benzoylpyrrolidin-2-yl)acetoxy)-2-(3-
    (cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-
    dichloropyridine 1-oxide
    195 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(2-((S)-1-(3-
    (dimethylcarbamoyl)benzoyl)pyrrolidin-2-yl)acetoxy)ethyl)pyridine 1-
    oxide
    198 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(2-(3-
    (dimethylcarbamoyl)phenyl)acetyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    199 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(2-(3-
    (dimethylcarbamoyl)phenyl)acetyl)pyrrolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    200 3,5-dichloro-4-((S)-2-((S)-3-(2-cyanophenylsulfonyl)thiazolidine-2-
    carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)ethyl)pyridine 1-oxide
    201 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(2,3-dihydrobenzo[b][1,4]dioxin-6-
    ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    202 3,5-dichloro-4-((S)-2-((S)-3-(2-cyano-5-
    methylphenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-
    (cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)pyridine 1-oxide
    203 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(2,5-dimethylthiophen-3-
    ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    204 4-((S)-2-((S)-3-(4-bromo-2-fluoro-5-methylphenylsulfonyl)thiazolidine-2-
    carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide
    205 4-((S)-2-((S)-3-(3-bromo-4-methylphenylsulfonyl)thiazolidine-2-
    carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide
    206 3,5-dichloro-4-((S)-2-((S)-3-(4-cyanophenylsulfonyl)thiazolidine-2-
    carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)ethyl)pyridine 1-oxide
    207 3,5-dichloro-4-((S)-2-((S)-3-(3-cyanophenylsulfonyl)thiazolidine-2-
    carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)ethyl)pyridine 1-oxide
    208 4-((S)-2-((S)-3-(4-(1H-pyrazol-1-yl)phenylsulfonyl)thiazolidine-2-
    carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide
    209 3,5-dichloro-4-((S)-2-((S)-3-(3-cyano-4-fluorophenylsulfonyl)thiazolidine-
    2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)ethyl)pyridine 1-oxide
    210 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(1-methyl-2-oxoindolin-5-
    ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    211 3,5-dichloro-4-((S)-2-((S)-3-(2-chloro-5-cyanophenylsulfonyl)thiazolidine-
    2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)ethyl)pyridine 1-oxide
    212 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(5-methylbenzo[b]thiophen-2-
    ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    213 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(4-(1-methyl-1H-pyrazol-3-
    yl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    214 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(4-
    (difluoromethoxy)phenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    215 3,5-dichloro-4-((S)-2-((S)-3-(4-chloro-2-
    (trifluoromethyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-
    (cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)pyridine 1-oxide
    216 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(5-fluoro-2-
    methoxyphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    217 4-((S)-2-((S)-3-(benzo[b]thiophen-2-ylsulfonyl)thiazolidine-2-
    carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide
    218 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(2-oxo-2,3-dihydrobenzo[d]oxazol-6-
    ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    219 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(4-(2-oxopyrrolidin-1-
    yl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    220 4-((S)-2-((S)-3-(1-acetyl-1,2,3,4-tetrahydroquinolin-6-
    ylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide
    221 4-((S)-2-((S)-3-(4-(2-acetamidoethyl)phenylsulfonyl)thiazolidine-2-
    carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide
    222 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(4-(2,2,2-
    trifluoroethoxy)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine
    1-oxide
    223 4-(2-((S)-3-(benzylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-
    (cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-
    dichloropyridine 1-oxide
    224 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(phenethylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    225 4-((S)-2-((S)-1-(benzylsulfonyl)pyrrolidine-2-carbonyloxy)-2-(3-
    (cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-
    dichloropyridine 1-oxide
    226 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(R)-3-(1-methyl-2-oxoindolin-5-
    ylsulfonyl)thiazolidine-4-carbonyloxy)ethyl)pyridine 1-oxide
    227 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(R)-1-(phenylsulfonyl)piperidine-3-
    carbonyloxy)ethyl)pyridine 1-oxide
    228 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(R)-1-(3-
    (dimethylcarbamoyl)phenylsulfonyl)piperidine-3-
    carbonyloxy)ethyl)pyridine 1-oxide
    229 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(phenylsulfonyl)piperidine-3-
    carbonyloxy)ethyl)pyridine 1-oxide
    230 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(3-
    (dimethylcarbamoyl)phenylsulfonyl)piperidine-3-
    carbonyloxy)ethyl)pyridine 1-oxide
    231 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(R)-4-(phenylsulfonyl)morpholine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    232 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(R)-4-(3-
    (dimethylcarbamoyl)phenylsulfonyl)morpholine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    233 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-4-(phenylsulfonyl)morpholine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    234 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-4-(3-
    (dimethylcarbamoyl)phenylsulfonyl)morpholine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    235 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(2-((S)-1-(phenylsulfonyl)pyrrolidin-2-
    yl)acetoxy)ethyl)pyridine 1-oxide
    236 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(2-((S)-1-(3-
    (dimethylcarbamoyl)phenylsulfonyl)pyrrolidin-2-yl)acetoxy)ethyl)pyridine
    1-oxide
    237 4-((S)-2-(2-((S)-1-(benzylsulfonyl)pyrrolidin-2-yl)acetoxy)-2-(3-
    (cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-
    dichloropyridine 1-oxide
    255 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(2-oxo-2-phenylethyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    256 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(2-oxo-2-phenylethyl)pyrrolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    257 4-((S)-2-((S)-1-benzylpyrrolidine-2-carbonyloxy)-2-(3-
    (cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-
    dichloropyridine 1-oxide
    258 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(3-
    (dimethylcarbamoyl)benzyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    261 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(2-(3-(dimethylcarbamoyl)phenyl)-2-
    oxoethyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    262 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(2-(3-(dimethylcarbamoyl)phenyl)-2-
    oxoethyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    264 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(cyclopropylmethyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    265 4-((S)-2-((S)-3-benzylthiazolidine-2-carbonyloxy)-2-(3-
    (cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-
    dichloropyridine 1-oxide
    266 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(3-
    (dimethylcarbamoyl)benzyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    267 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-phenethylthiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    268 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(2-((S)-1-(3-
    (dimethylcarbamoyl)benzyl)pyrrolidin-2-yl)acetoxy)ethyl)pyridine 1-oxide
    269 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(3-ureidophenylsulfonyl)thiazolidine-
    2-carbonyloxy)ethyl)pyridine 1-oxide
    271 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(3-
    (hydroxymethyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine
    1-oxide
    274 4-((2S)-2-(2-(3-benzoylthiazolidin-2-yl)acetoxy)-2-(3-
    (cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-
    dichloropyridine 1-oxide
    275 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(2-(3-(3-
    (dimethylcarbamoyl)benzoyl)thiazolidin-2-yl)acetoxy)ethyl)pyridine 1-
    oxide
    278 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(2-(3-(phenylsulfonyl)thiazolidin-2-
    yl)acetoxy)ethyl)pyridine 1-oxide
    279 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(2-(3-(3-
    (dimethylcarbamoyl)phenylsulfonyl)thiazolidin-2-
    yl)acetoxy)ethyl)pyridine 1-oxide
    281 (S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(1-(3-
    (dimethylcarbamoyl)phenylsulfonyl)azetidine-3-
    carbonyloxy)ethyl)pyridine 1-oxide
    282 (S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-(1-(phenylsulfonyl)azetidine-3-
    carbonyloxy)ethyl)pyridine 1-oxide
    283 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(3-
    (dimethylcarbamoyl)phenylsulfonyl)azetidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    284 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(phenylsulfonyl)azetidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    285 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(1-methyl-2-oxoindolin-5-
    ylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    287 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(2-
    morpholinoethylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    288 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(2-(4-methylpiperazin-1-
    yl)ethylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    291 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(2-(phenylsulfonyl)ethyl)pyrrolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    292 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(2-phenylacetyl)pyrrolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    295 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(3-
    (dimethylcarbamoyl)benzylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    296 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(3-
    (dimethylcarbamoyl)benzylsulfonyl)pyrrolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    299 3,5-dichloro-4-((S)-2-(4-(difluoromethoxy)-3-methoxyphenyl)-2-((S)-3-(3-
    (dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    300 3,5-dichloro-4-((S)-2-(4-(difluoromethoxy)-3-methoxyphenyl)-2-((S)-3-
    (phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    301 3,5-dichloro-4-((S)-2-(3-(cyclopentyloxy)-4-(difluoromethoxy)phenyl)-2-
    ((S)-3-(phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    302 3,5-dichloro-4-((S)-2-(3-(cyclopentyloxy)-4-(difluoromethoxy)phenyl)-2-
    ((S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    303 3,5-dichloro-4-((S)-2-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-2-((S)-3-(3-
    (dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide OR 3,5-dichloro-4-((R)-2-(2,2-
    difluorobenzo[d][1,3]dioxol-5-yl)-2-((S)-3-(3-
    (dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    305 3,5-dichloro-4-((S)-2-(4-(difluoromethoxy)-3-methoxyphenyl)-2-((S)-1-
    (phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    306 3,5-dichloro-4-((S)-2-(4-(difluoromethoxy)-3-methoxyphenyl)-2-((S)-1-(3-
    (dimethylcarbamoyl)phenylsulfonyl)pyrrolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    307 3,5-dichloro-4-((S)-2-(3-(cyclopentyloxy)-4-(difluoromethoxy)phenyl)-2-
    ((S)-1-(phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    308 3,5-dichloro-4-((S)-2-(3-(cyclopentyloxy)-4-(difluoromethoxy)phenyl)-2-
    ((S)-1-(3-(dimethylcarbamoyl)phenylsulfonyl)pyrrolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    309 3,5-dichloro-4-((S)-2-(3,4-dimethoxyphenyl)-2-((S)-1-
    (phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    310 3,5-dichloro-4-((S)-2-(3,4-dimethoxyphenyl)-2-((S)-1-(3-
    (dimethylcarbamoyl)phenylsulfonyl)pyrrolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    311 3,5-dichloro-4-(2-(3-(cyclopentyloxy)-4-methoxyphenyl)-2-((S)-1-
    (phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    312 3,5-dichloro-4-(2-(3-(cyclopentyloxy)-4-methoxyphenyl)-2-((S)-1-(3-
    (dimethylcarbamoyl)phenylsulfonyl)pyrrolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    313 (S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-methoxyphenyl)-2-(1-
    (phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    314 (S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-methoxyphenyl)-2-(1-(3-
    (dimethylcarbamoyl)phenylsulfonyl)pyrrolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    315 3,5-dichloro-4-((S)-2-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-2-((S)-1-(3-
    (dimethylcarbamoyl)phenylsulfonyl)pyrrolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide OR 3,5-dichloro-4-((R)-2-(2,2-
    difluorobenzo[d][1,3]dioxol-5-yl)-2-((S)-1-(3-
    (dimethylcarbamoyl)phenylsulfonyl)pyrrolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    316 3,5-dichloro-4-(2-(4-methoxyspiro[benzo[d][1,3]dioxole-2,1′-
    cyclopentane]-7-yl)-2-((S)-1-(phenylsulfonyl)pyrrolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    317 3,5-dichloro-4-(2-((S)-1-(3-
    (dimethylcarbamoyl)phenylsulfonyl)pyrrolidine-2-carbonyloxy)-2-(4-
    methoxyspiro[benzo[d][1,3]dioxole-2,1′-cyclopentane]-7-yl)ethyl)pyridine
    1-oxide
    320 3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-methoxyphenyl)-2-((S)-3-(3-
    (dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    321 3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-methoxyphenyl)-2-((S)-3-
    (phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    322 3,5-dichloro-4-(2-(3-(cyclopentyloxy)-4-methoxyphenyl)-2-((S)-3-
    (phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    323 3,5-dichloro-4-(2-(3-(cyclopentyloxy)-4-methoxyphenyl)-2-((S)-3-(3-
    (dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    324 3,5-dichloro-4-((S)-2-(3,4-dimethoxyphenyl)-2-((S)-3-
    (phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    325 3,5-dichloro-4-((S)-2-(3,4-dimethoxyphenyl)-2-((S)-3-(3-
    (dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    326 3,5-dichloro-4-(2-(4-methoxyspiro[benzo[d][1,3]dioxole-2,1′-
    cyclopentane]-7-yl)-2-((S)-3-(phenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    327 3,5-dichloro-4-(2-((S)-3-(3-
    (dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(4-
    methoxyspiro[benzo[d][1,3]dioxole-2,1′-cyclopentane]-7-yl)ethyl)pyridine
    1-oxide
    238 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(3-(N,N-
    dimethylsulfamoyl)phenylsulfonyl)pyrrolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    239 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(3-methylisoxazolo[5,4-b]pyridin-5-
    ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    240 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(1,3-dimethyl-1H-pyrazolo[3,4-
    b]pyridin-5-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    241 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(1-methyl-5-(methylcarbamoyl)-1H-
    pyrrol-3-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    242 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(5-(pyrrolidine-1-carbonyl)-1H-pyrrol-
    3-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    243 (S)-((S)-1-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3,5-
    dichloropyridin-4-yl)ethyl) 3-(1-methyl-1H-imidazol-2-
    ylsulfonyl)thiazolidine-2-carboxylate
    328 4-((S)-2-((S)-3-(1H-1,2,4-triazol-5-ylsulfonyl)thiazolidine-2-carbonyloxy)-
    2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-
    dichloropyridine 1-oxide
    186 4-((S)-2-((S)-3-benzoylthiazolidine-2-carbonyloxy)-2-(3-
    (cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-
    dichloropyridine 1-oxide
    187 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(3-
    (dimethylcarbamoyl)benzoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    244 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((R)-1-(phenylsulfonyl)pyrrolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    184 4-((S)-2-((R)-1-benzoylpyrrolidine-2-carbonyloxy)-2-(3-
    (cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-
    dichloropyridine 1-oxide
    185 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((R)-1-(3-
    (dimethylcarbamoyl)benzoyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-
    oxide
    245 3,5-dichloro-4-((R)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((R)-1-(3-
    (dimethylcarbamoyl)phenylsulfonyl)pyrrolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    246 3,5-dichloro-4-((R)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(3-
    (dimethylcarbamoyl)phenylsulfonyl)pyrrolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    247 (S)-((S)-1-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3,5-
    dichloropyridin-4-yl)ethyl) 3-(3-
    (dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carboxylate
    248 3,5-dichloro-4-((R)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((R)-3-(3-
    (dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    249 3,5-dichloro-4-((R)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(3-
    (dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    263 3,5-dichloro-4-((S)-2-(4-(difluoromethoxy)-3-hydroxyphenyl)-2-((S)-3-(3-
    (dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    250 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(4-methyl-3,4-dihydro-2H-
    benzo[b][1,4]oxazin-6-ylsulfonyl)pyrrolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide
    251 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-1-(3-methylisoxazolo[5,4-b]pyridin-5-
    ylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide
    252 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((R)-3-(4-methyl-3,4-dihydro-2H-
    benzo[b][1,4]oxazin-6-ylsulfonyl)thiazolidine-4-
    carbonyloxy)ethyl)pyridine 1-oxide
    253 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((R)-3-(3-methylisoxazolo[5,4-b]pyridin-5-
    ylsulfonyl)thiazolidine-4-carbonyloxy)ethyl)pyridine 1-oxide
    254 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-
    (difluoromethoxy)phenyl)-2-((S)-3-(3-
    (methylcarbamoyl)phenylsulfonyl)thiazolidine-2-
    carbonyloxy)ethyl)pyridine 1-oxide

    or pharmaceutically acceptable salts or solvates thereof.
  • In another preferred embodiment, the compounds of the invention are selected in the group consisting of:
    • 4-((S)-2-((S)-3-(4-aminophenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
    • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(3-(dimethylcarbamoyl)phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
    • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((R)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-4-carbonyloxy)ethyl)pyridine 1-oxide;
    • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
    • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(3-(dimethylcarbamoyl)phenylsulfonyl)piperidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
    • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(3-(dimethylcarbamoyl)-4-methoxyphenylsulfonyl)piperidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
    • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(4-methylpiperazine-1-carbonyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
    • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(pyridin-3-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
    • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(dimethylcarbamoyl)-4-methoxyphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
    • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
    • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(1-methyl-1H-imidazol-2-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
    • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-sulfamoylphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
    • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(4-(methylsulfonyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
    • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3,4-dimethoxyphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
    • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(N,N-dimethylsulfamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
    • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(4-methoxyphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
    • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(5-(pyrrolidine-1-carbonyl)-1H-pyrrol-3-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
    • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(1-methyl-5-(methylcarbamoyl)-1H-pyrrol-3-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
    • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-5-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
    • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-methylisoxazolo[5,4-b]pyridin-5-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
    • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(hydroxymethyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
    • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-ureidophenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
    • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(1-methyl-2-oxoindolin-5-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
    • 3,5-dichloro-4-((S)-2-((S)-3-(4-cyanophenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)pyridine 1-oxide;
      and pharmaceutically acceptable salts or solvates thereof.
  • In one aspect of the present invention, a process for the preparation of compounds of the invention is provided, according to general synthetic routes reported in Scheme 1 below, where reference is made to specific synthetic schemes which are better detailed in the following paragraphs.
  • The processes which can be used and are described below and reported in Schemes, should not be viewed as limiting the scope of the synthetic methods available for the preparation of the compounds of the invention.
  • Figure US20130005716A1-20130103-C00042
  • In the following Schemes, for compounds of formula (II) to (XIX), unless otherwise indicated, groups R1 to R20, Z, A, and K have the same meanings as described for compounds of formula (I) above.
  • Compounds of formula (Ia), i.e. compounds of formula (I) wherein K is a group —(CH2)R4, may be prepared according to Scheme 2a below by reaction of a compound of formula (II) wherein A′ is (C3-C7)heterocycloalkyl-ene group comprising a group —NH—, with an appropriate compound of formula (III).
  • Figure US20130005716A1-20130103-C00043
  • Typical reaction conditions comprise reacting a compound of formula (II) with a compound of formula (III) in a suitable dipolar solvent, such as THF, methanol, ethanol or DCM, in the presence of an appropriate reducing agent, such as sodium triacetoxy borohydride, sodium cyano borohydride or sodium borohydride, and of an appropriate acid, such as acetic acid, HCl in methanol or ammonium acetate. It could be useful to preform the imine before adding the reducing agent. The reaction proceeds smoothly at room temperature (RT) over 1 to 12 hours.
  • Alternatively compounds of formula (Ia), i.e. compounds of formula (I) wherein K is a group —(CH2)R4, may be prepared according to Scheme 2b below by reaction of a compound of formula (II) wherein A′ is (C3-C7)heterocycloalkyl-ene group comprising a group —NH—, with an appropriate compound of formula (XVI).
  • Figure US20130005716A1-20130103-C00044
  • Typical reaction conditions comprise reacting a compound of formula (XVI), where X is a leaving group such as Cl or Br, with a compound of formula (II) in a suitable polar aprotic solvent, such as acetonitrile or DMF, in the presence of an appropriate base such as K2CO3, alkaline bicarbonate, TEA or DIPEA, at a temperature ranging from RT to 70° C.
  • Compounds of formula (Ib), i.e. compounds of formula (I) wherein K is a group —C(O)(CH2)jR4, may be prepared according to Scheme 3a below by reaction of a compound of formula (II) as above defined, with an appropriate compound of formula (IV).
  • Figure US20130005716A1-20130103-C00045
  • Typical reaction conditions comprise reacting a compound of formula (II) with a compound of formula (IV) in a suitable dipolar aprotic solvent, such as DMF, chloroform or DCM, in the presence of an appropriate condensing agent such as EDC, DCC, HOBT, HOAT, or CDI, and, if necessary, of an appropriate agent, such as DMAP, HOBT, 4-pyrrolidinopyridine (4-PPY) or other 4-alkylamino pyridine, at room temperature.
  • Alternatively compounds of formula (Ib), i.e. compounds of formula (I) wherein K is a group —C(O)(CH2)jR4, may be prepared according to Scheme 3b below by reaction of a compound of formula (II) as above defined, with an appropriate compound of formula (XVII).
  • Figure US20130005716A1-20130103-C00046
  • Typical reaction conditions comprise reacting a compound of formula (II) with a compound of formula (XVII) in a suitable solvent such as pyridine or DCM, and in the presence, if necessary, of an appropriate base such as TEA, DIPEA, DBU, or another organic base at a temperature ranging from 0° C. to room temperature.
  • Compounds of formula (Ic), i.e. compounds of formula (I) wherein K is a group —(CH2)mC(O)R4, may be prepared according to Scheme 4 below by reaction of a compound of formula (II) as above defined, with an appropriate compound of formula (V), where Hal represents a suitable halogen leaving group.
  • Figure US20130005716A1-20130103-C00047
  • Typical reaction conditions comprise reacting a compound of formula (II) with a compound of formula (V) in a suitable polar aprotic solvent, such as DMF or acetonitrile, in the presence of an appropriate base such as K2CO3, alkaline bicarbonate, TEA or DIPEA, at a temperature ranging from RT to 50° C.
  • Compounds of formula (Id), i.e. compounds of formula (I) wherein K is a group —(CH2)ySO2R4, may be prepared according to Scheme 5 below by reaction of a compound of formula (II) as above defined, with an appropriate compound of formula (VI), where Hal represents a suitable halogen leaving group.
  • Figure US20130005716A1-20130103-C00048
  • Typical reaction conditions comprise reacting a compound of formula (II) with a compound of formula (VI) in a suitable polar aprotic solvent such as DMF or acetonitrile, in the presence of an appropriate base such as K2CO3, alkaline bicarbonate, TEA, or DIPEA, at a temperature ranging from RT to 50° C.
  • Compounds of formula (Id), i.e. compounds of formula (I) wherein K is a group —(CH2)ySO2R4 and y is 1, may also be prepared according to Scheme 46 below by reaction of a compound of formula (II) as above defined, with an appropriate compound of formula (XVIII), where Hal represents a suitable halogen leaving group.
  • Figure US20130005716A1-20130103-C00049
  • Typical reaction conditions comprise reacting a compound of formula (II) with a compound of formula (XVIII) in a suitable polar aprotic solvent, such as DMF or acetonitrile, in the presence of an appropriate base such as K2CO3, alkaline bicarbonate, TEA, or DIPEA, at a temperature ranging from RT to 50° C. Compound (XIX) thus obtained is successively reacted with a suitable oxidizing agent, such as MCPBA or hydrogen peroxide, in a suitable polar solvent, such as DCM, chloroform, EtOH or MeOH, at a temperature ranging from room temperature to 60° C. Compounds of formula (Ie), i.e. compounds of formula (I) wherein K is a group —SO2(CH2)pR4, may be prepared according to Scheme 6 below reported by reaction of a compound of formula (II) as above defined, with an appropriate compound of formula (VII).
  • Figure US20130005716A1-20130103-C00050
  • Typical reaction conditions comprise reacting a compound of formula (II) with a compound of formula (VII) in a suitable solvent such as pyridine or DCM, and in the presence, if necessary, of an appropriate base such as TEA, DIPEA, DBU, or another organic base at a temperature ranging from 0° C. to room temperature.
  • Alternatively, compounds of formula (I), may be prepared according to Scheme 7 below by reaction of a compound of formula (VIII), with an appropriate compound of formula (IX).
  • Figure US20130005716A1-20130103-C00051
  • Typical reaction conditions comprise reacting a compound of formula (VIII) with a compound of formula (IX) in a suitable polar aprotic solvent, such as DMF, THF, chloroform, or DCM, in the presence of an appropriate condensing agent such as EDC, DCC, or CDI and of an appropriate agent, such as DMAP, HOBT, 4-pyrrolidinopyridine (4-PPY) or other 4-alkylamino pyridine at room temperature; removal of possibly present protecting group is performed under conditions known to the person skilled in the art or as described in ‘Protection Groups in Organic Synthesis’ by T. W. Green and P. Wutz, (Wiley-Interscience publication, 1999, which is incorporated herein by reference in its entirety).
  • Compounds of formula (II), as above defined, may be prepared according to Scheme 8 below by reaction of a compound of formula (X), wherein A″ is (C3-C7) heterocycloalkyl-ene group comprising a group —N— which is protected with a suitable protecting group, with an appropriate compound of formula (XI), followed by removal of N— protecting group under appropriate conditions.
  • Figure US20130005716A1-20130103-C00052
  • Typical coupling reaction conditions comprise reacting a compound of formula (VIII) with a compound of formula (X) in a suitable polar aprotic solvent, such as DMF, THF, chloroform, or DCM, in the presence of an appropriate (coupling) condensing agent such as EDC, DCC, or CDI and of an appropriate agent such as DMAP, HOBT, 4-pyrrolidinopyridine (4-PPY) or other 4-alkylamino pyridine at room temperature; removal of protecting group is performed under conditions known to the person skilled in the art or as described in ‘Protection Groups in Organic Synthesis’ by T. W. Green and P. Wutz (Wiley-Interscience publication, 1999, which is incorporated herein by reference in its entirety), for example when the protecting group is represented by a t-butoxycarbonyl group then deprotection may be conveniently performed under acidic conditions (such as HCl in dioxane or in AcOEt or TFA in CH2Cl2).
  • Alternatively the corresponding acyl chloride can be preformed, by reacting compound (X) with oxalyl chloride or thionyl chloride or other reagents well known to those skilled in the art, in a suitable aprotic solvent such as DCM at 0 degrees, in presence, if necessary, of a catalytic amount of DMF, and successively adding compound (VIII) and an appropriate base such as TEA or DIPEA.
  • Compounds of formula (If), i.e. compounds of formula (I) wherein K is a group —SO2(CH2)pR4 and R2 is hydrogen, may be prepared according to Scheme 42 below by reaction of a compound of formula (Ie) as above defined, wherein R2 is (C1-C6)alkyl, optionally substituted by one (C3-C7)cycloalkyl under appropriate conditions.
  • Figure US20130005716A1-20130103-C00053
  • Typical reaction conditions comprise reacting a compound of formula (Ie) as above defined with a suitable acid, such as TFA or BBr3 or BCl3, at a temperature ranging from room temperature to 40 degrees.
  • The N-oxides on the 2-pyridinyl ring of the compounds of general formula (I) and embodiments thereof may be prepared according to methods available in the literature and well known to the skilled person. For instance, they may be prepared by dissolving the compound of general formula (I) or embodiments thereof in CH2Cl2 or CHCl3, then adding an oxidizing agent such as m-chloro perbenzoic acid (mCPBA) to the resulting solution. Other oxidizing agents which may be used are hydrogen peroxide, perbenzoic acid, and peracetic acid.
  • Alternatively, in particular for those compounds in which A or A′ is a ring substituted with a functional group sensitive to oxidation, the corresponding N-oxides are prepared by carrying out the oxidation step before further functional groups are introduced, for example on compounds of formula (II) or (VIII).
  • In a preferred embodiment, the process for preparation of compounds of formula (I) or embodiments thereof is performed starting from N-oxide on the pyridine ring of compound of formula (VIII), thus allowing the preparation of compound of formula (I) or embodiments thereof in the form of N-oxides on the pyridine ring. Compounds of general formula (III), (IV), (V), (VI), (VII), (VIII), (IX), (XVI), (XVII), (XVIII), (XIX), and (X) may be commercially available, their preparation may be specifically described in the literature or they may be prepared according to methods available in the literature and known to the person skilled in the art.
  • In particular, compounds of formula (VIII) and corresponding N-oxides on the pyridine ring may also be prepared as described in International Patent Application Nos. WO 2009/018909 or WO 2010/089107.
  • In one embodiment, a preferred process for the preparation of compounds of formula (IDa), i.e. N-oxide derivatives on pyridine ring of compounds of formula (ID) wherein R9 is hydrogen, K is a group —SO2(CH2)pR4 and wherein absolute configuration at the stereogenic centers is as below represented, is provided according to Scheme 43 below reported.
  • Figure US20130005716A1-20130103-C00054
  • Typical reaction conditions for the process described in Scheme 43 comprise: a) adding a solution of a compound of formula (VII) in pyridine (3-30 vol. preferably 8 vol.) to a refrigerated solution of a compound of formula (XI), in pyridine (3-30 vol. preferably 8 vol.) stirring the resulting solution at room temperature; c) pouring the solution into aqueous HCl in excess; d) filtering the precipitated material and washing it with water, or d′) extracting the aqueous phase with AcOEt, washing with aqueous HCl M, brine and evaporating the resulting organic phase; and optionally e) dissolving the solid obtained from step d) or d′) in AcOEt, charging it on a silica gel pad, eluting with AcOEt/MeOH [100:0 to (90:10)] and evaporating under vacuum the resulting solution, or e′) purifying the product by flash cromathography eluting with DCM/i-PrOH.
  • In a more preferred embodiment, compounds of formula (IDa) obtained as above reported according to Scheme 43 are crystallized by a process comprising: dissolving the compounds in EtOH (8 vol); g) vigorously stirring overnight at room temperature; h) filtering the solid formed; and, optionally, i) washing the solid obtained from step h) with EtOH (2 vol) and 1) drying the solid under vacuum.
  • In a further preferred embodiment, step 1) of Scheme 43 is conducted by drying first the solid under vacuum at room temperature, followed by drying under vacuum at 60° C.
  • In one embodiment, a preferred process is provided for the preparation of compounds of formula (XI) as above defined, according to Scheme 44 below reported:
  • Figure US20130005716A1-20130103-C00055
  • Typical reaction conditions for the process described in Scheme 44 comprise: a) adding under stirring a solution of conc. HCl (about 5M; large excess) in dry AcOEt (9 vol.) to a solution of a compound of formula (XII) in AcOEt (6 vol.) at room temperature; b) stirring; c) filtering the precipitated solid; optionally d) washing the obtained solid with AcOEt; and optionally e) drying the solid obtained under vacuum at room temperature.
  • In one embodiment, a preferred process is provided for the preparation of compounds of formula (XII) as above defined, according to Scheme 45 below reported:
  • Figure US20130005716A1-20130103-C00056
  • Typical reaction conditions for the process described in Scheme 45 comprise: a) adding a compound of formula (XIV), DMAP, and EDC to a solution of a compound of formula (XV) in DMF; b) stirring the mixture, preferably overnight; c) pouring the mixture into cold water; d) filtering the precipitate; optionally e) dissolving the precipitate in DCM, washing the solution with water, drying and evaporating the solvent; and optionally f) dissolving the solid obtained from step d) or e) in boiling MTBE (3.5 vol.) adding petroleum ether (4 vol.) under stirring, stirring at room temperature, filtering the solid obtained and drying it at room temperature under vacuum.
  • In a preferred embodiment, processes according to schemes 43, 44, and 45 are sequentially performed to obtain crystalline compounds of formula (IDa).
  • In a preferred embodiment, a process is provided for the preparation of compounds of formula (IDaa), i.e. a compound of formula (IDa) wherein R1 is (C1-C6) haloalkyl, R2 is (C1-C6)alkyl which is substituted by (C3-C7)cycloalkyl, 2-pyridinyl ring is substituted in 3 and 5 with two chlorine R3 groups, K is a group
  • Figure US20130005716A1-20130103-C00057
  • and R4 is a phenyl group which is optionally substituted by one or more groups R5; which process comprises sequentially performing reactions as provided in Schemes 43, 44, and 45 above described.
  • In one aspect of the present invention, compounds of formula (II), their N-oxides on the pyridine ring, or salts thereof are provided as intermediates in the process for the preparation of compounds of formula (I)
  • Figure US20130005716A1-20130103-C00058
  • wherein A′ is (C3-C7)heterocycloalkyl-ene group comprising a group —NH—.
  • In one embodiment, compounds of formula (XI) as above defined are provided as intermediates in the process of preparation of compounds of formula (IDa). In a further preferred embodiment, for compounds of formula (XI), R1 is (C1-C6)haloalkyl and R2 is (C1-C6)alkyl which is substituted by (C3-C7)cycloalkyl, and the pyridine ring is substituted by two groups R3 placed at position 3 and 5.
  • In another aspect of the present invention, compounds of formula (II) as above defined are provided which act as inhibitors of the phosphodiesterase 4 (PDE4) enzyme, thus solving the above mentioned need of identifying further PDE4 inhibitors endowed with a high affinity for PDE4 enzyme, and possibly showing an appropriate developability profile as an inhalation treatment for example in terms of reduced side effects.
  • Also provided by the present invention are compositions containing compounds of formula (II) and therapeutic uses thereof.
  • Where applicable, preferred embodiments and groups described above for compounds of formula (I), apply to compounds of formula (II) as well mutatis mutandis.
  • The process described is particularly advantageous as it is susceptible of being properly modulated, through any proper variant known to the skilled person, so as to obtain any of the desired compounds of the invention. Such variants are comprised within the scope of the present invention.
  • From all of the above, it should be clear to the skilled person that any of the described groups may be present as such or in any properly protected form. In particular, functional groups present in the compounds of formula (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII), (XIV), (XV), (XVI), (XVII), (XVIII), and (XIX) and which could generate unwanted side reaction and by-products, need to be properly protected before the alkylation, acylation, coupling, oxidation, or sulfonylation takes place. Likewise, subsequent deprotection of those same protected groups may follow upon completion of the said reactions.
  • In the present invention, unless otherwise indicated, the term “protecting group” designates a protective group adapted to preserve the function of the group it is bound to. Typically, protective groups are used to preserve amino, hydroxyl, or carboxyl functions. Appropriate protecting groups may thus include, for example, benzyl, benzyloxycarbonyl, t-butoxycarbonyl, alkyl, or benzyl esters or the like, which are well known to those skilled in the art (see, for a general reference, T. W. Green; Protective Groups in Organic Synthesis (Wiley, N.Y. 1999) which is incorporated herein by reference in its entirety). Likewise, selective protection and deprotection of any of the said groups, for instance including carbonyl, hydroxyl, or amino groups, may be accomplished according to very well known methods commonly employed in organic synthetic chemistry.
  • Optional salification of the compounds of formula (I) or N-oxides on the pyridine ring thereof may be carried out by properly converting any of the free acidic or amino groups into the corresponding pharmaceutically acceptable salts. In this case too, the operative conditions being employed for the optional salification of the compounds of the invention are all within the ordinary knowledge of the skilled person.
  • From all of the above, it should be clear to the skilled person that the above processes, comprehensive of any variant thereof for the preparation of suitable compounds of the invention, may be conveniently modified so that to adapt the reaction conditions to the specific needs, for instance by choosing appropriate condensing agents, solvents and protective groups, as the case may be.
  • The present invention also provides pharmaceutical compositions of compounds of the invention or of compounds of formula (II) in admixture with one or more pharmaceutically acceptable carriers, for example those described in Remington's Pharmaceutical Sciences Handbook, XVII Ed., Mack Pub., N.Y., U.S.A., which is incorporated herein by reference in its entirety.
  • Administration of the compounds of the present invention or of compounds of formula (II) may be accomplished according to patient needs, for example, orally, nasally, parenterally (subcutaneously, intravenously, intramuscularly, intrasternally, and by infusion), by inhalation, rectally, vaginally, topically, locally, transdermally, and by ocular administration. Various solid oral dosage forms may be used for administering compounds of the present invention including such solid forms as tablets, gelcaps, capsules, caplets, granules, lozenges, and bulk powders. The compounds of the present invention or compounds of formula (II) may be administered alone or combined with various pharmaceutically acceptable carriers, diluents (such as sucrose, mannitol, lactose, starches) and excipients known in the art, including but not limited to suspending agents, solubilizers, buffering agents, binders, disintegrants, preservatives, colorants, flavorants, lubricants, and the like. Time release capsules, tablets, and gels are also advantageous in administering the compounds of the present invention or compounds of formula (II).
  • Various liquid oral dosage forms may also be used for administering compounds of the present invention or compounds of formula (II), including aqueous and non-aqueous solutions, emulsions, suspensions, syrups, and elixirs. Such dosage forms can also contain suitable inert diluents known in the art such as water and suitable excipients known in the art such as preservatives, wetting agents, sweeteners, flavorants, as well as agents for emulsifying and/or suspending the compounds of the invention or compounds of formula (II). The compounds of the present invention or compounds of formula (II) may be injected, for example, intravenously, in the form of an isotonic sterile solution. Other preparations are also possible.
  • Suppositories for rectal administration of the compounds of the present invention or of compounds of formula (II) may be prepared by mixing the compound with a suitable excipient such as cocoa butter, salicylates, and polyethylene glycols. Formulations for vaginal administration may be in the form of cream, gel, paste, foam, or spray formula containing, in addition to the active ingredient, such suitable carriers as are known in the art.
  • For topical administration the pharmaceutical composition may be in the form of creams, ointments, liniments, lotions, emulsions, suspensions, gels, solutions, pastes, powders, sprays, and drops suitable for administration to the skin, eye, ear, or nose. Topical administration may also involve transdermal administration via means such as transdermal patches.
  • For the treatment of the diseases of the respiratory tract, the compounds according to the present invention or compounds of formula (II) are preferably administered by inhalation. Inhalable preparations include inhalable powders, propellant-containing metering aerosols, and propellant-free inhalable formulations.
  • For administration as a dry powder, single- or multi-dose inhalers known from the prior art may be utilized. In that case the powder may be filled in gelatine, plastic, or other capsules, cartridges, or blister packs or in a reservoir.
  • A diluent or carrier, generally non-toxic and chemically inert to the compounds of the invention, e.g. lactose or any other additive suitable for improving the respirable fraction may be added to the powdered compounds of the invention or compounds of formula (II).
  • Inhalation aerosols containing propellant gas such as hydrofluoroalkanes may contain the compounds of the invention or compounds of formula (II) either in solution or in dispersed form. The propellant-driven formulations may also contain other ingredients such as co-solvents, stabilizers, and optionally other excipients.
  • The propellant-free inhalable formulations comprising the compounds of the present invention or compounds of formula (II) may be in form of solutions or suspensions in an aqueous, alcoholic, or hydroalcoholic medium and they may be delivered by jet or ultrasonic nebulizers known from the prior art or by soft-mist nebulizers such as Respimat®.
  • The compounds of the present invention or compounds of formula (II) may be administered as the sole active agent or in combination with other pharmaceutical active ingredients including those currently used in the treatment of respiratory disorders, e.g. beta2-agonists, antimuscarinic agents, corticosteroids, mitogen-activated protein kinases (P38 MAP kinase) inhibitors, nuclear factor kappa-B kinase subunit beta (IKK2) inhibitors, human neutrophil elastase (FINE) inhibitors, phosphodiesterase 4 (PDE4) inhibitors, leukotriene modulators, non-steroidal anti-inflammatory agents (NSAIDs), and mucus regulators.
  • The present invention also provides combinations of a compound of the present invention or of compounds of formula (II), with a β2-agonist selected from the group consisting of carmoterol, GSK-642444, indacaterol, milveterol, arformoterol, formoterol, salbutamol, levalbuterol, terbutaline, AZD-3199, BI-1744-CL, LAS-100977, bambuterol, isoproterenol, procaterol, clenbuterol, reproterol, fenoterol and ASF-1020, and salts thereof.
  • The present invention also provides combinations of a compound of the present invention or of a compound of formula (II), with a corticosteroid selected from the group consisting of fluticasone propionate, fluticasone furoate, mometasone furoate, beclometasone dipropionate, ciclesonide, budesonide, GSK 685698, and GSK 870086.
  • The present invention also provides combinations of a compound of the present invention or of a compound of formula (II), with an antimuscarinic agent selected from the group consisting of aclidinium, tiotropium, ipratropium, trospium, glycopyrronium, and oxitropium salts.
  • The present invention also provides combinations of a compound of the present invention or of a compound of formula (II), with a PDE4 inhibitor selected from the group consisting of AN-2728, AN-2898, CBS-3595, apremilast, ELB-353, KF-66490, K-34, LAS-37779, IBFB-211913, AWD-12-281, cipamfylline, cilomilast, roflumilast, BAY19-8004 and SCH-351591, AN-6415, indus-82010, TP1-PD3, ELB-353, CC-11050, GSK-256066, oglemilast, OX-914, tetomilast, MEM-1414, and RPL-554.
  • The present invention also provides combinations of a compound of the present invention or of a compound of formula (II), with a P38 MAP kinase inhibitor selected from the group consisting of semapimod, talmapimod, pirfenidone, PH-797804, GSK-725, minokine, and losmapimod and salts thereof.
  • In a preferred embodiment, the present invention provides combinations of a compound of the present invention or of a compound of formula (II) with an IKK2 inhibitor.
  • The present invention also provides combinations of a compound of the present invention or of a compound of formula (II), with a HNE inhibitor selected from the group consisting of AAT, ADC-7828, Aeriva, TAPI, AE-3763, KRP-109, AX-9657, POL-6014, AER-002, AGTC-0106, respriva, AZD-9668, zemaira, AAT IV, PGX-100, elafin, SPHD-400, prolastin C, and prolastin inhaled.
  • The present invention also provides combinations of a compound of the present invention or of a compound of formula (II), with a leukotriene modulator selected from the group consisting of montelukast, zafirlukast, and pranlukast.
  • The present invention also provides combinations of a compound of the present invention or of a compound of formula (II), with a NSAID selected from the group consisting of ibuprofen and ketoprofen.
  • The present invention also provides combinations of a compound of the present invention or of a compound of formula (II), with a mucus regulator selected from the group consisting of INS-37217, diquafosol, sibenadet, CS-003, talnetant, DNK-333, MSI-1956, and gefitinib.
  • The dosages of the compounds of the present invention depend upon a variety of factors including the particular disease to be treated, the severity of the symptoms, the route of administration, the frequency of the dosage interval, the particular compound utilized, the efficacy, toxicology profile, and pharmacokinetic profile of the compound.
  • Advantageously, the compounds of the present invention or compounds of formula (II) may be administered for example, at a dosage comprised between 0.001 and 1000 mg/day, preferably between 0.1 and 500 mg/day.
  • When they are administered by inhalation route, the dosage of the compounds of the present invention or of compounds of formula (II) is advantageously comprised between 0.01 and 20 mg/day, preferably between 0.1 and 10 mg/day.
  • Preferably, the compounds of the present invention or compounds of formula (II) alone or combined with other active ingredients may be administered for the prevention and/or treatment of any obstructive respiratory disease such as asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD).
  • However the compounds of the present invention or compounds of formula (II) may be administered for the prevention and/or treatment of any disease wherein PDE4 inhibition is required. Said disease include: allergic disease states such as atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, eosinophilic granuloma, psoriasis, inflammatory arthritis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock, cystic fibrosis, arterial restenosis, artherosclerosis, keratosis, rheumatoid spondylitis, osteoarthritis, pyresis, diabetes mellitus, pneumoconiosis, toxic and allergic contact eczema, atopic eczema, seborrheic eczema, lichen simplex, sunburn, pruritus in the anogenital area, alopecia greata, hypertrophic scars, discoid lupus erythematosus, systemic lupus erythematosus, follicular and wide-area pyodermias, endogenous and exogenous acne, acne rosacea, Beghet's disease, anaphylactoid purpura nephritis, inflammatory bowel disease, leukemia, multiple sclerosis, gastrointestinal diseases, autoimmune diseases and the like.
  • Such diseases also include neurological and psychiatric disorders such as Alzheimer's disease, multiple sclerosis, amylolaterosclerosis (ALS), multiple systems atrophy (MSA), schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, depression, stroke, and spinal cord injury.
  • Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof.
    • EXAMPLES
  • Chemical names of the compounds were generated with Structure To Name Enterprise 10.0 Cambridge Software.
    • Abbreviations.
  • EDC=1-ethyl-3-(3-dimethylaminopropyl) carbodiimide) hydrochloride; DMAP=4-dimethylaminopyridine; DMF=dimethylformamide; EtOAc or AcOEt=Ethyl acetate; RT=room temperature; THF=tetrahydrofurane; DCM=dichloromethane; Et2O=diethyl ether; MeOH=methylic alcohol; n-BuOH=n-butylic alcohol; EtOH=ethyl alcohol; IprOH or IPA=isopropyl alcohol; (Ipr)2O=diisopropylether; MIK=methyl isobutyl ketone; MEK=methyl ethyl ketone; MTBE=methyl tert-butyl ether; AcOH=acetic acid; vv=volumes; v/w=ratio volume/weight; and w/w=ratio weight/weight.
    • General Experimental Details. NMR Characterization:
  • 1H-NMR spectra were recorded on a 400 MHz Varian AS400 spectrometer. Chemical shift are reported as 6 values in ppm relative to trimethyl silane (TMS) as an internal standard. Coupling constants (J values) are given in hertz (Hz) and multiplicities are reported using the following abbreviation (s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, b r=broad, nd=not determined).
  • or
  • 1H-NMR spectra were recorded on a Bruker ARX300 Spectrometer at 300.13 MHz (1H) using deuterated solvents, such as deuterated dimethylsulfoxide (DMSO-d6) or deuterated chloroform (CDCl3). The instrument was equipped with a multinuclear inverse probe and temperature controller. Chemical shifts are expressed in parts per million (ppm) downfield of tetramethylsilane (d units). Multiplicity is indicated as follow: (s) singlet, (d) doublet, (dd) double doublet, (ddd) triple doublet, (t) triplet, (dt) double triplet, (q) quartet, (m) multiplet, (br s) broad signal. Coupling constants J are expressed in units of hertz (Hz).
    • LC/UV/MS Analytical Methods
  • LC/MS retention times are estimated to be affected by an experimental error of ±0.5 min.
    • LC/UV/MS—Method 1
  • LC instrument: HPLC Alliance Waters (or equivalent)
    • Column: Kinetex 2.6 u C18 100 A 100×4.6 mm (Phenomenex) Column Temperature (° C.): 50.0
  • Mobile phases: HCOONH4 0.025M pH3 (A); Acetonitrile (B)
    Flow (ml/min): 2.0 (split in MS 1:10)
    Stop Time (mins): 17.0
    • Gradient:
  • Time (min) % A % B
    0.00 80.0 20.0
    10.00 20.0 80.0
    12.00 20.0 80.0
    14.00 80.0 20.0
    17.00 80.0 20.0

    UV detection: channel 1 245 nm; channel 2 254 nm
    • Injection Volume (ul): 5.00 Sample Solvent Acetonitrile
  • MS instrument: Waters Quattro Micro API (or equivalent)
  •
    Polarity ES+
    Capillary (kV) 3.20
    Cone (V) 20.00
    Extractor (V) 2.00
    RF Lens (V) 0.3
    Polarity ES−
    Capillary (kV) 3.20
    Cone (V) 20.00
    Extractor (V) 3.00
    RF Lens (V) 0.3
    Source Temperature (° C.) 110
    Desolvation Temperature (° C.) 210
    Cone Gas Flow (L/Hr) 150
    Desolvation Gas Flow (L/Hr) 650
    Scan duration (secs): 1.00
    Interscan delay (secs): 0.10
    Mass range: 125 to 1000
    • LC/UV/MS—Method 2
  • LC instrument: Acquity Waters HPLC (or equivalent)
    • Column: Kinetex 1.7 u XB-C18 100 A 100×2.1 mm (Phenomenex) Column Temperature (° C.) 50.0
  • Mobile phases: HCOONH4 0.025M pH3 (A); Acetonitrile+0.1% Formic Acid (B)
    Flow (ml/min) 0.65 (split in MS 1:3)
    Stop Time (mins) 10.0
    • Gradient:
  • Time (min) % A % B
    0.00 80.0 20.0
    5.50 20.0 80.0
    7.50 20.0 80.0
    8.00 80.0 20.0
    10.00 80.0 20.0

    UV detection: wavelength 254 nm
    Injection Volume (ul)—2.00
    Sample solvents: Acetonitrile
    MS instrument: Waters ZQ (or equivalent)
  • Polarity ES+
    Capillary (kV) 3.00
    Cone (V) 20.00
    Extractor (V) 3.00
    RF Lens (V) 1.0
    Polarity ES−
    Capillary (kV) 3.00
    Cone (V) 20.00
    Extractor (V) 3.00
    RF Lens (V) 1.0
    Source Temperature (° C.) 110
    Desolvation Temperature (° C.) 210
    Cone Gas Flow (L/Hr) 150
    Desolvation Gas Flow (L/Hr) 650
    Mass range: 100 to 950
    Scan time (sec): 0.32
    • LC/UV/MS—Method 3
  • LC instrument: Acquity Waters HPLC (or equivalent) interfaced with 2996 PDA detector
    • Column: Acquity HPLC BEH C18 1.7 um 50×2.1 mm Column Temperature (° C.) 40.0
  • Mobile phases: 95:5 H2O:ACN+(0.1% TFA) (A); 5:95 H2O:ACN+(0.1% TFA) (B)
    Flow (ml/min) 0.6 (split in MS 1:6)
    Stop Time (mins) 8.5
    • Gradient:
  • Time (min) % A % B
    0.00 95.0 5.0
    0.50 95.0 5.0
    6.00 0.0 100.0
    7.00 0.0 100.0
    7.10 95.0 5.0
    8.50 95.0 5.0

    UV detection: BPI Detection (Start Wavelength nm 210, End Wavelength nm 400,
    Sampling Rate spectra/sec=20)
    Injection Volume (ul)—1.00
    Sample solvents: DMSO:MeOH:ACN ratio 1:3:3
    MS instrument: Waters ZQ (or equivalent)
  • Polarity ES+
    Capillary (kV) 3.20
    Cone (V) 25.00
    Extractor (V) 3.00
    RF Lens (V) 0.1
    Polarity ES−
    Capillary (kV) 3.00
    Cone (V) 20.00
    Extractor (V) 3.00
    RF Lens (V) 0.3
    Source Temperature (° C.) 150
    Desolvation Temperature (° C.) 350
    Cone Gas Flow (L/Hr) 110
    Desolvation Gas Flow (L/Hr) 800
    Mass range: 60 to 1200
    Scan time (sec): 0.4
    • LC/UV/MS—Method 4
  • LC instrument: Acquity Waters HPLC (or equivalent) interfaced with 2996 PDA detector
    • Column: Kinetex C18 1.7 um 50×2.1 mm (Phenomenex) Column Temperature (° C.): 40.0
  • Mobile phases: 95:5 H2O:ACN+(0.1% TFA) (A); 5:95 H2O:ACN+(0.1% TFA) (B)
    Flow (ml/min): 0.5 (no split in MS)
    Stop Time (mins): 4.40
    • Gradient:
  • Time (min) % A % B
    0.00 95.0 5.0
    0.30 95.0 5.0
    3.30 0.0 100.0
    3.90 0.0 100.0
    4.40 95.0 5.0

    UV detection: BPI Detection (Start Wavelength nm 200, End Wavelength nm 400, Sampling Rate points/sec=20)
    • Injection Volume (ul): 4.00 Sample Solvent Acetonitrile
  • MS instrument: ZQ (or equivalent)
  • Polarity ES+
    Capillary (kV) 3.25
    Cone (V) 27.00
    Extractor (V) 3.00
    RF Lens (V) 0.4
    Source Temperature (° C.) 120
    Desolvation Temperature (° C.) 400
    Cone Gas Flow (L/Hr) 100
    Desolvation Gas Flow (L/Hr) 800
    Scan time (sec): 0.42
    Mass range: 100 to 800
    • Preparative REVERSE-PHASE HPLC Conditions Preparative HPLC—Method 1
  • Waters Micromass ZQ/Sample manager 2767 Photodiode array detector 2996;
    • Column: XTerra Prep MS C18 Column (5 μm, 19×150 mm, Waters)
  • Flow rate: 20 ml/min with MS detection
    UV wavelength: 254 nm.
    Mobile phase: Solvent A (water:MeCN:HCOOH 95:5:0.05); Solvent B (water:MeCN:HCOOH 5:95:0.05)
    • Gradient:
  • Time (min) % A % B
    0.00 100.0 0.00
    1.00 100 0.00
    10.00 0.00 100.0
    11.00 0.00 100.0
    12.00 100.0 0.00
    • Preparative HPLC—Method 2 Column: Waters Symmetry Prep C18 17 um 19×300
  • Flow: 20 ml/min
    Mobile phase: 90% H2O, 10% acetonitrile, 0.05% TFA (A); 10% H2O, 90% acetonitrile, 0.05% TFA (B)
    • Gradient:
  • Time (min) % A % B
    0.00 95 5
    2.5 95 5
    22 0 100
    30 0 100
    • Preparative HPLC—Method 3
  • Waters Micromass ZQ/sample manager 2767
    Photodiode array detector: 2996
    • Column: XTERRA Prep MS C18 10 um 19×300
  • Flow: 20 ml/min
    Mobile phases: H2O, 0.1% TFA (A); acetonitrile, 0.1% TFA (B)
    • Gradient:
  • Time (min) % A % B
    0.00 90 10
    2 90 10
    23 0 100
    30 0 100
    • Conditioning:
  • Time (min) % A % B
    30.5 90 10
    32 90 10
    • Chiral HLPC:
  • The enantiomeric purity was determined on Hewlett Packard 1050 HPLC system using Chiracel OD column (5μ 4.6×250 mm), eluting using isocratic mixture of hexane and isopropanol in different ratios as indicated in each specific example.
  • Flow=0.8 ml/min
    UV detection=230 nm.
    • Optical Rotation (Activity) Determination
  • Specific rotations of compounds were measured with a Polarimeter Perkin Elmer model 241 or 341.
  •
    Temperature (° C.) 25
    Path Length (dm)  1
    Wavelength Sodium D-line (589 nm)

    Experiments requiring microwave heating were performed using a Biotage Initiator Sixty instrument.
    • Procedures for Salt Formation
  • Unless otherwise stated, salts described in the experimental section were obtained according to one of the procedures herebelow described:
  • Formate Salts: when stated in the Salt Name column, compounds containing one or more basic centres and purified by reverse-phase HPLC (Method 1) were obtained as formic acid salts, once clean fractions collected form chromatography were evaporated under reduced pressure without any further basic treatment.
  • Trifluoroacetate Salts: when stated in the Salt Name column, compounds containing one or more basic centres and purified by reverse-phase HPLC (Method 2 or 3) were obtained as 2,2,2-trifluoroacetic acid salts, once clean fractions collected from chromatography were evaporated under reduced pressure without any further basic treatment.
  • Hydrochloride Salts: when stated in the Salt Name column, Compounds containing one or more basic centres which underwent Boc deprotection under acidic condition without any further basic work-up, were obtained as hydrochloride salts.
  • Any other salt was obtained treating the base with a solution of the corresponding acid under conditions know to the skilled person.
  • The salt stoichiometry was determined, if required, by NMR.
  • In the procedures that follow, after each starting material, reference to a compound number is typically provided. This is provided merely for assistance to the skilled chemist. The starting material may not necessarily have been prepared from the batch referred to.
  • When reference is made to the use of a “similar” or “analogous” procedure, as will be appreciated by those skilled in the art, such a procedure may involve minor variations, for example reaction temperature, reagent/solvent amount, reaction time, work-up conditions or chromatographic purification conditions. Stereogenic centers which are indicated by an undefined line bond, represent those in compounds which were obtained as single diastereisomers or enantiomers but whose absolute configuration was anyway not determined.
  • Many of the Compounds described in the following Examples have been prepared from sterochemically pure starting materials, for example 95% ee.
  • The stereochemistry of the compounds in the Examples, where indicated, has been assigned on the assumption that the absolute configuration at resolved stereogenic centers of staring materials is maintained throughout any subsequent reaction conditions. The absolute configuration for some of the Compounds described has been confirmed as correct by X-ray or VCD (Vibrational Circular Dichroism) analysis of crystalline material.
  • Diastereoisomeric ratio by LC/UV/MS, when indicated, is estimated to be affected by an experimental error of ±1%. Alternatively diastereoisomeric ratio is determined by 1H NMRand it is estimated to be >95:5 when a single diastereoisomer was detected using NMR analysis.
  • Detailed synthetic pathways and procedures for specific examples are outlined in Schemes 9-41 and 46 herebelow. The synthesis of alcohol intermediates listed in Table 12 is described in the listed patent applications, all of which are incorporated herein by reference in their entireties.
  • TABLE 12
    Entry Structure Preparation
     1
    Figure US20130005716A1-20130103-C00059
         		Prepared as described in patent WO 2010/089107
    156
    Figure US20130005716A1-20130103-C00060
         		Prepared as described in patent WO 2009/018909
    157
    Figure US20130005716A1-20130103-C00061
         		Prepared as described in patent WO 2009/018909
    158
    Figure US20130005716A1-20130103-C00062
         		Prepared as described in patent WO 2010/089107
    159
    Figure US20130005716A1-20130103-C00063
         		Prepared as described in patent WO 2010/089107
    160
    Figure US20130005716A1-20130103-C00064
         		Prepared as described in patent WO 2009/018909
  • The intermediates used in the procedures described below are commercially available, obtainable by the skilled person through synthetic approaches well known in the art, or obtainable following the synthetic procedures described in the Examples below.
    • Example 17 (S)-3,5-dichloro-4-(2-(4-(difluoromethoxy)-3-methoxyphenyl)-2-hydroxyethyl)pyridine 1-oxide 164)
  • Figure US20130005716A1-20130103-C00065
    • Step 1: 4-((S)-2-((S)-2-acetoxy-2-phenylacetoxy)-2-(3-(cyclopropyl-methoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (161)
  • A mixture of (S)-2-acetoxy-2-phenylacetic acid (0.924 g, 4.76 mmol), (S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-hydroxyethyl)pyridine 1-oxide (1.0 g, 2.380 mmol), EDC (0.684 g, 3.57 mmol), and DMAP (0.436 g, 3.57 mmol) in DCM (150 ml) was stirred at RT for 24 hours. More (S)-2-acetoxy-2-phenylacetic acid (0.350 g, 1.802 mmol), EDC (0.456 g, 2.380 mmol), and DMAP (0.300 g, 2.456 mmol) were added and the stirring was continued for 3 hours to complete conversion. The reaction mixture was washed twice with aqueous 1N HCl and then with aqueous 1M K2CO3; the organic layer was dried over Na2SO4 and evaporated to dryness. The residue was triturated with iPrOH (30 ml) and filtered to afford the desired product (1.27 g, 2.129 mmol, 89% yield). MS/ESI+ 596.18 [MH]+
    • Step 2: 4-((S)-2-((S)-2-acetoxy-2-phenylacetoxy)-2-(4-(difluoromethoxy)-3-hydroxyphenyl)ethyl)-3,5-dichloropyridine 1-oxide (162)
  • 4-((S)-2-((S)-2-acetoxy-2-phenylacetoxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (1.27 g, 2.129 mmol) was treated with trifluoroacetic acid (15 ml, 195 mmol), and the resulting solution was stirred at RT for 20 hours. The reaction mixture was diluted with DCM and washed twice with water; the organic layer was dried over Na2SO4 and evaporated to dryness. The residue was purified by chromatography on silica gel (DCM/EtOAc=3:2 to 1:1). The mixed fractions were combined and triturated with a mixture of iPr2O/Et2O (10:1). The collected solid was then combined to pure fractions from chromatography to afford the desired compound (1.08 g, 1.991 mmol, 94% yield); MS/ESI+ 542.11 [MH]+
  • 1H NMR (300 MHz, DMSO-d6) δ ppm 8.56 (s, 2H), 7.27-7.50 (m, 5H), 6.98 (d, 1H), 6.81 (d, 1H), 7.00 (t, 1H), 6.54 (dd, 1H), 5.89 (dd, 1H), 5.84 (s, 1H), 3.40 (dd, 1H), 3.18 (dd, 1H), 2.13 (s, 3H)
    • Step 3: 4-((S)-2-((S)-2-acetoxy-2-phenylacetoxy)-2-(4-(difluoromethoxy)-3-methoxyphenyl)ethyl)-3,5-dichloropyridine 1-oxide (163)
  • A suspension of 4-((S)-2-((S)-2-acetoxy-2-phenylacetoxy)-2-(4-(difluoromethoxy)-3-hydroxyphenyl)ethyl)-3,5-dichloropyridine 1-oxide (1.080 g, 1.991 mmol), methyl iodide (0.162 ml, 2.59 mmol), and potassium carbonate (0.550 g, 3.98 mmol) in CH3CN (40 ml) was vigorously stirred at RT for 20 hours. The reaction mixture was partitioned between DCM and water and the organic layer was dried over Na2SO4. The solvent was removed under vacuum to afford the desired compound (0.984 g, 1.769 mmol, 89% yield). MS/ESI+ 556.17 [MH]+. The raw compound was used without further purification.
    • Step 4: (S)-3,5-dichloro-4-(2-(4-(difluoromethoxy)-3-methoxyphenyl)-2-hydroxyethyl)pyridine 1-oxide (164)
  • 4-((S)-2-((S)-2-acetoxy-2-phenylacetoxy)-2-(4-(difluoromethoxy)-3-methoxyphenyl)ethyl)-3,5-dichloropyridine 1-oxide (984 mg, 1.769 mmol) was dissolved in a mixture of MeOH (50 ml) and DCM (10 ml). Aqueous sat. NaHCO3 solution (10 ml, 11.00 mmol) was added, and the resulting suspension was stirred at RT for 2 hours. The reaction mixture was partitioned between water and DCM; the organic layer was dried over Na2SO4 and evaporated to dryness to afford the desired compound (650 mg, 1.71 mmol, 97% yield). MS/ESI+ 380.03 [MH].
  • The compound listed in Table 13 was prepared with an analogous procedure to that described in Scheme 23, by using suitable alkylation reagent and performing Step 3 at 65° C.
  • TABLE 13
    MS/ESI+
    Entry Structure [MH]
    165
    Figure US20130005716A1-20130103-C00066
         		610.24
    • Example 18 Synthesis of (S)-3,5-dichloro-4-(2-(3,4-dimethoxyphenyl)-2-hydroxyethyl)pyridine 1-oxide (170)
  • Figure US20130005716A1-20130103-C00067
    • Step 1: Synthesis of 2-(3,5-dichloropyridin-4-yl)-1-(3,4-dimethoxyphenyl)ethanol (166)
  • 3,5-dichloro-4-methylpyridine (160) (54 g, 331 mmol) was dissolved in dry THF (480 mL) under anargon atmosphere and it was cooled at −78° C. in dry-ice/acetone bath. LHMDS 1N THF solution (331 ml, 331 mmol) was added drop-wise by keeping the temperature at −78°. The mixture was stirred at −78° for 1 hour. After that, a solution of 3,4-dimethoxybenzaldehyde (50 g, 301 mmol) in dry THF (120 ml) was added drop-wise by keeping the temperature at −78° C. When the addition was completed, the mixture was allowed to warm at RT.
  • The reaction was poured in ice and water (1 L), and the mixture was stirred until a copious precipitate formed. The solid was filtered, and dissolved in ethyl acetate (500 ml), dried over Na2SO4 and the solvent evaporated under vacuum. The crude was crystallized in CHCl3/hexane. The precipitate was filtered, washed with hexane and dried under vacuum at 40° C. for 8 hours to give 55 g (yield 45%). The mother liquor solution was evaporated under vacuum at 40° C., dissolved in ethyl acetate (200 ml) and extracted with 200 ml of water. The organic solution was dried over Na2SO4 and the solvent evaporated under vacuum at 40° C. The crude was crystallized in CHCl3/hexane, and additional 15 g of the desired product (166) were obtained (overall yield 70%).
    • Step 2: Synthesis of ((R)-2-(3,5-dichloropyridin-4-yl)-1-(3,4-dimethoxyphenyl)ethyl) 2-(6-methoxynaphthalen-2-yl)propanoate (167)
  • Intermediate 166 (50 g, 152 mmol), (R)-2-(6-methoxynaphthalen-2-yl)propanoic acid (38.6 g, 168 mmol), DMAP (20.5 g, 168 mmol), and EDC (43.8 g, 229 mmol) were dissolved in DMF (300 ml), and the reaction mixture was stirred at RT for 2 hours. After that time water (500 ml) was added, and the solution stirred upon precipitation occurs. The solid was filtered and dissolved in DCM (500 ml). The organic solution was washed with aqueous HCl 1N (2×500 ml), saturated aqueous NaHCO3 solution (500 ml) and dried over Na2SO4. The solvent was evaporated under vacuum and the solid residue sonicated in EtOH (300 ml) and triturated for 1 hour. The resulting precipitate was collected by filtration and dried under vacuum at 40° C. for 4 hours to give 79 g (yield 99%) of compound 167, as diastereoisomeric mixture.
    • Step 3: Synthesis of (R)-((S)-2-(3,5-dichloropyridin-4-yl)-1-(3,4-dimethoxyphenyl)ethyl) 2-(6-methoxynaphthalen-2-yl)propanoate (168)
  • Intermediate 167 (79 g, 146 mmol) was dissolved in CHCl3 (100 ml), and MeOH (30 ml) was slowly added up to persistent opalescence and the mixture lewft at RT for 2 hours. The solid formed was collected by filtration and re-crystallized by CHCl3/MeOH (70 ml/20 ml) solvent system to obtain 35 g of compound 168 (yield 88%, ee 98%). Chiral HPLC analysis Rt=42.33 min (fast isomer); eluent: hexane:isopropanol 97:3 1H NMR (600 MHz, CHLOROFORM-d) δ ppm 8.04 (s, 2H), 7.67 (d, J=8.79 Hz, 1H), 7.58 (d, J=8.52 Hz, 1H), 7.53 (m, 1H), 7.12-7.20 (m, 3H), 6.95 (dd, J=8.24, 1.92 Hz, 1 H), 6.78-6.88 (m, 2H), 6.14 (dd, J=10.44, 4.12 Hz, 1H), 3.95 (s, 3H), 3.88 (s, 3H), 3.78-3.81 (m, 4H), 3.55 (dd, J=13.73, 10.44 Hz, 1H), 3.14 (dd, J=13.60, 4.26 Hz, 1H), 1.44 (d, J=7.14 Hz, 3H).
    • Step 4: Synthesis of (S)-2-(3,5-dichloropyridin-4-yl)-1-(3,4-dimethoxyphenyl)ethanol (169)
  • Intermediate 168 (30 g, 56 mmol) was dissolved in MeOH, and toluene was slowly added. Potassium terbutoxide was slowly added to the suspension. The mixture was stirred for 24 hours at RT. The reaction was diluted with water (500 ml), and the aqueous mixture was extracted with CHCl3 (500 ml). The organic layer was dried over Na2SO4 and the solvent was evaporated under vacuum. The residue was crystallized from CHCl3 (100 ml) and hexane (20 ml, till persistent opalescence). The mother liquor was concentrated and recrystallized in the same way giving a second crop of desired compound. Totally 16 g of compound 169 (yield 87%) were obtained.
  • Chiral HPLC analysis Rt=58.03 min; eluent:hexane:isopropanol 95:5. [α]D 20=+10.21 (c=0.506, methanol)
  • 1H NMR (400 MHz, acetone) δ ppm 8.47 (s, 2H), 6.96-7.15 (m, 1H), 6.87 (m, 2H), 4.93-5.21 (m, 1H), 4.50 (d, J=3.97 Hz, 1H), 3.78 (s, 6H), 3.44 (dd, J=12.79, 8.38 Hz, 1H), 3.22 (dd, J=13.01, 5.51 Hz, 1H).
  • MS/ESI+ [MH]+: 328.19
    • Step 5: Synthesis of (S)-3,5-dichloro-4-(2-(3,4-dimethoxyphenyl)-2-hydroxyethyl)pyridine 1-oxide (170)
  • Compound 169 (4 g, 12 mmol) was dissolved in ethyl acetate, and m-CPB acid was added to the solution. The mixture was stirred at RT for 5 hours. The formed solid was collected by filtration, washed with ethyl acetate and dried under vacuum to give 1.72 g of title compound (yield 41%).Chiral HPLC analysis Rt=22.16 min; eluent: hexane:isopropanol 6:4. [α]D 20=+68.91 (c=0.253, Methanol/CHCl3 1:1). MS/ESI+ [MH]+: 344.19
  • 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 8.15 (s, 2H), 6.99 (m, 1H), 6.79-6.88 (m, 2H), 5.03 (dd, J=8.50, 5.32 Hz, 1H), 3.75-3.98 (m, 6H), 3.42 (dd, J=13.57, 8.56 Hz, 1H), 3.19 (dd, J=13.51, 5.32 Hz, 1H), 2.06-2.15 (m, 1H).
    • Example 36 Synthesis of 3,5-dichloro-4-(2-(2,2-dimethylbenzo[d][1,3]dioxol-5-yl)-2-hydroxyethyl)pyridine 1-oxide (172)
  • Figure US20130005716A1-20130103-C00068
    • Step 1: Synthesis of 2-(3,5-dichloropyridin-4-yl)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)ethanol (171)
  • 3,5-dichloro-4-methylpyridine (166) (4.37 g, 0.016 mol) was dissolved in dry THF (40 mL) under an argon atmosphere and it was cooled at −78° C. in dry-ice/acetone bath. LHMDS IN THF solution (28 ml, 28 mmol) was added drop-wise by keeping the temperature at −78°. The mixture was stirred at −78° for 1 hour. After that, a solution of 2,3-difluoro-3,4-benzodioxolocarboxaldheyde (5 g, 0.026 mol) in dry THF (10 ml) was added drop-wise by keeping the temperature at −78° C. When the addition was completed, the mixture was allowed to warm at RT. The reaction was poured in ice and water, and the aqueous phase extracted with ethyl acetate (3×). The combined organic phases were dried over Na2SO4 and the solvent evaporated under vacuum. The crude was crystallized in petroleum ether/hexane 1/1. The precipitate was filtered, washed with hexane and dried under vacuum at 40° C. for 8 h to give 6.4 g (yield 45%).
  • MS/ESI+ 349.14 [MH]+; 1H NMR (200 MHz, CHLOROFORM-d) δ ppm 8.71 (s, 2H), 7.48-7.68 (m, 2H), 6.85-7.07 (m, 1H), 4.61 (m, 1H), 4.11-4.44 (m, 2H).
    • Step 2: Synthesis of 3,5-dichloro-4-(2-(2,2-dimethylbenzo[d][1,3]dioxol-5-yl)-2-hydroxyethyl)pyridine 1-oxide (172)
  • 2-(3,5-dichloropyridin-4-yl)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)ethanol (2 g, 5.74 mmol) was dissolved in EtOAc (40 ml), and the solution was cooled to 0° C. m-CPBA (5.29 g, 22.98 mmol) was added, and the resulting mixture was stirred at RT for 24 hours. The reaction mixture was cooled to 0° C., and the white solid precipitate was filtered and washed twice with cold DCM to afford the desired product (1.738 g, 4.77 mmol, 83%); MS/ESI+ 364.03 [MH]+
    • Example 19 Synthesis of 3,5-dichloro-4-(2-hydroxy-2-(4-methoxyspiro[benzo[d][1,3]dioxole-2,1′-cyclopentane]-7-yl)ethyl)pyridine 1-oxide (174)
  • Figure US20130005716A1-20130103-C00069
    • Step 1: 3,5-dichloro-4-(2-(4-methoxyspiro[benzo[d][1,3]dioxole-2,1′-cyclopentane]-'7-yl)-2-oxoethyl)pyridine 1-oxide (173)
  • To a solution of 2-(3,5-dichloropyridin-4-yl)-1-(4-methoxyspiro[benzo[d][1,3]dioxole-2,1′-cyclopentane]-7-yl)ethanone, (prepared as described in EP 1 535 920, which is incorporated herein by reference in its entirety, 4.75 g, 12.05 mmol) in EtOAc (125 ml) cooled at 0° C., m-CPBA (11.09 g, 48.2 mmol) was added and the reaction mixture was stirred at RT for 24 hours. More m-CPBA (5.54 g, 24.10 mmol) was added, and the stirring was continued for additional 24 hours. The mixture was washed several times with aqueous 1M K2CO3 and the organic layer was dried over Na2SO4 and evaporated to dryness. The residue was purified by chromatography on silica gel, (DCM/EtOAc=3/1 to 1/2) to afford 3,5-dichloro-4-(2-(4-methoxyspiro[benzo[d][1,3]dioxole-2,1′-cyclopentane]-7-yl)-2-oxoethyl)pyridine 1-oxide (2.14 g, 5.22 mmol, 43.3% yield); MS/ESI+ 410.10 [MH]+.
    • Step 2: 3,5-dichloro-4-(2-hydroxy-2-(4-methoxyspiro[benzo[d][1,3]dioxole-2,1′-cyclopentane]-7-yl)ethyl)pyridine 1-oxide (174)
  • To a solution of 3,5-dichloro-4-(2-(4-methoxyspiro[benzo[d][1,3]dioxole-2,1′-cyclopentane]-7-yl)-2-oxoethyl)pyridine 1-oxide (2.14 g, 5.22 mmol) in MeOH (100 ml), solid sodium borohydride (0.197 g, 5.22 mmol) was added portion-wise, and the mixture was stirred at RT overnight. Additional sodium borohydride (0.394 g, 10.44 mmol) was added and over 2 hours, and the stirring was continued for further 12 hours. The mixture was concentrated under vacuum, diluted with EtOAc, and washed twice with aqueous 1N NaOH. The organic layer was dried over Na2SO4, the solvent was removed under reduced pressure, and the residue was purified by chromatography on silica gel (EtOAc) to afford 3,5-dichloro-4-(2-hydroxy-2-(4-methoxyspiro[benzo[d][1,3]dioxole-2,1′-cyclopentane]-7-yl)ethyl)pyridine 1-oxide (650 mg, 1.577 mmol, 30.2% yield); MS/ESI+ 412.10 [MH]+.
    • Example 1 Synthesis of 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-pyrrolidine-2 carbonyloxy)ethyl)pyridine 1-oxide hydrochloride (3)
  • Figure US20130005716A1-20130103-C00070
    • Step 1: 4-((S)-2-((S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (2)
  • (S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-hydroxyethyl)pyridine 1-oxide (1) (550 mg, 1.309 mmol), (S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid (282 mg, 1.309 mmol), EDC (251 mg, 1.309 mmol), and DMAP (160 mg, 1.309 mmol) were dissolved in DMF (5 ml). The reaction was stirred at RT for 48 hours to achieve completion. After that time, the reaction was quenched with HCl 1M and extracted with EtOAc. The organic extract was washed with HCl 1M (×3) and with K2CO3 5% (×3) before being dried over Na2SO4 and concentrated under vacuum to yield 800 mg of desired product (yield 99%). MS/ESI+ 617.16 [MH]+
    • Step 2: 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide hydrochloride (3) 4-((S)-2-((S)-1-(tert-butoxycarbonyppyrrolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (2) (300 mg, 0.486 mmol) was dissolved in Dioxane/HCl (4M, 2 ml) and stirred at RT for 8 hours. After that time, the solvent was removed on a rotavapour under reduced pressure and dried in a vacuum oven overnight to yield the wanted product as an hydrochloride salt (200 mg; yield 80%).
  • MS/ESI+ 517.2 [MH]+; tR/min (Methods 1)=3.75; Diastereomeric Ratio=>99:1; [αD]=−32.80 (c=0.25; CHCl3)
  • 1H NMR (400 MHz, METHANOL-d4) S ppm 8.49 (s, 2H), 7.18 (d, J=7.94 Hz, 1H), 7.11 (d, J=1.76 Hz, 1H), 7.04 (d, J=1.76 Hz, 1H), 6.78 (t, J=75.00 Hz, 1H), 6.10-6.17 (m, 1H), 4.38-4.51 (m, 1H), 3.85-3.99 (m, 2H), 3.66 (m, 2H), 3.39-3.51 (m, 1H), 2.40-2.60 (m, 1H), 1.89-2.17 (m, 4H), 1.15-1.36 (m, 1H), 0.64 (dd, J=7.94, 1.32 Hz, 2H), 0.33-0.47 (m, 2H).
  • The compounds listed in Table 2 were prepared with an analogous procedure to that described in Example 1, by using suitable starting materials.
  • Compounds obtained as free bases underwent a basic work-up in place of removal of the solvent under reduced pressure described above (Ex: NaHCO3 saturated solution), followed by extraction with polar organic solvent (Ex: AcOEt) in order to remove the salification with HCl, which spontaneously occurs performing Step 2 (Scheme 9).
  • Compound 6, 7, 181, and 183 were obtained by reacting its appropriate Boc-protected precursor with AcOEt/HCl (5M), followed by filtration at room temperature of the hydrochloride salt, which spontaneously precipitates from the reaction mixture. Compounds 177, 178, and 179 were obtained by performing Step 2 with HCl in EtOAc and removing the solvent without heating.
  • TABLE 1
    HPLC-MS characterization
    tR/min
    Entry Structure SALT NAME MS/ESI+ [MH]+ Methods 1 or 2 Distaereomeric Ratio 1H NMR [α]D
    4
    Figure US20130005716A1-20130103-C00071
         		Free base 517.2
    5
    Figure US20130005716A1-20130103-C00072
         		Free base 535.2 3.19; 3.26 (2)  40:60
    6
    Figure US20130005716A1-20130103-C00073
         		hydrochloride 535.2 3.26 (2) 99:1 1H NMR (400 MHz, DMSO-d6) δppm 8.57 (s, 2 H), 7.19 (d, J = 7.94 Hz, 1 H), 7.12 (d, J = 1.76 Hz, 1 H), 7.08 (t, J = 75.00 Hz, 1 H), 6.93- 7.00 (m, 1 H), 5.89-5.98 (m, 1 H), 5.12 (s, 1 H), 3.91 (d, J = 7.06 Hz, 2 H), 3.37-3.47 (m, 1 H), 3.10-3.31 (m, 3 H), 2.77-2.93 (m, 2 H), 1.05-1.36 (m, 1 H), 0.51-0.63 (m, 2 H), 0.34 (d, J = 4.85 Hz, 2 H).
    7
    Figure US20130005716A1-20130103-C00074
         		Hydrochloride 535.2
    8
    Figure US20130005716A1-20130103-C00075
         		Free base 533.2 1.86; 1.90 (2) 64:36
    9
    Figure US20130005716A1-20130103-C00076
         		hydrochloride 531.2 2.03 (2) 97:3 1H NMR (400 MHz, DMSO-d6) δ ppm 8.96- 9.18 (bs, 1 H), 8.80-8.96 (bs, 1 H), 8.62 (s, 2 H), 7.22 (d, J = 8.38 Hz, 1 H), 7.18 (d, J = 1.76 Hz, 1 H), 7.02-7.10 (m, 2 H), 6.12 (dd, J = 9.48, 4.63 Hz, 1 H), 4.16 (m, 1 H), 3.94 (dd, J = 7.06, 1.32 Hz, 2 H), 3.49-3.62 (m, 1 H), 3.17-3.34 (m, 3 H), 2.76-2.95 (m, 1 H), 2.04-2.17 (m, 1 H), 1.69 (d, J = 4.85 Hz, 2 H), 1.38-1.60 (m, 2 H), 1.23 (d, J = 3.53 Hz, 1 H), 0.51-0.66 (m, 2 H), 0.31-0.45 (m, 2 H). −10.83 (c = 0.48; CHCl3)
    10
    Figure US20130005716A1-20130103-C00077
         		hydrochloride 531.2
    11
    Figure US20130005716A1-20130103-C00078
         		Free base 535.2 3.19 (2) 99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 8.56 (s, 2 H), 7.18 (d, J = 7.94 Hz, 1 H), 7.04-7.13 (m, 2 H), 6.97 (dd, J = 8.16, 1.54 Hz, 1 H), 5.88-6.03 (m, 1 H), 3.97-4.15 (m, 3 H), 3.90 (d, J = 7.06 Hz, 2 H), 3.43 (dd, J = 14.11, 9.26 Hz, 1 H), 3.24 (dd, J = 14.11, 4.85 Hz, 1 H), 3.08 (dd, J = 10.14, 7.06 Hz, 1 H), 2.80 (dd, J = 10.14, 5.73 Hz, 1 H), 1.14-1.28 (m, 1 H), 0.48-0.67 (m, 2 H), 0.26-0.46 (m, 2 H). −45.77 (c = 0.48; CHCl3)
    12
    Figure US20130005716A1-20130103-C00079
         		hydrochloride 535.2
    13
    Figure US20130005716A1-20130103-C00080
         		Free base 548.6
    14
    Figure US20130005716A1-20130103-C00081
         		Bis hydrochloride 545.1 1H NMR (400 MHz, DMSO-d6) δ ppm 8.89 (bs, 3 H), 8.58 (s, 2 H), 7.19 (d, J = 7.94 Hz, 1 H), 7.07-7.14 (m, 2 H), 6.98 (dd, J = 8.38, 1.76 Hz, 1 H), 6.00 (dd, J = 9.04, 4.63 Hz, 1 H), 3.90-3.92 (d, 2 H), 3.45 (dd, J = 14.11, 9.26 Hz, 1 H), 3.34 (s, 2H), 3.25 (dd, J = 14.11, 4.85 Hz, 1 H), 3.09 (m, 4 H), 2.80 (m, 4 H), 1.12- 1.32 (m, 1 H), 0.52-0.66 (m, 2 H), 0.27- 0.44 (m, 2 H)
    175
    Figure US20130005716A1-20130103-C00082
         		hydrochloride 531.2 1.86 (Method 4) >95:5 1H NMR 1H NMR (300 MHz, DMSO-d6) δ ppm 8.87 (br. s., 2 H), 8.56 (s, 2 H), 7.19 (d, 1 H), 7.09 (d, 1 H), 6.97 (dd, 1 H), 7.07 (t, 1 H), 5.94 (dd, 1 H), 3.91 (d, 2 H), 3.46 (dd, 1 H), 3.28- 3.38 (m, 1 H), 3.23 (dd, 1 H), 3.09-3.19 (m, 1 H), 2.69-3.00 (m, 3 H), 1.90-2.11 (m, 1 H), 1.41-1.84 (m, 3 H), 1.09-1.30 (m, 1 H), 0.49-0.65 (m, 2 H), 0.30-0.42 (m, 2H)
    176
    Figure US20130005716A1-20130103-C00083
         		hydrochloride 531.2 1.84 (Method 4) >95:5 1H NMR 1H NMR (300 MHz, DMSO-d6) δ ppm 8.97- 9.15 (m, 1 H), 8.81-8.97 (m, 1 H), 8.57 (s, 2 H), 7.20 (d, 1 H), 7.11 (d, 1 H), 7.00 (dd, 1 H), 7.08 (t, 1 H), 5.99 (dd, 1 H), 3.93 (d, 2H), 3.49 (dd, 1 H), 3.28-3.37 (m, 1 H), 3.22 (dd, 1 H), 3.07-3.18 (m, 1 H), 2.69-3.00 (m, 3 H), 1.85-2.06 (m, 1 H), 1.60-1.85 (m, 2 H), 1.37-1.60 (m, 1 H), 1.01-1.32 (m, 1 H), 0.47-0.74 (m, 2 H), 0.19-0.47 (m, 2 H)
    177
    Figure US20130005716A1-20130103-C00084
         		hydrochloride 533.1 1.78 (Method 4) >95:5 1H NMR 1H NMR (300 MHz, DMSO-d6) δ ppm 9.45 (br. s., 1 H), 9.35 (br. s., 1 H), 8.55 (s, 2 H), 7.19 (d, 1 H), 7.10 (d, 1 H), 6.98 (dd, 1 H), 7.08 (t, 1 H), 5.99 (dd, 1 H), 4.52 (dd, 1 H), 3.98 (ddd, 1 H), 3.91 (d, 2 H), 3.79 (ddd, 1 H), 3.50 (dd, 1 H), 3.35-3.44 (m, 1 H), 3.25 (dd, 1 H), 2.88-3.21 (m, 3 H), 1.07-1.31 (m, 1 H), 0.47-0.77 (m, 2 H), 0.15-0.45 (m, 2H)
    178
    Figure US20130005716A1-20130103-C00085
         		hydrochloride 533.0 1.78 (Method 4) >95:5 1H NMR 1H NMR (300 MHz, DMSO-d6) δ ppm 9.65- 10.08 (m, 1 H), 9.36-9.65 (m, 1 H), 8.55 (s, 2 H), 7.19 (d, 1 H), 7.11 (d, 1 H), 6.98 (dd, 1 H), 7.08 (t, 1 H), 5.98 (dd, 1 H), 4.53 (dd, 1 H), 3.96-4.07 (m, 1 H), 3.92 (d, 2 H), 3.82 (ddd, 1 H), 3.49 (dd, 1 H), 3.38-3.47 (m, 1 H), 3.26 (dd, 1 H), 3.10-3.21 (m, 1 H), 2.87- 3.11 (m, 2 H), 1.12-1.32 (m, 1 H), 0.49- 0.68 (m, 2 H), 0.15-0.49 (m, 2 H)
    179
    Figure US20130005716A1-20130103-C00086
         		hydrochloride 531.11
    180
    Figure US20130005716A1-20130103-C00087
         		Free base 517.2 1.92 (2) 98:2
    181
    Figure US20130005716A1-20130103-C00088
         		Hydrochloride salt 535.2
    182
    Figure US20130005716A1-20130103-C00089
         		Free base 517.2 1.99 (2) 98:2
    183
    Figure US20130005716A1-20130103-C00090
         		Hydrochloride salt 535.2
    • Example 2 Synthesis of 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(1-((4-(methoxycarbonyl)-5-methylfuran-2-yl)methyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (15)
  • Figure US20130005716A1-20130103-C00091
  • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (3) (40 mg, 0.077 mmol) was dissolved in THF (1 ml), and methyl 5-formyl-2-methylfuran-3-carboxylate (13.00 mg, 0.077 mmol) and acetic acid (4.64 mg, 0.077 mmol) were added to it. The reaction was stirred at RT for 30 minutes before adding sodium triacetoxyhydroborate (16.39 mg, 0.077 mmol). After that time, the reaction was stirred for further 2 hours to get to completion. The solvent was removed, and the residue was partitioned between EtOAc and aq HCl 1M. The organic layer was then washed with aq K2CO3 5% and dried over Na2SO4. The solvent was removed under vacuum to obtain a transparent oil (35 mg; yield 68%) that was purified by preparative HPLC to yield 18 mg of diasteromeric mixture (47.5:52.5) of the desired product as transparent oil (yield 36%). MS/ESI+ 668.9 [MH]+; tR=5.97; 6.15 min (Methodl); Diastereomeric Ratio=47:53.
  • The compounds listed in Table 3 were prepared with an analogous procedure to that described in Step 1; Scheme 10, and by reacting the precursor (5) with suitable reagents.
  • A diastereomeric mixture was obtained from (5) which was were separated by means of preparative HPLC instrument (Method 1 General Experimental Details section) to give the two diastereomers, (16) and (17) identified as fast and slow isomer, respectively, according to their observed retention times under the chromatographic conditions described in the General Experimental Details section (Method 1).
  • TABLE 3
    HPLC-MS characterization
    tR/min Dia-
    MS/ Me- stereo- Pre-
    En- SALT ESI+ thods meric cur-
    try Structure NAME [MH]+ 1 or 2 ratio 1H NMR [α]D sor
    16
    Figure US20130005716A1-20130103-C00092
         		Free Base 696.0 6.52 (1) >99:1 1H NMR (400 MHz, DMSO- d6) δ ppm 8.55 (s, 2 H), 7.32-7.43 (m, 4 H), 7.17 (m, 1 H), 7.05-7.11 (m, 2 H), 6.92-6.97 (m, 1 H), 5.83- 5.96 (m, 1 H), 4.74 (s, 1 H), 3.90 (d, J = 7.06 Hz, 2 H), 3.56 (d, J = 8.38 Hz, 2 H), 3.36 (m, 4 H), 3.07-3.26 (m, 2 H), 2.84 and 3.04 (2s, 6 H), 1.16-1.30 (m, 1 H), 0.58 (m, 2 H), 0.34 (d, J = 3.97 Hz, 2 H). 5
    17
    Figure US20130005716A1-20130103-C00093
         		Free Base 695.9 6.87 (1) >99:1 1H NMR (400 MHz δ ppm 8.56-8.67 (m, 2 H), 7.29-7.37 (m, 4 H), 7.20 (d, J = 7.94 Hz, 1 H), 7.05-7.11 (m, 2 H), 6.88- 6.95 (m, 1 H), 5.88 (dd, J = 10.14, 4.41 Hz, 1H), 4.85 (s, 1 H), 3.76-3.96 (m, 2 H), 3.50-3.69 (m, 2 H), 3.07-3.46 (m, 6 H), 2.83 and 3.02 (2s, 6 H), 1.18-1.30 (m, 1 H), 0.47-0.66 (m, 2 H), 0.22-0.42 (m, 2 H). 5
    • Example 3 Synthesis of 3,5-dichloro-4-((S)-2-((S)-1-(4-(cyclopropylmethoxy)-3-(methylsulfonamido)benzoyl)pyrrolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)pyridine 1-oxide (19)
  • Figure US20130005716A1-20130103-C00094
    • Step 1: 4-((S)-2-((S)-1-(3-(N-(tert-butoxycarbonyl)methylsulfonamido)-4-(cyclopropylmethoxy)benzoyl)pyrrolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (18)
  • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (3) (40 mg; 0.077 mmol) was placed in a 50 ml round bottom flask and dissolved in DMF (2 ml). 3-(N-(tert-butoxycarbonyl)methylsulfonamido)-4-(cyclopropylmethoxy)benzoic acid (40 mg, 0.104 mmol, obtainable as described in WO 2010/089107, which is incorporated herein by reference in its entirety), was added to the reaction solution followed by EDC (20.0 mg, 0.104 mmol) and DMAP (15.0 mg, 0.123 mmol). The reaction was stirred at RT for 6 hours to get to completion and quenched by adding 20 ml of aq HCl 1M. The aqueous layer was extracted with EtOAc and washed with HCl 1M (×3) and with aq K2CO3 5% (×3). The resulting organic extract was dried with Na2SO4, filtered on a filter paper, and the solvent removed on a rotary evaporator under reduced pressure. The oil residue was purified by preparative HPLC (Method 1) to yield 30 mg of desired product (yield 44%).
  • MS/ESI+ 884.1 [MH]+
  • 1H NMR (400 MHz, acetone) δ ppm 8.28 (s, 2H), 7.33 (d, J=7.94 Hz, 1H), 7.14-7.23 (m, 4H), 6.68-7.13 (m, 2H), 6.16 (dd, J=9.92, 4.19 Hz, 1H), 4.52 (dd, J=7.94, 6.17 Hz, 1H), 3.88-4.12 (m, 6H), 3.56-3.74 (m, 3H), 3.53 (s, 3H), 3.34 (dd, J=14.11, 4.41 Hz, 1H), 1.74-1.93 (m, 2H), 1.47 (s, 9H), 1.25-1.35 (m, 2H), 0.51-0.69 (m, 4H), 0.27-0.48 (m, 4H).
    • Step 2: 3,5-dichloro-4-((S)-2-((S)-1-(4-(cyclopropylmethoxy)-3-(methylsulfonamido)benzoyl)pyrrolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)pyridine 1-oxide (19)
  • 4-((S)-2-((S)-1-(3-(N-(tert-butoxycarbonyl)methylsulfonamido)-4-(cyclopropylmethoxy)benzo yl)pyrrolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (18) (30 mg, 0.034 mmol) was dissolved in HCl/EOAc (4M; 2 ml) and stirred for 10 hours at RT to achieve completion. The reaction was quenched by adding K2CO3 5% and extracted with EtOAc. The resulting organic extract was dried over Na2SO4, filtered on a filter paper, and the solvent removed on a rotary evaporator under reduced pressure. The residue was recrystallised from EtOH:hexane (1:3) to yield a white solid (18 mg; yield 68%) of the title compound. MS/ESI+ 784.1 [MH]+; tR=5.72 (Method 1); [αD]=−48.92 (c=3.7; DCM); Diastereomeric Ratio >99:1.
  • 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 8.16 (br. s., 2H), 7.53 (m, 1H), 7.09-7.20 (m, 3H), 7.05 (m, 1H), 6.96 (m, 2H), 6.41-6.63-6.84 (t, 1H, CHF2), 6.08-6.17 (m, 1H), 4.53-4.66 (m, 1H), 3.81-3.98 (m, 4H), 3.61 (m, 3H), 3.22-3.39 (m, 1H), 3.02 (s, 3H), 2.20-2.34 (m, 1H), 1.78-2.02 (m, 3H), 1.27 (m, 2H), 0.59-0.75 (m, 4H), 0.28-0.42 (m, 4H).
  • The compounds listed in Table 4 were prepared with an analogous procedure to that described above in Example 3, Scheme 11, by reacting the appropriate precursors listed with suitable reagents, followed by a purification step as indicated in the table below in place of recrystallization above described.
  • TABLE 4
    HPLC-MS characterization
    tR/min Puri-
    MS/ Me- Diastereo- Pre- fica-
    En- SALT ESI+ thods meric cur- tion
    try Structure NAME [MH]+ 1 or 2 ratio 1H NMR sor method
    20
    Figure US20130005716A1-20130103-C00095
         		formate 669.3 3.07 (2) 99:1  5 Pre- para- tive HPLC
    21
    Figure US20130005716A1-20130103-C00096
         		hydro- chloride 668.3 2.57 (2) >99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 9.54 (bs, 1 H), 8.57 (s, 2 H), 7.40-7.65 (m, 4 H), 7.20 (d, J = 7.94 Hz, 1 H), 7.10 (m, 2 H), 6.95-7.04 (m, 1 H), 5.91-6.13 (m, 1 H), 5.51 (s, 1 H), 4.04-4.21 (m, 3 H), 3.83-4.03 (m, 2 H), 3.67-3.82 (m, 1 H), 3.25-3.37 (m, 2 H), 3.19 (m, 4 H), 1.09-1.32 (m, 1 H), 0.56 (d, J = 7.94 Hz, 2 H), 0.32 (d, J = 4.41 Hz, 2 H) 6 Filtra- tion of the hydro- chloride salt from reac- tion mix- ture
    22
    Figure US20130005716A1-20130103-C00097
         		formate 682.3 2.69; 2.82 (2) 14:86 5 Pre- para- tive HPLC
    • Example 4 Synthesis of 4-((2S)-2-(3-(4-aminobenzoyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (26)
  • Figure US20130005716A1-20130103-C00098
    • Step 1: methyl 3-(4-nitrobenzoyl)thiazolidine-2-carboxylate (23)
  • Methyl thiazolidine-2-carboxylate hydrochloride (200 mg, 1.089 mmol) was dissolved in DCM (2 ml). DMAP (173 mg, 1.416 mmol) and 4-nitrobenzoyl chloride (263 mg, 1.416 mmol) were added, and the reaction was stirred at RT for 2 hours to achieve completion. The reaction mixture was diluted with DMC and extracted with aq HCl 1M. The organic phase was washed with HCl 1N and brine, dried over Na2SO4 and concentrated under vacuum to give methyl 3-(4-nitrobenzoyl)thiazolidine-2-carboxylate (220 mg, 0.742 mmol, 68% yield). MS/ESI+ 297.05 [MH]+
    • Step 2: 3-(4-nitrobenzoyl)thiazolidine-2-carboxylic acid (24)
  • Methyl 3-(4-nitrobenzoyl)thiazolidine-2-carboxylate (220 mg, 0.742 mmol) was dissolved in THF (2 ml). LiOH 1M (1 ml, 1.000 mmol) was added, and the reaction was stirred at RT for 6 hours to achieve completion. The reaction mixture was diluted with HCl 1N and extracted with EtOAc. The organic phase was dried over Na2SO4 and concentrated under vacuum to give 3-(4-nitrobenzoyl)thiazolidine-2-carboxylic acid (180 mg, 0.638 mmol, 86% yield). MS/ESI+ 283.03 [MH]+
    • Step 3: 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(4-nitrobenzoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (25)
  • (S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-hydroxyethyl)pyridine 1-oxide (100 mg, 0.238 mmol), 3-(4-nitrobenzoyl)thiazolidine-2-carboxylic acid (134 mg, 0.476 mmol), DMAP (34.9 mg, 0.286 mmol), and EDC (137 mg, 0.714 mmol) were dissolved in DMF (1.5 ml). The reaction was stirred at RT for 2 hours to achieve completion. The reaction mixture was diluted with water, and the precipitate was washed with water, dissolved in EtOAc and extracted with HCl 1N, Na2CO3 sat. sol. and brine. The organic phase was dried over Na2SO4 and concentrated under vacuum to give 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(4-nitrobenzoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (130 mg, 0.190 mmol, 80% yield).
  • MS/ESI+ 684.07 [MH]+
    • Step 4: 4-((2S)-2-(3-(4-aminobenzoyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (26) 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(4-nitrobenzoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (130 mg, 0.190 mmol) was dissolved in THF (3 ml). Tin(II) chloride dihydrate (257 mg, 1.140 mmol) was added, and the mixture was stirred at RT for 4 days. The solvent was removed under vacuum, and the crude product was dissolved in EtOAc and diluted with Na2CO3 sat. sol. Diatomaceus earth was added to the two phases, and the mixture was filtered on a Diatomaceus earth pad. The organic phase was washed with Na2CO3 sat. sol., brine, dried over Na2SO4 and concentrated under vacuum. The crude product was triturated in Et2O to give 4-((2S)-2-(3-(4-aminobenzoyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyeethyl)-3,5-dichloropyridine 1-oxide (30 mg, 0.046 mmol, 24% yield). MS/ESI+ 653.8 [MH]+; tR=5.80; 6.00 (Method 1); Diastereomeric Ratio 30:70. Example 5 Synthesis of 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(4-methoxy-3-(methylsulfonyloxy)benzoyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-(30)
  • Figure US20130005716A1-20130103-C00099
    • Step 1: 5-formyl-2-methoxyphenyl methanesulfonate (28)
  • 3-hydroxy-4-methoxybenzaldehyde (27) (0.5 g, 3.291 mmol) was dissolved in DCM, and methanesulfonyl chloride (0.376 g, 3.29 mmol) followed by triethylamine (0.499 g, 4.931 mmol) were added. The reaction solution was stirred at RT for 2 hours, after that time, it was quenched with aq HCl 1M and extracted with EtOAc. The organic extract was then washed with aq K2CO3 5%, dried over Na2SO4 and the solvent removed on a rotary evaporator. The desired product was obtained as a white powder (0.750 g, yield 99%). MS/ESI+ 231.02 [MH]+
    • Step 2: 4-methoxy-3-(methylsulfonyloxy)benzoic acid (29)
  • 5-formyl-2-methoxyphenyl methanesulfonate (28) (0.750 g, 3.261 mmol) and sulfamic acid (0.316 g, 3.261 mmol) were dissolved in acetic acid (10 ml) and cooled down by ice bath. Sodium chlorite (0.589 g, 6.521 mmol) was dissolved in water (4 ml) and slowly added to the cold reaction solution. The reaction mixture was allowed to warm at RT and stirred for about 2 hours. After that time, full conversion was observed by UPLC-MS analysis. Addition of water (15 ml) caused precipitation of a white solid, which was filtered and washed several times with water (0.700 g, yield 87%).
  • MS/ESI+ 247.02 [MH]+
    • Step 3: 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoro methoxy)phenyl)-2-((S)-1-(4-methoxy-3-(methylsulfonyloxy)benzoyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (30)
  • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(4-methoxy-3-(methylsulfonyloxy)benzoyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine-1-oxide (30) was prepared by following an analogous procedure to that described in Step 1 (Example 3). MS/ESI+ 745.0 [MH]+; [αD]=31.30 (c=0.34; CHCl3), tR=5.57 (Method 1); Diastereomeric Ratio >99:1. 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 8.17 (s, 2H), 7.56 (m, 2H), 7.13 (m, 4H), 6.60 (t, J=75.00 Hz, 1H), 6.04-6.21 (m, 1H), 4.46-4.75 (m, 1H), 3.95 (s, 3H), 3.85 (m, 2H), 3.50-3.70 (m, 3H), 3.25-3.31 (m, 1H), 3.22 (s, 3H), 2.19-2.41 (m, 1H), 1.74-2.03 (m, 3H), 1.14-1.34 (m, 1H), 0.64 (d, J=7.09 Hz, 2H), 0.34 (d, J=4.16 Hz, 2H).
  • The compounds listed in Table 5 were prepared according to an analogous procedure to that described in Step 3 (Scheme 13) and by reacting the appropriate precursors listed with suitable commercial reagents, followed by an appropriate purification step in place of preparative HPLC as below indicated.
  • TABLE 5
    HPLC-MS characterization
    tR/min Purification
    Entry Structure SALT NAME MS/ES+ [MH]+ Methods 1 or 2 Distereomeric ratio 1H NMR Precursor Method
    31
    Figure US20130005716A1-20130103-C00100
         		Free Base 768.65 2.65; 2.82 (2) 6:94 1H NMR (400 MHz, DMSO- d6) δ ppm 8.56 (s, 1 H), 7.36- 7.55 (m, 2 H), 7.16-7.21 (m, 1 H), 7.01-7.11 (m, 3 H), 6.92- 6.99 (m, 1 H), 5.93-6.05 (m, 1 H), 5.52 (s, 1 H), 3.92-4.12 (m, 1 H), 3.84 (m, 6 H), 3.52- 3.64 (m, 4 H), 3.47 (m, 3 H), 3.25-3.29 (m, 1 H), 3.06-3.18 (m, 1 H), 2.89-3.03 (m, 1 H), 2.38 (m, 4 H) 1.09-1.20 (m, 1 H), 0.46-.61 (m, 2 H), 0.19- 0.29 (m, 2 H). 5 Filtration of the precipitation obtained after water addition, and trituration with MeOH
    32
    Figure US20130005716A1-20130103-C00101
         		Free Base 776.65 3.77; 3.81 (2) 38:62 5 Preparative HPLC
    33
    Figure US20130005716A1-20130103-C00102
         		Free Base 738.62 2.56; 2.69 (2) 38:62 5 Preparative HPLC
    34
    Figure US20130005716A1-20130103-C00103
         		Free Base 696.3 2.49; 2.67 (2) 16:84 5 Preparative HPLC
    35
    Figure US20130005716A1-20130103-C00104
         		Free Base 630.2 3.19; 3.29 (2) 24:76 5 No purification of the crude performed
    36
    Figure US20130005716A1-20130103-C00105
         		Free Base 772.2 4.14 (2) >99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 8.55 (s, 2 H), 7.36-7.45 (m, 2 H), 7.15-7.22 (m, 1 H), 7.01-7.12 (m, 4 H), 6.92-7.00 (m, 1 H), 5.94-6.06 (m, 1 H), 5.50 (s, 1 H), 3.97-4.11 (m, 1 H), 3.84 (m, 7 H), 3.39-3.50 (m, 1 H), 3.26(d, J = 5.73 Hz, 1 H), 3.12 (m, 5 H), 2.91-3.04 (m, 1 H), 1.12-1.30 (m, 1 H), 0.45-0.61 (m, 2 H), 0.24-0.32 (m, 2 H). 6 Tituration with MeOH
    37
    Figure US20130005716A1-20130103-C00106
         		Free Base 682.2 3.75 (2) 96:4 1H NMR (400 MHz, DMSO-d6) δ ppm 8.47-8.73 (m, 2 H), 8.07-8.20 (m, 1 H), 7.91-8.04 (m, 2 H), 7.49-7.65 (m, 2 H), 7.16-7.22 (m, 1 H), 7.07-7.14 (m, 1 H), 6.93-7.03 (m, 1 H), 5.86-6.12 (m, 1 H), 5.53 (s, 1 H), 3.68-4.00 (m, 5 H), 3.39- 3.54 (m, 1 H), 3.06-3.21 (m, 1 H), 2.89-3.05 (m, 1 H), 1.06- 1.32 (m, 1 H), 0.42-0.64 (m, 2 H), 0.12-0.36 (m, 2 H). 6 Trituration with MeOH
    38
    Figure US20130005716A1-20130103-C00107
         		Free Base 646.2 3.32; 3.40 (2) 11:89 5 Trituration with MeOH
    39
    Figure US20130005716A1-20130103-C00108
         		formate 738.3 2.67 (2) 98:2 1H NMR (400 MHz, DMSO- d6) δ ppm 8.56 (s, 2 H), 7.31- 7.52 (m, 4 H), 7.14-7.22 (m, 1 H), 7.05-7.12 (m, 2 H), 6.93- 7.00 (m, 1 H), 5.93-6.14 (m, 1 H), 5.50 (s, 1 H), 3.89-3.97 (m, 1 H), 3.82-3.88 (m, 2 H), 3.70-3.81 (m, 1 H), 3.58 (m, 4 H), 3.52 (s, 2 H), 3.41-3.48 (m, 1 H), 3.20-3.25 (m, 1 H), 3.06-3.18 (m, 1 H), 2.93-3.03 (m, 1 H), 2.28-2.41 (m, 4 H), 1.13-1.21 (m, 1 H), 0.45-0.64 (m, 2 H), 0.19-0.33 (m, 2 H) 6 No purification of the crude performed
    40
    Figure US20130005716A1-20130103-C00109
         		Free Base 786.2 3.58 (2) 97:3 1H NMR (400 MHz, DMSO- d6) δ ppm 8.56 (s, 2 H), 7.33- 7.50 (m, 4 H), 7.15-7.22 (m, 1 H), 7.06-7.12 (m, 2 H), 6.93- 7.00 (m, 1 H), 5.93-6.10 (m, 1 H), 5.50 (s, 1 H), 3.90-4.00 (m, 1 H), 3.83-3.88 (m, 2 H), 3.73 (m, 3 H), 3.37-3.52 (m, 2 H), 3.05-3.21 (m, 5 H), 2.94- 3.04 (m, 1 H), 2.82-2.92 (m, 4 H), 1.11-1.28 (m, 1 H), 0.46- 0.61 (m, 2 H), 0.17-0.41 (m, 2 H). 6 Trituration with EtOH
    41
    Figure US20130005716A1-20130103-C00110
         		Free Base 706.2 3.73 (2) >99:1 1H NMR (400 MHz, DMSO- d6) δ ppm 8.53-8.64 (s, 1 H), 8.43-8.51 (s, 2 H), 7.73-7.93 (m, 3 H), 7.37-7.67 (m, 2 H), 7.14-7.22 (m, 1 H), 7.05-7.13 (m, 2 H), 6.96-7.04 (m, 1 H), 5.98-6.12 (m, 1 H), 5.53 (s, 1 H), 3.74-3.99 (m, 4 H), 3.41- 3.57 (m, 1 H), 3.07-3.20 (m, 2 H), 2.92-3.06 (m, 1 H), 1.06- 1.29 (m, 1 H), 0.47-0.62 (m, 2 H), 0.13-0.37 (m, 2 H) 6 No purification of the crude performed
    42
    Figure US20130005716A1-20130103-C00111
         		formate 640.3 4.05; 4.15 (2) 38:62 5 Preparative HPLC
    184
    Figure US20130005716A1-20130103-C00112
         		Free Base 621.3 80:20 (1H NMR)
    185
    Figure US20130005716A1-20130103-C00113
         		Free Base 692.2 3.14 (2) 98/2 1H NMR (400 MHz, DMSO-d6) δ ppm 8.56 (s, 2 H), 7.47-7.65 (m, 4 H), 7.11-7.25 (m, 2 H), 7.07 (t, J = 75.00 Hz, 1 H), 7.04 (d, J = 1.76 Hz, 1 H), 5.98-6.10 (m, 1 H), 4.49 (s, 1 H), 3.89- 4.02 (m, 2 H), 3.34-3.64 (m, 4 H), 2.82-3.03 (m, 6 H), 2.14- 2.29 (m, 1 H), 1.85 (t, J = 6.62 Hz, 2 H), 1.55-1.67 (m, 1 H), 1.12-1.30 (m, 1 H), 0.54 (dd, J = 8.16, 1.54 Hz, 3 H), 0.30 (d, J = 4.41 Hz, 2 H).
    186
    Figure US20130005716A1-20130103-C00114
         		Free Base 639.1 3.92 >99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 8.55 (s, 2 H), 7.34-7.59 (m, 5 H), 7.13-7.21 (m, 1 H), 7.08 (s, 2 H), 6.93-7.01 (m, 1 H), 5.93-6.11 (m, 1 H), 5.40- 5.59 (m, 1 H), 3.83-4.03 (m, 3 H), 3.69-3.82 (m, 1 H), 3.40- 3.54 (m, 1 H), 3.05-3.18 (m, 1 H), 2.93-3.04 (m, 1 H), 1.14- 1.28 (m, 1 H), 0.46-0.63 (m, 2 H), 0.22-0.40 (m, 2 H).
    187
    Figure US20130005716A1-20130103-C00115
         		Free Base 710.2 3.38 (2) 3/97 1H NMR (400 MHz, DMSO-d6) δ ppm 8.55 (s, 2 H), 7.40-7.65 (m, 4 H), 6.78-7.31 (m, 4 H), 5.85-6.14 (m, 1 H), 5.24 (s, 1 H), 3.69-4.02 (m, 4 H), 3.36- 3.63 (m, 2 H), 3.09-3.21 (m, 1 H), 2.74-3.07 (m, 7 H), 1.12- 1.28 (m, 1 H), 0.42-0.66 (m, 2 H), 0.18-0.39 (m, 2 H)
  • The compounds listed in Table 14 were prepared according to an analogous procedure to that described in Step 3 (Scheme 13) and by reacting the appropriate precursors listed with suitable commercial reagents using DCM instead of DMF as the solvent, followed by an appropriate purification step as below indicated. Compounds 193, 194, and 195 were prepared starting from intermediate 3 or 179 obtained as free bases after a basic treatment of hydrochloride salts with aqueous 1M NaHCO3 followed by extraction with DCM.
  • TABLE 14
    HPLC-MS characterization
    tR/min Diastereo-
    MS/ESI+ Method meric Purification
    Entry Structure SALT NAME [MH]+ 1, 2 or 3 ratio 1H NMR [α] D Precursor Method
    188
    Figure US20130005716A1-20130103-C00116
         		Free Base 653.24 4.03 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6 353K) δ ppm 8.38 (s, 2 H), 7.18-7.36 (m, 5 H), 7.15 (d, 1 H), 7.08 (d, 1 H), 6.94 (dd, 1 H), 6.98 (t, 1 H), 6.01 (dd, 1 H), 5.50 (br. s., 1 H), 3.95-4.10 (m, 1 H), 3.92 (d, 2 H), 3.63- 3.89 (m, 3 H), 3.47 (dd, 1 H), 3.31 (dd, 1 H), 3.06-3.23 (m, 2 H), 1.06-1.37 (m, 1 H), 0.47-0.69 (m, 2 H), 0.21-0.46 (m, 2 H) −33.6 (c = 0.46, DCM) 6 Treatment with polymer supported isocyanate scavenger followed by preparative HPLC (Method 2)
    189
    Figure US20130005716A1-20130103-C00117
         		Free Base 617.08 3.78 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.54 (s, 2 H), 7.16 (d, 1 H), 7.04-7.10 (m, 1 H), 6.93 (dd, 1 H), 7.07 (t, 1 H), 5.95 (dd, 1 H), 5.37 and 5.64 (s, 1 H), 3.93 (d, 2 H), 3.84 (dd, 2 H), 3.42 (dd, 1 H), 3.28 (dd, 1 H), 3.16 (dt, 1 H), 2.93-3.07 (m, 1 H), 2.32 (d, 2 H), 1.10-1.36 (m, 1 H), 0.84- 1.04 (m, 1 H), 0.51-0.67 (m, 2 H), 0.40-0.51 (m, 2 H), 0.26-0.39 (m, 2 H), −0.03-0.18 (m, 2 H) −42.5 (c = 0.54, DCM) 6 Preparative HPLC (Method 2)
    190
    Figure US20130005716A1-20130103-C00118
         		Free Base 731.3 3.85 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.52 (s, 2 H), 7.87-8.01 (m, 2 H), 7.73- 7.84 (m, 1 H), 7.58-7.73 (m, 2 H), 7.16 (d, 1 H), 7.05 (d, 1 H), 6.92 (dd, 1 H), 7.07 (t, 1 H), 5.93 (dd, 1 H), 5.17 (s, 1 H), 3.91 (d, 2 H), 3.70-3.88 (m, 2 H), 3.35-3.63 (m, 4 H), 2.76-3.25 (m, 4 H), 1.08-1.31 (m, 1 H), 0.43-0.69 (m, 2 H), 0.20-0.43 (m, 2 H) −27.4 (c = 0.3, DCM) 6 Flash chromato- graphy on silca gel followed by preparative HPLC (Method 3)
    191
    Figure US20130005716A1-20130103-C00119
         		trifluoroacetate 676.01 3.19 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 9.41 (br. s., 1 H), 8.56 (s, 2 H), 7.22 (d, 1 H), 7.10 (d, 1 H), 6.98 (dd, 1 H), 7.09 (t, 1 H), 6.04 (dd, 1 H), 5.29 (s, 1 H), 3.96-4.15 (m, 2 H), 3.93 (d, 2 H), 3.62-3.90 (m, 4 H), 3.00-3.37 (m, 10 H), 2.90 (t, 2 H), 1.07- 1.45 (m, 1 H), 0.51-0.68 (m, 2 H), 0.28- 0.44 (m, 2 H) −27.1 (c = 0.5, DCM) 6 Preparative HPLC (Method 3)
    192
    Figure US20130005716A1-20130103-C00120
         		trifluoroacetate mono salt 689.44 2.92 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.55 (s, 2 H), 7.20 (d, 1 H), 7.08 (s, 1 H), 6.96 (dd, 1 H), 7.08 (t, 1 H), 6.00 (dd, 1 H), 5.30 (s, 1 H), 3.93 (d, 2 H), 2.75-3.84 (m, 18 H), 2.76 (s, 3 H), 1.11-1.40 (m, 1 H), 0.49-0.66 (m, 2 H), 0.24-0.44 (m, 2 H) −32.4 (c = 0.3, DCM) 6 Preparative HPLC (Method 3)
    193
    Figure US20130005716A1-20130103-C00121
         		Free Base 692.43 3.39 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6 353K) δ ppm 8.41 (s, 2 H), 7.37-7.61 (m, 4 H), 7.15 (d, 1 H), 7.07 (d, 1 H), 6.96 (dd, 1 H), 6.97 (t, 1 H), 6.01 (br. s., 1 H), 4.52 (dd, 1 H), 3.88 (d, 2 H), 3.50-3.64 (m, 2 H), 3.15-3.29 (m, 2 H), 2.97 (s, 6 H), 2.16-2.42 (m, 1 H), 1.52-2.03 (m, 3 H), 0.99-1.32 (m, 1 H), 0.42-0.73 (m, 2 H), 0.14-0.40 (m, 2 H) −32.8 (c = 0.51, DCM) Free base of 3 Preparative HPLC (Method 2)
    194
    Figure US20130005716A1-20130103-C00122
         		Free Base 635.34 3.88 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.55 (s, 2 H), 7.36-7.52 (m, 5 H), 7.19 (d, 1 H), 7.12 (br. s., 1 H), 6.99 (d, 1 H), 7.07 (t, 1 H), 5.87-6.14 (m, 1 H), 4.28 (br. s., 1 H), 3.91 (d, 2 H), 3.32-3.56 (m, 2 H), 3.13-3.32 (m, 2 H), 2.95 (dd, 1 H), 2.39-2.46 (m, 1 H), 1.91-2.10 (m, 1 H), 1.59-1.90 (m, 2 H), 1.35-1.59 (m, 1 H), 1.08-1.33 (m, 1 H), 0.45-0.71 (m, 2 H), 0.08-0.45 (m, 2 H) −60.9 (c = 0.72, DCM) Free Base of 179 Preparative HPLC (Method 2)
    195
    Figure US20130005716A1-20130103-C00123
         		Free Base 706.38 3.42 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.55 (s, 2 H), 7.41-7.55 (m, 4 H), 7.18 (d, 1 H), 7.12 (s, 1 H), 6.99 (d, 1 H), 7.07 (t, 1 H), 6.00 (dd, 1 H), 4.18-4.45 (m, 1 H), 3.91 (d, 2 H), 3.77-4.01 (m, 2 H), 3.34-3.58 (m, 2 H), 3.15-3.34 (m, 2 H), 2.98 (br. s., 3 H), 2.91 (br. s., 3 H), 1.90-2.13 (m, 1 H), 1.60-1.90 (m, 2 H), 1.34-1.60 (m, 1 H), 1.02-1.32 (m, 1 H), 0.49-0.67 (m, 2 H), 0.24-0.42 (m, 2 H) −60.1 (c = 0.48, DCM) Free base of 179 Preparative HPLC (Method 2)
    • Example 20 Synthesis of 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoro-methoxy)phenyl)-2-((S)-3-(2-(3-(dimethylcarbamoyl)phenyl)acetyl)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (198)
  • Figure US20130005716A1-20130103-C00124
    • Step 1: 3-((1,3-dioxolan-2-yl)methyl)-N,N-dimethylbenzamide (196) 3-((1,3-dioxolan-2-yl)methyl)benzoic acid (250 mg, 1.201 mmol), dimethylamine hydrochloride (147 mg, 1.801 mmol), EDC (345 mg, 1.801 mmol), and DMAP (513 mg, 4.20 mmol) were dissolved in DCM (30 ml) and the solution was stirred at RT for 1 hour. The reaction mixture was washed twice with 1N HCl, and the organic layer was dried over Na2SO4. The solvent was removed under reduced pressure to give the desired product (244 mg, 1.037 mmol, 86% yield) MS/ESI+ 236.18 [MH]+ Step 2: 2-(3-(dimethylcarbamoyl)phenyl)acetic acid (197)
  • To a solution of 3-((1,3-dioxolan-2-yl)methyl)-N,N-dimethylbenzamide (244 mg, 1.037 mmol) in THF (30 ml), water (20 ml), oxone (1913 mg, 3.11 mmol), and aqueous 37% HCl (2 ml, 23.92 mmol) were added, and the mixture was stirred at RT for 24 hours. Additional oxone (1.0 g, 1.627 mmol) and aqueous 37% HCl (1 ml, 11.96 mmol) were added, and the stirring was continued at RT for further 24 hours. The reaction mixture was diluted with water (100 ml) and extracted twice with DCM; (2×70 ml); the combined organic layers were dried over Na2SO4 and evaporated to dryness to afford the desired product (200 mg, 0.965 mmol, 93% yield) MS/ESI+ 208.20 [MH]+.
    • Step 3: 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoro-methoxy)phenyl)-2-((S)-3-(2-(3-(dimethylcarbamoyl)phenyl)acetyl)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (198)
  • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoro-methoxy)phenyl)-2-((S)-3-(2-(3-(dimethylcarbamoyl)phenyl)acetyl)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide was prepared according to an analogous procedure to that described in Step 3 (Scheme 13) Example 5, using DCM as the solvent. It was purified by treatment with polymer supported isocyanate followed by preparative HPLC (Method 2) (10% yield).
  • MS/ESI+ 724.28 [MH]+, tR=3.82 min (Method 3); Diastereomeric Ratio >95:5 (1H NMR);
  • 1H NMR (300 MHz, DMSO-d6) δ ppm 8.52 (s, 2H), 7.23-7.48 (m, 4H), 7.15 (d, 1H), 7.06 (d, 1H), 6.91 (dd, 1H), 6.79-7.43 (m, 1H), 5.93 (dd, 1H), 5.41 (s, 1H), 3.93 (dd, 2H), 3.88 (d, 2H), 3.82 (s, 2H), 3.41 (dd, 1H), 3.27 (dd, 1H), 3.00-3.22 (m, 2H), 2.96 (br. s., 3H), 2.90 (br. s., 3H), 1.06-1.39 (m, 1H), 0.46-0.63 (m, 2H), 0.06-0.41 (m, 2H)
  • The compound listed in Table 15 was prepared according to an analogous procedure to that described in Scheme 27 and by reacting the appropriate precursor listed (obtained as free base after basic treatment of hydrochloride salt with aqueous sat. NaHCO3 followed by extraction with DCM), followed by an appropriate purification step as below indicated.
  • TABLE 15
    HPLC-MS
    characterization
    SALT MS/ESI+ tR/min Method Diastereomeric
    Entry Structure NAME [MH]+ 1, 2 or 3 ratio
    199
    Figure US20130005716A1-20130103-C00125
         		Free Base 706.36 3.50 (3) >95:5 (1H NMR B)
    Pur-
    Pre- ification
    Entry 1H NMR [α] D cursor Method
    199 1H NMR (300 MHz, DMSO-d6) δ ppm 8.56 (s, 2 H), 7.23-7.43 (m, 4 H), 7.13 (d, 1 H), 7.06 (d, 1 H), 6.90 (dd, 1 H), 7.05 (t, 1 H), 5.88 (dd, 1 H), 4.32 (dd, 1 H), 3.78-3.95 (m, 2 H), 3.73 (s, 2 H), 3.49-3.67 (m, 2 H), 3.39 (dd, 1 H), 3.22 (dd, 1 H), 2.94 (br. s., 3 H), 2.90 (br. s., 3 H), 2.05-2.24 (m, 1 H), 1.76-1.95 (m, 1 H), 1.47-1.76 (m, 2 H), 1.05-1.23 (m, 1 H), 0.46-0.62 (m, 2 H), 0.20-0.38 (m, 2 H) −18.2 (c = 0.57, DCM). Free base of 3 Preparative HPLC (Method 2) folowed by flash chromato- graphy on silica gel
    • Example 6 Synthesis of 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(3-(cyclopropylmethoxy)-5-(N-(2-morpholinoethyl)methylsulfonamido)benzoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide formate (49)
  • Figure US20130005716A1-20130103-C00126
    • Step 1: methyl 3-(cyclopropylmethoxy)-5-nitrobenzoate (44)
  • Methyl 3-hydroxy-5-nitrobenzoate (43) (1.6 g, 8.1 mmol) was dissolved in DMF (15 ml). (Bromomethyl)cyclopropane (2.2 g, 16.2 mmol) and K2CO3 (1.7 g, 12.2 mmol) were added, and the mixture was stirred at 80° C. for 2 hours. The reaction was cooled at RT, diluted with water and filtered. The precipitate was dissolved in ethyl acetate, and the organic phase was dried over Na2SO4 and evaporated under vacuum to give 1.65 g of the desired product (yield 81%).
  • MS/ESI+ 252.08 [MH]+
    • Step 2: methyl 3-amino-5-(cyclopropylmethoxy)benzoate (45)
  • Methyl 3-(cyclopropylmethoxy)-5-nitrobenzoate (44) (4.9 g, 19.5 mmol) was dissolved in MeOH (200 ml), and Pd/C5% (1.5 g, 0.7 mmol) was added. The solution was shaken under hydrogen atmosphere on a Parr apparatus at 40 psi for 1 hour. The catalyst was filtered on a Diatomaceus earth pad, and the solvent was evaporated under vacuum to give 3.67 g of the desired product (yield 85%).
  • MS/ESI+ 222.11 [MH]+
    • Step 3: methyl 3-(cyclopropylmethoxy)-5-(methylsulfonamido)benzoate (46)
  • Methyl 3-amino-5-(cyclopropylmethoxy)benzoate (45) (1.3 g, 5.9 mmol) was dissolved in pyridine (4 ml). Methanesulfonyl chloride (0.6 ml, 7.7 mmol) was added slowly at 0° C., and the mixture was stirred at RT for 2.5 hours. The reaction was diluted with aq HCl 1N, and the product was extracted with ethyl acetate. The organic phase was washed with HCl 1N, dried over Na2SO4 and evaporated under vacuum to give 1.7 g of the desired product (yield 97%). MS/ESI+ 300.08 [MH]+
    • Step 4: methyl 3-(cyclopropylmethoxy)-5-(N-(2-morpholinoethyl)methylsulfonamido)benzoate (47)
  • Methyl 3-(cyclopropylmethoxy)-5-(methylsulfonamido)benzoate (46) (3 g, 10.02 mmol) was dissolved in DMF (25 ml). 4-(2-chloroethyl)morpholine (4.5 g, 30.1 mmol) and K2CO3 (2.1 g, 15.03 mmol) were added, and the mixture was stirred at 60° C. for 2 hours. The reaction was diluted with water and extracted with ethyl acetate. The organic phase was washed with water, dried over Na2SO4 and evaporated under vacuum to give 3 g of the desired product (yield 73%).
  • MS/ESI+ 413.17 [MH]+
    • Step 5: 3-(cyclopropylmethoxy)-5-(N-(2-morpholinoethyl)methylsulfonamido)benzoic acid (48)
  • Methyl 3-(cyclopropylmethoxy)-5-(N-(2-morpholinoethyl)methylsulfonamido)benzoate (47) (3 g, 7.3 mmol) was dissolved in MeOH (45 ml). Aq. NaOH 1N (9 ml) was added, and the mixture was stirred at RT overnight. The reaction was diluted with aq. HCl 1N (9 ml), and the solvent was removed under vacuum to yield 3.7 g of the desired product (quantitative yield).
  • MS/ESI+ 399.15 [MH]+
    • Step 6: 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(3-(cyclopropylmethoxy)-5-(N-(2-morpholinoethyl)methylsulfonamido)benzoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide formate (49)
  • Compound (49) was prepared according to an analogous procedure to that described in Example 3, step 1, starting from compound 5. The crude product was purified by preparative HPLC to obtain compound (49) as a formate salt.
  • MS/ESI+ 915.3 [MH]+; tR=3.37; 3.43 (Method 2); Diastereomeric Ratio=47:53.
    • Example 7 Synthesis of 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(5-((dimethylamino)methyl)thiophene-2-carbonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide formate (51)
  • Figure US20130005716A1-20130103-C00127
    • Step 1: 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(5-formylthiophene-2-carbonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (50) 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (5) (200 mg, 0.374 mmol), 5-formylthiophene-2-carboxylic acid (233 mg, 1.494 mmol), DMAP (100 mg, 0.822 mmol), and EDC (358 mg, 1.868 mmol) were dissolved in DMF (2 ml). The reaction was stirred at RT overnight, then it was diluted with water, and the precipitate was washed with water, dissolved in AcOEt and washed with aq. HCl 1N, aq. Na2CO3 sat. sol., and brine. The organic phase was dried over Na2SO4 and concentrated under vacuum to give 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(5-formylthiophene-2-carbonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (150 mg, yield 60%).
  • MS/ESI+ 673.04 [MH]+
    • Step 2: 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(5-((dimethylamino)methyl)thiophene-2-carbonyl)thiazolidine-2-carbonyl oxy)ethyl)pyridine 1-oxide (51)
  • 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(3-formyl benzoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (50) (50 mg, 0.075 mmol) was dissolved in THF (1 ml). Acetic acid (8.58 μl, 0.150 mmol) and dimethylamine 2M in THF (7.95 μl, 0.150 mmol) were added, and the mixture was stirred at RT for 30 minutes. Sodium triacetoxyborohydride (32 mg, 0.150 mmol) was added, and the mixture was stirred at RT for 3 hours to achieve completion. The reaction mixture was diluted with water and extracted with AcOEt. The organic phase was dried over Na2SO4 and concentrated under vacuum. The crude product was purified by semi-preparative HPLC (Method 1) to give the wanted product as formate salt (16 mg, yield 31%). MS/ESI+ 702.2 [MH]+; tR (Method 2)=2.54; 2.68 min; Diastereomeric Ratio=21:79
    • Example 8 Synthesis of 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (52)
  • Figure US20130005716A1-20130103-C00128
  • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide hydrochloride (6) (300 mg, 0.525 mmol) was dissolved in Py (3 ml, 37.1 mmol). 3-(dimethylcarbamoyl)benzene-1-sulfonyl chloride (156 mg, 0.630 mmol) was added, and the reaction was stirred at RT for 4 hours to achieve completion. The reaction mixture was diluted with aqueous HCl 1N, and extracted with ethyl acetate. The organic phase was washed with aqueous HCl 1N and brine, dried over Na2SO4 and concentrated under vacuum. The crude product was purified by flash chromatography (DCM/IsoPrOH 98/2) to give 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (250 mg, 0.335 mmol, 63.8% yield).
  • MS/ESI+ 746.2 [MH]+; [α]D]=−43.30 (c=0.51; CHCl3), tR=3.66 (Method 1); Diastereomeric Ratio=>99/1; 1H NMR (400 MHz, DMSO-d6) δ ppm 8.58 (s, 2H), 7.88-7.97 (m, 1H), 7.75-7.82 (m, 1H), 7.68-7.74 (m, 1H), 7.14-7.21 (m, 1H), 7.09-7.13 (m, 1H), 7.08 (t, J=75.00 Hz, 1H), 6.92-6.99 (m, 1H), 5.91-6.10 (m, 1H), 5.54 (s, 1 H), 3.79-3.94 (m, 3H), 3.60-3.71 (m, 1H), 3.41-3.51 (m, 1H), 3.26-3.32 (m, 1H),3.02 (s, 3H), 2.92-3.00 (m, 1H), 2.89 (s, 3H), 2.56-2.70 (m, 1H), 1.20-1.27 (m, 1H), 0.53-0.60 (m, 1H), 0.29-0.36 (m, 1H).
  • The compounds listed in Table 6 were prepared according to an analogous procedure to that described for Scheme 16 by reacting the appropriate precursors listed with commercial suitable reagents, followed by appropriate purification step as below reported, if needed. Heating under MW irradiation (50° C., 30 minutes) was used for the synthesis of compound 224.
  • TABLE 6
    HPLC-MS characterization
    MS/ tR/min Diaste-
    SALT ESI+ Method reomeric Purification
    Entry Structure NAME [MH]+ 1, 2 or 3 ratio 1H NMR [α] D Precursor Method
    53
    Figure US20130005716A1-20130103-C00129
         		Free Base 717.2  6.97 (1) >99:1 1H NMR (400 MHz, acetone) δ ppm 8.30 (s, 2 H), 7.39-7.48 (m, 1 H), 7.25-7.35 (m, 2 H), 7.17 (dd, J = 14.77, 8.16 Hz, 2 H), 7.03- 7.10 (m, 1 H), 6.93 (t, J = 75.00 Hz, 1 H), 6.10-6.19 (m, 1 H), 4.21-4.31 (m, 1 H), 4.00 (d, J = 7.06 Hz, 2 H), 3.91 and 3.92 (2s, 2CH3, 6 H), 3.54-3.65 (m, 1 H), 3.40-3.50 (m, 1 H), 3.22-3.38 (m, 2 H), 1.70-1.86 (m, 2 H), 1.55- 1.71 (m, 1 H), 1.29 (m, 2 H), 0.53- 0.66 (m, 2 H), 0.32-0.46 (m, 2 H). 3 Preparative HPLC (Method 1)
    54
    Figure US20130005716A1-20130103-C00130
         		Free Base 728.1  6.12 (1) >99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 8.60 (s, 2 H), 7.80-7.87 (m, 1 H), 7.68-7.80 (m, 3 H), 7.19 (d, J = 7.94 Hz, 1 H), 7.14 (d, J = 1.76 Hz, 1 H), 7.09 (t, J = 75.00 Hz, 1 H), 6.98 (dd, J = 8.38, 1.76 Hz, 1 H), 6.01 (dd, J = 9.70, 4.41 Hz, 1 H), 4.18 (dd, J = 8.60, 4.19 Hz, 1 H), 3.91 (d, J = 7.06 Hz, 2 H), 3.47 (dd, J = 14.33, 9.92 Hz, 1 H), 3.35-3.41 (m, 1 H), 3.26 (dd, J = 14.11, 4.41 Hz, 1 H), 3.18 (dt, J = 9.70, 6.84 Hz, 1 H), 3.02 (s, 3 H), 2.89 (s, 3 H), 1.88-2.02 (m, 1 H), 1.60-1.73 (m, 2 H), 1.47-1.60 (m, 1 H), 1.13-1.28 (m, 1 H), 0.51-0.60 (m, 2 H), 0.26-0.40 (m, 2 H). 3 Flash Cromatography
    55
    Figure US20130005716A1-20130103-C00131
         		Free Base 728.1  6.20 (1) >99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 8.54 (s, 2 H), 7.79-7.87 (m, 1 H), 7.70-7.76 (m, 2 H), 7.67 (d, J = 7.50 Hz, 1 H), 7.21 (d, J = 8.38 Hz, 1 H), 7.13 (d, J = 1.76 Hz, 1 H), 7.10 (t, J = 75.00 Hz, 1 H), 6.96-7.03 (m, 1 H), 5.94-6.01 (m, 1 H), 4.13-4.25 (m, 1 H), 3.85-3.97 (m, 2 H), 3.34-3.53 (m, 2 H), 3.23-3.30 (m, 1 H), 3.12- 3.22 (m, 1 H), 3.00 (s, 3 H), 2.87 (s, 3 H), 1.86-2.01 (m, 1 H), 1.64- 1.83 (m, 2 H), 1.52-1.63 (m, 1 H), 1.13-1.29 (m, 1 H), 0.56 (dd, J = 7.94, 1.32 Hz, 2 H), 0.25-0.41 (m, 2 H).  +39.02 (c = 0.51; CHCl3) 4 Preparative HPLC (Method 1)
    56
    Figure US20130005716A1-20130103-C00132
         		Free Base 745.8  6.20; 6.30 (1)   41:59 5 Preparative HPLC (Method 1)
    57
    Figure US20130005716A1-20130103-C00133
         		Free Base 674.1  7.15; 7.27 (1)   40:60 5 Preparative HPLC (Method 1)
    58
    Figure US20130005716A1-20130103-C00134
         		Free Base 744.0  6.44; 6.35 (1)   40:60 5 Triturated with Et2O
    59
    Figure US20130005716A1-20130103-C00135
         		Free Base 753.9  6.02; 6.22 (1)   36:64 5 Preparative HPLC (Method 1)
    60
    Figure US20130005716A1-20130103-C00136
         		Free Base 693.0  7.52; 7.62 (1)   38:62 5 Preparative HPLC (Method 1)
    61
    Figure US20130005716A1-20130103-C00137
         		Free Base 703.1  8.23; 8.32 (1)   37:63 5 Preparative HPLC (Method 1)
    62
    Figure US20130005716A1-20130103-C00138
         		Free Base 681.0  7.17; 7.27 (1)   42:58 5 Preparative HPLC (Method 1)
    63
    Figure US20130005716A1-20130103-C00139
         		Free Base 708.8  7.92; 8.02 (1)   38:62 5 Preparative HPLC (Method 1)
    64
    Figure US20130005716A1-20130103-C00140
         		Free Base 678.9  6.35; 6.44 (1)   41:59 5 Preparative HPLC (Method 1)
    65
    Figure US20130005716A1-20130103-C00141
         		Free Base 652.8  6.97; 7.12 (1)   51:49 5 Preparative HPLC (Method 1)
    66
    Figure US20130005716A1-20130103-C00142
         		hydro- chloride 675.7  6.40; 6.48 (1)   38:62 5 Preparative HPLC (Method 1)
    67
    Figure US20130005716A1-20130103-C00143
         		Free Base 710.9  7.63; 7.73 (1)   41:59 5 Preparative HPLC (Method 1)
    68
    Figure US20130005716A1-20130103-C00144
         		Free Base 726.9  7.90; 7.98 (1)   40:60 5 Preparative HPLC (Method 1)
    69
    Figure US20130005716A1-20130103-C00145
         		Free Base 706.7  7.95; 8.05 (1)   45:55 5 Preparative HPLC (Method 1)
    70
    Figure US20130005716A1-20130103-C00146
         		Free Base 708.8  7.72; 7.80 (1)   39:61 5 Preparative HPLC (Method 1)
    71
    Figure US20130005716A1-20130103-C00147
         		Free Base 680.9  7.87; 7.97 (1)   32:68 5 Preparative HPLC (Method 1)
    72
    Figure US20130005716A1-20130103-C00148
         		Free Base 758.8  5.53; 5.63 (1)   37:63 5 Trituration with ethyl ether
    73
    Figure US20130005716A1-20130103-C00149
         		Free Base 735.2  4.03; 4.09 (2)   60:40 5 Preparative HPLC (Method 1)
    74
    Figure US20130005716A1-20130103-C00150
         		formate 761.2  3.97; 4.02 (2)   35:65 5 Preparative HPLC (Method 1)
    75
    Figure US20130005716A1-20130103-C00151
         		Free Base 719.1  3.60 (2)   96:4 1H NMR (400 MHz, DMSO-d6) δ ppm 13.23-13.92 (bs, 1 H), 8.58 (s, 2 H), 8.20-8.41 (m, 2 H), 8.00- 8.17 (m, 1 H), 7.78 (m, 1 H), 7.17 (d, J = 8.38 Hz, 1 H), 7.04-7.14 (m, 2 H), 6.96 (d, J = 1.76 Hz, 1 H), 5.94-6.13 (m, 1 H), 5.46 (s, 1 H), 3.90 (d, J = 6.62 Hz, 2 H), 3.69 (m, 2 H), 3.42-3.54 (m, 1 H), 3.25-3.30 (m, 1 H), 2.89-3.03 (m, 1 H), 2.64-2.73 (m, 1 H), 1.11- 1.31 (m, 1 H), 0.56 (dd, J = 7.94, 1.76 Hz, 2 H), 0.33 (d, J = 4.85 Hz, 2 H). 5 Triturated with Et2O
    76
    Figure US20130005716A1-20130103-C00152
         		Free Base 694.2  4.09; 4.13 (2)   33:67 5 Preparative HPLC (Method 1)
    77
    Figure US20130005716A1-20130103-C00153
         		Free Base 751.8  5.62 (1) >99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 8.55 (s, 2 H), 8.15 (m, 2 H), 7.96-8.02 (m, 1 H), 7.91 (m, 1 H), 7.65 (s, 2 H), 7.17 (m, 1 H), 7.05- 7.13 (m, 2 H), 6.94-7.04 (m, 1 H), 5.65-6.06 (m, 1 H), 4.37-4.50 (m, 1 H), 3.92 (d, J = 7.06 Hz, 2 H), 3.72-3.82 (m, 1 H), 3.57-3.68 (m, 1 H), 3.41-3.53 (m, 1 H), 3.19- 3.27 (m, 2 H), 3.09-3.18 (m, 1 H), 2.91-3.02 (m, 1 H), 2.78-2.89 (m, 1 H), 1.20-1.26 (m, 1 H), 0.49- 0.65 (m, 2 H), 0.35 (d, J = 5.73 Hz, 2 H). 8 Preparative HPLC (Method 1)
    78
    Figure US20130005716A1-20130103-C00154
         		Free Base 744.0  5.84; 6.00 (1)   64:36 8 Preparative HPLC (Method 1)
    79
    Figure US20130005716A1-20130103-C00155
         		Free Base 673.2  3.92; 3.93 (2)   67:33 8 Triturated with MeOH
    80
    Figure US20130005716A1-20130103-C00156
         		Free Base 759.8  6.27; 6.45 (1)   47:53 13 Preparative HPLC (Method 1)
    81
    Figure US20130005716A1-20130103-C00157
         		Free Base 781.8  6.52; 6.77 (1)   39:61 13 Preparative HPLC (Method 1)
    82
    Figure US20130005716A1-20130103-C00158
         		Free Base 742.2  3.85 (2) >99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 8.50 (s, 2 H), 7.57-7.84 (m, 4 H), 7.08-7.17 (m, 1 H), 7.02- 7.08 (m, 2 H), 6.83-6.93 (m, 1 H), 5.77-5.96 (m, 1 H), 4.56-4.73 (m, 1 H), 3.78-3.99 (m, 2 H), 3.56- 3.74 (m, 1 H), 3.33-3.46 (m, 2 H), 3.17-3.26 (m, 1 H), 2.99 (s, 3 H), 2.86 (s, 3 H), 1.99-2.17 (m, 1 H), 1.43-1.69 (m, 3 H), 1.08-1.31 (m, 2 H), 0.71-0.99 (m, 1 H), 0.43- 0.61 (m, 2 H), 0.25-0.38 (m, 2 H). 10 Preparative HPLC (Method 1)
    83
    Figure US20130005716A1-20130103-C00159
         		Free Base 742.3  3.74 (2)   96:4 1H NMR (400 MHz, DMSO-d6) δ ppm 8.58 (s, 2 H), 7.67-7.75 (m, 2 H), 7.56-7.64 (m, 1 H), 7.40- 7.50 (m, 1 H), 7.18-7.24 (m, 1 H), 7.05-7.13 (m, 2 H), 6.89-6.95 (m, 1 H), 5.92-6.00 (m, 1 H), 4.68- 4.80 (m, 1 H), 3.85-4.02 (m, 2 H), 3.54-3.66 (m, 1 H), 3.36-3.48 (m, 2 H), 3.16-3.26 (m, 1 H), 2.97 (s, 3 H), 2.81 (s, 3 H), 1.88-2.02 (m, 1 H), 1.38-1.64 (m, 4 H), 1.11- 1.29 (m, 2 H), 0.65-0.80 (m, 1 H), 0.50-0.64 (m, 2 H), 0.29-0.42 (m, 2 H).  +16.33 (c = 0.24; CHCl3) 9 Preparative HPLC (Method 1)
    84
    Figure US20130005716A1-20130103-C00160
         		Free Base 746.1  6.30 (1) >99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 8.59 (s, 2 H), 7.85-7.99 (m, 2 H), 7.65-7.79 (m, 2 H), 7.13- 7.22 (m, 2 H), 7.09 (t, J = 75.00 Hz, 1 H), 6.98 (dd, J = 8.38, 1.76 Hz, 1 H), 6.00 (dd, J = 9.26, 4.41 Hz, 1 H), 4.89 (dd, J = 7.28, 4.63 Hz, 1 H), 4.73 (d, J = 10.58 Hz, 1 H), 4.32 (d, J = 10.58 Hz, 1 H), 3.92 (d, J = 7.06 Hz, 2 H), 3.46 (dd, J = 14.11, 9.70 Hz, 1 H), 3.23-3.30 (m, 1 H), 2.93-3.08 (m, 5 H), 2.88 (s, 3 H), 1.23 (d, J = 7.06 Hz, 1 H), 0.49-0.64 (m, 2 H), 0.33 (q, J = 4.85 Hz, 2 H). 11 Preparative HPLC (Method 1)
    85
    Figure US20130005716A1-20130103-C00161
         		Free Base 680.8  7.07; 7.18 (1)   36:64 5 Triturated with Et2O
    86
    Figure US20130005716A1-20130103-C00162
         		Free Base 657.3  4.09 (2)   98:2 1H NMR (400 MHz, DMSO-d6) δ ppm 8.61 (s, 2 H), 7.69-7.82 (m, 3 H), 7.60-7.68 (m, 2 H), 7.19 (d, J = 7.94 Hz, 1 H), 7.14 (d, J = 1.76 Hz, 1 H), 7.08 (t, J = 75.00 Hz, 1 H), 6.98 (dd, J = 8.38, 1.76 Hz, 1 H), 6.02 (dd, J = 9.70, 4.41 Hz, 1 H), 4.13 (dd, J = 8.60, 4.19 Hz, 1 H), 3.92 (d, J = 6.62 Hz, 2 H), 3.47 (dd, J = 14.11, 9.70 Hz, 1 H), 3.33-3.41 (m, 1 H), 3.26 (dd, J = 14.11, 4.41 Hz, 1 H), 3.16 (ddd, J = 9.81, 6.84, 6.73 Hz, 1 H), 1.83-1.98 (m, 1 H), 1.58-1.74 (m, 2 H), 1.41-1.57 (m, 1 H), 1.14-1.27 (m, 1 H), 0.48-0.63 (m, 2 H), 0.26-0.40 (m, 2 H) 3 No purification
    87
    Figure US20130005716A1-20130103-C00163
         		Free Base 739.1  4.30; 4.25 (2)   32:68 5 Preparative HPLC (Method 1)
    88
    Figure US20130005716A1-20130103-C00164
         		Free Base 676.2  3.62 (2)   99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 9.05 (d, J = 2.20 Hz, 1 H), 8.91 (dd, J = 4.63, 1.54 Hz, 1 H), 8.58 (s, 2 H), 8.31 (ddd, J = 8.27, 1.87, 1.76 Hz, 1 H), 7.69 (dd, J = 8.38, 4.85 Hz, 1 H), 7.18 (d, J = 7.94 Hz, 1 H), 7.05-7.14 (m, 2 H), 6.95 (dd, J = 8.16, 1.54 Hz, 1 H), 6.01 (dd, J = 9.04, 5.07 Hz, 1 H), 5.63 (s, 1 H), 3.80-3.96 (m, 3 H), 3.61-3.72 (m, 1 H), 3.46 (dd, J = 14.11, 9.26 Hz, 1 H), 3.28-3.40 (m, 2 H), 2.91-3.04 (m, 1 H), 2.69 (ddd, J = 11.14, 6.39, 6.28 Hz, 1 H), 1.21 (ddd, J = 12.13, 7.50, 4.63 Hz, 1 H), 0.49-0.64 (m, 2 H), 0.26-0.41 (m, 2 H).  −43.74 (c = 0.53; CHCl3) 6 Preparative HPLC (Method 1)
    89
    Figure US20130005716A1-20130103-C00165
         		Free Base 675.2  4.20 (2)   97:3 1H NMR (400 MHz, DMSO-d6) δ ppm 8.60 (s, 2 H), 7.87 (d, J = 7.50 Hz, 2 H), 7.75 (d, J = 7.50 Hz, 1 H), 7.61-7.70 (m, 2 H), 7.18 (d, J = 7.94 Hz, 1 H), 7.05- 7.14 (m, 2 H), 6.96 (dd, J = 8.38, 1.76 Hz, 1 H), 6.01 (dd, J = 9.26, 4.85 Hz, 1 H), 5.43 (s, 1 H), 3.90 (d, J = 7.06 Hz, 2 H), 3.75-3.85 (m, 1 H), 3.59-3.68 (m, 1 H), 3.44 (d, J = 9.26 Hz, 1 H), 3.29 (m, 1 H), 2.91-3.00 (m, 1 H), 2.64 (d, J = 11.03 Hz, 1 H), 1.18 (d, J = 7.06 Hz, 1 H), 0.56 (dd, J = 7.94, 1.76 Hz, 2 H), 0.26-0.40 (m, 2 H).  −37.96 (c = 0.56; CHCl3) 6 Flash Cromatography
    90
    Figure US20130005716A1-20130103-C00166
         		Free Base 679.2  3.61 (2)   99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 8.54 (s, 2 H), 7.52 (m, 1 H), 7.18 (d, J = 8.38 Hz, 1 H), 7.10- 7.16 (m, 2 H), 7.09 (t, J = 75.00 Hz, 1 H), 6.97 (dd, J = 8.38, 1.76 Hz, 1 H), 6.02 (dd, J = 9.26, 4.85 Hz, 1 H), 5.49 (s, 1 H), 3.86-3.99 (m, 6 H), 3.71-3.80 (m, 1 H), 3.43 (dd, J = 14.11, 9.70 Hz, 1 H), 3.25-3.31 (m, 1 H), 2.92-3.10 (m, 2 H), 1.15-1.30 (m, 1 H), 0.49- 0.65 (m, 2 H), 0.29-0.42 (m, 2 H).  −43.30 (c = 0.48; CHCl3) 6 Preparative HPLC (Method 1)
    91
    Figure US20130005716A1-20130103-C00167
         		Free Base 754.1  3.58 (2) >99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 8.59 (s, 2 H), 8.28 (m, 1 H), 8.14 (dd, J = 15.66, 8.16 Hz, 2 H), 7.87 (t, J = 7.94 Hz, 1 H), 7.56- 7.72 (m, 2 H), 7.18 (d, J = 8.38 Hz, 1 H), 7.06-7.15 (m, 2 H), 6.96 (dd, J = 8.38, 1.76 Hz, 1 H), 6.03 (dd, J = 8.82, 5.29 Hz, 1H), 5.50 (s, 1 H), 3.85-3.99 (m, 2 H), 3.65- 3.82 (m, 2 H), 3.47 (dd, J = 14.11, 8.82 Hz, 1 H), 3.25-3.30 (m, 1 H), 2.94-3.05 (m, 1 H), 2.63-2.78 (m, 1 H), 1.13-1.32 (m, 1 H), 0.46- 0.63 (m, 2 H), 0.26-0.43 (m, 2 H). 6 Preparative HPLC (Method 1)
    92
    Figure US20130005716A1-20130103-C00168
         		Free Base 753.1  3.70; 3.77 (2)   27:73 5 Preparative HPLC (Method 1)
    93
    Figure US20130005716A1-20130103-C00169
         		Free Base 735.2  4.12 (2)   97:3 1H NMR (400 MHz, DMSO-d6) δ ppm 8.59 (s, 2 H), 7.45 (dd, J = 8.38, 2.21 Hz, 1 H), 7.32 (d, J = 1.76 Hz, 1 H), 7.15-7.21 (m, 2 H), 7.11 (d, J = 1.76 Hz, 1 H), 7.08 (t, J = 75.00 Hz, 1 H), 6.95 (dd, J = 8.38, 1.76 Hz, 1 H), 6.01 (dd, J = 9.26, 4.85 Hz, 1 H), 5.51 (s, 1 H), 3.77-3.95 (m, 9 H), 3.54-3.66 (m, 1 H), 3.45 (dd, J = 14.11, 9.26 Hz, 1 H), 3.25-3.28 (m, 1 H), 2.87- 3.00 (m, 1 H), 2.52-2.64 (m, 1 H), 1.19-1.28 (m, 1 H), 0.47-0.65 (m, 2 H), 0.27-0.39 (m, 2 H). 6 No purification
    94
    Figure US20130005716A1-20130103-C00170
         		Free Base 768.1  4.00 (2)   99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 8.60 (s, 2 H), 8.07-8.16 (m, 2 H), 7.94-8.05 (m, 2 H), 7.71- 7.84 (bs, 1 H), 7.14-7.21 (m, 1 H), 7.08 (m, 2 H), 6.91-6.99 (m, 1 H), 5.92-6.11 (m, 1 H), 5.51 (s, 1 H), 3.90 (d, J = 7.06 Hz, 2 H), 3.76- 3.85 (m, 1 H), 3.63-3.74 (m, 1 H), 3.40-3.52 (m, 1 H), 3.25-3.35 (m, 1 H), 2.92-3.07 (m, 1 H), 2.63- 2.80 (m, 1 H), 2.48 (s, 3 H), 1.13- 1.30 (m, 1 H), 0.49-0.63 (m, 2 H), 0.26-0.40 (m, 2 H). 6 Preparative HPLC (Method 1)
    95
    Figure US20130005716A1-20130103-C00171
         		Free Base 665.2  4.19 (2)   99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 8.59 (s, 2 H), 8.06-8.11 (m, 1 H), 7.32-7.41 (m, 1 H), 7.15- 7.22 (m, 1 H), 7.06-7.14 (m, 2 H), 6.94-7.01 (m, 1 H), 6.76-6.82 (m, 1 H), 5.95-6.07 (m, 1 H), 5.33 (s, 1 H), 3.84-3.98 (m, 2 H), 3.67- 3.83 (m, 2 H), 3.39-3.53 (m, 1 H), 3.24-3.29 (m, 1 H), 2.98-3.09 (m, 1 H), 2.77-2.88 (m, 1 H), 1.16- 1.29 (m, 1 H), 0.52-0.63 (m, 2 H), 0.29-0.40 (m, 2 H). 6 Preparative HPLC (Method 1)
    96
    Figure US20130005716A1-20130103-C00172
         		Free Base 665.2  4.13 (2) >99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 8.58 (s, 2 H), 8.45-8.52 (m, 1 H), 7.89-8.00 (m, 1 H), 7.15- 7.22 (m, 1 H), 7.05-7.14 (m, 2 H), 6.93-7.01 (m, 2 H), 5.92-6.09 (m, 1 H), 5.45 (s, 1 H), 3.84-3.96 (m, 2 H), 3.60-3.82 (m, 2 H), 3.37- 3.52 (m, 2 H), 2.94-3.09 (m, 1 H), 2.79-2.89 (m, 1 H), 1.13-1.32 (m, 1 H), 0.48-0.65 (m, 2 H), 0.26- 0.42 (m, 2 H). 6 Preparative HPLC (Method 1)
    97
    Figure US20130005716A1-20130103-C00173
         		Free Base 782.1  4.35 (2)   98:2 1H NMR (400 MHz, DMSO-d6) δ ppm 8.57 (s, 2 H), 8.23 (m, 1 H), 8.11 (m, 2 H), 7.95 (m, 1 H), 7.18 (d, J = 7.94 Hz, 1 H), 7.11 (d, J = 2.20 Hz, 1 H), 7.08 (t, J = 75.00 Hz, 1 H), 6.91-6.98 (m, 1 H), 5.95-6.06 (m, 1 H), 5.61 (s, 1 H), 3.90 (dd, J = 7.06, 1.32 Hz, 3 H), 3.61-3.72 (m, 1 H), 3.42-3.51 (m, 1 H), 3.26-3.31 (m, 1 H), 2.92- 3.05 (m, 1 H), 2.62-2.75 (m, 7 H), 1.14-1.28 (m, 1 H), 0.56 (dd, J = 7.94, 1.76 Hz, 2 H), 0.33 (dd, J = 4.63, 1.10 Hz, 2 H). 6 Preparative HPLC (Method 1)
    98
    Figure US20130005716A1-20130103-C00174
         		Free Base 731.2  4.52 (2)   98:2 1H NMR (400 MHz, DMSO-d6) δ ppm 8.62 (s, 2 H), 7.20 (m, 2 H), 7.12-7.17 (m, 1 H), 7.07 (d, J = 2.21 Hz, 3 H), 6.86-6.93 (m, 1 H), 5.81-5.96 (m, 1 H), 4.53-4.70 (m, 1 H), 3.85 (m, 5 H), 3.80 (s, 3 H), 3.51-3.65 (m, 1 H), 3.35-3.47 (m, 1 H), 3.17-3.28 (m, 1 H), 2.93- 3.06 (m, 1 H), 1.97-2.10 (m, 1 H), 1.40-1.64 (m, 3 H), 1.12-1.29 (m, 2 H), 0.80-0.99 (m, 1 H), 0.50- 0.62 (m, 2 H), 0.25-0.40 (m, 2 H). 10 Preparative HPLC (Method 1)
    99
    Figure US20130005716A1-20130103-C00175
         		Free Base 672.3  4.17 (2)   98:2 1H NMR (400 MHz, DMSO-d6) δ ppm 8.78-8.86 (m, 2 H), 8.66 (s, 2 H), 7.99-8.11 (m, 1 H), 7.55- 7.65 (m, 1 H), 7.11-7.21 (m, 1 H), 7.02-7.10 (m, 2 H), 6.84-6.93 (m, 1 H), 5.83-5.92 (m, 1 H), 4.65- 4.76 (m, 1 H), 3.79-3.96 (m, 2 H), 3.62-3.74 (m, 1 H), 3.35-3.47 (m, 1 H), 3.18-3.26 (m, 1 H), 2.86- 3.05 (m, 1 H), 2.05-2.17 (m, 1 H), 1.46-1.74 (m, 3 H), 1.12-1.32 (m, 2 H), 0.80-0.98 (m, 1 H), 0.50- 0.63 (m, 2 H), 0.26-0.41 (m, 2 H). 10 Preparative HPLC (Method 1)
    100
    Figure US20130005716A1-20130103-C00176
         		Free Base 733.1  4.54 (2) >99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 8.60 (s, 2 H), 8.17 (d, J = 8.38 Hz, 2 H), 8.03 (m, 2 H), 7.15-7.20 (m, 1 H), 7.05-7.13 (m, 2 H), 6.92-6.98 (m, 1 H), 5.93- 6.09 (m, 1 H), 5.49 (s, 1 H), 3.91 (m, 5 H), 3.77-3.86 (m, 1 H), 3.64-3.72 (m, 1 H), 3.41-3.51 (m, 1 H), 3.26-3.30 (m, 1 H), 2.91- 3.03 (m, 1 H), 2.64-2.77 (m, 1 H), 1.14-1.29 (m, 1 H), 0.51-0.60 (m, 2 H), 0.28-0.37 (m, 2 H). 6 Preparative HPLC (Method 1)
    101
    Figure US20130005716A1-20130103-C00177
         		Free Base 733.1  4.44 (2)   96:4 1H NMR (400 MHz, DMSO-d6) δ ppm 8.57 (s, 2 H), 7.96-8.04 (m, 1 H), 7.71-7.84 (m, 2 H), 7.62- 7.69 (m, 1 H), 7.13-7.20 (m, 1 H), 7.05-7.12 (m, 2 H), 6.91-6.98 (m, 1 H), 5.92-6.02 (m, 1 H), 5.68 (s, 1 H), 3.96-4.06 (m, 1 H), 3.86- 3.92 (m, 2 H), 3.84 (s, 3 H), 3.56- 3.67 (m, 1 H), 3.39-3.51 (m, 1 H), 3.24-3.29 (m, 1 H), 2.95-3.06 (m, 1 H), 2.74-2.84 (m, 1 H), 1.16- 1.27 (m, 1 H), 0.51-0.63 (m, 2 H), 0.29-0.37 (m, 2 H). 6 Preparative HPLC (Method 1)
    102
    Figure US20130005716A1-20130103-C00178
         		Free Base 746.2  4.12 (2)   99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 8.54 (s, 2 H), 7.92-7.98 (m, 1 H), 7.84-7.91 (m, 1 H), 7.63- 7.77 (m, 2 H), 7.18-7.25 (m, 1 H), 7.12-7.17 (m, 1 H), 7.09 (t, J = 75.00 Hz, 1 H), 6.96-7.03 (m, 1 H), 5.95-6.02 (m, 1 H), 4.92-5.04 (m, 1 H), 4.67-4.78 (m, 1 H), 4.25-4.34 (m, 1 H), 3.86-4.00 (m, 2 H), 3.42-3.56 (m, 1 H), 3.21- 3.29 (m, 1 H), 3.00 (m, 4 H), 2.86 (m, 4 H), 1.14-1.29 (m, 1 H), 0.50-0.63 (m, 2 H), 0.28-0.39 (m, 2 H). 12 Preparative HPLC (Method 1)
    103
    Figure US20130005716A1-20130103-C00179
         		Free Base 705.2  4.80 (2)   97:3 1H NMR (400 MHz, DMSO-d6) δ ppm 8.58 (s, 2 H), 7.53-7.60 (m, 1 H), 7.40-7.46 (m, 1 H), 7.29- 7.37 (m, 2 H), 7.16-7.20 (m, 1 H), 7.09-7.12 (m, 1 H), 7.08 (t, J = 75.00 Hz, 1 H), 6.93-6.98 (m, 1 H), 5.96-6.07 (m, 1 H), 5.50 (s, 1 H), 3.88-3.94 (m, 2 H), 3.87 (s, 3 H), 3.77-3.85 (m, 1 H), 3.59-3.67 (m, 1 H), 3.40-3.50 (m, 1 H), 3.25-3.30 (m, 1 H), 2.91-3.02 (m, 1 H), 2.61-2.70 (m, 1 H), 1.15- 1.29 (m, 1 H), 0.53-0.61 (m, 2 H), 0.29-0.38 (m, 2 H) 6 Trituration with Et2O
    104
    Figure US20130005716A1-20130103-C00180
         		Free Base 759.1  5.20 (2)   98:2 1H NMR (400 MHz, DMSO-d6) δ ppm 8.57 (s, 2 H), 7.89-7.98 (m, 2 H), 7.80 (d, J = 5.29 Hz, 2 H), 7.18 (d, J = 8.38 Hz, 1 H), 7.07- 7.13 (m, 2 H), 6.95 (dd, J = 8.38, 1.76 Hz, 1 H), 6.01 (dd, J = 8.82, 5.29 Hz, 1 H), 5.62 (s, 1 H), 3.79- 3.97 (m, 3 H), 3.58-3.73 (m, 1 H), 3.41-3.53 (m, 1 H), 3.29 (d, J = 4.85 Hz, 1 H), 2.90-3.03 (m, 1 H), 2.62-2.74 (m, 1 H), 1.14-1.31 (m, 1 H), 0.48-0.65 (m, 2 H), 0.26- 0.41 (m, 2 H). 6 No purification
    105
    Figure US20130005716A1-20130103-C00181
         		Free Base 761.2  4.74 (2) >99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 8.57 (s, 2 H), 8.45-8.50 (m, 1 H), 7.83-7.93 (m, 1 H), 7.14- 7.21 (m, 1 H), 7.04-7.12 (m, 2 H), 6.89-6.99 (m, 2 H), 5.92-6.05 (m, 1 H), 5.46 (s, 1 H), 3.85-3.94 (m, 2 H), 3.75-3.84 (m, 1 H), 3.66 (d, J = 9.26 Hz, 9 H), 3.39-3.49 (m, 1 H), 3.18-3.28 (m, 1 H), 2.90-3.03 (m, 1 H), 2.59-2.74 (m, 1 H), 1.13-1.30 (m, 1 H), 0.48-0.60 (m, 2 H), 0.26-0.38 (m, 2 H). 6 Preparative HPLC (Method 1)
    106
    Figure US20130005716A1-20130103-C00182
         		Free Base 719.2  5.12 (2)   97:3 1H NMR (400 MHz, DMSO-d6) δ ppm 8.59 (s, 2 H), 7.64 (d, J = 7.94 Hz, 1 H), 7.17 (d, J = 8.38 Hz, 1 H), 7.10 (dd, J = 6.39, 2.43 Hz, 3 H), 6.95 (m, 2 H), 5.89-6.09 (m, 1 H), 5.51 (s, 1 H), 3.83-4.00 (m, 5 H), 3.62-3.79 (m, 1 H), 3.51-3.62 (m, 1 H), 3.36-3.48 (m, 1 H), 3.22-3.31 (m, 1 H), 2.93- 3.04 (m, 1 H), 2.63-2.81 (m, 1 H), 2.39 (s, 3 H), 1.15-1.31 (m, 1 H), 0.51-0.65 (m, 2 H), 0.33 (d, J = 4.85 Hz, 2 H). 6 Preparative HPLC (Method 1)
    107
    Figure US20130005716A1-20130103-C00183
         		Free Base 710.1  4.79 (2)   98:2 1H NMR (400 MHz, DMSO-d6) δ ppm 8.58 (s, 2 H), 7.16-7.23 (m, 1 H), 7.07-7.14 (m, 2 H), 6.94- 7.00 (m, 1 H), 5.87-6.14 (m, 1 H), 5.31 (s, 1 H), 3.84-3.97 (m, 2 H), 3.73 (m, 2 H), 3.40-3.58 (m, 1 H), 3.19-3.28 (m, 1 H), 2.88-3.15 (m, 2 H), 2.69 (s, 3 H), 2.55 (s, 3 H), 1.14-1.31 (m, 1 H), 0.51-0.64 (m, 2 H), 0.26-0.42 (m, 2 H). 6 Preparative HPLC (Method 1)
    108
    Figure US20130005716A1-20130103-C00184
         		Free Base 746.2  5.13 (2)   98:2 1H NMR (400 MHz, DMSO-d6) δ ppm 8.58 (s, 2 H), 7.18 (d, J = 8.38 Hz, 1 H), 7.11 (d, J = 1.76 Hz, 1 H), 7.08 (t, J = 75.00 Hz, 1 H), 7.03 (m, 1 H), 7.00 (d, J = 2.21 Hz, 1 H), 6.93-6.98 (m, 1 H), 6.86 (d, J = 8.38 Hz, 1 H), 5.92- 6.09 (m, 1 H), 5.42 (s, 1 H), 4.32 (m, 2 H), 3.90 (d, J = 6.17 Hz, 2 H), 3.69-3.84 (m, 1 H), 3.56-3.66 (m, 1 H), 3.33-3.53 (m, 3 H), 3.24-3.29 (m, 1 H), 2.91 (m, 4 H), 2.59-2.68 (m, 1 H), 1.15-1.27 (m, 1 H), 0.56 (dd, J = 7.94, 1.76 Hz, 2 H), 0.33 (d, J = 5.73 Hz, 2 H). 6 Preparative HPLC (Method 1)
    109
    Figure US20130005716A1-20130103-C00185
         		Free Base 753.1  5.40 (2) >99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 8.60 (s, 2 H), 8.17 (d, J = 10.58 Hz, 4 H), 7.15-7.21 (m, 1 H), 7.05-7.14 (m, 2 H), 6.93-7.00 (m, 1 H), 5.96-6.08 (m, 1 H), 5.54 (s, 1 H), 3.86-3.97 (m, 2 H), 3.76- 3.84 (m, 1 H), 3.62-3.74 (m, 1 H), 3.39-3.53 (m, 1 H), 3.35 (s, 3 H), 3.24-3.31 (m, 1 H), 2.91-3.05 (m, 1 H), 2.69-2.82 (m, 1 H), 1.13- 1.27 (m, 1 H), 0.47-0.65 (m, 2 H), 0.25-0.44 (m, 2 H). 6 Crystallized from EtOH/iprOH
    110
    Figure US20130005716A1-20130103-C00186
         		Free Base 705.1  4.41 (2)   97:3 1H NMR (400 MHz, DMSO-d6) δ ppm 8.60 (s, 2 H), 7.80 (d, J = 9.26 Hz, 2 H), 7.13-7.22 (m, 3 H), 7.11 (d, J = 1.76 Hz, 1 H), 7.08 (t, J = 75.00 Hz, 1 H), 6.93-6.99 (m, 1 H), 5.95-6.07 (m, 1 H), 5.39 (s, 1 H), 3.84-3.94 (m, 5 H), 3.72- 3.82 (m, 1 H), 3.54-3.65 (m, 1 H), 3.40-3.50 (m, 1 H), 3.20-3.29 (m, 1 H), 2.89-2.99 (m, 1 H), 2.57- 2.70 (m, 1 H), 1.14-1.27 (m, 1 H), 0.56 (dd, J = 7.94, 1.76 Hz, 2 H), 0.33 (dd, J = 4.63, 1.54 Hz, 2 H). 6 Flash Cromatography
    111
    Figure US20130005716A1-20130103-C00187
         		Free Base 752.2  4.36 (2)   98:2 1H NMR (400 MHz, DMSO-d6) δ ppm 8.63 (s, 2 H), 8.24 (d, J = 2.65 Hz, 1 H), 7.64 (dd, J = 9.26, 2.65 Hz, 1 H), 7.16 (d, J = 8.38 Hz, 1 H), 7.04-7.09 (m, 2 H), 6.80-6.95 (m, 2 H), 5.89 (dd, J = 8.82, 4.85 Hz, 1 H), 4.61 (d, J = 3.97 Hz, 1 H), 3.88 (t, J = 6.62 Hz, 2 H), 3.67-3.75 (m, 4 H), 3.59-3.65 (m, 4 H), 3.50-3.58 (m, 1 H), 3.35-3.46 (m, 1 H), 3.22 (dd, J = 14.11, 5.29 Hz, 1 H), 2.96 (d, J = 2.65 Hz, 1 H), 2.07 (m, 1 H), 1.57-1.70 (m, 1 H), 1.51 (d, J = 11.03 Hz, 2 H), 1.15-1.35 (m, 2 H), 0.80-0.96 (m, 1 H), 0.49-0.62 (m, 2 H), 0.28-0.41 (m, 2 H). 10 Preparative HPLC (Method 1)
    112
    Figure US20130005716A1-20130103-C00188
         		Free Base 716.1  4.66 (2)   98:2 1H NMR (400 MHz, DMSO-d6) δ ppm 8.62 (s, 2 H), 8.37 (d, J = 8.82 Hz, 2 H), 7.97 (d, J = 8.82 Hz, 2 H), 7.14 (m, 1 H), 7.06 (m, 2 H), 6.83-6.92 (m, 1 H), 5.84- 5.96 (m, 1 H), 4.64-4.75 (m, 1 H), 3.86 (m, 2 H), 3.64-3.75 (m, 1 H), 3.35-3.47 (m, 1 H), 3.16-3.27 (m, 1 H), 2.90-3.05 (m, 1 H), 2.08- 2.17 (m, 1 H), 1.49-1.70 (m, 3 H), 1.13-1.31 (m, 2 H), 0.78-0.98 (m, 1 H), 0.48-0.66 (m, 2 H), 0.32 (m, 2 H). 10 Preparative HPLC (Method 1)
    113
    Figure US20130005716A1-20130103-C00189
         		Free Base 778.2  4.45 (2)   98:2 1H NMR (400 MHz, DMSO-d6) δ ppm 8.60 (s, 2 H), 7.99-8.06 (m, 2 H), 7.97 (d, J = 1.76 Hz, 1 H), 7.80-7.90 (m, 1 H), 7.14 (d, J = 8.38 Hz, 1 H), 7.07 (t, J = 75.00 Hz, 1 H), 7.04 (d, J = 1.76 Hz, 1 H), 6.83-6.90 (m, 1 H), 5.85 (dd, J = 8.38, 5.29 Hz, 1 H), 4.73 (d, J = 4.41 Hz, 1 H), 3.86 (t, J = 7.50 Hz, 2 H), 3.63-3.74 (m, 1 H), 3.36-3.46 (m, 1 H), 3.18-3.26 (m, 1 H), 2.94 (m, 1 H), 2.65 (s, 6 H), 2.09-2.19 (m, 1 H), 1.54 (d, J = 15.88 Hz, 3 H), 1.19 (d, J = 4.85 Hz, 2 H), 0.78-0.98 (m, 1 H), 0.48-0.63 (m, 2 H), 0.26-0.40 (m, 2 H). 10 Preparative HPLC (Method 1)
    114
    Figure US20130005716A1-20130103-C00190
         		Free Base 671.2  4.44 (2)   99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 8.64 (s, 2 H), 7.62-7.70 (m, 3 H), 7.57 (d, J = 7.50 Hz, 2 H), 7.15 (m, 1 H), 7.02-7.10 (m, 2 H), 6.89 (m, 1 H), 5.84-5.91 (m, 1 H), 4.56-4.66 (m, 1 H), 3.87 (m, 2 H), 3.57-3.67 (m, 1 H), 3.36-3.48 (m, 1 H), 3.16-3.27 (m, 1 H), 2.90- 3.08 (m, 1 H), 1.98-2.12 (m, 1 H), 1.41-1.66 (m, 3 H), 1.10-1.30 (m, 2 H), 0.78-0.98 (m, 1 H), 0.57 (m, 2 H), 0.33 (dd, J = 4.85, 1.32 Hz, 2 H). 10 Preparative HPLC (Method 1)
    115
    Figure US20130005716A1-20130103-C00191
         		Free Base 735.1  4.30 (2)   98:2 1H NMR (400 MHz, DMSO-d6) δ ppm 8.56 (s, 2 H), 7.15-7.33 (m, 4 H), 7.11 (m, 1 H), 7.09 (t, J = 75.00 Hz, 1 H), 6.92-6.99 (m, 1 H), 5.95-6.11 (m, 1 H), 5.59 (s, 1 H), 3.87-3.97 (m, 2 H), 3.85 (s, 3 H), 3.78 (m, 4 H), 3.52-3.63 (m, 1 H), 3.37-3.50 (m, 1 H), 3.28 (m, 1 H), 2.94-3.04 (m, 1 H), 2.67-2.80 (m, 1 H), 1.15-1.30 (m, 1 H), 0.52-0.60 (m, 2 H), 0.28-0.41 (m, 2 H). 6 Preparative HPLC (Method 1)
    116
    Figure US20130005716A1-20130103-C00192
         		Free Base 675.3  3.79 (2)   98:2 1H NMR (400 MHz, DMSO-d6) δ ppm 8.55 (s, 2 H), 7.42 (m, 1 H), 7.12-7.20 (m, 1 H), 7.07 (d, J = 1.32 Hz, 2 H), 6.99 (d, J = 0.88 Hz, 1 H), 6.84-6.95 (m, 1 H), 5.86- 5.96 (m, 1 H), 4.56-4.65 (m, 1 H), 3.87 (m, 2 H), 3.78 (s, 3 H), 3.60- 3.69 (m, 1 H), 3.36-3.47 (m, 1 H), 3.17-3.26 (m, 1 H), 3.00-3.14 (m, 1 H), 2.03-2.13 (m, 1 H), 1.68-1.86 (m, 1 H), 1.43-1.64 (m, 2 H), 1.25-1.43 (m, 1 H), 1.11-1.24 (m, 1 H), 0.84-1.01 (m, 1 H), 0.47- 0.62 (m, 2 H), 0.28-0.40 (m, 2 H). 10 No purification
    117
    Figure US20130005716A1-20130103-C00193
         		Free Base 717.1  4.06 (2) >99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 8.58 (s, 2 H), 8.26-8.36 (m, 2 H), 8.10-8.16 (m, 1 H), 7.77- 7.86 (m, 1 H), 7.15-7.21 (m, 1 H), 7.10-7.14 (m, 1 H), 7.08 (t, J = 75.00 Hz, 1 H), 6.92-6.98 (m, 1 H), 5.97-6.06 (m, 1 H), 5.56 (s, 1 H), 3.87-3.94 (m, 2 H), 3.75-3.86 (m, 1 H), 3.63-3.72 (m, 1 H), 3.42-3.51 (m, 1 H), 3.38 (d, J = 7.06 Hz, 1 H), 2.91-3.03 (m, 1 H), 2.68 (m, 4 H), 1.15-1.33 (m, 1 H), 0.50-0.62 (m, 2 H), 0.27-0.41 (m, 2 H). 6 No purification
    118
    Figure US20130005716A1-20130103-C00194
         		Free Base 768.1  3.75; 3.84 (2)   22:78 6 Preparative HPLC (Method 1)
    119
    Figure US20130005716A1-20130103-C00195
         		Free Base 679.2  3.28 (2) >99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 8.56 (s, 2 H), 7.93 (m, 1 H), 7.87 (m, 1 H), 7.17 (m, 1 H), 7.10 (d, J = 9.70 Hz, 2 H), 6.92-6.98 (m, 1 H), 5.94-6.11 (m, 1 H), 5.35 (s, 1 H), 3.91 (d, J = 7.06 Hz, 2 H), 3.73 (m, 4 H), 3.61-3.71 (m, 1 H), 3.40-3.49 (m, 1 H), 3.23-3.30 (m, 1 H), 2.94-3.04 (m, 1 H), 2.76-2.88 (m, 1 H), 1.16-1.28 (m, 1 H), 0.56 (d, J = 7.94 Hz, 2 H), 0.34 (d, J = 4.41 Hz, 2 H). 6 Preparative HPLC (Method 1)
    121
    Figure US20130005716A1-20130103-C00196
         		Free Base 757.1 1H NMR (400 MHz, DMSO-d6) δ ppm 8.56 (s, 2 H), 7.70-7.82 (m, 3 H), 7.66-7.70 (m, 1 H), 7.13- 7.20 (m, 1 H), 7.06 (t, J = 75.00 Hz, 2 H), 6.92-6.99 (m, 1 H), 5.89-6.07 (m, 1 H), 3.83-3.93 (m, 2 H), 3.34-3.48 (m, 2 H), 3.16- 3.24 (m, 2 H), 2.95-3.07 (m, 3 H), 2.89 (m, 7 H), 2.42-2.48 (m, 4 H), 1.13-1.26 (m, 1 H), 0.49-0.62 (m, 2 H), 0.28-0.38 (m, 2 H). na 14 Preparative HPLC (Method 1)
    200
    Figure US20130005716A1-20130103-C00197
         		Free Base 699.98  4.03 (3)   95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.55 (s, 2 H), 8.12-8.21 (m, 1 H), 8.04-8.12 (m, 1 H), 7.96 (td, 1 H), 7.91 (td, 1 H), 7.17 (d, 1 H), 7.10 (d, 1 H), 6.94 (dd, 1 H), 7.08 (t, 1 H), 5.94 (dd, 1 H), 5.62 (s, 1 H), 3.93-4.00 (m, 1 H), 3.90 (d, 2 H), 3.67-3.73 (m, 1 H), 3.44 (dd, 1 H), 3.27 (dd, 1 H), 3.07 (ddd, 1 H), 2.90 (dt, 1 H), 1.12-1.29 (m, 1 H), 0.46-0.66 (m, 2 H), 0.18-0.42 (m, 2 H)  −56.05 (c = 0.4, DCM) 6 Preparative HPLC (Method 2)
    201
    Figure US20130005716A1-20130103-C00198
         		Free Base 732.96  4.12 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.56 (s, 2 H), 7.29-7.36 (m, 2 H), 7.18 (d, 1 H), 7.07-7.14 (m, 2 H), 6.96 (dd, 1 H), 7.08 (t, 1 H), 6.02 (dd, 1 H), 5.41 (s, 1 H), 4.27- 4.47 (m, 4 H), 3.91 (d, 2 H), 3.77 (dt, 1 H), 3.61 (dt, 1 H), 3.46 (dd, 1 H), 3.32-3.35 (m, 1 H), 2.97 (dt, 1 H), 2.69 (ddd, 1 H), 1.10-1.36 (m, 1 H), 0.48-0.68 (m, 2 H), 0.22- 0.43 (m, 2 H)  −50.2 (c = 0.44, DCM) 6 Chromatogrphy on silica gel followed by treatment with polymer supported carbonate in DCM/CH3CN, filtration and evaporation
    202
    Figure US20130005716A1-20130103-C00199
         		Free Base 714.01  4.18 (3) >95:5 (1H NMR B) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.53 (s, 2 H), 8.03 (d, 1 H), 7.96 (d, 1 H), 7.72 (dd, 1 H), 7.17 (d, 1 H), 7.10 (d, 1 H), 6.94 (dd, 1 H), 7.08 (t, 1 H), 5.98 (dd, 1 H), 5.67 (s, 1 H), 3.94 (ddd, 1 H), 3.83-3.92 (m, 2 H), 3.65 (dt, 1 H), 3.45 (dd, 1 H), 3.29 (dd, 1 H), 3.07 (ddd, 1 H), 2.86 (dt, 1 H), 2.50 (s, 3 H), 1.11-1.30 (m, 1 H), 0.50-0.66 (m, 2 H), 0.27-0.40 (m, 2 H)  −81.2 (c = 0.7, DCM) 6 Chromatography on silca gel followed by preparative HPLC (Method 2)
    203
    Figure US20130005716A1-20130103-C00200
         		Free Base 709.02  4.41 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.56 (s, 2 H), 7.19 (d, 1 H), 7.12 (d, 1 H), 6.98 (s, 1 H), 6.97 (dd, 1 H), 7.08 (t, 1 H), 6.02 (dd, 1 H), 5.40 (s, 1 H), 3.91 (d, 2 H), 3.78 (dt, 1 H), 3.62 (dt, 1 H), 3.45 (dd, 1 H), 3.30 (dd, 1 H), 3.03 (dt, 1 H), 2.80 (dt, 1 H), 2.57 (s, 3 H), 2.40 (s, 3 H), 1.11-1.34 (m, 1 H), 0.45-0.70 (m, 2 H), 0.24-0.45 (m, 2 H)  −50.27 (c = 0.3, DCM) 6 Preparative HPLC (Method 2)
    204
    Figure US20130005716A1-20130103-C00201
         		Free Base 786.87  4.68 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.57 (s, 2 H), 7.88 (d, 1 H), 7.83 (d, 1 H), 7.18 (d, 1 H), 7.11 (d, 1 H), 6.96 (dd, 1 H), 7.08 (t, 1 H), 6.01 (dd, 1 H), 5.46 (s, 1 H), 3.91 (d, 2 H), 3.80-3.88 (m, 1 H), 3.68 (dt, 1 H), 3.44 (dd, 1 H), 3.30 (dd, 1 H), 3.06 (dt, 1 H), 2.91 (dt, 1 H), 2.42 (s, 3 H), 1.05-1.32 (m, 1 H), 0.47-0.66 (m, 2 H), 0.21- 0.47 (m, 2 H)  −74.95 (c = 0.4, DCM) 6 Preparative HPLC (Method 2)
    205
    Figure US20130005716A1-20130103-C00202
         		Free Base 766.98  4.57 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.56 (s, 2 H), 8.05 (d, 1 H), 7.79 (dd, 1 H), 7.63 (d, 1 H), 7.18 (d, 1 H), 7.11 (d, 1 H), 6.96 (dd, 1 H), 7.08 (t, 1 H), 6.02 (dd, 1 H), 5.56 (s, 1 H), 3.91 (d, 2 H), 3.82 (dt, 1 H), 3.59-3.69 (m, 1 H), 3.46 (dd, 1 H), 3.31 (dd, 1 H), 2.98 (dt, 1 H), 2.71 (dt, 1 H), 2.46 (s, 3 H), 1.07-1.34 (m, 1 H), 0.47-0.67 (m, 2 H), 0.24-0.47 (m, 2 H)  −58.39 (c = 1.5, DCM) 6 Preparative HPLC (Method 2)
    206
    Figure US20130005716A1-20130103-C00203
         		Free Base 700.06  4.05 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.59 (s, 2 H), 8.11-8.22 (m, 2 H), 7.98-8.11 (m, 2 H), 7.18 (d, 1 H), 7.11 (d, 1 H), 6.96 (dd, 1 H), 7.08 (t, 1 H), 6.02 (dd, 1 H), 5.56 (s, 1 H), 3.90 (d, 2 H), 3.84 (dt, 1 H), 3.67 (dt, 1 H), 3.46 (dd,1 H), 3.31 (dd, 1 H), 2.99 (dt, 1 H), 2.75 (dt, 1 H), 1.00-1.34 (m, 1 H), 0.47-0.66 (m, 2 H), 0.26-0.42 (m, 2 H)  −52.16 (c = 0.5, DCM) 6 Preparative HPLC (Method 2)
    207
    Figure US20130005716A1-20130103-C00204
         		Free Base 700.1  4.02 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.57 (s, 2 H), 8.44 (t, 1 H), 8.08-8.29 (m, 2 H), 7.85 (t, 1 H), 7.18 (d, 1 H), 7.11 (d, 1 H), 6.96 (dd, 1 H), 7.08 (dd, 1 H), 6.03 (dd, 1 H), 5.70 (s, 1 H), 3.90 (d, 2 H), 3.85 (t, 1 H), 3.67 (dt, 1 H), 3.47 (dd, 1 H), 3.32 (dd, 1 H), 2.89- 3.12 (m, 1 H), 2.59-2.79 (m, 1 H), 1.22 (m, 1 H), 0.46-0.77 (m, 2 H), 0.31-0.37 (m, 2 H)  −38.8 (c = 0.3, DCM) 6 Preparative HPLC (method 2)
    208
    Figure US20130005716A1-20130103-C00205
         		Free Base 741.07  5.99 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.70 (d, 1 H), 8.59 (s, 2 H), 8.07-8.20 (m, 2 H), 7.93-8.06 (m, 2 H), 7.87 (d, 1 H), 7.18 (d, 1 H), 7.12 (d, 1 H), 6.97 (dd, 1 H), 7.08 (t, 1 H), 6.65 (dd, 1 H), 6.03 (dd, 1 H), 5.51 (s, 1 H), 3.91 (d, 2 H), 3.86 (dt, 1 H), 3.66 (dt, 1 H), 3.47 (dd, 1 H), 3.32 (dd, 1 H), 2.98 (dt, 1 H), 2.70 (dt, 1 H), 1.05-1.41 (m, 1 H), 0.45-0.67 (m, 2 H), 0.23- 0.45 (m, 2 H)  −50.75 (c = 0.4, DCM) 6 Preparative HPLC (Method 2)
    209
    Figure US20130005716A1-20130103-C00206
         		Free Base 718.08  4.16 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.57-8.63 (m, 0 H), 8.56 (s, 2 H), 8.18-8.36 (m, 0 H), 7.80 (t, 1 H), 7.18 (d, 1 H), 7.10 (d, 1 H), 6.95 (dd, 1 H), 7.08 (t, 1 H), 6.03 (dd, 1 H), 5.73 (s, 1 H), 3.90 (d, 2 H), 3.79-3.88 (m, 1 H), 3.59-3.74 (m, 1 H), 3.18-3.41 (m, 2 H), 2.91-3.05 (m, 1 H), 2.65-2.77 (m, 3 H), 1.01-1.34 (m, 1 H), 0.44- 0.66 (m, 2 H), 0.21-0.44 (m, 2 H) −108 (c = 0.7, DCM) 6 Preparative HPLC (Method 2)
    210
    Figure US20130005716A1-20130103-C00207
         		Free Base 744.15  3.79 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.58 (s, 2 H), 7.80 (dd, 1 H), 7.73 (d, 1 H), 7.19 (d, 1 H), 7.19 (d, 1 H), 7.11 (d, 1 H), 6.96 (dd, 1 H), 7.08 (t, 1 H), 6.03 (dd, 1 H), 5.40 (s, 1 H), 3.91 (d, 2 H), 3.78 (dt, 1 H), 3.69 (s, 2 H), 3.58- 3.68 (m, 1 H), 3.46 (dd, 1 H), 3.31 (dd, 1 H), 3.18 (s, 3 H), 2.97 (dt, 1 H), 2.65-2.79 (m, 1 H), 1.02-1.37 (m, 1 H), 0.45-0.68 (m, 2 H), 0.27-0.45 (m, 2 H)  −61.80 (c = 0.4, DCM) 6 Preparative HPLC (Method 2)
    211
    Figure US20130005716A1-20130103-C00208
         		Free Base 734.04  4.27 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.52 (s, 2 H), 8.19 (d, 1 H), 8.14 (d, 1 H), 8.03 (dd, 1 H), 7.17 (d, 1 H), 7.10 (d, 1 H), 6.94 (dd, 1 H), 7.08 (t, 1 H), 5.97 (dd, 1 H), 5.77 (s, 1 H), 3.95-4.11 (m, 1 H), 3.76-3.95 (m, 2 H), 3.67 (dt, 1 H), 3.45 (dd, 1 H), 3.29 (dd, 1 H), 3.08 (ddd, 1 H), 2.95 (dt, 1 H), 1.05-1.33 (m, 1 H), 0.46-0.69 (m, 2 H), 0.22-0.46 (m, 2 H)  −40.70 (c = 0.4, DCM) 6 Preparative HPLC (Method 2)
    212
    Figure US20130005716A1-20130103-C00209
         		Free Base 745.17  4.79 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.60 (s, 2 H), 8.13 (s, 1 H), 8.04 (d, 1 H), 7.88 (s, 1 H), 7.45 (dd, 1 H), 7.18 (d, 1 H), 7.12 (d, 1 H), 6.97 (dd, 1 H), 7.08 (t, 1 H), 6.03 (dd, 1 H), 5.41 (s, 1 H), 3.91 (d, 2 H), 3.80 (t, 2 H), 3.47 (dd, 1 H), 3.32 (dd, 1 H), 3.04 (dt, 1 H), 2.89 (dt, 1 H), 2.47 (s, 3 H), 1.05- 1.36 (m, 1 H), 0.46-0.81 (m, 2 H), 0.07-0.46 (m, 2 H)  −72.10 (c = 0.4, DCM) 6 Preparative HPLC (Method 2)
    213
    Figure US20130005716A1-20130103-C00210
         		Free Base 755.21  4.15 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.60 (s, 2 H), 8.03 (m, 2 H), 7.87 (m, 2 H), 7.82 (d, 1 H), 7.18 (d, 1 H), 7.12 (d, 1 H), 6.96 (dd, 1 H), 6.88 (d, 1 H), 7.08 (t, 1 H), 6.02 (dd, 1 H), 5.45 (s, 1 H), 3.93 (s, 3 H), 3.91 (d, 2 H), 3.83 (dt, 1 H), 3.65 (dt, 1 H), 3.47 (dd, 1 H), 3.31 (dd, 1 H), 2.98 (dt, 1 H), 2.67 (dt, 1 H), 1.01-1.37 (m, 1 H), 0.46- 0.69 (m, 2 H), 0.20-0.44 (m, 2 H)  −53.00 (c = 0.7, DCM) 6 Preparative HPLC (Method 2)
    214
    Figure US20130005716A1-20130103-C00211
         		Free Base 741.19  4.36 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.59 (s, 2 H), 7.86-8.03 (m, 2 H), 7.37-7.44 (m, 2 H), 7.45 (t, 1 H), 7.19 (d, 1 H), 7.11 (d, 1 H), 6.96 (dd, 1 H), 7.08 (t, 1 H), 6.02 (dd, 1 H), 5.47 (s, 1 H), 3.91 (d, 2 H), 3.80 (dt, 1 H), 3.65 (dt, 1 H), 3.46 (dd, 1 H), 3.31 (dd, 1 H), 2.98 (dt, 1 H), 2.70 (dt, 1 H), 1.04- 1.38 (m, 1 H), 0.46-0.68 (m, 2 H), 0.24-0.42 (m, 2 H)  −42.49 (c = 1.4, DCM) 6 Preparative HPLC (Method 2)
    215
    Figure US20130005716A1-20130103-C00212
         		Free Base 777.16  4.68 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.53 (s, 2 H), 8.12 (d, 1 H), 8.08 (d, 1 H), 8.02 (dd, 1 H), 7.16 (d, 1 H), 7.09 (d, 1 H), 6.92 (dd, 1 H), 7.08 (t, 1 H), 5.94 (dd, 1 H), 5.61 (s, 1 H), 3.90-4.00 (m, 1 H), 3.90 (d, 2 H), 3.60-3.69 (m, 1 H), 3.43 (dd, 1 H), 3.26 (dd, 1 H), 3.02-3.19 (m, 2 H), 0.91-1.43 (m, 1 H), 0.44-0.85 (m, 2 H), 0.23- 0.44 (m, 2 H)  −48.29 (c = 0.7, DCM) 6 Preparative HPLC (Method 2)
    216
    Figure US20130005716A1-20130103-C00213
         		Free Base 723.15 54.25 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.55 (s, 2 H), 7.51-7.63 (m, 2 H), 7.31 (dd, 1 H), 7.18 (d, 1 H), 7.11 (d, 1 H), 6.96 (dd, 1 H), 7.08 (t, 1 H), 6.03 (dd, 1 H), 5.58 (s, 1 H), 3.91 (s, 3 H), 3.86-3.97 (m, 2 H), 3.71-3.84 (m, 1 H), 3.60 (dt, 1 H), 3.44 (dd, 1 H), 3.31 (dd, 1 H), 3.03 (ddd, 1 H), 2.78 (dt, 1 H), 1.04-1.35 (m, 1 H), 0.43-0.69 (m, 2 H), 0.24-0.43 (m, 2 H)  −26.09 (c = 1.6, DCM) 6 Preparative HPLC (Method 2)
    217
    Figure US20130005716A1-20130103-C00214
         		Free Base 731.18  4.58 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.60 (s, 2 H), 8.23 (s, 1 H), 8.14-8.20 (m, 1 H), 8.00-8.14 (m, 1 H), 7.50-7.68 (m, 2 H), 7.19 (d, 1 H), 7.12 (d, 1 H), 6.98 (dd, 1 H), 7.08 (t, 1 H), 6.04 (dd, 1 H), 5.43 (s, 1 H), 3.91 (d, 2 H), 3.81 (t, 2 H), 3.48 (dd, 1 H), 3.32 (dd, 1 H), 3.05 (dt, 1 H), 2.91 (dt, 1 H), 1.05-1.40 (m, 1 H), 0.45-0.66 (m, 2 H), 0.18-0.45 (m, 2 H)  −46.14 (c = 0.7, DCM) 6 Preparative HPLC (Method 2)
    218
    Figure US20130005716A1-20130103-C00215
         		Free Base 732.18  3.66 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.57 (s, 2 H), 7.79 (d, 1 H), 7.64 (dd, 1 H), 7.26 (d, 1 H), 7.18 (d, 1 H), 7.11 (d, 1 H), 6.96 (dd, 1 H), 7.08 (t, 1 H), 6.02 (dd, 1 H), 5.49 (s, 1 H), 3.90 (d, 2 H), 3.75- 3.88 (m, 1 H), 3.62 (dt, 1 H), 3.46 (dd, 1 H), 3.31 (dd, 1 H), 2.95 (dt, 1 H), 2.60-2.68 (m, 1 H), 0.97- 1.37 (m, 1 H), 0.45-0.71 (m, 2 H), 0.18-0.45 (m, 2 H)  −32.95 (c = 0.4, DCM) 6 Preparative HPLC (Method 2) followed by flash chromatography on silica gel and further preparative HPLC (Method 2)
    219
    Figure US20130005716A1-20130103-C00216
         		Free Base 758  3.92 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.58 (s, 2 H), 7.91-8.00 (m, 2 H), 7.80-7.91 (m, 2 H), 7.18 (d, 1 H), 7.11 (d, 1 H), 6.96 (dd, 1 H), 7.08 (t, 1 H), 6.02 (dd, 1 H), 5.42 (s, 1 H), 3.91 (d, 2 H), 3.90 (t, 2 H), 3.81 (dt, 1 H), 3.63 (dt, 1 H), 3.46 (dd, 1 H), 3.31 (dd, 1 H), 2.97 (dt, 1 H), 2.64 (dt, 1 H), 2.57 (t, 2 H), 2.10 (quin, 2 H), 1.07- 1.38 (m, 1 H), 0.47-0.71 (m, 2 H), 0.22-0.41 (m, 2 H)  −65.83 (c = 1.8, DCM) 6 Preparative HPLC (Method 2)
    220
    Figure US20130005716A1-20130103-C00217
         		Free Base 772.09  3.93 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.58 (s, 2 H), 7.88 (d, 1 H), 7.69 (d, 1 H), 7.62 (dd, 1 H), 7.18 (d, 1 H), 7.12 (d, 1 H), 6.97 (dd, 1 H), 7.08 (t, 1 H), 6.03 (dd, 1 H), 5.43 (s, 1 H), 3.91 (d, 2 H), 3.77- 3.84 (m, 1 H), 3.71-3.77 (m, 2 H), 3.64 (ddd, 1 H), 3.47 (dd, 1 H), 3.31 (dd, 1 H), 2.98 (dt, 1 H), 2.83 (t, 2 H), 2.68 (dt, 1 H), 2.25 (s, 3 H), 1.91 (quin, 2 H), 1.06-1.36 (m, 1 H), 0.45-0.68 (m, 2 H), 0.23- 0.45 (m, 2 H)  −67.13 (c = 0.6, DCM) 6 Preparative HPLC (Method 2)
    221
    Figure US20130005716A1-20130103-C00218
         		Free Base 760.15  3.61 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.58 (s, 2 H), 7.90 (t, 1 H), 7.70-7.85 (m, 2 H), 7.40-7.59 (m, 2 H), 7.18 (d, 1 H), 7.12 (d, 1 H), 6.96 (dd, 1 H), 7.08 (t, 1 H), 6.02 (dd, 1 H), 5.42 (s, 1 H), 3.91 (d, 2 H), 3.78 (dt, 1 H), 3.63 (dt, 1 H), 3.46 (dd, 1 H), 3.23-3.39 (m, 3 H), 2.96 (dt, 1 H), 2.83 (t, 2 H), 2.63 (dt, 1 H), 1.77 (s, 3 H), 1.05-1.48 (m, 1 H), 0.47-0.66 (m, 2 H), 0.25-0.47 (m, 2 H)  −51.61 (c = 1.6, DCM) 6 Preparative HPLC (Method 2)
    222
    Figure US20130005716A1-20130103-C00219
         		Free Base 773.19  4.46 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.59 (s, 2 H), 7.72-8.01 (m, 2 H), 7.25-7.32 (m, 2 H), 7.19 (d, 1 H), 7.11 (d, 1 H), 6.96 (dd, 1 H), 7.08 (t, 1 H), 6.02 (dd, 1 H), 5.44 (s, 1 H), 4.94 (q, 2 H), 3.91 (d, 2 H), 3.80 (dt, 1 H), 3.62 (dt, 1 H), 3.46 (dd, 1 H), 3.31 (dd, 1 H), 2.97 (dt, 1 H), 2.65 (dt, 1 H), 1.13- 1.35 (m, 1 H), 0.47-0.71 (m, 2 H), 0.25-0.40 (m, 2 H)  −51.04 (c = 0.50, DCM) 6 Trituration with EtOH
    223
    Figure US20130005716A1-20130103-C00220
         		Free Base 689.17  4.26 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.53 (s, 2 H), 7.36-7.50 (m, 5 H), 7.17 (d, 1 H), 7.09 (d, 1 H), 6.94 (dd, 1 H), 7.07 (t, 1 H), 5.99 (dd, 1 H), 5.20 (s, 1 H), 4.61 (d, 1 H), 4.54 (d, 1 H), 3.86-3.96 (m, 2 H), 3.82 (dt, 1 H), 3.57 (dt, 1 H), 3.41 (dd, 1 H), 3.28 (dd, 1 H), 2.92-3.14 (m, 2 H), 1.05-1.37 (m, 1 H), 0.46-0.66 (m, 2 H), 0.18- 0.44 (m, 2 H)  −18.6 (c = 0.9, DCM) 6 Treatment with polymer supported isocyanate followed by preparative HPLC (Method 2)
    224
    Figure US20130005716A1-20130103-C00221
         		Free Base 703  4.33 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.52 (s, 2 H), 7.20-7.41 (m, 5 H), 7.16 (s, 1 H), 7.11 (d, 1 H), 6.96 (dd, 1 H), 7.07 (t, 1 H), 6.03 (dd, 1 H), 5.59 (s, 1 H), 3.94-4.13 (m, 1 H), 3.91 (d, 2 H), 3.39-3.67 (m, 4 H), 3.28 (d, 1 H), 3.02-3.19 (m, 2 H), 2.97 (t, 2 H), 1.08-1.36 (m, 1 H), 0.47-0.68 (m, 2 H), 0.23-0.42 (m, 2 H)  −58.4 (c = 0.4 DCM) 6 Preparative (Method 3)
    225
    Figure US20130005716A1-20130103-C00222
         		Free Base 671.24  4.06 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.54 (s, 2 H), 7.33-7.46 (m, 5 H), 7.16 (d, 1 H), 7.10 (d, 1 H), 6.95 (dd, 1 H), 7.06 (t, 1 H), 5.98 (dd, 1 H), 4.48 (d, 1 H), 4.39 (d, 1 H), 4.03 (dd, 1 H), 3.91 (dd, 1 H), 3.87 (dd, 1 H), 3.42 (dd, 1 H), 3.30-3.37 (m, 2 H), 3.23 (dd, 1 H), 1.97-2.22 (m, 1 H), 1.75-1.92 (m, 1 H), 1.59-1.75 (m, 2 H), 1.08-1.32 (m, 1 H), 0.46-0.70 (m, 2 H), 0.14-0.40 (m, 2 H)  −14.55 (c = 0.22, DCM) 3 Flash chromatography on silica gel followed by trituration with MeOH
    226
    Figure US20130005716A1-20130103-C00223
         		Free Base 744.11  3.72 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.58 (s, 2 H), 7.81 (dd, 1 H), 7.73 (d, 1 H), 7.18 (d, 2 H), 7.15 (d, 1 H), 6.98 (dd, 1 H), 7.08 (t, 1 H), 6.03 (dd, 1 H), 4.80 (dd, 1 H), 4.63 (d, 1 H), 4.31 (d, 1 H), 3.93 (d, 2 H), 3.67 (s, 2 H), 3.47 (dd, 1 H), 3.27 (dd, 1 H), 3.18 (s, 3 H), 3.03 (dd, 1 H), 2.96 (dd, 1 H), 1.10-1.36 (m, 1 H), 0.49-0.69 (m, 2 H), 0.24-0.42 (m, 2 H)  −95.8 (c = 0.52, DCM) 11 Preparative HPLC (Method 2)
    227
    Figure US20130005716A1-20130103-C00224
         		Free Base 671.12  4.19 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.56 (s, 2 H), 7.61-7.81 (m, 5 H), 7.18 (d, 1 H), 7.09 (d, 1 H), 6.96 (dd, 1 H), 7.07 (t, 1 H), 5.93 (dd, 1 H), 3.92 (d, 2 H), 3.45 (dd, 2 H), 3.31-3.37 (m, 1 H), 3.21 (dd, 1 H), 2.54-2.70 (m, 2 H), 2.30- 2.46 (m, 1 H), 1.80 (m, 1 H), 1.58- 1.74 (m, 1 H), 1.40-1.58 (m, 1 H), 1.27-1.40 (m, 1 H), 1.07-1.27 (m, 1 H), 0.46-0.71 (m, 2 H), 0.08- 0.46 (m, 2 H)  +1.349 (c = 0.43, MeOH) 15 Flash chromatogrphy on silica gel
    228
    Figure US20130005716A1-20130103-C00225
         		Free Base 742.12  3.78 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.55 (s, 2 H), 7.72-7.84 (m, 3 H), 7.70 (t, 1 H), 7.18 (d, 1 H), 7.10 (d, 1 H), 6.96 (dd, 1 H), 7.07 (t, 1 H), 5.94 (dd, 1 H), 3.92 (d, 2 H), 3.47-3.59 (m, 1 H), 3.45 (dd, 1 H), 3.32-3.39 (m, 1 H), 3.21 (dd, 1 H), 3.02 (br. s., 3 H), 2.90 (br. s., 3 H), 2.55-2.69 (m, 2 H), 1.03- 1.96 (m, 6 H), 0.47-0.69 (m, 2 H), 0.20-0.47 (m, 2 H)  +2.018 (c = 0.565, MeOH) 15 Flash chromatogrphy on silica gel
    229
    Figure US20130005716A1-20130103-C00226
         		Free Base 671.17  4.22 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.56 (s, 2 H), 7.60-7.81 (m, 5 H), 7.18 (d, 1 H), 7.10 (d, 1 H), 7.00 (dd, 1 H), 7.08 (t, 1 H), 5.93 (dd, 1 H), 3.93 (d, 2 H), 3.44 (dd, 1 H), 3.33-3.39 (m, 1 H), 3.21 (dd, 1 H), 3.06-3.17 (m, 1 H), 2.55- 2.86 (m, 3 H), 1.63-1.82 (m, 1 H), 1.29-1.63 (m, 3 H), 1.04-1.29 (m, 1 H), 0.47-0.72 (m, 2 H), 0.18- 0.43 (m, 2 H)  −25.04 (c = 0.46, MeOH) 16 Flash chromatogrphy on silica gel
    230
    Figure US20130005716A1-20130103-C00227
         		Free Base 742.23  3.83 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.56 (s, 2 H), 7.80 (dt, 1 H), 7.76 (dt, 1 H), 7.75 (t, 1 H), 7.70 (t, 1 H), 7.18 (d, 1 H), 7.10 (d, 1 H), 6.99 (dd, 1 H), 7.08 (t, 1 H), 5.93 (dd, 1 H), 3.93 (d, 2 H), 3.44 (dd, 1 H), 3.35-3.42 (m, 1 H), 3.21 (dd, 1 H), 3.09-3.17 (m, 1 H), 3.01 (br. s., 3 H), 2.89 (br. s., 3 H), 2.79-2.88 (m, 1 H), 2.55-2.71 (m, 2 H), 1.65-1.86 (m, 1 H), 1.31- 1.65 (m, 3 H), 1.05-1.30 (m, 1 H), 0.49-0.66 (m, 2 H), 0.22-0.43 (m, 2 H)  −25.66 (c = 0.265, MeOH) 16 Flash chromatogrphy on silica gel
    231
    Figure US20130005716A1-20130103-C00228
         		Free Base 673.15  3.96 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.58 (s, 2 H), 7.53-7.87 (m, 5 H), 7.19 (d, 1 H), 7.12 (d, 1 H), 6.99 (dd, 1 H), 7.07 (t, 1 H), 5.95 (dd, 1 H), 4.38 (dd, 1 H), 3.88 (dt, 1 H), 3.93 (d, 2 H), 3.46-3.69 (m, 3 H), 3.08-3.29 (m, 2 H), 2.54- 2.61 (m, 2 H), 1.15-1.29 (m, 1 H), 0.49-0.71 (m, 2 H), 0.17-0.44 (m, 2 H)  +5.102 (c = 0.49, DCM) 17 Flash chromatogrphy on silica gel followed by preparative HPLC (Method 2)
    232
    Figure US20130005716A1-20130103-C00229
         		Free Base 744.18  3.58 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.56 (s, 2 H), 7.73-7.86 (m, 3 H), 7.67-7.73 (m, 1 H), 7.19 (d, 1 H), 7.12 (d, 1 H), 6.99 (dd, 1 H), 7.07 (t, 1 H), 5.96 (dd, 1 H), 4.39 (dd, 1 H), 3.93 (d, 2 H), 3.89 (dt, 1 H), 3.61 (ddd, 1 H), 3.50 (dd, 1 H), 3.38-3.48 (m, 1 H), 3.13-3.27 (m, 2 H), 3.03 (br. s., 3H), 2.91 (br. s., 3 H), 2.55-2.70 (m, 2 H), 1.06-1.37 (m, 1 H), 0.51-0.65 (m, 2 H), 0.30-0.42 (m, 2 H)  −9.114 (c = 0.7, DCM) 17 Trituration with EtOH
    233
    Figure US20130005716A1-20130103-C00230
         		Free Base 673.29  3.97 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.54 (s, 2 H), 7.60-7.84 (m, 5 H), 7.19 (d, 1 H), 7.11 (d, 1 H), 7.01 (dd, 1 H), 7.09 (t, 1 H), 5.92 (dd, 1 H), 4.38 (dd, 1 H), 3.93 (d, 2 H), 3.77 (ddd, 1 H), 3.53-3.69 (m, 1 H), 3.45 (dd, 1 H), 3.17-3.29 (m, 2 H), 3.02 (dd, 1 H), 2.86-2.98 (m, 1 H), 2.69-2.83 (m, 1 H), 1.07-1.40 (m, 1 H), 0.47-0.66 (m, 2 H), 0.28-0.45 (m, 2 H)  −31.66 (c = 0.47, DCM) 18 Preparative HPLC (Method 2)
    234
    Figure US20130005716A1-20130103-C00231
         		Free Base 744.4  3.59 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.54 (s, 2 H), 7.69-7.89 (m, 4 H), 7.19 (d, 1 H), 7.12 (d, 1 H), 7.00 (dd, 1 H), 7.09 (t, 1 H), 5.93 (dd, 1 H), 4.39 (dd, 1 H), 3.85- 4.01 (m, 2 H), 3.72-3.85 (m, 1 H), 3.52-3.71 (m, 1 H), 3.45 (dd, 1 H), 3.17-3.27 (m, 2 H), 3.08 (dd, 1 H), 3.02 (br. s., 3 H), 2.93-2.99 (m, 1 H), 2.90 (br. s., 3 H), 2.75-2.85 (m, 1 H), 1.09-1.38 (m, 1 H), 0.48-0.66 (m, 2 H), 0.28-0.43 (m, 2 H)  −28.12 (c = 0.51, DCM) 18 Flash chromatography on silca gel
    235
    Figure US20130005716A1-20130103-C00232
         		Free Base 671.34  4.09 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.56 (s, 2 H), 7.76-7.86 (m, 2 H), 7.69-7.76 (m, 1 H), 7.57- 7.69 (m, 2 H), 7.19 (d, 1 H), 7.10 (d, 1 H), 6.98 (dd, 1 H), 7.07 (t, 1 H), 5.99 (dd, 1 H), 3.92 (dd, 1 H), 3.88 (dd, 1 H), 3.72-3.80 (m, 1 H), 3.47 (dd, 1 H), 3.28-3.37 (m, 1 H), 3.24 (dd, 1 H), 3.04-3.16 (m, 1 H), 2.83 (dd, 1 H), 2.55 (dd, 1 H), 1.62-1.91 (m, 1 H), 1.43-1.62 (m, 1 H), 1.29-1.45 (m, 2 H), 1.09- 1.29 (m, 1 H), 0.44-0.67 (m, 2 H), 0.21-0.43 (m, 2 H)  −79 (c = 0.23 DCM) 19 Preparative HPLC (Method 2)
    236
    Figure US20130005716A1-20130103-C00233
         		Free Base 742.43  3.74 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.56 (s, 2 H), 7.85 (dt, 1 H), 7.65-7.80 (m, 3 H), 7.19 (d, 1 H), 7.10 (d, 1 H), 6.98 (dd, 1 H), 7.07 (t, 1 H), 5.98 (dd, 1 H), 3.92 (dd, 1 H), 3.88 (dd, 1 H), 3.70-3.84 (m, 1 H), 3.46-3.54 (m, 2 H), 3.28-3.37 (m, 2 H), 3.24 (dd, 1 H), 3.07-3.19 (m, 1 H), 3.00 (br. s., 3 H), 2.88 (br. s., 3 H), 2.83 (dd, 1 H), 2.54- 2.65 (m, 1 H), 1.63-1.91 (m, 0 H), 1.48-1.63 (m, 0 H), 1.29-1.48 (m, 2 H), 1.05-1.29 (m, 1 H), 0.46-0.62 (m, 2 H), 0.17-0.46 (m, 2 H) 19 Preparative HPLC (Method 2)
    237
    Figure US20130005716A1-20130103-C00234
         		Free Base 685.41  4.11 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.56 (s, 2 H), 7.34-7.46 (m, 5 H), 7.19 (d, 1 H), 7.07 (d, 1 H), 6.93 (dd, 1 H), 7.07 (t, 1 H), 5.95 (dd, 1 H), 4.42 (s, 2 H), 3.91 (d, 2 H), 3.76-3.88 (m, 1 H), 3.35-3.43 (m, 2 H), 3.07-3.30 (m, 2 H), 2.61 (dd, 1 H), 2.34 (dd, 1 H), 1.64- 1.99 (m, 3 H), 1.27-1.49 (m, 1 H), 1.09-1.28 (m, 1 H), 0.48-0.67 (m, 2 H), 0.24-0.43 (m, 2 H)  −23.8 (c = 0.18, DCM) 19 Preparative HPLC (Method 2) followed by chromatograohy on silica gel
    238
    Figure US20130005716A1-20130103-C00235
         		Free Base 764.1  4.06 (2) >99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 8.58 (s, 2 H), 8.10 (m, 2 H), 8.01 (m, 1 H), 7.93 (m, 1 H), 7.15- 7.21 (m, 1 H), 7.13 (m, 1 H), 7.08 (t, J = 75.00 Hz, 1 H), 6.94-7.03 (m, 1 H), 5.95-6.08 (m, 1 H), 4.18-4.28 (m, 1 H), 3.92 (d, J = 7.06 Hz, 2 H), 3.43-3.55 (m, 1 H), 3.36-3.43 (m, 1 H), 3.25-3.30 (m, 1 H), 3.16-3.23 (m, 1 H), 2.67 (s, 6 H), 1.94-2.05 (m, 1 H), 1.54- 1.79 (m, 3 H), 1.14-1.29 (m, 1 H), 0.48-0.63 (m, 2 H), 0.33 (d, J = 4.85 Hz, 2 H).
    239
    Figure US20130005716A1-20130103-C00236
         		hydro- chloride 731.1  4.10 (2) >99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 9.14 (d, J = 2.20 Hz, 1 H), 9.06 (d, J = 2.21 Hz, 1 H), 8.59 (s, 2 H), 7.16 (m, 1 H), 7.05-7.13 (m, 2 H), 6.92-6.99 (m, 1 H), 5.95- 6.10 (m, 1 H), 5.78 (s, 1 H), 3.82- 3.98 (m, 3 H), 3.65-3.79 (m, 1 H), 3.41-3.55 (m, 1 H), 3.34-3.38 (m, 1 H), 2.90-3.01 (m, 1 H), 2.67 (m, 4 H), 1.14-1.27 (m, 1 H), 0.56 (d, J = 7.94 Hz, 2 H), 0.33 (d, J = 4.85 Hz, 2 H).
    240
    Figure US20130005716A1-20130103-C00237
         		hydro- chloride 744.2  4.07 (2) >99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 8.93-8.97 (m, 1 H), 8.85- 8.90 (m, 1 H), 8.58 (s, 2 H), 7.14- 7.19 (m, 1 H), 7.05-7.12 (m, 2 H), 6.91-6.97 (m, 1 H), 5.96-6.04 (m, 1 H), 5.70 (s, 1 H), 4.03 (s, 3 H), 3.80-3.97 (m, 4 H), 3.60-3.76 (m, 1 H), 3.39-3.53 (m, 1 H), 3.23- 3.27 (m, 1 H), 2.88-2.98 (m, 1 H), 2.58 (m, 4 H), 1.12-1.33 (m, 1 H), 0.47-0.62 (m, 2 H), 0.20-0.41 (m, 2 H).
    241
    Figure US20130005716A1-20130103-C00238
         		Free Base 735.2  3.47 (2) >99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 12.45-12.98 (bs, 1 H), 8.59 (s, 2 H), 8.27 (d, J = 4.85 Hz, 1 H), 7.67 (d, J = 1.76 Hz, 1 H), 7.18 (d, J = 8.38 Hz, 1 H), 7.06- 7.13 (m, 3 H), 6.96 (dd, J = 8.38, 1.76 Hz, 1 H), 6.03 (dd, J = 9.26, 4.85 Hz, 1 H), 5.22 (s, 1 H), 3.84- 3.96 (m, 5 H), 3.58-3.73 (m, 2 H), 3.45 (dd, J = 14.11, 9.26 Hz, 1 H), 3.28-3.30 (m, 1 H), 2.94-3.05 (m, 1 H), 2.75-2.84 (m, 1 H), 2.72 (d, J = 4.41 Hz, 3 H), 1.22 (d, J = 7.50 Hz, 1 H), 0.48-0.63 (m, 2 H), 0.33 (q, J = 4.85 Hz, 2 H)
    242
    Figure US20130005716A1-20130103-C00239
         		Free Base 761.2  3.61 >99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 12.46 (bs, 1 H), 8.57 (s, 2 H), 7.54 (dd, J = 3.53, 1.32 Hz, 1 H), 7.17 (d, J = 8.38 Hz, 1 H), 7.10 (d, J = 1.76 Hz, 1 H), 7.08 (t, J = 75.00 Hz, 1 H), 6.92-7.00 (m, 2 H), 6.01 (dd, J = 9.04, 5.07 Hz, 1 H), 5.46 (s, 1 H), 3.90 (dd, J = 7.06, 1.32 Hz, 2 H), 3.81 (ddd, J = 11.69, 6.17, 5.95 Hz, 1 H), 3.72 (t, J = 6.84 Hz, 2 H), 3.56-3.66 (m, 1 H), 3.39-3.55 (m, 3 H), 3.29 (d, J = 5.29 Hz, 1 H), 2.88-2.99 (m, 1 H), 2.64 (ddd, J = 10.81, 6.62, 6.39 Hz, 1 H), 1.91-2.02 (m, 2 H), 1.84 (q, J = 6.62 Hz, 2 H), 1.21 (ddd, J = 7.83, 4.52, 3.09 Hz, 1 H), 0.49-0.62 (m, 2 H), 0.28-0.40 (m, 2 H).
    243
    Figure US20130005716A1-20130103-C00240
         		Free Base 663.2  4.62 (2) >99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 8.59 (s, 2 H), 7.52 (m, 1 H), 7.17 (m, 1 H), 7.08-7.12 (m, 2 H), 7.07 (t, J = 75.00 Hz, 1 H), 6.95 (m, 1 H), 6.02-6.10 (m, 1 H), 5.46 (s, 1 H), 3.77-3.95 (m, 6 H), 3.65- 3.75 (m, 1 H), 3.47-3.59 (m, 1 H), 3.33-3.41 (m, 1 H), 2.96 (d, J = 15.88 Hz, 2H), 1.09-1.30 (m, 1 H), 0.46-0.62 (m, 2 H), 0.21-0.39 (m, 2 H).
    328
    Figure US20130005716A1-20130103-C00241
         		Free Base 666.1  3.07; 3.11 (2)   21:79
    244
    Figure US20130005716A1-20130103-C00242
         		Free Base 657.2  4.03; (3)   97:3 1H NMR (400 MHz, DMSO-d6) δ ppm 8.54 (s, 2 H), 7.74-7.83 (m, 2 H), 7.66-7.74 (m, 1 H), 7.57- 7.65 (m, 2 H), 7.21 (d, J = 8.38 Hz, 1 H), 7.14 (d, J = 1.76 Hz, 1 H), 7.09 (t, J = 75.00 Hz, 1 H), 7.00 (dd, J = 8.38, 1.76 Hz, 1 H), 5.98 (dd, J = 9.48, 4.63 Hz, 1 H), 4.14 (dd, J = 8.60, 4.63 Hz, 1 H), 3.86-4.01 (m, 2 H), 3.37-3.50 (m, 2 H), 3.27 (dd, J = 14.11, 4.41 Hz, 1 H), 3.14 (ddd, J = 9.81, 7.06, 6.95 Hz, 1 H), 1.45-1.98 (m, 4 H), 1.14-1.30 (m, 1 H), 0.48-0.63 (m, 2 H), 0.25-0.39 (m, 2 H).
    245
    Figure US20130005716A1-20130103-C00243
         		Free Base 728.2  3.52 (2)    1:99 1H NMR (400 MHz, DMSO-d6) δ ppm 8.58 (s, 2 H), 7.65-7.87 (m, 4 H), 7.18 (d, J = 7.94 Hz, 1 H), 7.14 (d, J = 1.76 Hz, 1 H), 7.07 (t, J = 75.00 Hz, 1 H), 6.99 (m, 1 H), 5.96-6.08 (m, 1 H), 4.11-4.24 (m, 1 H), 3.91 (d, J = 7.06 Hz, 2 H), 3.33-3.51 (m, 2 H), 3.28 (m, 2 H), 2.83-3.06 (m, 6 H), 1.88-2.04 (m, 1 H), 1.45-1.76 (m, 3 H), 1.12- 1.29 (m, 1 H), 0.55 (dd, J = 8.16, 1.54 Hz, 2 H), 0.25-0.38 (m, 2 H).
    246
    Figure US20130005716A1-20130103-C00244
         		Free Base 728.2  3.47 (2)   98:2 1H NMR (400 MHz, DMSO-d6) δ ppm 8.58 (s, 2 H), 7.65-7.87 (m, 4 H), 7.18 (d, J = 7.94 Hz, 1H), 7.14 (d, J = 1.76 Hz, 1 H), 7.07 (t, J = 75.00 Hz, 1 H), 6.99 (m, 1 H), 5.96-6.08 (m, 1 H), 4.11-4.24 (m, 1 H), 3.91 (d, J = 7.06 Hz, 2 H), 3.33-3.51 (m, 2 H), 3.28 (m, 2 H), 2.83-3.06 (m, 6 H), 1.88-2.04 (m, 1 H), 1.45-1.76 (m, 3 H), 1.12- 1.29 (m, 1 H), 0.55 (dd, J = 8.16, 1.54 Hz, 2 H), 0.25-0.38 (m, 2 H).
    247
    Figure US20130005716A1-20130103-C00245
         		Free Base 730.2   65:35 (1H NMR)
    248
    Figure US20130005716A1-20130103-C00246
         		Free Base 746.0  3.63 (2) >99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 8.57 (s, 2 H), 7.86-8.00 (m, 2 H), 7.65-7.83 (m, 2 H), 7.18 (d, J = 7.94 Hz, 1 H), 7.11 (d, J = 1.32 Hz, 1 H), 7.08 (t, J = 75.00 Hz, 1 H), 6.86-6.96 (m, 1 H), 6.01 (dd, J = 9.04, 5.07 Hz, 1 H), 5.54 (s, 1 H), 3.80-3.98 (m, 3 H), 3.60-3.72 (m, 1 H), 3.46 (dd, J = 14.11, 9.26 Hz, 1 H), 3.30-3.35 (m, 1 H), 2.82-3.06 (m, 7 H), 2.63-2.73 (m, 1 H), 1.15-1.33 (m, 1 H), 0.47- 0.65 (m, 2 H), 0.33 (q, J = 4.85 Hz, 2 H)
    249
    Figure US20130005716A1-20130103-C00247
         		Free Base 746.0  3.57; 3.64 (2)   84:16 1H NMR (400 MHz, DMSO-d6) δ ppm 8.54 (s, 2 H), 7.89-7.98 (m, 2 H), 7.63-7.80 (m, 2 H), 7.22 (d, J = 7.94 Hz, 1 H), 7.06-7.15 (m, 2 H), 7.00 (dd, J = 8.38, 1.32 Hz, 1 H), 5.97 (dd, J = 9.70, 4.41 Hz, 1 H), 5.57 (s, 1 H), 3.89-4.02 (m, 2 H), 3.57-3.86 (m, 2 H), 3.47 (dd, J = 14.11, 9.70 Hz, 1 H), 3.26 (d, J = 4.85 Hz, 1 H), 2.80-3.10 (m, 7 H), 2.61-2.74 (m, 1 H), 1.15-1.31 (m, 1 H), 0.50-0.64 (m, 2 H), 0.34 (q, J = 4.85 Hz, 2 H)
    250
    Figure US20130005716A1-20130103-C00248
         		Free Base 728.1  4.26 (2)    3:97 1H NMR (400 MHz, DMSO-d6) δ ppm 8.48 (s, 2 H), 7.12-7.21 (m, 2 H), 7.08 (t, J = 75.00 Hz, 1 H), 6.95-7.02 (m, 2 H), 6.93 (d, J = 2.21 Hz, 1 H), 6.86 (d, J = 8.38 Hz, 1 H), 6.03 (dd, J = 9.70, 4.41 Hz, 1 H), 4.22-4.40 (m, 2 H), 4.11 (dd, J = 8.82, 3.97 Hz, 1 H), 3.92 (d, J = 7.06 Hz, 2 H), 3.45 (dd, J = 14.11, 9.70 Hz, 1 H), 3.08-3.27 (m, 5 H), 2.90 (s, 3 H), 1.83-2.01 (m, 1 H), 1.45-1.74 (m, 3 H), 1.13- 1.28 (m, 1 H), 0.48-0.65 (m, 2 H), 0.33 (q, J = 4.85 Hz, 2 H).
    251
    Figure US20130005716A1-20130103-C00249
         		Free Base 713.1  4.00 (2) >99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 8.92-9.04 (m, 1 H), 8.86- 8.92 (m, 1 H), 8.61 (s, 2 H), 7.12- 7.23 (m, 2 H), 7.07 (t, J = 75.00 Hz, 1 H), 6.95-7.02 (m, 1 H), 5.97-6.09 (m, 1 H), 4.34-4.41 (m, 1 H), 3.85-3.96 (m, 2 H), 3.38- 3.55 (m, 2 H), 3.19-3.29 (m, 2 H), 2.67 (s, 3 H), 1.89-2.06 (m, 1 H), 1.52-1.77 (m, 3 H), 1.10-1.31 (m, 1 H), 0.47-0.62 (m, 2 H), 0.27- 0.41 (m, 2 H).
    252
    Figure US20130005716A1-20130103-C00250
         		Free Base 746.1  4.35 (2) >99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 8.57 (s, 2 H), 7.13-7.22 (m, 2 H), 6.94-7.10 (m, 4 H), 6.85 (d, J = 7.94 Hz, 1 H), 5.96-6.06 (m, 1 H), 4.85 (m, 1 H), (4.63 (d, J = 10.14 Hz, 1 H), 4.23-4.38 (m, 3 H), 3.92 (d, J = 7.06 Hz, 2 H), 3.40-3.52 (m, 1 H), 3.28 (m, 3 H), 2.96-3.08 (m, 1 H), 2.90 (m, 4 H), 1.13-1.29 (m, 1 H), 0.56 (dd, J = 8.38, 1.76 Hz, 2 H), 0.33 (d, J = 4.41 Hz, 2 H).
    253
    Figure US20130005716A1-20130103-C00251
         		Free Base 731.0  4.08 (2) >99:1 1H NMR (400 MHz, DMSO-d6) δ ppm 9.13 (d, J = 2.21 Hz, 1 H), 9.02 (d, J = 2.21 Hz, 1 H), 8.59 (s, 2 H), 7.14-7.22 (m, 2 H), 7.08 (t, J = 75.00 Hz, 1 H), 6.94-7.02 (m, 1 H), 5.93-6.10 (m, 1 H), 4.95- 5.09 (m, 1 H), 4.73-4.86 (m, 1 H), 4.27-4.44 (m, 1 H), 3.82-4.01 (m, 2 H), 3.41-3.55 (m, 1 H), 3.22- 3.28 (m, 1 H), 2.96-3.10 (m, 2 H), 2.66 (s, 3 H), 1.12-1.30 (m, 1 H), 0.50-0.64 (m, 2 H), 0.22-0.42 (m, 2 H).
    254
    Figure US20130005716A1-20130103-C00252
         		Free Base 731.9  3.52 (2)    2:98 1H NMR (400 MHz, DMSO-d6) δ ppm 8.77 (d, J = 4.41 Hz, 1 H), 8.60 (s, 2 H), 8.30 (m, 1 H), 8.13- 8.22 (m, 1 H), 8.02 (d, J = 7.94 Hz, 1 H), 7.76 (t, J = 7.94 Hz, 1 H), 7.18 (d, J = 7.94 Hz, 1 H), 7.11 (d, J = 1.32 Hz, 1 H), 7.08 (t, J = 75.00 Hz, 1 H), 6.95 (dd, J = 8.38, 1.76 Hz, 1 H), 6.01 (dd, J = 8.82, 4.85 Hz, 1 H), 5.51 (s, 1 H), 3.87-3.97 (m, 2 H), 3.82 (ddd, J = 11.58, 5.95, 5.84 Hz, 1 H), 3.68 (ddd, J = 11.80, 6.39, 6.06 Hz, 1 H), 3.46 (dd, J = 14.11, 9.26 Hz, 1 H), 3.35 (m, 1 H), 2.90-3.03 (m, 1 H), 2.56-2.70 (m, 1 H), 1.13-1.31 (m, 1 H), 0.50-0.64 (m, 2 H), 0.27- 0.43 (m, 2 H).
  • Some of the compounds described above in Table 6 were further crystallized under the conditions described below in Table 7 to obtain one or more crystalline forms. Where reference in Table 7 is made to crystallization conditions (A), (B), (C), (D), or (E), the following operating conditions were used:
    • Temperature Cycling Experiments—(A)
  • Slurries of the materials were prepared in each of the selected solvent systems. Approximately 10 mg of material was slurried in ca. 200 μl of solvent (if material dissolved the clear solution was used). The slurries were temperature cycled at 40° C. in 4 hour cycles for a period of 3 days (the cooling/heating rates after the 4 hour periods were up was ca. 1° C./minute). Any solids present were isolated and allowed to dry at ambient conditions prior to analysis.
    • Slow Cooling Experiments—(B)
  • This was carried out by placing saturated solutions of the material in each of the selected solvent systems in an environment of 2° C. for ca. 3 days. A saturated solution was created and this exposed to the relevant experimental condition. Any solid material was then recovered and allowed to dry at ambient conditions prior to analysis.
    • Rapid Cooling Experiments—(C)
  • This was carried out by placing saturated solutions of the material, in each of the selected solvent systems in environment of −18° C. for ca. 3 days. A saturated solution was created and this exposed to the relevant experimental condition. Any solid material was then recovered and allowed to dry at ambient conditions prior to analysis.
    • Evaporation Experiments—(D)
  • Evaporation experiments were conducted on saturated mixtures as above described. This was carried out by allowing the solvents to evaporate freely at ambient conditions. Any solid material was then recovered and analysed after the solvent had evaporated to dryness.
    • Anti-Solvent Addition Experiments—(E)
  • Anti-solvent addition experiments were conducted on saturated solutions of the material in each of the respective solvent systems and adding anti-solvent until precipitation occurred. Any solid material was then recovered and allowed to dry at ambient conditions prior to analysis.
  • TABLE 7
    Crystallization
    Entry Structure Solvent systems conditions Crystalline Form
     52a
    Figure US20130005716A1-20130103-C00253
         		EtOH RT; 7.5 vv w/w I
     52a
    Figure US20130005716A1-20130103-C00254
         		AcOEt/Heptane from 60 degrees to RT; 15 vv/12.5 vv w/w I
     52a
    Figure US20130005716A1-20130103-C00255
         		IprOAc from RT to −20 degrees; 5 vv w/w I
     52a
    Figure US20130005716A1-20130103-C00256
         		MeOH from 40 degrees to RT; 4 vv w/w I
     52a
    Figure US20130005716A1-20130103-C00257
         		nBuOH; IprOH; Toluene; MTBE; (Ipr)2O; EtOH (A) or (B) or (C) or (D) I
     90a
    Figure US20130005716A1-20130103-C00258
         		MeOH From 50 degrees to RT; 10 vv v/w N/A
     90b
    Figure US20130005716A1-20130103-C00259
         		nBuOH; MeoH; EtOH (A) or (B) or (C) or (D) I
     90b
    Figure US20130005716A1-20130103-C00260
         		Dioxane; MIK (C) or (D) I
     90b
    Figure US20130005716A1-20130103-C00261
         		Acetone; MEK (D) I
     90c
    Figure US20130005716A1-20130103-C00262
         		(Ipr)2O; IprOH; MTBE; Toluene (A) or (B) or (C) or (D) II
     88a
    Figure US20130005716A1-20130103-C00263
         		Acetone (Ipr)2O (A) I
     88b
    Figure US20130005716A1-20130103-C00264
         		EtOH; Methyl Isobutyl Ketone (A) or (B) (with MIK) or (C) (with MIK) III
     88c
    Figure US20130005716A1-20130103-C00265
         		MeOH (A) or (B) or (C) II
     89a
    Figure US20130005716A1-20130103-C00266
         		n-BuOH; (Ipr)2O ; IprOH; MTBE; (A) or (B) or (C) or (D) I
     89b
    Figure US20130005716A1-20130103-C00267
         		EtOH; MeOH (A) or (B) or (C) or (D) II
     93a
    Figure US20130005716A1-20130103-C00268
         		EtOH; MeOH; IprOH (A) or (B) or (C) or (D) I
     93a
    Figure US20130005716A1-20130103-C00269
         		Acetone (D) I
     93b
    Figure US20130005716A1-20130103-C00270
         		n-BuOH (B) or (C) or (D) II
     91a
    Figure US20130005716A1-20130103-C00271
         		Acetone/MeOH From 50 degrees to RT; From 5/5 to 100% MeOH (acetone was evaporated) I
     54a
    Figure US20130005716A1-20130103-C00272
         		EtOH From 50 degrees to RT; 5 vv v/w I
    110a
    Figure US20130005716A1-20130103-C00273
         		MeOH RT, 5 vv v/w I
    150a
    Figure US20130005716A1-20130103-C00274
         		EtOH (A) or (B) or (C) or (D) II
    150b
    Figure US20130005716A1-20130103-C00275
         		nBuOH; MeOH (B) or (C) or (D) I
     84a
    Figure US20130005716A1-20130103-C00276
         		EtOH (anti-solvent Cyclohexane) (A) or (B) or (C) or (D) or (E) I
     84b
    Figure US20130005716A1-20130103-C00277
         		IprOH (anti- solvent Cyclohexane) (A) or (B) or (C) or (D) or (E) II
     84b
    Figure US20130005716A1-20130103-C00278
         		nBuOH (anti- solvent Cyclohexane) (B) or (C) or (D) or (E) II
     84c
    Figure US20130005716A1-20130103-C00279
         		(Ipr)2O (anti- solvent Cyclohexane) (B) or (C) or (D) or (E) III
    131a
    Figure US20130005716A1-20130103-C00280
         		nBuOH (anti- solvent Diisopropyl Ether) (C) or (D) or (E) I
     97a
    Figure US20130005716A1-20130103-C00281
         		DCM; (Ipr)2O; MTBE; Toluene; (A) I
     97b
    Figure US20130005716A1-20130103-C00282
         		nBuOH; EtOH; Ethyl Acetate; MeOH; MEK; MIK; IprOH (A) II
     97a
    Figure US20130005716A1-20130103-C00283
         		nBuOH; (Ipr)2O; EtOH; IprOH; MTBE (B) or (C) I
     97b
    Figure US20130005716A1-20130103-C00284
         		CH3CN; EtOAc; MeOH;MIK; Toluene (B) or (C) II
    109a
    Figure US20130005716A1-20130103-C00285
         		Acetone; nBuOH; EtOH; Ethyl Acetate; MeOH; MIK; IprOH; Toluene Temperature Cycling (or Slow Cooling, except for MeOH, IprOH and Acetone) II
    109b
    Figure US20130005716A1-20130103-C00286
         		MeOH; IprOH; (B) I
    109c
    Figure US20130005716A1-20130103-C00287
         		(Ipr)2O; MTBE (A) or (B) III
    • Example 9 Synthesis of 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(3-(dimethylcarbamoyl)-4-methoxyphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (123)
  • Figure US20130005716A1-20130103-C00288
    • Step 1: 4-((2S)-2-(3-(3-carboxy-4-methoxyphenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide, (122)
  • 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (5) (60 mg, 0.112 mmol) was dissolved in pyridine (1 ml), then 5-(chlorosulfonyl)-2-methoxybenzoic acid (56 ml, 0.224 mmol) was added at 0° C., and the mixture was stirred at RT for 2 hours. The reaction was quenched with HCl 1N, and the product was extracted with AcOEt. The organic phase was washed with HCl 1N (×2) and brine, then dried over Na2SO4. The solvent was removed to yield 70 mg of the desired compound (yield 83%). MS/ESI+ 749.0 [MH]+; tR=5.94; 6.02 (Method 1); Diastereomeric Ratio=32:68.
    • Step 2: 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(3-(dimethylcarbamoyl)-4-methoxyphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (123)
  • 4-((2S)-2-(3-(3-carboxy-4-methoxyphenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (122) (70 mg, 0.093 mmol) was dissolved in DMF (1 ml). CDI (18 mg, 0.112 mmol) was added, and the mixture stirred for 30 minutes at RT. Then dimethylamine 2M in THF was added (3000, 0.600 mmol), and the mixture stirred at RT for 2 hours. The reaction was quenched with water, and the product was extracted with AcOEt. The organic layer was washed with water (2×) and NaCl saturated solution, dried over Na2SO4 and evaporated under vacuum. The crude product was purified by preparative HPLC (Method 1) condition to give 70 mg of the desired compound (yield 97%). MS/ESI+ 776.1 [MH]+; tR (Method 1)=6.40; 6.50 min; Diasteromeric Ratio=36:64.
  • The compounds listed in Table 8 were prepared according to analogous procedure as that described for Scheme 17 and by reacting the appropriate precursors listed with suitable reagents, followed by an appropriate purification procedure as below indicated.
  • TABLE 8
    HPLC-MS characterization
    tR/min
    Methods Diastereomeric Purification
    Entry Structure SALT NAME MS/ESI+ [MH]+ 1 or 2 ratio 1H NMR [α]D Precursor Method Amine
    124
    Figure US20130005716A1-20130103-C00289
         		Free Base 757.09 3.56 (2) >99:1  1H NMR (400 MHz, DMSO-d6) δ ppm 8.54 (s, 2 H), 7.80 (dd, J = 8.60, 2.43 Hz, 1 H), 7.56 (d, J = 2.65 Hz, 1 H), 7.32 (d, J = 8.82 Hz, 1 H), 7.10- 7.21 (m, 2 H), 7.08 (t, J = 75.00 Hz, 1 H), 6.98 (dd, J = 8.38, 1.76 Hz, 1 H), 5.89- 6.11 (m, 1 H), 4.04- 4.20 (m, 1 H), 3.87- 3.97 (m, 5 H), 3.46 (m, 1 H), 3.08-3.30 (m, 3 H), 2.99 (s, 3 H), 2.75 (s, 3 H), 1.60-1.75 (m, 2 H), 1.43-1.59 (m, 2 H), 0.85 (m, 1 H), 0.49- 0.62 (m, 2 H), 0.33 (d, J = 4.41 Hz, 2 H). −55.88 (c = 0.48; CHCl3) 3 Preparative HPLC (Method 1)
    Figure US20130005716A1-20130103-C00290
    125
    Figure US20130005716A1-20130103-C00291
         		Free Base 747.0 6.37; 6.47 (1) 38:62 5 Preparative HPLC (Method 1)
    Figure US20130005716A1-20130103-C00292
    126
    Figure US20130005716A1-20130103-C00293
         		formate 801.1 4.78; 4.88 (1) 38:62 5 Preparative HPLC (Method 1)
    Figure US20130005716A1-20130103-C00294
    127
    Figure US20130005716A1-20130103-C00295
         		Free Base 831.1 4.85; 4.92 (2) 26:74 5 No purification
    Figure US20130005716A1-20130103-C00296
    128
    Figure US20130005716A1-20130103-C00297
         		Free Base 818.0 6.32; 6.40 (2) 33:67 5 No purification
    Figure US20130005716A1-20130103-C00298
    129
    Figure US20130005716A1-20130103-C00299
         		Free Base 772.3 3.84 (2) >99:1  1H NMR (400 MHz, DMSO-d6) δ ppm 8.62 (s, 2 H), 7.59- 7.77 (m, 1 H), 7.45- 7.56 (m, 1 H), 7.18- 7.22 (m, 1 H), 7.13- 7.17 (m, 1 H), 7.03- 7.09 (m, 2 H), 6.79- 6.95 (m, 1 H), 5.83- 5.94 (m, 1 H), 4.53- 4.72 (m, 1 H), 3.81- 3.96 (m, 5 H), 3.60 (d, J = 11.91 Hz, 1 H), 3.40 (d, J = 10.58 Hz, 1 H), 3.28-3.29 (m, 1 H), 3.23 (dd, J = 14.11, 5.29 Hz, 1 H), 2.98 (s, 3 H), 2.74 (s, 3 H), 2.06 (d, J = 12.79 Hz, 1 H), 1.43-1.61 (m, 3 H), 1.12-1.31 (m, 2 H), 0.88 (d, J = 12.79 Hz, 1 H), 0.52-0.61 (m, 2 H), 0.29-0.36 (m, 2 H). 10  Preparative HPLC (Method 1)
    Figure US20130005716A1-20130103-C00300
    130
    Figure US20130005716A1-20130103-C00301
         		formate 801.2 2.59; 2.64 (2) 29:71 5 Triturated with Et2O
    Figure US20130005716A1-20130103-C00302
    131
    Figure US20130005716A1-20130103-C00303
         		Free Base 776.2 3.64 (2) 97:3  1H NMR (400 MHz, DMSO-d6) δ ppm 8.57 (s, 2 H), 7.81- 7.97 (m, 1 H), 7.68- 7.76 (m, 1 H), 7.32 (m, 1 H), 7.18 (d, J = 7.94 Hz, 1 H), 7.05- 7.13 (m, 2 H), 6.91- 6.98 (m, 1 H), 5.92- 6.07 (m, 1 H), 5.57- (s, 1 H), 3.75-4.06 (m, 6 H), 3.55-3.68 (m, 1 H), 3.37-3.49 (m, 1 H), 3.25-3.35 (m, 1 H), 2.99 (s, 4 H), 2.75 (s, 3 H), 2.54-2.65 (m, 1 H), 1.14-1.29 (m, 1 H), 0.56 (dd, J = 7.94, 1.76 Hz, 2 H), 0.33 (d, J = 5.29 Hz, 2 H). 6 Preparative HPLC (Method 1)
    Figure US20130005716A1-20130103-C00304
    132
    Figure US20130005716A1-20130103-C00305
         		Free Base 801.2 2.66 (2) >99:1  1H NMR (400 MHz, DMSO-d6) δ ppm 9.66-9.90 (bs, 1 H), 8.58 (s, 2 H), 7.95 (m, 2 H), 7.65-7.86 (m, 2 H), 7.19 (d, J = 8.38 Hz, 1 H), 7.10 (d, J = 9.26 Hz, 2 H), 6.97 (m, 1 H), 5.94- 6.12 (m, 1 H), 5.53 (s, 1 H), 3.90 (m, 3 H), 3.60-3.77 (m, 2 H), 3.38 (m, 3 H), 3.25-3.30 (m, 3 H), 2.93-3.22 (m, 4 H), 2.81 (s, 3 H), 2.55- 2.73 (m, 1 H), 2.29 (s, 3 H), 1.16-1.30 (m, 1 H), 0.57 (d, J = 7.94 Hz, 2 H), 0.33 (d, J = 4.41 Hz, 2 H). 6 Preparative HPLC (Method 1)
    Figure US20130005716A1-20130103-C00306
  • The compound listed in Table 9 was prepared under analogous conditions to those described in Scheme 17 by reacting the appropriate precursor listed with suitable reagents and using an alcohol nucleofile in step 2 in place of an amine, followed by a purification step as below indicated.
  • TABLE 9
    HPLC-MS
    characterization
    MS/ tR/min Diastereo- Pur-
    SALT ESI+ Methods meric Pre- ification
    Entry Structure NAME [MH]+ 1 or 2 ratio 1H NMR cursor Method Alcohol
    133
    Figure US20130005716A1-20130103-C00307
         		for- mate 832.1 3.12 (2) 97:3 1H NMR (400 MHz, DMSO-d6) δ ppm 8.58 (s, 2 H), 8.23-8.35 (m, 2 H), 8.12-8.20 (m, 1 H), 7.84 (t, J = 7.94 Hz, 1 H), 7.18 (d, J = 8.38 Hz, 1 H), 7.05- 7.15 (m, 2 H), 6.95 (dd, J = 8.38, 1.76 Hz, 1 H), 6.01 (dd, J = 9.04, 5.07 Hz, 1 H), 5.48 (s, 1 H), 4.45 (t, J = 5.51 Hz, 2 H), 3.89 (d, J = 6.62 Hz, 2 H), 3.74- 3.82 (m, 1 H), 3.64-3.72 (m, 1 H), 3.50-3.60 (m, 4 H), 3.46 (dd, J = 14.11, 9.26 Hz, 1 H), 3.30 (dd, J = 14.11, 4.85 Hz, 1 H), 2.94-3.04 (m, 1 H), 2.66- 2.78 (m, 3 H), 2.47 (d, J = 4.41 Hz, 4 H), 1.15- 1.28 (m, 1 H), 0.51-0.60 (m, 2 H), 0.28-0.38 (m, 2H). 5 No pur- ification
    Figure US20130005716A1-20130103-C00308
    • Example 10 Synthesis of 4-((2S)-2-(3-(4-aminophenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (135)
  • Figure US20130005716A1-20130103-C00309
    • Step 1: 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(4-nitrophenyl sulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (134)
  • 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide hydrochloride (6) (1.2 g, 2.24 mmol) was dissolved in pyridine (6 ml), then 4-nitrobenzene-1-sulfonyl chloride (596 mg, 2.69 mmol) was added at 0° C., and the mixture was stirred at RT for 2 hours. The reaction was quenched with HCl 1N, and the product was extracted with AcOEt. The organic phase was washed with HCl 1N (×2) and brine, then dried over Na2SO4. The solvent was removed to yield 1.5 g of the desired compound (yield 93%). MS/ESI+ 720.04 [MH]+
    • Step 2: 4-((2S)-2-(3-(4-aminophenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (135) 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(4-nitrophenyl sulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (134) (1 g, 1.388 mmol), was dissolved in THF (10 ml). Tin(II) chloride dihydrate (3.13 g, 13.881 mmol) was added, and the mixture was stirred at RT for 2 days. The solvent was removed under vacuum, and the crude product was dissolved in AcOEt and diluted with HCl 1N. Diatomaceus earth was added to the emulsion, and the mixture was filtered on a Diatomaceus earth pad. The organic phase was washed with HCl 1N, brine, dried over Na2SO4 and concentrated under vacuum to give 1.5 g of crude, that was purified by Flash Chromatography (DCM/IPA 97:3) to obtain 780 mg of the final compound (1.130 mmol, yield 81%). MS/ESI+ 689.9 [MH]+; tR=6.30; 6.40 (Method 1); Diastereomeric Ratio=38:62
  • The compounds listed in Table 10 were prepared according to analogous procedures as those described for Scheme 11 and by reacting the corresponding precursors listed with suitable reagents, followed by a purification step as below indicated.
  • TABLE 10
    HPLC-MS characterization
    tR/min
    Methods Diastereomeric Purification Sulfonyl
    Entry Structure SALT NAME MS/ESI+ [MH]+ 1 or 2 ratio 1H NMR [α]D Precursor Method chloride
    136
    Figure US20130005716A1-20130103-C00310
         		Free Base 671.9 6.14 (1) >99:1  1H NMR (400 MHz, DMSO- d6) δ ppm 8.59 (s, 2 H), 7.35- 7.44 (m, 2 H),7.12-7.22 (m, 2 H), 7.08 (t, J = 75.00 Hz, 1 H), 6.95-7.02 (m, 1 H), 6.53-6.71 (m, 2 H), 6.06-6.17 (bs, 2 H),5.95- 6.04 (m, 1 H), 3.95-4.01 (m, 1 H), 3.86- 3.94 (m, 2 H), 3.43-3.53 (m, 1 H), 3.21- 3.30 (m, 3 H), 2.99-3.13 (m,1 H), 1.83- 1.95 (m, 1 H), 1.55-1.68 (m, 2 H), 1.35- 1.54 (m, 1 H), 1.18-1.29 (m, 1 H), 0.49- 0.63 (m, 2 H), 0.26-0.39 (m, 2 H). 3 Crystallization from AcOEt/Hexane
    Figure US20130005716A1-20130103-C00311
    137
    Figure US20130005716A1-20130103-C00312
         		Free Base 719.8 6.67; 6.79 (1) 41:59 +88.93 (c = 0.51; CHCl3) 5 Preparative HPLC (Method 1)
    Figure US20130005716A1-20130103-C00313
    138
    Figure US20130005716A1-20130103-C00314
         		Free Base 690.0 6.34 (1) >99:1  1H NMR (400 MHz, DMSO- d6) δ ppm 8.57 (s, 2 H), 7.46 (d, J = 8.82 Hz, 2 H), 7.15-7.20 (m, 1 H), 7.11- 7.15 (m, 1 H), 7.08 (t, J = 75.00 Hz, 1 H), 6.93- 6.99 (m, 1 H), 6.62 (d, J = 8.38 Hz, 2 H), 6.15 (s, 2 H), 5.96- 6.05 (m, 1 H), 4.63-4.74 (m, 1 H), 4.50- 4.59 (m, 1 H), 4.19-4.27 (m, 1 H), 3.91 (d, J = 6.62 Hz, 2 H), 3.39-3.50 (m, 1 H), 3.21- 3.29 (m, 1 H), 2.93-3.02 (m, 1 H), 2.82- 2.90 (m, 1 H), 1.16-1.27 (m, 1 H), 0.51- 0.61 (m, 2 H), 0.28-0.39 (m, 2 H). 11 Preparative HPLC (Method 1)
    Figure US20130005716A1-20130103-C00315
    139
    Figure US20130005716A1-20130103-C00316
         		Free Base 688.0 5.80; 5.97 (1) 63:37 8 Preparative HPLC (Method 1)
    Figure US20130005716A1-20130103-C00317
    140
    Figure US20130005716A1-20130103-C00318
         		Free Base 690.2 3.79 (2) 99:1  1H NMR (400 MHz, DMSO- d6) δ ppm 8.59 (s, 2 H), 7.22- 7.30 (m, 1 H), 7.15-7.21 (m, 1 H), 7.08 (m, 2 H), 6.93-7.03 (m, 2 H), 6.80- 6.92 (m, 2 H), 5.92-6.07 (m, 1 H), 5.61- 5.74 (bs, 2 H), 5.25 (s, 1 H), 3.90 (d, J = 7.06 Hz, 2 H), 3.59- 3.79 (m, 2 H), 3.39-3.51 (m, 1 H), 3.14- 3.24 (m, 1 H), 2.90-3.05 (m, 1 H), 2.62- 2.75 (m, 1 H), 1.14-1.28 (m, 1 H), 0.51- 0.60 (m, 1 H), 0.27-0.41 (m, 1 H). 6 Preparative HPLC (Method 1)
    Figure US20130005716A1-20130103-C00319
    141
    Figure US20130005716A1-20130103-C00320
         		Free Base 701.3 1H NMR (400 MHz, DMSO- d6)  
    Figure US20130005716A1-20130103-P00001
      ppm 8.56 (s, 2 H), 7.32 (d, J = 8.82 Hz, 2 H), 7.14-7.20 (m, 1 H), 7.06 (m, 2 H), 6.91- 6.98 (m, 1 H), 6.64 (d, J = 8.82 Hz, 2 H), 6.08 (bs, 2 H), 5.93- 6.03 (m, 1 H), 3.79-4.05 (m, 2 H), 3.37- 3.58 (m, 2 H), 3.21 (dd, J = 13.89, 4.63 Hz, 2 H), 2.68- 2.83 (m, 4 H), 2.40-2.48 (m, 4 H), 1.09- 1.28 (m, 1 H), 0.50-0.65 (m, 2 H), 0.23- 0.44 (m, 2 H).    		 na 14 Preparative HPLC (Method 1)
    Figure US20130005716A1-20130103-C00321
    • Example 11 Synthesis of 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(4-(N-(2-morpholinoethyl)methylsulfonamido)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide formate (143)
  • Figure US20130005716A1-20130103-C00322
    • Step 1: 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(4-(methylsulfonamido)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (142)
  • 4-((2S)-2-(3-(4-aminophenyl sulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (135) (128 mg, 0.185 mmol), obtained according to analogous procedure as that described in Example 9, was dissolved in DCM (1.5 ml). Pyridine (29.3 mg, 0.371 mmol) and methanesulfonyl chloride (36.1 mg, 0.315 mmol) were added, and the reaction was stirred at RT for 3 hours to achieve completion. The reaction mixture was diluted with DCM and extracted with HCl 1N. The organic phase was washed with HCl 1N and brine, dried over Na2SO4 and concentrated under vacuum. The crude product was purified by preparative HPLC (Method 1) to give 80 mg of the final compound (yield 56%). MS/ESI+ 767.9 [MH]+, tR=6.25; 6.35 min (Method 1); Diastereomeric Ratio: 40:60.
    • Step 2: 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(4-(N-(2-morpholinoethyl)methylsulfonamido)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide formate (143)
  • 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(4-(methyl sulfonamido)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide, (142) (80 mg, 0.104 mmol) was dissolved in DMF (1.5 ml). 4-(2-chloroethyl)morpholine (78 mg, 0.520 mmol) and K2CO3 (17.26 mg, 0.125 mmol) were added, and the reaction is stirred at 45° C. for 6 hours to achieve completion. The reaction mixture was diluted with water and extracted with AcOEt. The organic phase was dried over Na2SO4 and concentrated under vacuum. The crude product was purified by preparative HPLC (Method 1) to give 40 mg of the final compound as formate salt (yield 44%).
  • MS/ESI+ 880.9 [MH]+; 5 tR=5.15; 5.28 min (Method 1); Diastereomeric Ratio=37:63.
    • Example 12 Synthesis of 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(2-oxo-2-(thiophen-2-yl)ethyl)thiazolidine-2-carbonyloxy)ethyl)pyridine1-oxide (144)
  • Figure US20130005716A1-20130103-C00323
  • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (5) (70 mg, 0.131 mmol) was dissolved in DMF (1 ml). K2CO3 (22 mg, 0.157 mmol) and 2-bromo-1-(thiophen-2-yl)ethanone (80 mg, 0.392 mmol) were added, and the reaction is stirred at 45° C. for 3 hours to achieve completion. The reaction mixture was diluted with water and extracted with AcOEt. The organic phase was dried over Na2SO4 and concentrated under vacuum. The crude product was purified by preparative HPLC (Method 1) to give 50 mg of the final product, (yield 58%). MS/ESI+ 658.9 [MH]+; tR (Method 2)=7.10; 7.24 min; Diastereomeric Ratio=44:56
  • The compounds listed in Table 16 were prepared according to analogous procedure as that described for Scheme 20 and by reacting the appropriate precursors listed (obtained as free base after basic treatment of hydrochloride salt with aqueous sat. NaHCO3 followed by extraction with DCM) with suitable commercial reagents, using CH3CN instead of DMF as the solvent and heating at 70° C., followed by an appropriate purification step as below indicated.
  • TABLE 16
    HPLC-MS characterization
    MS/ tR/min Diastere-
    ESI+ Method omeric Purification Alkylation
    Entry Structure SALT NAME [MH]+ 1, 2 or 3 ratio 1H NMR [α]D Precursor Method reagent
    255
    Figure US20130005716A1-20130103-C00324
         		Free Base 653.19 4.21:4.28 (3)    5:95 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.54 (s, 2 H), 7.87-8.02 (m, 2 H), 7.61-7.71 (m, 1 H), 7.47-7.61 (m, 2 H), 7.18 (d, 1 H), 7.13 (d, 1 H), 6.96 (dd, 1 H), 7.08 (t, 1 H), 5.98 (dd, 1 H), 4.89 (s, 1H), 4.11 (d, 1 H), 3.99 (d, 1 H), 3.92 (d, 2 H), 3.41-3.56 (m, 2 H), 3.13-3.32 (m, 2 H), 2.83-3.08 (m, 2 H), 1.02-1.41 (m, 1 H), 0.50-0.65 (m, 2 H), 0.23-0.43 (m, 2 H) −38.6  (c = 0.62, DCM) Free Base of 6 Preparative HPLC (Method 2)
    Figure US20130005716A1-20130103-C00325
    256
    Figure US20130005716A1-20130103-C00326
         		Free Base 635.28 3.16 (3) >95:5  (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.50 (s, 2 H), 7.82-8.01 (m, 2 H), 7.56-7.69 (m, 1 H), 7.41-7.56 (m, 2 H), 7.16 (d, 1 H), 7.07 (d, 1 H), 6.96 (dd, 1 H), 7.05 (t, 1 H), 5.99 (dd, 1 H), 4.18 (d, 1 H), 3.82-3.93 (m, 2 H), 3.86 (d, 1 H), 3.51 (dd, 1 H), 3.44 (dd, 1 H), 3.23 (dd, 1 H), 2.87-3.05 (m, 1 H), 2.54-2.69 (m, 1 H), 2.02-2.22 (m, 1 H), 1.52-1.89 (m, 3 H), 1.02-1.34 (m, 1 H), 0.44-0.64 (m, 2 H), 0.15-0.44 (m, 2 H) −52.52 (c = 0.23, MeOH) Free Base of 3 Flash chromatography on silica gel followed by trituration with iPr2O
    Figure US20130005716A1-20130103-C00327
    257
    Figure US20130005716A1-20130103-C00328
         		trifluoroacetate 607.28 3.02 (3) >95:5  (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 10.04 (br. s., 1 H), 8.59 (s, 2 H), 7.40 (br. s., 5 H), 7.19 (d, 1 H), 7.08 (d, l H), 6.95 (dd, 1 H), 7.07 (t, 1 H), 5.50-5.96 (m, 1 H), 4.08-4.68 (m, 3 H), 3.89 (d, 2 H), 3.42 (dd, 1 H), 3.26-3.37 (m, 2 H), 3.21 (dd, 1 H), 2.31-2.47 (m, 1 H), 1.96-2.17 (m, 1 H), 1.60-1.93 (m, 2 H), 1.12-1.31 (m, 1 H), 0.47-0.73 (m, 2 H), 0.23-0.45 (m, 2 H) −31.90 (c = 0.2, DCM) Free Base of 3 Flash chromatography on silica gel followed by preparative HPLC (Method 2)
    Figure US20130005716A1-20130103-C00329
    258
    Figure US20130005716A1-20130103-C00330
         		hydrochloride 678.43 2.86 (3) >95:5  (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 10.30 (br. s., 1 H), 8.59 (s, 2 H), 7.37-7.60 (m, 4 H), 7.19 (d, 1 H), 7.09 (d, 1H), 6.94 (dd, 1 H), 7.07 (t, 1 H), 5.80 (br. s., 1 H), 4.22-4.68 (m, 3 H), 3.89 (d, 2 H), 3.44 (dd, 1 H), 3.27-3.38 (m, 1 H), 3.23 (dd, 1 H), 2.99 (br. s., 3 H), 2.92-2.98 (m, 1 H), 2.90 (br. s., 3 H), 2.56-2.68 (m, 1 H), 1.67-2.23 (m, 3 H), 1.14-1.35 (m, 1 H), 0.48-0.75 (m, 2 H), 0.24-0.44 (m, 2 H) −37.2  (c = 0.32, DCM) Free Base of 3 Preparative HLC (method 2) followed by dissolution in DCM, treatment with 4M HCl in dioxane, evaporation and trituration with Et2O
    Figure US20130005716A1-20130103-C00331
    • Example 21 Synthesis of 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(2-(3-(dimethylcarbamoyl)phenyl)-2-oxoethyl)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (261)
  • Figure US20130005716A1-20130103-C00332
    • Step 1: Acetyl-N,N-dimethylbenzamide (259)
  • 3-Acetylbenzoic acid (400 mg, 2.437 mmol), dimethylamine hydrochloride (238 mg, 2.92 mmol), EDC (701 mg, 3.66 mmol), and DMAP (447 mg, 3.66 mmol) were dissolved in DCM (80 ml), and the resulting solution was stirred at RT overnight. The reaction mixture was washed twice with aqueous 1N HCl and with brine; the organic phase was dried over Na2SO4, filtered and evaporated to give the desired product (450 mg, 2.353 mmol, 97% yield); MS/ESI+ 192.12 [MH]+.
    • Step 2: 3-(2-bromoacetyl)-N,N-dimethylbenzamide (260)
  • To a solution of 3-acetyl-N,N-dimethylbenzamide (450 mg, 2.353 mmol) in DCM (20 ml), bromine (0.121 ml, 2.353 mmol) was added drop-wise. The resulting dark solution was stirred at RT for 24 hours. More bromine (60 ml, 1164 mmol) was added, and the stirring was continued for 4 hours. The solution was washed twice with aqueous sat. NaHCO3 solution, and the organic layer was dried over Na2SO4. The solvent was removed under vacuum to afford the desired product (526 mg, 1.947 mmol, 83% yield), which was employed in the next step without further purification. MS/ESI+ 269.96 [MH]+.
    • Step 3: 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoro-methoxy)phenyl)-2-((S)-3-(2-(3-(dimethylcarbamoyl)phenyl)-2-oxoethyl)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (261)
  • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoro-methoxy)phenyl)-2-((S)-3-(2-(3-(dimethylcarbamoyl)phenyl)-2-oxoethyl)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide was prepared according to analogous procedure as that described for Scheme 20 (Example 12) starting from intermediate (6), obtained as free base after basic treatment of the hydrochloride salt with aqueous sat. NaHCO3 followed by extraction with DCM, usign CH3CN as the solvent and heating at 60° C. It was purified by preparative HPLC (Method 2) (41% yield); MS/ESI+ 724.24 [MH]+; tR (Method 3)=3.82 min; Diastereomeric Ratio >95:5 (1H NMR); □□D]=−40.6 (c=0.38, DCM).
  • 1H NMR (B) (300 MHz, DMSO-d6) 8 ppm 8.54 (s, 2H), 8.00 (dt, 1H), 7.96 (t, 1H), 7.67 (dt, 1H), 7.60 (t, 1H), 7.18 (d, 1H), 7.13 (d, 1H), 6.96 (dd, 1H), 6.81-7.41 (m, 1H), 5.98 (dd, 1H), 4.90 (s, 1H), 4.13 (d, 1H), 4.02 (d, 1H), 3.92 (d, 2H), 3.45-3.55 (m, 1H), 3.40 (dd, 1H), 3.28 (m, 0H), 3.13-3.23 (m, 1H), 3.01 (br. s., 3H), 2.86-2.94 (m, 4H), 2.82-3.05 (m, 2H), 1.07-1.39 (m, 1H), 0.45-0.70 (m, 2H), 0.18-0.44 (m, 2H)
  • The compound listed in Table 17 was prepared according to analogous procedures as those described for Scheme 28 and by reacting the appropriate precursor listed (obtained as free base after basic treatment of the hydrochloride salt with aqueous sat. NaHCO3 followed by extraction with DCM), heating at 70° C. in Step 3, followed by an appropriate purification step as below indicated.
  • TABLE 17
    HPLC-MS
    characterization
    Dia-
    MS/ tR/min stereo- Purifi-
    SALT ESI+ Method meric Pre- cation
    Entry Structure NAME [MH]+ 1 or 2 ratio 1H NMR [α]D cursor Method
    262
    Figure US20130005716A1-20130103-C00333
         		tri- fluoro- acetate 706.25 2.98 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO- d6) δ ppm 8.56 (s, 2 H), 8.01 (dt, 1 H), 7.97 (t, 1 H), 7.77 (dt, 1 H), 7.66 (t, 1 H), 7.21 (d, 1 H), 7.14 (d, 1 H), 7.00 (dd, 1 H), 7.08 (t, 1 H), 6.08 (dd, 1 H), 5.00 (br. s., 2 H), 4.38 (br. s., 1 H), 3.91 (d, 2 H), 3.60 (br. s., 1 H), 3.53 (dd, 1 H), 3.30 (dd, 1 H), 3.19 (br. s., 1 H), 3.02 (br. s., 3 H), 2.92 (br. s., 3 H), 2.32- 2.46 (m, 1 H), 1.68-2.18 (m, 3 H), 1.05- 1.36 (m, 1 H), 0.51-0.72 (m, 2 H), 0.22- 0.40 (m, 2 H) −19.6 (c = 0.37, DCM). Free Base of 3 Prepar- ative HPLC (Meth- od 2)
    • Example 13 Synthesis of 4-((S)-2-((S)-3-(4-aminophenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (150)
  • Figure US20130005716A1-20130103-C00334
    • Step 1: methyl 3-(4-nitrophenylsulfonyl)thiazolidine-2-carboxylate (146)
  • Methyl thiazolidine-2-carboxylate hydrochloride (145) (20 g; 109 mmol) was dissolved in pyridine (100 ml), then 4-nitrobenzene-1-sulfonyl chloride (27 g, 124 mmol) was added at 0° C., and the mixture was stirred for 3 hours. After that time, the reaction was quenched with HCl 1N to precipitate a solid that was filtered on a fit and washed with water several times. The orange solid was triturated in acetone, washed with acetone (×2) and dried under vacuum to yield 27 g (76%).
  • MS/ESI+ 333.01 [MH]+
    • Step 2: methyl 3-(4-aminophenylsulfonyl)thiazolidine-2-carboxylate hydrochloride (147)
  • A mixture of methyl 3-(4-nitrophenylsulfonyl)thiazolidine-2-carboxylate (146) (5.74 g; 17.27 mmol) and 5% Pd/C (16 g; 7.547 mmol) in 600 ml of MeOH and 400 ml of HCl 1N was hydrogenated for 10 hrs at 50 psi. After that time, the reaction was filtered over Celite, washed with MeOH and the solution was concentrated under vacuum to yield the desired product (10.47 g; 72%). MS/ESI+ 312.04 [MH]+
    • Step 3: 3-(4-aminophenylsulfonyl)thiazolidine-2-carboxylic acid (148)
  • To a solution of methyl 3-(4-aminophenylsulfonyl)thiazolidine-2-carboxylate hydrochloride (147) (7.43 g, 24.57 mmol) in MeOH (62 ml), LiOH 1M (62 ml) was added. The solution was stirred at room temperature for 1 hour, then the pH was adjusted to 6 with HCl 1M. MeOH was evaporated under reduced pressure, and HCl 1M was added until the pH=3 and the mixture cooled at 0 degrees for 3 hours, until complete precipitation. The solid was filtered, washed with water and dried in vacuo at 45 degrees to give 6.44 g of the desired product (yield 91%).
  • MS/ESI+ 289.02 [MH]+
    • Step 4: 4-((2S)-2-(3-(4-aminophenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (149)
  • To a solution of (S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-hydroxyethyl)pyridine 1-oxide (1.55 g, 3.69 mmol) dissolved in DMF (20 ml), EDC (2.83 g, 14.77 mmol) and 3-(4-aminophenylsulfonyl)thiazolidine-2-carboxylic acid (148) (1.81 g, 6.28 mmol) were added. The mixture was cooled at 0 degrees, and DMAP (0.541 g. 4.43 mmol) was added. The mixture was stirred at −20 degrees for 20 minutes, then it was allowed to warm to room temperature and stirred for 3 hours. The reaction mixture was poured into water (500 ml), and the precipitate isolated by filtration. The filtered solid was washed with water (150 ml) and dried in vacuo at 45 degrees to afford 2.49 g of the desired product (yield 98%). MS/ESI+ 689.8 [MH]+
    • Step 5: 4-((S)-2-((S)-3-(4-aminophenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (150)
  • 4-((2S)-2-(3-(4-aminophenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (149) (2.49 g, 3.61 mmol) was dissolved in EtOH (35 ml) at 50 degrees, and a solution of methansulfonic acid in EtOH 10% w/w was added (3.47 g, 3.61 mmol) to achieve salification. The methanesulfonate salt was filtered off and crystallized again from hot EtOH (25 ml). The salt was dissolved in CH2Cl2 (40 ml), and NaHCO3 sat sol (30 ml) was added. The mixture was stirred for 30 minutes at RT, and then the two phases were separated. The organic phase was dried over Na2SO4 and evaporated under reduced pressure to afford a solid which was crystallized again from hot EtOH (25 ml) to yield 800 mg of the desired product. MS/ESI+ 689.8 [MH]+; tR (Method 1)=6.37 min; [αD]=+38.57 (c=0.49; CHCl3). 1H NMR (400 MHz, DMSO-d6) δ ppm 8.58 (s, 2H), 7.42-7.52 (m, 2H), 7.14-7.20 (m, 1H), 7.05-7.12 (m, 2H), 6.90-6.97 (m, 1H), 6.60-6.69 (m, 2H), 6.15-6.24 (s, 2H), 5.96-6.05 (m, 1H), 5.29 (s, 1H), 3.86-3.95 (m, 2H), 3.68-3.80 (m, 1H), 3.52 (d, J=47.63 Hz, 1H), 3.38-3.48 (m, 1H), 3.29 (m, 1H), 2.84-2.99 (m, 1H), 2.53-2.60 (m, 1H), 1.22-1.36 (m, 1H), 0.46-0.63 (m, 2H), 0.28-0.40 (m, 2H).
  • The compound listed in Table 11 was prepared according to analogous procedures as those described for Scheme 21 (Steps 1-4), followed by purification of compound (131), through Flash Cromatography eluting with DCM/n-Hexane/i-PrOH/EtOH=55/40/4/1.
  • TABLE 11
    HPLC-MS characterization
    tR/min Diastere-
    SALT MS/ESI+ Methods omeric
    Entry Structure NAME [MH]+ 1 or 2 ratio 1H NMR [α]D
    151
    Figure US20130005716A1-20130103-C00335
         		Free Base 689.8 6.28 (1) >99:1 1H NMR (400 MHz, DMSO-d6) □ ppm 8.54 (s, 2 H), 7.44-7.50 (m, 2 H), 7.17-7.24 (m, 1 H), 7.07- 7.14 (m, 2 H), 6.94-7.03 (m, 1 H), 6.57-6.64 (m, 2 H), 6.18 (s, 2 H), 5.84-6.01 (m, 1 H), 5.27 (s, 1 H), 3.86-3.99 (m, 2 H), 3.55-3.72 (m, 2 H), 3.38- 3.51 (m, 1 H), 3.25 (m, 1 H), 2.94-3.06 (m, 1 H), 2.55-2.64 (m, 1 H), 1.24-1.31 (m, 1 H), 0.46- 0.67 (m, 2 H), 0.27-0.42 (m, 2 H) −41.36 (c = 0.51; CHCl3)
    • Example 14 Synthesis of 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(1-methyl-1H-imidazol-2-ylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (155)
  • Figure US20130005716A1-20130103-C00336
    • Step 1: (S)-methyl 1-(1-methyl-1H-imidazol-2-ylsulfonyl)pyrrolidine-2-carboxylate (153)
  • (S)-methylpyrrolidine-2-carboxylate (152) (50 mg; 0.387 mmol) was dissolved in pyridine (1 ml), then 1-methyl-1H-imidazole-2-sulfonyl chloride (70 mg, 0.387 mmol) was added at 0° C., and the mixture was stirred for 3 hours. After that time, the reaction was quenched with HCl 1N and extracted with AcOEt twice. The organic phase was dried over Na2SO4 and evaporated under vacuum to yield 50 mg (yield 47%).
  • MS/ESI+ 274.08 [MH]+
    • Step 2: (S)-1-(1-methyl-1H-imidazol-2-ylsulfonyl)pyrrolidine-2-carboxylic acid (154)
  • A solution of (S)-methyl 1-(1-methyl-1H-imidazol-2-ylsulfonyl)pyrrolidine-2-carboxylate (153) (50 mg, 0.183 mmol) in HCl/Dioxane 4M (1 ml) was reacted under microwave irradiation at 100 degrees for 30 minutes. Then Dioxane was evaporated under reduced pressure to yield 40 mg of the desired compound (yield 84%).
  • MS/ESI+ 260.06 [MH]+
    • Step 3: 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(1-methyl-1H-imidazol-2-ylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (155)
  • To a solution of (S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-hydroxyethyl)pyridine 1-oxide (20 mg, 0.048 mmol) dissolved in DMF (1 ml), EDC (9 mg, 0.048 mmol) and 3-(4-aminophenylsulfonyl)thiazolidine-2-carboxylic acid (154) (40 mg, 0.154 mmol) were added. The mixture was cooled at 0 degrees, and DMAP (6 mg. 0.048 mmol) was added. The mixture was stirred at −20 degrees for 20 minutes, and then it was allowed to warm to RT and stirred for 3 hours. The reaction mixture was poured into water and extracted with AcOEt (×3). The organic phase was dried over Na2SO4, evaporated in vacuo to afford 30 mg of the desired product (yield 95%). MS/ESI+ 661.3 [MH]+; tR (Method 2)=3.60 min; Diastereomeric Ratio=99:1; 1H NMR (400 MHz, DMSO-d6) δ ppm 8.51 (s, 2 H), 7.47 (m, 1H), 7.18 (d, J=7.94 Hz, 1H), 7.13 (d, J=1.76 Hz, 1H), 7.08 (d, J=4.41 Hz, 2H), 6.98 (dd, J=8.38, 1.76 Hz, 1H), 6.00 (dd, J=9.48, 4.63 Hz, 1H), 4.47 (dd, J=8.82, 4.41 Hz, 1H), 3.92 (dd, J=7.06, 1.76 Hz, 2H), 3.84 (s, 3H), 3.37-3.55 (m, 3H), 3.24 (dd, J=14.11, 4.41 Hz, 1H), 2.22-2.37 (m, 1H), 1.83-1.95 (m, 1H), 1.65-1.82 (m, 2 H), 1.12-1.30 (m, 1H), 0.49-0.64 (m, 2H), 0.28-0.42 (m, 2H).
    • Example 22 Synthesis of 3,5-dichloro-4-((S)-2-(4-(difluoromethoxy)-3-hydroxyphenyl)-2-((S)-3-(3-(dimethylcarbamoyl)phenyl sulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (263)
  • Figure US20130005716A1-20130103-C00337
  • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (Compound 52) (200 mg, 0.268 mmol) was dissolved in 2,2,2-trifluoroacetic acid (2 ml, 0.268 mmol), and the solution stirred overnight at RT. The reaction mixture was diluted with DCM and concentrated under vacuum (2×) to give a crude which was purified through preparative HPLC (method 1) to give 3,5-dichloro-4-((S)-2-(4-(difluoromethoxy)-3-hydroxyphenyl)-2-((S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (90 mg, 0.130 mmol, 49% yield). MS/ESI+ 661.3 [MH]+; tR (Method 2)=2.49; Diastereomeric Ratio=99:1; 1H NMR (400 MHz, DMSO-d6) δ ppm 10.05 (s, 1H), 8.58 (s, 2H), 7.85 7.97 (m, 2H), 7.67-7.80 (m, 2H), 7.11 (d, J=8.38 Hz, 1H), 7.04 (t, J=75.00 Hz, 1H), 6.94 (d, J=2.21 Hz, 1H), 6.83 (m, 1H), 5.86-6.02 (m, 1H), 5.47 (s, 1 H), 3.78-3.92 (m, 1H), 3.56-3.68 (m, 1H), 3.37-3.49 (m, 1H), 3.20-3.28 (m, 1H), 2.93-3.09 (m, 4H), 2.89 (s, 3H), 2.66 (m 1H).
    • Example 23 Synthesis of 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(cyclopropylmethyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (264)
  • Figure US20130005716A1-20130103-C00338
  • 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide hydrochloride (6) (150 mg, 0.262 mmol) was dissolved in MeOH (10 ml), and cyclopropanecarbaldehyde (19.60 μl, 0.262 mmol) was added followed by sodium cyanoborohydride (33.0 mg, 0.525 mmol). The resulting mixture was stirred at RT for 2 hours. The volatiles were removed under reduced pressure, and the residue was purified by preparative HPLC (Method 2). A further purification by flash chromatography on silica gel (DCM/MeOH=99/1) was required to afford 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(cyclopropylmethyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (25 mg, 0.042 mmol, 16.17% yield). MS/ESI+ 588.94 [MH]+; tR (Method 3)=3.54; Diastereomeric Ratio=>95:5 (1H NMR); [αD]=−30.1 (c=0.31, DCM);
  • 1H NMR (B) (300 MHz, DMSO-d6) δ ppm 8.58 (s, 2H), 7.19 (d, 1H), 7.13 (d, 1H), 6.97 (dd, 1H), 7.08 (t, 1H), 5.95 (dd, 1H), 4.96 (s, 1H), 3.93 (d, 2H), 3.38-3.56 (m, 1H), 3.40 (dd, 1H), 3.26 (dd, 1H), 2.98-3.17 (m, 1H), 2.76-2.95 (m, 2H), 2.31 (dd, 1H), 2.17 (dd, 1H), 1.14-1.35 (m, 1H), 0.72-0.98 (m, 1H), 0.53-0.66 (m, 2H), 0.43-0.53 (m, 2H), 0.26-0.42 (m, 2H), −0.03-0.19 (m, 2H)
  • The compounds listed in Table 18 were prepared according to analogous procedure as that described for Scheme 30 and by reacting the appropriate precursors listed with commercial suitable reagents, followed by appropriate purification step as below reported.
  • TABLE 18
    HPLC-MS characterization
    MS/ tR/min
    ESI+ Method Diastereomeric Purification Starting
    Entry Structure SALT NAME [MH]+ 1, 2 or 3 ratio 1H NMR [α]D Precursor Method aldehyde
    265
    Figure US20130005716A1-20130103-C00339
         		Free Base 625.11 4.36 (3) >95:5  (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.46 (s, 2 H), 7.24-7.44 (m, 5 H), 7.18 (d, 1 H), 7.10 (d, 1 H), 6.95(dd, 1 H), 7.08 (t, 1 H), 5.92 (dd, 1 H), 4.73 (s, 1 H), 3.91 (d, 2 H), 3.57 (d, 1 H), 3.51 (d, 1 H), 3.32-3.43 (m, 2 H), 3.21 (dd, 1 H), 3.05-3.17 (m, 1 H), 2.79-3.04 (m, 2 H), 1.05-1.38 (m, 1 H), 0.48-0.72 (m, 2 H), 0.21-0.43 (m, 2 H) +1.3 (c = 0.51; DCM)  6 Preparative HPLC (Method 2)
    Figure US20130005716A1-20130103-C00340
    266
    Figure US20130005716A1-20130103-C00341
         		Free Base 696.27 3.79 (3) >95:5  (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.50 (s, 2 H), 7.28-7.49 (m, 4 H), 7.18 (d, 1 H), 7.10 (d, 1 H), 6.94 (dd, 1 H), 7.07 (t, 1 H), 5.90 (dd, 1 H), 4.78 (s, 1 H), 3.91 (d, 2 H), 3.59 (s, 2 H), 3.32-3.44 (m, 2 H), 3.22 (dd, 1 H), 3.06-3.17 (m, 1 H), 2.81-3.05 (m, 8 H), 1.06-1.33 (m, 1 H), 0.45-0.71 (m, 2 H), 0.21-0.45 (m, 2 H) +4.0 (c = 0.9, DCM)  6 Preparative HPLC (Method 2)
    Figure US20130005716A1-20130103-C00342
    267
    Figure US20130005716A1-20130103-C00343
         		Free Base 639.37 4.25 (minor) 4.34 (major) (3)   85:15 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.56 (s, 2 H), 7.14-7.32 (m, 6 H), 7.11 (d, 1 H), 6.94 (dd, 1 H), 7.08 (t, 1 H), 5.93 (dd, 1 H), 4.93 (s, 1 H), 3.91 (d, 2 H), 3.45-3.52 (m, 1 H), 3.40 (dd, 1 H), 3.25 (dd, 1 H), 2.98-3.15 (m, 1 H), 2.69-2.90 (m, 4 H), 2.54-2.68 (m, 2 H), 1.02-1.34 (m, 1 H), 0.48-0.66 (m, 2 H), 0.16-0.42 (m, 2 H)  6 Preparative HPLC (Method 2)
    Figure US20130005716A1-20130103-C00344
    268
    Figure US20130005716A1-20130103-C00345
         		Trifluoroacetate 692.39 2.99 (3)   90:10 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 9.70 (br. s., 1 H), 8.59 (s, 2 H), 7.42-7.62 (m, 4 H), 7.22 (d, 1 H), 7.13 (d, 1 H), 7.01 (dd, 1 H), 7.07 (t, 1 H), 6.03 (dd, 1 H), 4.59 (d, 1 H), 4.08-4.37 (m, 1 H), 3.93(d, 2 H), 3.69-3.84 (m, 1 H), 3.37-3.49 (m, 2 H), 3.10-3.33 (m, 2 H), 2.99 (br. s., 3 H), 2.89 (br. s., 3 H), 2.58-2.77 (m, 1 H), 2.54-2.61 (m, 1 H), 2.09-2.25 (m, 1 H), 1.71-2.09 (m, 2 H), 1.42-1.64 (m, 1 H), 1.08-1.33 (m, 1 H), 0.47-0.70 (m, 2 H), 0.27-0.44 (m, 2 H) −7.7 (c = 0.25, DCM) 179 Preparative HPLC (Method 2)
    Figure US20130005716A1-20130103-C00346
    • Example 24 Synthesis of 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-ureidophenyl sulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (269)
  • Figure US20130005716A1-20130103-C00347
    • 4-((S)-2-((S)-3-(3-aminophenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide
  • 140 (140, prepared as described in Example 10, 210 mg, 0.304 mmol), was dissolved in a mixture of AcOH (4 ml) and water (2 ml) at 10° C., and potassium cyanate (99 mg, 1.216 mmol) was immediately added. The reaction was stirred for 1 hour at 10° C. Water was added (30 ml), and the precipitate was collected by filtration and purified by preparative HPLC (Method 2) to afford 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-ureidophenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (136 mg, 0.185 mmol, 61.0% yield). MS/ESI+ 733.05 [MH]+; tR (Method 3)=5.39; Diastereomeric Ratio >95:5 (1H NMR); [αD]=−78.85 (c=0.4, DCM);
  • 1H NMR (B) (300 MHz, DMSO-d6) δ ppm 8.95 (s, 1H), 8.58 (s, 2H), 8.08 (t, 1H), 7.62 (ddd, 1H), 7.49 (t, 1H), 7.36 (dt, 1H), 7.18 (d, 1H), 7.12 (d, 1H), 6.96 (dd, 1H), 7.08 (t, 1H), 6.02 (dd, 1H), 6.01 (br. S., 2H), 5.30 (s, 1H), 3.91 (d, 2H), 3.61-3.82 (m, 2 H), 3.49-3.54 (m, 1H), 3.31 (dd, 1H), 2.99 (dt, 1H), 2.73 (dt, 1H), 1.09-1.38 (m, 1H), 0.48-0.62 (m, 2H), 0.21-0.45 (m, 2H)
    • Example 25 Synthesis of 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(hydroxymethyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (271)
  • Figure US20130005716A1-20130103-C00348
    • Step 1: 3-(hydroxymethyl)benzene-1-sulfonyl chloride (270)
  • To a solution of 3-(chlorosulfonyl)benzoic acid (0.300 g, 1.360 mmol) in dry THF (6 ml) cooled at 0° C., BH3*THF complex 1M in THF (5.44 ml, 5.44 mmol) was added. and the resulting mixture was left to warm to RT and stirred overnight. Additional BH3*THF complex 1M in THF (1.360 ml, 1.360 mmol) was added, and the stirring was continued for 3 days at RT. The mixture was carefully quenched with 2M HCl, diluted with brine and extracted twice with EtOAc. The combined organic layers were washed with brine and dried over sodium sulfate. The solvent was removed and the crude was purified by filtration through a silica gel cartridge (petroleum ether:EtOAc=70:30) affording 3-(hydroxymethyl)benzene-1-sulfonyl chloride (0.086 g, 0.416 mmol, 30.6% yield). MS/ESI+ not detectable [MH]+.
    • Step 2: 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(hydroxymethyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (271)
  • To a solution of 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide hydrochloride (6) (0.183 g, 0.320 mmol) in DCM (5 ml), CH3CN (2 ml), and pyridine (0.078 ml, 0.960 mmol) cooled at 0° C., a solution of 3-(hydroxymethyl)benzene-1-sulfonyl chloride (0.086 g, 0.416 mmol) in DCM (2 ml) was added, and the resulting mixture was warmed to RT and stirred. The volatiles were removed under vacuum; the residue was purified by preparative HPLC (Method 2 under neutral conditions, whithout TFA) and the collected fractions were frozen dry to afford 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(hydroxymethyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (0.100 g, 0.142 mmol, 44.3% yield); MS/ESI+ 705.14 [MH]+; tR (Method 3)=3.78; Diastereomeric Ratio >95:5 (1H NMR); [αD]=−65.67 (c=0.42; MeOH);
  • 1H NMR (B) (300 MHz, DMSO-d6) δ ppm 8.58 (s, 2H), 7.83 (t, 1H), 7.73 (dt, 1H), 7.68 (dt, 1H), 7.61 (t, 1H), 7.19 (d, 1H), 7.12 (d, 1H), 6.97 (dd, 1H), 7.08 (t, 1H), 6.03 (dd, 1H), 5.44 (t, 1H), 5.38 (s, 1H), 4.62 (d, 2H), 3.91 (d, 2H), 3.76 (dt, 1H), 3.67 (dt, 1H), 3.47 (dd, 1H), 3.31 (dd, 1H), 2.98 (dt, 1H), 2.68 (dt, 1H), 1.03-1.38 (m, 1H), 0.49-0.67 (m, 2H), 0.15-0.45 (m, 2H).
    • Example 26 Synthesis of 4-((2S)-2-(2-(3-benzoylthiazolidin-2-yl)acetoxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (274)
  • Figure US20130005716A1-20130103-C00349
    • Step 1: ethyl 2-(3-benzoylthiazolidin-2-yl]acetate (272)
  • A mixture of ethyl 2-(thiazolidin-2-yl)acetate (0.100 g, 0.571 mmol) (prepared following the synthetic protocol described in J. Chem. Soc. Perkin Trans. I, 1987, 1845-1851, which is incorporated herein by reference in its entirety), benzoic acid (0.084 g, 0.685 mmol), EDC (0.219 g, 1.141 mmol), and DMAP (0.070 g, 0.571 mmol) in DCM (10 ml) was stirred at RT for 1 hour. The mixture was diluted with DCM and washed with aqueous 1N HCl, 1N NaHCO3 and brine; the organic phase was dried over sodium sulfate and the solvent was removed. The residue was purified by flash chromatography on silica gel cartridge (petroleum ether:EtOAc=80:20 to 70:30) yielding ethyl 2-(3-benzoylthiazolidin-2-yl)acetate (0.085 g, 0.304 mmol, 53% yield). MS/ESI+ 280.0 [MH]+.
    • Step 2: 2-(3-benzoylthiazolidin-2-yl)acetic acid (273)
  • To a solution of ethyl 2-(3-benzoylthiazolidin-2-yl)acetate (0.083 g, 0.297 mmol) in dioxane (4 ml), aqueous 37% HCl (4 ml) was added, and the mixture was stirred at RT for 20 hours. The volatiles were removed under vacuum yielding crude 2-(3-benzoylthiazolidin-2-yl)acetic acid (0.074 g, 0.294 mmol, 99% yield) which was used without purification. MS/ESI+ 251.9 [MH]+.
    • Step 3: 4-((2S)-2-(2-(3-benzoylthiazolidin-2-yl)acetoxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (274)
  • A mixture of 2-(3-benzoylthiazolidin-2-yl)acetic acid (0.074 g, 0.294 mmol), (S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-hydroxyethyl)pyridine 1-oxide (0.103 g, 0.245 mmol), EDC (0.141 g, 0.736 mmol), and DMAP (0.030 g, 0.245 mmol) in DCM (10 ml) was stirred at RT for 2 hours. The mixture was diluted with DCM and washed with 1N HCl, 1N NaHCO3 and brine; the organic phase was dried over sodium sulfate and the solvent was removed. The crude was purified by preparative HPLC (Method 2) followed by flash chromatography on silica gel cartridge (DCM:MeOH=99:1) yielding title compound as a distereomeric mixture (0.065 g, 0.099 mmol, 40.5% yield); MS/ESI+ 653.19 [MH]+; tR (Method 3)=3.92; Diastereomeric Ratio=1:1 (1H NMR).
  • The compound listed in Table 19 was prepared according to analogous procedures as those described for Scheme 33 and using suitable reagents, followed by appropriate purification step as below reported.
  • TABLE 19
    HPLC-MS characterization
    tR/min Diastere-
    SALT MS/ESI+ Method omeric Purification
    Entry Structure NAME [MH]+ 1, 2 or 3 ratio Method
    275
    Figure US20130005716A1-20130103-C00350
         		Free Base 724.39 3.53 (3) 1:1 (1H NMR) Preparative HPLC (Method 2)
    • Example 27 Synthesis of 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(2-(3-(phenylsulfonyl)thiazolidin-2-yl)acetoxy)ethyl)pyridine 1-oxide (278)
  • Figure US20130005716A1-20130103-C00351
    • Step 1: ethyl 2-(3-(phenylsulfonyl)thiazolidin-2-yl)acetate (276)
  • To a solution of ethyl 2-(thiazolidin-2-yl)acetate (0.100 g, 0.571 mmol) (prepared following the synthetic protocol described in J. Chem. Soc. Perkin Trans. I, 1987, 1845-1851, which is incorporated herein by reference in its entirety) in pyridine (4 ml) cooled at 0° C., benzenesulfonyl chloride (0.088 ml, 0.685 mmol) was added, and the reaction was stirred for 2 hours at RT. The mixture was partitioned between EtOAc and 1N HCl; the organic phase was washed with 1N HCl and brine and dried over sodium sulfate. The solvent was removed and the crude was purified by flash chromatography on silica gel (petroleum ether:EtOAc=90:10 to 80:20) affording ethyl 2-(3-(phenylsulfonyl)thiazolidin-2-yl)acetate (0.096 g, 0.304 mmol, 53.3% yield). MS/ESI+ 316.0 [MH]+.
    • Step 2: 2-(3-(phenylsulfonyl)thiazolidin-2-yl)acetic acid (277)
  • To a solution of ethyl 2-(3-(phenylsulfonyl)thiazolidin-2-yl)acetate (0.096 g, 0.304 mmol) in dioxane (5 ml), aqueous 37% HCl (5 ml) was added, and the mixture was stirred at RT for 25 hours. The volatiles were removed under vacuum to afford 2-(3-(phenylsulfonyl)thiazolidin-2-yl)acetic acid (0.083 g, 0.289 mmol, 95% yield) which was used without purification. MS/ESI+ 310.0 [Mna]+.
    • Step 3: 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(2-(3-(phenylsulfonyl)thiazolidin-2-yl)acetoxy)ethyl)pyridine 1-oxide (278)
  • A mixture of 2-(3-(phenylsulfonyl)thiazolidin-2-yl)acetic acid (0.083 g, 0.289 mmol), (S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-hydroxyethyl)pyridine 1-oxide (0.101 g, 0.241 mmol), EDC (0.046 g, 0.241 mmol), and DMAP (0.029 g, 0.241 mmol) in DCM (10 ml) was stirred at RT for 1 hour. The mixture was diluted with DCM and washed with 1N HCl, 1N NaHCO3 and brine; the organic phase was dried over sodium sulfate and the solvent was removed. The crude was purified by preparative HPLC (Method 2) affording 3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(2-(3-(phenylsulfonyl)thiazolidin-2-yl)acetoxy)ethyl)pyridine 1-oxide (0.122 g, 0.177 mmol, 73.5% yield); MS/ESI+ 689.14 [MH]+; tR (Method 3)=4.09; Diastereomeric Ratio=1:1 (1H NMR).
  • The compound listed in Table 20 was prepared according to analogous procedures as those described for Scheme 42 and using suitable reagents, followed by appropriate purification step as below reported.
  • TABLE 20
    HPLC-MS characterization
    tR/min Diastere-
    SALT MS/ESI+ Method omeric Purification
    Entry Structure NAME [MH]+ 1, 2 or 3 ratio Method
    279
    Figure US20130005716A1-20130103-C00352
         		Free Base 760.23 3.67 (3) 1:1 (1H NMR) Flash chromatography on silica gel
    • Example 28 (S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(1-(3-(dimethylcarbamoyl)phenylsulfonyl)azetidine-3-carbonyloxy)ethyl)pyridine 1-oxide (281)
  • Figure US20130005716A1-20130103-C00353
    • Step 1: 1-(3-(dimethylcarbamoyl)phenylsulfonyl)azetidine-3-carboxylic acid (280)
  • To a suspension of azetidine-3-carboxylic acid (100 mg, 0.989 mmol) in a mixture of THF (6 ml) and aqueous 1M Na2CO3 (6 ml, 6.00 mmol) cooled at 0° C., 3-(dimethylcarbamoyl)benzene-1-sulfonyl chloride (269 mg, 1.088 mmol) was added, and the reaction was stirred at 0° C. for 1 hour. The mixture was extracted with Et2O, and the organic layer was discarded. The aqueous layer was carefully acidified by addition of solid KHSO4 (pH=3) and extracted twice with EtOAc. The combined organic layers were dried over Na2SO4 and evaporated to dryness yielding crude 1-(3-(dimethylcarbamoyl)phenylsulfonyl)azetidine-3-carboxylic acid (255 mg, 0.816 mmol, 83% yield) which was used without purification.
  • MS/ESI+ 313.12 [MH]
    • Step 2: (S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(1-(3-(dimethylcarbamoyl)phenylsulfonyl)azetidine-3-carbonyloxy)ethyl)pyridine 1-oxide (281)
  • A solution of 1-(3-(dimethylcarbamoyl)phenylsulfonyl)azetidine-3-carboxylic acid (255 mg, 0.816 mmol), (S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-hydroxyethyl)pyridine 1-oxide (175 mg, 0.416 mmol), EDC (96 mg, 0.500 mmol), and DMAP (61.0 mg, 0.500 mmol) in DCM (30 ml) was stirred at RT overnight. More EDC (80 mg, 0.416 mmol) and DMAP (61.0 mg, 0.500 mmol) were added, and the stirring was continued for further 2 hours. The reaction mixture was washed twice with aqueous 1N HCl then with aqueous 1M Na2CO3, the organic phase was dried over Na2SO4 and the solvent was removed under reduced pressure. The residue was purified by preparative HPLC (Method 2) to afford (S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(1-(3-(dimethylcarbamoyl)phenylsulfonyl)azetidine-3-carbonyloxy)ethyl)pyridine 1-oxide (192 mg, 0.269 mmol, 64.5% yield); MS/ESI+ 714.16 [MH]+; [αn]=−14.3 (c=0.37, DCM); 1H NMR (B) (300 MHz, DMSO-d6) δ ppm 8.56 (s, 2H), 7.68-7.90 (m, 4H), 7.16 (d, 1 H), 7.02 (d, 1H), 6.85 (dd, 1H), 7.07 (t, 1H), 5.82 (dd, 1H), 3.85-4.06 (m, 2H), 3.89 (d, 2H), 3.71 (dd, 1H), 3.56 (dd, 1H), 3.42-3.49 (m, 2H), 3.14 (dd, 1H), 3.01 (br. S., 3H), 2.86 (br. S., 3H), 1.02-1.37 (m, 1H), 0.50-0.78 (m, 2H), 0.07-0.50 (m, 2H)
  • The compounds listed in Table 21 were prepared according to analogous procedures as those described for Scheme 34 and by reacting the appropriate aminoacid precursor listed with commercial suitable reagents, followed by appropriate purification step as below reported, if needed. For the preparation of compound 283 and compound 284, Step 1 was accomplished using water as the solvent.
  • TABLE 21
    HPLC-MS characterization
    MS/ tR/min
    ESI+ Method Diastereomeric Purification Sulfonyl
    Entry Structure SALT NAME [MH]+ 1, 2 or 3 ratio 1H NMR [α]D Precursor Method aldehyde
    282
    Figure US20130005716A1-20130103-C00354
         		Free Base 643.14 3.93 (3) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.58 (s, 2 H), 7.60-7.85 (m, 5 H), 7.16 (d, 1 H), 7.02 (d, 1 H), 6.84 (dd, 1 H), 7.07 (t, 1 H), 5.82 (dd, 1 H), 3.89 (d, 2 H), 3.84-3.98 (m, 2 H), 3.69 (dd, 1 H), 3.51 (dd, 1 H), 3.36-3.47 (m, 2 H), 3.13 (dd, 1 H), 1.08-1.39 (m, 1 H), 0.47-0.67 (m, 2 H), 0.20-0.44 (m, 2 H) −10.9  (c = 0.48, DCM)
    Figure US20130005716A1-20130103-C00355
         		Preparative HPLC (Method 2)
    Figure US20130005716A1-20130103-C00356
    283
    Figure US20130005716A1-20130103-C00357
         		Free Base 714.14 6.74 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.57 (s, 2 H), 7.65-7.90 (m, 4 H), 7.18 (d, 1 H), 7.14 (d, 1 H), 6.96 (dd, 1 H), 7.07 (t, 1 H), 6.03 (dd, 1 H), 4.50 (dd, 1 H), 3.91 (d, 2 H), 3.68-3.80 (m, 1 H), 3.59-3.68 (m, 1 H), 3.47 (dd, 1 H), 3.20-3.27 (m, 1 H), 3.02 (br. S., 3 H), 2.92 (br. S., 3 H), 2.19-2.39 (m, 1 H), 2.02-2.19 (m, 1 H), 1.03-1.34 (m, 1 H), 0.47-0.64 (m, 2 H), 0.15-0.43 (m, 2 H) −73.97 (c = 1.2, DCM)
    Figure US20130005716A1-20130103-C00358
         		Preparative HPLC (Method 2)
    Figure US20130005716A1-20130103-C00359
    284
    Figure US20130005716A1-20130103-C00360
         		Free Base 643.23 3.93 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.59 (s, 2 H), 7.74-7.89 (m, 3 H), 7.61-7.74 (m, 2 H), 7.18 (d, 1 H), 7.14 (d, 1 H), 6.96 (dd, 1 H), 7.08 (t, 1 H), 6.03 (dd, 1 H), 4.42 (dd, 1 H), 3.91 (d, 2 H), 3.65-3.78 (m, 1 H), 3.55-3.67 (m, 1 H), 3.47 (dd, 1 H), 3.21-3.26 (m, 1 H), 2.13-2.26 (m, 1 H), 1.91-2.15 (m, 1 H), 1.05-1.34 (m, 1 H), 0.48-0.63 (m, 2 H), 0.24-0.41 (m, 2 H) −85.36 (c = 0.53, DCM)
    Figure US20130005716A1-20130103-C00361
         		Trituration with MeOH
    Figure US20130005716A1-20130103-C00362
    285
    Figure US20130005716A1-20130103-C00363
         		Free Base 726.1 3.66 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.60 (s, 2 H), 7.71 (dd, 1 H), 7.64 (d, 1 H), 7.19 (d, 1 H), 7.18 (d, 1 H), 7.14 (d, 1 H), 6.99 (dd, 1 H), 7.08 (t, 1 H), 6.04 (dd, 1 H), 4.10 (dd, 1 H), 3.93 (d, 2 H), 3.69 (s, 2 H), 3.32-3.58 (m, 3 H), 3.18 (s, 3 H), 2.99-3.26 (m, 1 H), 1.80-2.10 (m, 1 H), 1.60-1.80 (m, 2 H), 1.54 (d, 1 H), 0.93-1.32 (m, 1 H), 0.44-0.71 (m, 2 H), 0.05-0.44 (m, 2 H) −48.1  (c = 0.46, DCM)
    Figure US20130005716A1-20130103-C00364
         		Flash chromatography on silica gel
    Figure US20130005716A1-20130103-C00365
    • Example 29 Synthesis of 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(2-morpholinoethylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (287)
  • Figure US20130005716A1-20130103-C00366
    • Step 1: 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(vinylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (286)
  • To a solution of 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide hydrochloride (6) (500 mg, 0.874 mmol) in DCM (10 ml) cooled at 0° C., pyridine (212 μl, 2.62 mmol) and 2-chloroethanesulfonyl chloride (137 μl, 1.312 mmol) were added, and the mixture was left to warm to RT and stirred for 2 hours. Additional pyridine (707 μl, 8.74 mmol) and 2-chloroethanesulfonyl chloride (137 μl, 1.312 mmol) were added at 0° C., and the mixture reacted for 6 hours at RT. The mixture was diluted with DCM and washed with 1N HCl and brine; the organic layer was dried over Na2SO4 and the solvent was removed under vacuum. The resulting crude was purified by flash chromatography on silica gel (DCM/MeOH=98/2) yielding 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(vinylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (360 mg, 0.576 mmol, 66% yield); MS/ESI+ 624.9 [MH]+.
    • Step 2: 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(2-morpholinoethylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (287)
  • To a solution of 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(vinylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (110 mg, 0.176 mmol) in EtOH (5 ml), morpholine (35.2 μl, 0.352 mmol) was added and the mixture was reacted at RT for 1 hour. The solvent was removed under reduced pressure, and the crude was purified by preparative HPLC (Method 3) yielding 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(vinylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide as trifluoroacetate salt; MS/ESI+ 712.14 [MH]+; tR (Method 3)=3.16; Diastereomeric Ratio >95:5 (1H NMR); [αD]=−126.6 (c=0.23 DCM);
  • 1H NMR (B) (300 MHz, DMSO-d6) δ ppm 8.55 (s, 2H), 7.19 (d, 1H), 7.11 (d, 1H), 6.97 (dd, 1H), 7.08 (t, 1H), 6.03 (dd, 1H), 5.58 (s, 1H), 3.94-4.02 (m, 1H), 3.91 (d, 2H), 3.61-3.74 (m, 1H), 3.45 (dd, 1H), 3.31 (dd, 1H), 3.06-3.81 (m, 12H), 3.00-3.25 (m, 2H), 1.03-1.35 (m, 1H), 0.47-0.70 (m, 2H), 0.10-0.45 (m, 2H)
  • The compound listed in Table 22 was prepared according to analogous procedures as those described for Scheme 35 and by reacting the appropriate precursor listed with commercial suitable reagents, followed by appropriate purification step.
  • TABLE 22
    HPLC-MS characterization
    tR/min Dia-
    Meth- stereo- Pre- Purifi-
    SALT MS/ESI+ od 1, meric cur- cation
    Entry Structure NAME [MH]+ 2 or 3 ratio 1H NMR [α]D sor Method Amine
    288
    Figure US20130005716A1-20130103-C00367
         		Tri- fluoro- acetate (mono salt) 725.15 3.09 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.58 (s, 2 H), 7.60-7.85 (m, 5 H), 7.16 (d, 1 H), 7.02 (d, 1 H), 6.84 (dd, 1 H), 7.07 (t, 1 H), 5.82 (dd, 1 H), 3.89 (d, 2 H), 3.84-3.98 (m, 2 H), 3.69 (dd, 1 H), 3.51 (dd, 1 H), 3.36-3.47 (m, 2 H), 3.13 (dd, 1 H), 1.08-1.39 (m, 1 H), 0.47-0.67 (m, 2 H), 0.20-0.44 (m, 2 H) −80.24 (c = 0.325, DCM) 6 Prepar- ative HPLC (Method 3)
    Figure US20130005716A1-20130103-C00368
    • Example 30 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(2-(phenylsulfonyl)ethyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (291)
  • Figure US20130005716A1-20130103-C00369
    • Step 1: (S)-benzyl 1-(2-(phenylsulfonypethyl)pyrrolidine-2-carboxylate (289)
  • A solution of (S)-benzyl pyrrolidine-2-carboxylate hydrochloride (250 mg, 1.034 mmol), vinylsulfonylbenzene (261 mg, 1.551 mmol), and TEA (0.216 ml, 1.551 mmol) in EtOH (15 ml) was stirred at RT for 24 hours. The reaction mixture was then diluted with DCM (50 ml) and washed twice with aqueous sat. NH4Cl. The organic layer was dried over Na2SO4 and the solvent was removed under vacuum. The residue was dissolved in DCM (15 ml) and EtOH (15 ml), and PS-trisamine (free —NH2 group: 4.7 mmol/g, 0.5 g, 0.35 mmol) was added. The suspension was stirred at RT for 3 days. The resin was filtered off and the solution evaporated to dryness to afford the desired product (379 mg, 1.01 mmol, 98% yield). MS/ESI+ 374.10 [MH]+.
    • Step 2: (S)-1-(2-(phenylsulfonyl)ethyl)pyrrolidine-2-carboxylic acid (290)
  • A suspension of 10% Pd/C (10.80 mg, 0.101 mmol) in water (2 ml) was added to a solution of (S)-benzyl 1-(2-(phenylsulfonyl)ethyl)pyrrolidine-2-carboxylate (379 mg, 1.015 mmol) in MeOH (15 ml). The mixture was hydrogenated in a Parr apparatus at 30 psi for 1 hour at RT. The catalyst was filtered off and the resulting clear solution was evaporated to dryness to afford the desired product (272 mg, 0.860 mmol, 95% yield).
  • MS/ESI+ 284.02 [MH]+.
    • Step 3: 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoro-methoxy)phenyl)-2-((S)-1-(2-(phenylsulfonyl)ethyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (291)
  • A solution of (S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-hydroxyethyl)pyridine 1-oxide (150 mg, 0.357 mmol), (S)-1-(2-(phenylsulfonyl)ethyl)pyrrolidine-2-carboxylic acid (152 mg, 0.535 mmol), EDC (103 mg, 0.535 mmol), and DMAP (21.80 mg, 0.178 mmol) in DCM (30 ml) was stirred at RT for 1 hour. The reaction mixture was washed twice with 1N HCl, dried over Na2SO4 and evaporated to dryness. The residue was purified by preparative HPLC (Method 2), and the collected fractions were evaporated to dryness, redissolved DCM and eluted through a PL-HCO3 cartridge (200 mg, 0.36 mmoles). The eluted solution was evaporated to dryness affording title compound (110 mg, 0.160 mmol, 45% yield); [αD]=−33.8 (c=0.44, DCM); MS/ESI+ 685.42 [MH]+; tR=3.15 min (Method 3); Diastereomeric Ratio >95:5 ('H NMR);
  • 1H NMR (B) (300 MHz, DMSO-d6) δ ppm 8.55 (s, 2H), 7.83-7.98 (m, 2H), 7.69-7.82 (m, 1H), 7.53-7.69 (m, 2H), 7.17 (d, 1H), 7.06 (d, 1H), 6.93 (dd, 1H), 7.06 (t, 1 H), 5.92 (dd, 1H), 3.80-4.04 (m, 2H), 3.43-3.58 (m, 1H), 3.41 (dd, 1H), 3.23 (dd, 1 H), 2.61-3.09 (m, 5H), 2.25-2.44 (m, 1H), 1.84-2.08 (m, 1H), 1.37-1.78 (m, 3H), 1.09-1.33 (m, 1H), 0.48-0.73 (m, 2H), 0.25-0.43 (m, 2H)
    • Example 31 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(2-phenylacetyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (292)
  • Figure US20130005716A1-20130103-C00370
  • To a solution of 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide hydrochloride (6) (200 mg, 0.361 mmol) and pyridine (292 μl, 3.61 mmol) in dry DCM (5 ml), a solution of phenyl-acetyl chloride (84 mg, 0.542 mmol) in dry DCM (1 ml) was added dropwise at 0° C. and the mixture was left to warm to RT and stirred for 2 hours. EtOAc (20 ml) was added, and the mixture was washed with aqueous 5% citric acid and brine; the organic phase was dried over Na2SO4, filtered and evaporated. The residue was purified by flash chromatography on silica gel (DCM/MeOH=95/5). A further purification by preparative HPLC (Method 2) was required to afford 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(2-phenylacetyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (35 mg, 0.055 mmol, 15.25% yield); MS/ESI+ 635.23 [MH]+; tR=3.91 min (Method 3); Diastereomeric Ratio >95:5 (1H NMR); [αD]=−28.26 (c=0.23, MeOH);
  • 1H NMR (B) (300 MHz, DMSO-d6 353K) δ ppm 8.40 (s, 2H), 7.16-7.39 (m, 5H), 7.13 (d, 1H), 7.08 (d, 1H), 6.89-6.95 (m, 1H), 6.97 (t, 1H), 5.85-6.08 (m, 1H), 4.26-4.45 (m, 1H), 3.91 (d, 2H), 3.66 (br. S., 2H), 3.47-3.63 (m, 3H), 3.27 (dd, 1H), 2.01-2.25 (m, 1H), 1.83-1.99 (m, 1H), 1.49-1.83 (m, 2H), 1.07-1.26 (m, 1H), 0.44-0.69 (m, 2H), 0.19-0.40 (m, 2H)
    • Example 32 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(dimethylcarbamoyl)benzylsulfonyl)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (295)
  • Figure US20130005716A1-20130103-C00371
    • Step 1: (3-(dimethylcarbamoyl)phenyl)methanesulfonic acid (293)
  • To a suspension of 3-(chloromethyl)-N,N-dimethylbenzamide (1.15 g, 5.82 mmol) in water (30 ml), sodium sulfite (1.100 g, 8.73 mmol) was added, and the mixture was heated at 100° C. for 1 hour. The solvent was removed under vacuum, and the residue was suspended in MeOH (40 ml). HCl 4M in dioxane (5 ml) was added, and the insoluble inorganic salts were filtered off. The filtrate was evaporated to dryness and the residue was purified by several trituration with CH3CN affording (3-(dimethylcarbamoyl)phenyl)methanesulfonic acid (1.04 g, 4.27 mmol, 73.5% yield).
  • MS/ESI+ 243.95 [MH]
    • Step 2: (3-(dimethylcarbamoyl)phenyl)methanesulfonyl chloride (294)
  • To a suspension of (3-(dimethylcarbamoyl)phenyl)methanesulfonic acid (500 mg, 2.055 mmol) in DCM (40 ml), thionyl chloride (0.900 ml, 12.33 mmol) was added, and the resulting mixture was stirred at RT for 20 hours. The reaction mixture was poured into crushed ice and the organic phase was separated and dried over Na2SO4. The solvent was removed under vacuum to afford desired product (357 mg, 1.364 mmol, 66% yield).
  • MS/ESI+ 261.96 [MH]+
    • Step 3: 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoro-methoxy)phenyl)-2-((S)-3-(3-(dimethylcarbamoyl)benzylsulfonyl)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (295) 3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoro-methoxy)phenyl)-2-((S)-3-(3-(dimethylcarbamoyl)benzylsulfonyl)-thiazolidine-2-carbonyloxy)ethyl)pyridine
  • 1-oxide was obtained according to analogous procedure as that described for Scheme 16 (Example 8). It was purified by treatment with polymer supported isocyanate scavenger followed by preparative HPLC (Method 2) (20% yield); MS/ESI+ 760.17 [MH]+, tR=3.78 min (Method 3); Diastereomeric Ratio >95:5 (1H NMR); [αD]=−15.8 (c=3.0, DCM);
  • 1H NMR (B) (300 MHz, DMSO-d6) 8 ppm 8.53 (s, 2H), 7.38-7.55 (m, 4H), 7.17 (d, 1 H), 7.08 (d, 1H), 6.94 (dd, 1H), 7.07 (t, 1H), 6.00 (dd, 1H), 5.27 (s, 1H), 4.67 (d, 1H), 4.61 (d, 1H), 3.85-3.98 (m, 2H), 3.74-3.85 (m, 1H), 3.51-3.66 (m, 1H), 3.36-3.50 (m, 2H), 3.20-3.26 (m, 1H), 3.04-3.14 (m, 1H), 2.99 (br. S., 3H), 2.92 (br. S., 3 H), 1.04-1.42 (m, 1H), 0.46-0.66 (m, 2H), 0.20-0.41 (m, 2H)
  • The compound listed in Table 23 was obtained according to analogous procedures as those described for Scheme 38, and by reacting the appropriate precursor, obtained as free base after basic treatment of hydrochloride salt with aqueous sat. NaHCO3 followed by extraction with DCM. The purification step is described below.
  • TABLE 23
    HPLC-MS characterization
    tR/min Dia-
    Meth- stereo- Pre- Purifi-
    SALT MS/ESI+ od 1, meric cur- cation
    Entry Structure NAME [MH]+ 2 or 3 ratio 1H NMR [α]D sor Method
    296
    Figure US20130005716A1-20130103-C00372
         		Free Base 742.30 3.61 (3) >95:5 (1H NMR B) 11H NMR (300 MHz, DMSO-d6) δ ppm 8.54 (s, 2 H), 7.36-7.54 (m, 4 H), 7.16 (d, 1 H), 7.10 (d, 1 H), 6.94 (dd, 1 H), 7.06 (t, 1 H), 5.98 (dd, 1 H), 4.54 (d, 1 H), 4.46 (d, 1 H), 4.07 (dd, 1 H), 3.83- 3.97 (m, 2 H), 3.42 (dd, 1 H), 3.27-3.36 (m, 2 H), 3.23 (dd, 1 H), 2.98 (br. S., 3 H), 2.91 (br. S., 3 H), 2.00- 2.24 (m, 1 H), 1.57- 1.95 (m, 3 H), 0.93- 1.31 (m, 1 H), 0.45- 0.64 (m, 2H), 0.12- 0.44 (m, 2 H) −8.7 (c 0.33 in DCM) Free Base of 3 Prepar- ative HPLC (Method 2)
    • Example 33 Synthesis of 3,5-dichloro-4-((S)-2-(4-(difluoromethoxy)-3-methoxyphenyl)-2-((S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (299)
  • Figure US20130005716A1-20130103-C00373
    • Step 1: 4-((S)-2-((S)-3-(tert-butoxycarbonyl)thiazolidine-2-carbonyloxy)-2-(4-(difluoromethoxy)-3-methoxyphenyl)ethyl)-3,5-dichloropyridine 1-oxide (297)
  • A solution of (S)-3-(tert-butoxycarbonyl)thiazolidine-2-carboxylic acid (479 mg, 2.052 mmol), (S)-3,5-dichloro-4-(2-(4-(difluoromethoxy)-3-methoxyphenyl)-2-hydroxyethyl)pyridine 1-oxide (164) (prepared according to analogous procedure as that described for Scheme 23), (650 mg, 1.710 mmol), EDC (492 mg, 2.56 mmol), and DMAP (313 mg, 2.56 mmol) in DCM (60 ml) was stirred at RT for 3 hours. The reaction mixture was diluted with DCM and washed twice with aqueous 1N HCl; the organic layer was dried over Na2SO4 and evaporated to dryness to afford the desired compound (quantitative yield). MS/ESI+ 595.24 [MH]+.
    • Step 2: 3,5-dichloro-4-((S)-2-(4-(difluoromethoxy)-3-methoxyphenyl)-2-((S)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide hydrochloride (298)
  • To a solution of 4-((S)-2-((S)-3-(tert-butoxycarbonyl)thiazolidine-2-carbonyloxy)-2-(4-(difluoromethoxy)-3-methoxyphenyl)ethyl)-3,5-dichloropyridine 1-oxide (1.710 mmol) in EtOAc (10 ml) cooled at 0° C., HCl, 4M solution in EtOAc (10 ml, 40.0 mmol) was added, and the resulting mixture was stirred at RT for 2 hours. More HCl, 4M solution in EtOAc (10 ml, 40.0 mmol) was added, and the solution was stirred at 0° C. for additional 2 hours to reach complete conversion. The solution was concentrated to 10 ml under reduced pressure (bath temperature: 10° C.; partial pressure: 8 psi), then iPr2O (20 ml) was added and the product precipitated as a sticky gummy solid. After the solid was allowed to settle down, the solvent was removed by aspiration. The residue was dried in vacuo at RT to afford 3,5-dichloro-4-((S)-2-(4-(difluoromethoxy)-3-methoxyphenyl)-2-((S)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide hydrochloride (0.890 g, 1.674 mmol, 97% yield), which was employed in the next step without any additional purification. MS/ESI+ 494.97 [MH].
    • Step 3: 3,5-dichloro-4-((S)-2-(4-(difluoromethoxy)-3-methoxyphenyl)-2-((S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (299)
  • To a solution of 3,5-dichloro-4-((S)-2-(4-(difluoromethoxy)-3-methoxyphenyl)-2-((S)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide hydrochloride (350 mg, 0.658 mmol) in pyridine (6 ml) cooled at 0° C., a solution of 3-(dimethylcarbamoyl)benzene-1-sulfonyl chloride (245 mg, 0.987 mmol) in DCM (3 ml) was added drop-wise, and the reaction was stirred at 0° C. for 1 hour. The mixture was diluted with DCM (30 ml) and washed twice with aqueous 1N HCl; the organic layer was dried over Na2SO4 and the solvent was removed under vacuum. The residue was purified by preparative HPLC (Method 2) followed by flash chromatography on silica gel (DCM/MeOH=97/3) to afford 3,5-dichloro-4-((S)-2-(4-(difluoromethoxy)-3-methoxyphenyl)-2-((S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (147 mg, 0.208 mmol, 31.6% yield); MS/ESI+ 705.97 [MH]+, tR=3.28 min (Method 3); Diastereomeric Ratio=95:5 (1H NMR); [αD]=−43.1 (c=0.57, DCM);
  • 1H NMR (300 MHz, DMSO-d6) δ ppm 8.57 (s, 2H), 7.94 (dt, 1H), 7.90 (t, 1H), 7.77 (dt, 1H), 7.71 (t, 1H), 7.18 (d, 1H), 7.15 (d, 1H), 6.97 (dd, 1H), 7.07 (t, 1H), 6.04 (dd, 1 H), 5.54 (s, 1H), 3.84 (s, 3H), 3.75-3.94 (m, 1H), 3.66 (dt, 1H), 3.48 (dd, 1H), 3.33 (dd, 1H), 3.02 (br. S., 3H), 2.98 (dd, 1H), 2.90 (br. S., 3H), 2.66 (dt, 1H)
  • The compounds listed in Table 24 were prepared according to analogous procedures as those described for Scheme 39 and by reacting the appropriate alcohol listed with commercial suitable reagents, followed by appropriate purification step as below reported. Compound 303 was obtained as second eluted diastereoisomer from a mixture of diastereoisomers
  • TABLE 24
    HPLC-MS characterization
    tR/min Dia-
    Meth- stereo- Purifi-
    SALT MS/ESI+ od 1, meric Alco- cation
    Entry Structure NAME [MH]+ 2 or 3 ratio 1H NMR [α]D hol Method
    300
    Figure US20130005716A1-20130103-C00374
         		Free Base 653.03 3.69 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.59 (s, 2 H), 7.83-7.93 (m, 2 H), 7.71-7.81 (m, 0 H), 7.58-7.71 (m, 2 H), 7.19 (d, 1 H), 7.15 (d, 1 H), 6.97 (dd, 1 H), 7.08 (t, 1 H), 6.04 (dd, 1 H), 5.44 (s, 1 H), 3.85 (s, 3 H), 3.81 (dt, 1 H), 3.65 (dt, 1 H), 3.48 (dd, 1 H), 3.32 (dd, 1 H), 2.99 (dt, 1 H), 2.66 (dt, 1 H) −51.1 (c = 0.52, DCM) 164 Prepar- ative HPLC (Method 2)
    301
    Figure US20130005716A1-20130103-C00375
         		Free Base 689.13 4.37 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.58 (s, 2 H), 7.84-7.97 (m, 2 H), 7.72-7.83 (m, 1 H), 7.59-7.70 (m, 2 H), 7.17 (d, 1 H), 7.08 (d, 1 H), 6.94 (dd, 1 H), 7.00 (t, 1 H), 6.02 (dd, 1 H), 5.46 (s, 1 H), 4.69-5.06 (m, 1 H), 3.82 (dt, 1 H), 3.64 (dt, 1 H), 3.46 (dd, 1 H), 3.31 (dd, 1 H), 2.98 (dt, 1 H), 2.65 (dt, 1 H), 1.42-2.03 (m, 8 H) −43.0 (c = 0.53; DCM) 165 Prepar- ative HPLC (Method 2)
    302
    Figure US20130005716A1-20130103-C00376
         		Free Base 760.17 3.98 (3) 95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.57 (s, 2 H), 7.95 (dt, 1 H), 7.91 (t, 1 H), 7.77 (dt, 1 H), 7.72 (td, 1 H), 7.16 (d, 1 H), 7.08 (d, 1 H), 6.94 (dd, 1 H), 6.99 (t, 1 H), 6.02 (dd, 1 H), 5.57 (s, 1 H), 4.82-5.00 (m, 1 H), 3.87 (dt, 1 H), 3.65 (dt, 1 H), 3.46 (dd, 1 H), 3.32 (dd, 1 H), 3.03 (br. S., 3 H), 2.93-3.01 (m, 1 H), 2.90 (br. S., 3 H), 2.65 (dt, 1 H), 1.38- 2.04 (m, 8 H) −42.7 (c = 0.50; DCM) 165 Prepar- ative HPLC (Method 2)
    303
    Figure US20130005716A1-20130103-C00377
         		Free Base 689.97 3.59 (3) 95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.56 (s, 2 H), 7.94 (dt, 1 H), 7.89 (t, 1 H), 7.77 (dt, 1 H), 7.71 (t, 1 H), 7.51 (d, 1 H), 7.43 (d, 1 H), 7.23 (dd, 1 H), 6.04 (dd, 1 H), 5.53 (s, 1 H), 3.83 (dt, 1 H), 3.65 (dt, 1 H), 3.48 (dd, 1 H), 3.31 (dd, 1 H), 3.02 (br. S., 3 H), 2.93- 3.01 (m, 1 H), 2.90 (br. S., 3H), 2.67 (dt, 1 H) −48.68 (c = 0.49, DCM) 172 Prepar- ative HPLC (Method 2)
    • Example 34 Synthesis of 3,5-dichloro-4-((S)-2-(4-(difluoromethoxy)-3-methoxyphenyl)-2-((S)-1-(phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (Compound 305)
  • Figure US20130005716A1-20130103-C00378
    • Step 1: (S)-1-(phenylsulfonyl)pyrrolidine-2-carboxylic acid (304)
  • Benzenesulfonyl chloride (4.03 ml, 31.3 mmol) was added to a cooled suspension (0° C.) of (S)-pyrrolidine-2-carboxylic acid (3 g, 26.1 mmol) in THF (50 ml) and aqueous 1M Na2CO3 (60 ml, 60.0 mmol), and the reaction was stirred at 0° C. for 1 hour. The mixture was extracted twice with Et2O, and the organic layers were discarded. The aqueous phase was cautiously acidified by addition of solid KHSO4 to pH=3 and extracted twice with EtOAc. The combined organic layers were dried over Na2SO4 and evaporated to dryness to afford (S)-1-(phenylsulfonyl)pyrrolidine-2-carboxylic acid (6.1 g, 23.89 mmol, 92% yield). MS/ESI+ 256.10 [MH]
    • Step 2: 3,5-dichloro-4-((S)-2-(4-(difluoromethoxy)-3-methoxyphenyl)-2-((S)-1-(phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (305)
  • A mixture of (S)-3,5-dichloro-4-(2-(4-(difluoromethoxy)-3-methoxyphenyl)-2-hydroxyethyl)pyridine 1-oxide (164) (55 mg, 0.145 mmol), (S)-1-(phenylsulfonyl)pyrrolidine-2-carboxylic acid (111 mg, 0.434 mmol), EDC (83 mg, 0.434 mmol), and DMAP (53.0 mg, 0.434 mmol) in DCM (20 ml) was stirred at RT for 3 hours. The reaction mixture was washed twice with aqueous 1N HCl and then with aqueous 1M K2CO3; the organic layer was dried over Na2SO4 and the solvent was removed under reduced pressure. The residue was purified by preparative HPLC (Method 2) to afford 3,5-dichloro-4-((S)-2-(4-(difluoromethoxy)-3-methoxyphenyl)-2-((S)-1-(phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (45 mg, 0.073 mmol, 50.4% yield); MS/ESI+ 617.15 [MH]+, tR=3.71 min (Method 3); Diastereomeric Ratio >95:5 (1H NMR); [αD]=−60.3 (c=0.39, DCM);
  • 1H NMR (B) (300 MHz, DMSO-d6) 8 ppm 8.61 (s, 2H), 7.75-7.85 (m, 2H), 7.69-7.76 (m, 1H), 7.56-7.69 (m, 2H), 7.19 (d, 1H), 7.18 (d, 1H), 7.00 (dd, 1H), 7.07 (t, 1 H), 6.05 (dd, 1H), 4.16 (dd, 1H), 3.86 (s, 3H), 3.49 (dd, 1H), 3.39-3.44 (m, 1H), 3.29 (dd, 1H), 3.09-3.23 (m, 1H), 1.83-2.10 (m, 1H), 1.59-1.82 (m, 2H), 1.44-1.59 (m, 1H)
  • The compounds listed in Table 25 were prepared according to analogous procedures as those described for Scheme 40 using commercial suitable reagents and by reacting the appropriate alcohol listed, followed by appropriate purification step as below reported. Compound 315 was obtained as second eluted diastereoisomer from a mixture of diastereoisomers
  • TABLE 25
    HPLC-MS characterization Alco-
    tR/min Dia- hol
    Method stereo- Pre- Purifi-
    SALT MS/ESI+ 1, 2 meric cur- cation
    Entry Structure NAME [MH]+ or 3 ratio 1H NMR [α]D sor Method
    306
    Figure US20130005716A1-20130103-C00379
         		Free Base 688.22 3.24 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.58 (s, 2 H), 7.84 (dt, 1 H), 7.64-7.80 (m, 3 H), 7.13-7.26 (m, 2 H), 7.00 (dd, 1 H), 7.07 (t, 1 H), 6.05 (dd, 1 H), 4.21 (dd, 1 H), 3.86 (s, 3 H), 3.50 (dd, 1 H), 3.34-3.44 (m, 1 H), 3.29 (dd, 1 H), 3.20 (dt, 1 H), 3.02 (br. S., 3 H), 2.90 (br. S., 3 H), 1.89- 2.13 (m, 1 H), 1.50- 1.77 (m, 3 H) −56.63 c = 0.47, DCM 164 Prepar- ative HPLC (Method 2)
    307
    Figure US20130005716A1-20130103-C00380
         		Free Base 671.24 4.32 (3) 80:20 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.60 (s, 2 H), 7.58-7.81 (m, 5 H), 7.17 (d, 1 H), 7.11 (d, 1 H), 6.97 (dd, 1 H), 7.00 (t, 1 H), 6.02 (dd, 1 H), 4.75-5.06 (m, 1 H), 3.99-4.31 (m, 1 H), 3.36-3.55 (m, 2 H), 3.06-3.27 (m, 2 H), 1.81-1.97 (m, 3 H), 1.47-1.79 (m, 9 H) −56.4 c = 0.53, DCM 165 Prepar- ative HPLC (Method 2)
    308
    Figure US20130005716A1-20130103-C00381
         		Free Base 742.12 3.86 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.57 (s, 2 H), 7.84 (dt, 1 H), 7.72-7.80 (m, 2 H), 7.71 (t, 1 H), 7.17 (d, 1 H), 7.11 (d, 1 H), 6.97 (dd, 1 H), 6.99 (t, 1 H), 6.02 (dd, 1 H), 4.93 (tt, 1 H), 4.22 (dd, 1 H), 3.48 (dd, 1 H), 3.15-3.38 (m, 3 H), 3.02 (br. S., 3 H), 2.90 (br. S., 3 H), 1.42-2.10 (m, 12 H) −55.6, (c = 0.49, DCM 165 Prepar- ative HPLC (Method 2)
    309
    Figure US20130005716A1-20130103-C00382
         		Free Base 581.15 3.14 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.60 (s, 2 H), 7.74-7.83 (m, 2 H), 7.69-7.74 (m, 1 H), 7.56-7.69 (m, 2 H), 6.98 (d, 1 H), 6.95 (d, 1 H), 6.91 (dd, 1 H), 6.02 (dd, 1 H), 4.14 (dd, 1 H), 3.77 (s, 3 H), 3.76 (s, 3 H), 3.50 (dd, 1 H), 3.33-3.42 (m, 1 H), 3.26 (dd, 1 H), 3.17 (dt, 1 H), 1.77-2.03 (m, 1 H), 1.59-1.77 (m, 2 H), 1.36-1.59 (m, 1 H) −71.5, (c = 0.46, DCM 170 Prepar- ative HPLC (Method 2)
    310
    Figure US20130005716A1-20130103-C00383
         		Free Base 652.25 2.74 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.57 (s, 2 H), 7.83 (dt, 1 H), 7.60-7.80 (m, 3 H), 6.98 (d, 1 H), 6.95 (d, 1 H), 6.91 (dd, 1 H), 6.02 (dd, 1 H), 4.18 (dd, 1 H), 3.77 (s, 3 H), 3.76 (s, 3 H), 3.50 (dd, 1 H), 3.31-3.42 (m, 1 H), 3.26 (dd, 1 H), 3.12-3.22 (m, 1 H), 3.02 (br. S., 3 H), 2.90 (br. S., 3 H), 1.80-2.06 (m, 1 H), 1.41-1.80 (m, 3 H) −70.4 (c = 0.85, DCM 170 Prepar- ative HPLC (Method 2)
    311
    Figure US20130005716A1-20130103-C00384
         		Free Base 635.23 3.84, 3.88 (3) 1:1 (1H NMR) 157 Prepar- ative HPLC (Method 2)
    312
    Figure US20130005716A1-20130103-C00385
         		Free Base 706.16 3.41, 3.45 (3) 1:1 (1H NMR) 157 Prepar- ative HPLC (Method 2)
    313
    Figure US20130005716A1-20130103-C00386
         		Free Base 621.2 3.63 (3) 6:4 (1H NMR) 156 Prepar- ative HPLC (Method 2)
    314
    Figure US20130005716A1-20130103-C00387
         		Free Base 692.28 3.23 (3) 6:4 (1H NMR) 156 Prepar- ative HPLC (Method 2)
    315
    Figure US20130005716A1-20130103-C00388
         		Free Base 672.13 3.42; 3.47 (3) 5:95 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.57 (s, 2 H), 7.83 (dt, 1 H), 7.72-7.79 (m, 2 H), 7.70 (td, 1 H), 7.54 (d, 1 H), 7.43 (d, 1 H), 7.26 (dd, 1 H), 6.04 (dd, 1 H), 4.19 (dd, 1 H), 3.49 (dd, 1 H), 3.32-3.44 (m, 1 H), 3.28 (dd, 1 H), 3.19 (dt, 1 H), 3.02 (br. S., 3 H), 2.90 (br. S., 3 H), 1.90-2.07 (m, 1 H), 1.46-1.81 (m, 3 H) −67.58, (c = 0.47, DCM 172 Prepar- ative HPLC (Method 2)
    316
    Figure US20130005716A1-20130103-C00389
         		Free Base 649.35 3.97 (3) 1:1 (1H NMR) 173 SCX cartridge followed by preparatibe HPLC (Mehtod 2)
    317
    Figure US20130005716A1-20130103-C00390
         		Free Base 720.43 3.56 (3) 1:1 (1H NMR) 173 SCX cartridge followed by preparatibe HPLC (Mehtod 2)
    • Example 35 3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-methoxyphenyl)-2-((S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (320)
  • Figure US20130005716A1-20130103-C00391
    • Step 1: (S)-ethyl 3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carboxylate (318)
  • (S)-ethyl thiazolidine-2-carboxylate (2R,3R)-2,3-dihydroxysuccinate (prepared as described in Bull. Korean Chem. Soc., 2010, 31, 2709, which is incorporated herein by reference in its entirety), (4 g, 12.85 mmol) was poured into a separation funnel containing aqueous sat. NaHCO3 (50 ml, 55.0 mmol) and Et2O (100.0 ml), previously cooled to 0° C. in an ice bath. The mixture was shaken to dissolution of the solid; the phases were separated, and the aqueous layer was extracted again with Et2O (100 ml). The combined organic layers were dried over Na2SO4 and evaporated to dryness without heating. The residue was dissolved in THF (50 ml), the solution was cooled to 0° C., and aqueous sat. NaHCO3 (50 ml, 55.0 mmol) was added. A solution of 3-(dimethylcarbamoyl)benzene-1-sulfonyl chloride (3.18 g, 12.85 mmol) in THF (50 ml) was added to the biphasic mixture at 0° C. under vigorous stirring, and the reaction was left at RT for 4 hours. The mixture was partitioned between EtOAc and water, and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with aqueous 1N HCl and brine, dried over Na2SO4 and evaporated to dryness to afford (S)-ethyl 3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carboxylate (3.79 g, 10.18 mmol, 79% yield); MS/ESI+ 373.04 [MH]+
    • Step 2: (S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carboxylic acid (319)
  • (S)-ethyl 3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carboxylate (3.79 g, 10.18 mmol) was dissolved in mixture of MeOH (30 ml), THF (30.0 ml), and water (30.0 ml). LiOH (0.487 g, 20.35 mmol) was added, and the reaction was stirred at RT for 30 minutes. The mixture was acidified with aqueous 1N HCl (pH=1), diluted with water, and extracted twice with EtOAc. The combined organic layers were dried over Na2SO4 and evaporated to dryness. The residue was triturated with a mixture of Et2O (15 ml) and petroleum ether (25 ml) yielding after filtration (S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carboxylic acid (1.86 g, 5.40 mmol, 53.1% yield); MS/ESI+ 344.94 [MH]+; [αD]=−36.1 (c=1.67, MeOH). To determine the enantiomeric purity, this intermediate was coupled with alcohol 1 (EDC, DMAP, DCM) to afford compound 52: Diastereomeric Ratio=95:5.
    • Step 3: 3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-methoxyphenyl)-2-((S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (320)
  • To a solution of 3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-methoxyphenyl)-2-hydroxyethyl)pyridine 1-oxide (156) (160 mg, 0.416 mmol), EDC (160 mg, 0.833 mmol), and DMAP (102 mg, 0.833 mmol) in DCM (50 ml), (S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carboxylic acid (172 mg, 0.500 mmol) was added, and the resulting mixture was stirred at RT for 24 hours. The reaction mixture was washed twice with aqueous 1N HCl, and the organic layer was dried over Na2SO4. The solvent was removed under vacuum, and the residue was purified by preparative HPLC (Method 2) to afford 3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-methoxyphenyl)-2-((S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (122 mg, 0.172 mmol, 41% yield); MS/ESI+ 710.25 [MH]+, tR=3.25 min (Method 3); Diastereomeric Ratio 1:1 (1H NMR).
  • The compounds listed in Table 26 were prepared according to Scheme 41 using commercial suitable reagents and by reacting the appropriate alcohol listed, followed by appropriate purification step as below reported. The enantiomeric purity of intermediate obtained using benzenesulfonylchloride was determined as described above in Step 2 (reference compound: 89; Diastereomeric Ratio=92:8)
  • TABLE 26
    HPLC-MS characterization Alco-
    tR/min Dia- hol
    Method stereo- Pre- Purifi-
    En- SALT MS/ESI+ 1, 2 meric cur- cation
    try Structure NAME [MH]+ or 3 ratio 1H NMR [α]D sor Method
    321
    Figure US20130005716A1-20130103-C00392
         		Free Base 639.08 3.66, 3.69 (3) 1:1 (1H NMR) 156 Prepar- ative HPLC (Method 2)
    322
    Figure US20130005716A1-20130103-C00393
         		Free Base 653.08 3.91, 3.96 (3) 1:1 (1H NMR) 157 Prepar- ative HPLC (Method 2)
    323
    Figure US20130005716A1-20130103-C00394
         		Free Base 724.26 3.48, 3.52 (3) 1:1 (1H NMR) 157 Prepar- ative HPLC (Method 2)
    324
    Figure US20130005716A1-20130103-C00395
         		Free Base 599.22 3.23 (3) >95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.58 (s, 2 H), 7.83-7.92 (m, 2 H), 7.72-7.81 (m, 1 H), 7.60-7.71 (m, 2 H), 6.95 (d, 1 H), 6.88 (dd, 1 H), 6.00 (dd, 1 H), 5.41 (s, 1 H), 3.78-3.86 (m, 1 H), 3.77 (s, 3 H), 3.75 (s, 3 H), 3.57- 3.71 (m, 1 H), 3.48 (dd, 1 H), 3.30 (dd, 1 H), 2.88-3.14 (m, 1 H), 2.64 (dt, 1 H) −60.50 (c = 0.4, DCM) 170 Prepar- ative HPLC (Method 2)
    325
    Figure US20130005716A1-20130103-C00396
         		Free Base 670.17 2.83 (3) 95:5 (1H NMR) 1H NMR (300 MHz, DMSO-d6) δ ppm 8.56 (s, 2 H), 7.93 (dt, 1 H), 7.90 (t, 1 H), 7.77 (dt, 1 H), 7.71 (t, 1 H), 6.95 (d, 1 H), 6.94 (d, 1 H), 6.88 (dd, 1 H), 6.00 (dd, 1 H), 5.51 (s, 1 H), 3.81- 3.96 (m, 1 H), 3.76 (s, 3 H), 3.75 (s, 3 H), 3.58-3.70 (m, 1 H), 3.48 (dd, 1 H), 3.31 (dd, 1 H), 3.02 (br. S., 3 H), 2.92-3.02 (m, 1 H), 2.89 (br. S., 3 H), 2.64 (dt, 1 H) −50.25 (c = 0.40, DCM) 170 Prepar- ative HPLC (Method 2)
    326
    Figure US20130005716A1-20130103-C00397
         		Free Base 667.31 4.05 (3) 1:1 (1H NMR) 174 SCX cartridge followed by preparative HPLC (Method 2)
    327
    Figure US20130005716A1-20130103-C00398
         		Free Base 738.39 3.63 1:1 (1H NMR) 174 SCX cartridge followed by preparative HPLC (Method 2)
    • Pharmacological Activity of the Compounds of the Invention Example 15 In Vitro Determination of PDE4 Inhibitory Activity in the Cell Free Assay
  • PDE4 activity was determined in U937 human monocytic supernatants cells lysate. Cells were cultured, harvested and supernatant fraction prepared essentially as described in Torphy T J, et al., 1 J. Pharmacol. Exp. Ther., 1992; 263:1195-1205, which is incorporated herein by reference in its entirety. U937 cells (Cell Bank, Interlab Cell Line Collection, ICLC HTL94002) were grown at 37° C., 5% CO2 in RPMI 1640 with GlutaMAX™-I medium supplemented with 10% fetal bovine serum and 100 μg/ml Pen-strep (Gibco). Cells were harvested and washed twice by centrifugation (150×g, 8 minutes) in cold PBS. Washed cells were resuspended in cold Krebs-Ringer-Henseleit buffer at a final concentration 20×10−6 cells/ml and sonicated. After centrifugation at 15000×g for 20 min, the supernatants were pooled, divided in aliquots and stored at −80° C.
  • PDE4 activity was determined in cells supernatants by assaying cAMP disappearance from the incubation mixtures. The concentration of the test compounds ranged between 10−12 M and 10−6 M. Reactions were stopped by enzyme heat inactivation (2.5 minutes at 100° C.), and residual cAMP content was determined using the ‘LANCE cAMP Assay’ from PerkinElmer following the providers instructions. The results of the tested compounds, representatives of the invention, expressed as mean±standard deviation of the nM concentration of the test compound producing 50% inhibition of cAMP disappearance (IC50) are shown in the following Table:
  • PDE4
    Compound No. inhibition
    209, 234, 238, 239, 240, 241, 242, 227, 228, 206, 207, ++++
    269, 198, 271, 295, 210, 186, 244, 185, 281, 232, 218,
    219, 220, 309, 310, 287, 288, 305, 283, 250, 314, 301,
    302, 224, 300, 287, 288, 226, 299, 312, 285, 308, 189,
    264, 278, 225, 191, 256, 274, 266, 275, 291, 195, 190,
    237, 15, 17, 30, 31, 32, 33, 34, 38, 42, 52, 53, 54, 55, 56,
    58, 64, 65, 66, 73, 75, 77, 78, 82, 84, 85, 88, 90, 91, 93,
    94, 97, 100, 101, 102, 106, 107, 109, 110, 114, 118, 119,
    121, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132,
    135, 137, 138, 139, 141, 143, 150, 151
    200, 201, 202, 203, 204, 205, 208, 229, 263, 284, 307, +++
    311, 257, 292, 258, 199, 281, 19, 49, 57, 59, 62, 63, 67,
    68, 69, 70, 71, 72, 74, 76, 79, 80, 81, 83, 86, 89, 103,
    104, 105, 108, 136, 144
    245, 246, 248, 249, 315, 303, 26 ++
  • In the table above, PDE4 binding potencies (IC50 values) are indicated as follows: >10 nM “+”; 10-1 nM “++”; 1-0.1 nM “+++”; <0.1 nM “++++”.
  • Percentage of inhibition of PDE4 activity was calculated, assuming cAMP disappearance in the absence of inhibitors as 100% and cAMP disappearance in heat inactivated samples as 0%.
  • Analogously, results for tested compounds of formula (II) (expressed as mean±standard deviation of the nM concentration of the test compound producing 50% inhibition of cAMP disappearance) (IC50) are shown in the following Table:
  • Compound No. PDE4 inhibition
    8, 11, +++
    3, 9, 10, 14 ++
  • In the table above, PDE4 binding potencies (IC50 values) are indicated as follows: >10 nM “+”; 10-1 nM “++”; 1-0.1 nM “+++”; <0.1 nM “++++”.
    • Example 16 In Vitro Determination of PDE4 Inhibitory Activity in the Peripheral Blood Mononuclear Cells (PBMCs) Assay
  • The assay, which is based on the known inhibitory activity exerted by PDE4 inhibitors on the lipopolyshaccarides (LPS)-induced tumour necrosis factor-alpha (TNF-α release in peripheral blood mononuclear cells (PBMCs), was performed according to a method previously described (Hatzelmann A et al., J. Pharmacol. Exp. Ther., 2001; 297:267-279; and Draheim R et al., J. Pharmacol. Exp. Ther., 2004; 308:555-563, which are incorporated herein by reference in their entireties). Cryopreserved human PBMCs, (100 μl/well) were incubated in 96-well plates (105 cells/well), for 30 minutes, in the presence or absence (50 microl) of the test compounds whose concentrations ranged from 10−12 M to 10−6 M or from 10−13 M to 10−7 M. Subsequently, LPS (3 ng/ml) was added.
  • After 18 hours of incubation at 37° C. in a humidified incubator under an atmosphere of 95% air and 5% CO2, culture medium was collected and TNF-α measured by ELISA. The results of the tested compounds, representatives of the invention, expressed as mean±95% confidence limits of the molar concentration of the test compound producing 50% inhibition of LPS-induced TNF-α release (IC50) are shown in the following Table:
  • PDE4
    Compound No. inhibition
    239, 240, 241, 242, 206, 271, 210, 310, 250, 251, 252, ++++
    269, 287, 299, 35, 37, 38, 52, 54, 56, 59, 64, 66, 73, 74,
    82, 83, 84, 85, 88, 90, 91, 92, 93, 94, 95, 96, 97, 101,
    106, 107, 109, 113, 115, 116, 118, 119, 123, 124, 128,
    129, 130, 131, 132, 133, 139, 140, 150, 155
    238, 201, 203, 228, 207, 198, 209, 295, 243, 186, 187, +++
    185, 281, 253, 288, 200, 16, 17, 20, 22, 26, 31, 32, 34,
    36, 39, 40, 41, 49, 51, 53, 55, 57, 58, 60, 61, 62, 63, 65,
    67, 68, 69, 70, 75, 76, 77, 78, 79, 80, 81, 86, 87, 89, 98,
    103, 104, 105, 108, 110, 111, 114, 117, 121, 125, 126,
    127, 135, 136, 137, 138, 141, 142, 143, 144, 151
    244, 263, 15, 19, 21, 30, 71, 99, 100 ++
  • In the table above, PDE4 binding potencies (IC50 values) are indicated as follows: >10 nM “+”; 10-1 nM “++”; 1-0.1 nM “+++”; <0.1 nM “++++”.
  • The effects of the tested compounds were calculated as percentage of inhibition of TNF-α release, assuming LPS-induced TNF-α production in the absence of inhibitor compound as 100% and basal TNF-α production of PBMCs in the absence of LPS as 0%.
  • Analogously, results of tested compounds for compounds of formula (II) expressed as mean±95% confidence limits of the molar concentration of the test compound producing 50% inhibition of LPS-induced TNF-α release (IC50) are shown in the following Table:
  • Compound No. PDE4 inhibition
    6, 11 +++
    8, 9, ++
  • In the table above, PDE4 binding potencies (IC50 values) are indicated as follows: >10 nM “+”; 10-1 nM “++”; 1-0.1 nM “+++”; <0.1 nM “++++”.
  • Where a numerical limit or range is stated herein, the endpoints are included. Also, all values and subranges within a numerical limit or range are specifically included as if explicitly written out.
  • Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that, within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.
  • All patents and other references mentioned above are incorporated in full herein by this reference, the same as if set forth at length.

Claims (18)

1. A compound of formula (I):
Figure US20130005716A1-20130103-C00399
wherein:
R1 is:
H;
(C3-C7)cycloalkylcarbonyl;
(C1-C6)alkyl, optionally substituted by one or more substituents selected from (C3-C7) cycloalkyl or (C5-C7)cycloalkenyl;
(C1-C6)haloalkyl;
(C3-C7)cycloalkyl;
(C5-C7)cycloalkenyl;
(C2-C6)alkenyl; or
(C2-C6)alkynyl;
R2 is:
H;
(C3-C7)cycloalkylcarbonyl;
(C1-C6)alkyl, optionally substituted by one or more substituents selected from (C3-C7) cycloalkyl or (C5-C7)cycloalkenyl;
(C1-C6)haloalkyl;
(C3-C7)cycloalkyl;
(C5-C7)cycloalkenyl;
(C2-C6)alkenyl; or
(C2-C6)alkynyl;
or, when R19 is different from hydrogen, R2 forms together with R19 a group of formula (x) as defined below;
or R1 and R2, together with the interconnecting atoms, form a 2,2-difluoro-1,3-dioxolane ring of formula (q) fused to the phenyl moiety which bears groups —OR1 and —OR2, wherein asterisks indicate carbon atoms shared with such phenyl ring:
Figure US20130005716A1-20130103-C00400
R19 is hydrogen or, if different from hydrogen, it forms together with R2 a group of formula (x) wherein bonds labeled with (1) and (2) indicate the points of attachment for group (x) to atoms bearing groups R19 and R2 respectively
Figure US20130005716A1-20130103-C00401
in such a way that R2 and R19 together with the interconnecting atoms form a ring of formula (w) which is fused to phenyl ring which bears groups —OR2 and R19, wherein asterisks indicate carbon atoms shared with such phenyl ring:
Figure US20130005716A1-20130103-C00402
R3 is one or more substituents independently selected from the group consisting of H, CN, NO2, CF3 and a halogen atom;
Z is a group —(CH2)n— wherein n is 0 or 1;
A is a saturated and monocyclic (C3-C7)heterocycloalkyl-ene group;
K is:
—(CH2)mC(O)R4 wherein m may be 0 or 1;
—C(O)(CH2)jR4, wherein j may be 1 or 2;
—SO2 (CH2)pR4 wherein p may be zero, 1 or 2;
—(CH2)ySO2R4 wherein y may be 1 or 2;
—(CH2)nR4 wherein z may be 1 or 2; or
—C(O)(CH2)2SO2R4;
R4 is a ring system, that is a mono- or bicyclic ring which may be saturated, partially unsaturated or fully unsaturated, such as aryl, (C3-C8)cycloalkyl, (C3-C7) heterocycloalkyl, or heteroaryl, such ring being optionally substituted by one or more groups R5 which may be the same or different, and which are independently selected from the group consisting of:
(C1-C6)alkyl optionally substituted by one or more groups independently selected in the list consisting of: (C3-C7)cycloalkyl, —OH and a group —NR18C(O)(C1-C4)alkyl, wherein R18 is hydrogen or (C1-C4)alkyl;
(C3-C7)heterocycloalkyl;
5 or 6-membered heteroaryl which is optionally substituted by one or two
(C1-C4)alkyl groups;
(C1-C6)haloalkyl;
(C3-C7)heterocycloalkyl(C1-C4)alkyl;
a group —OR6 wherein R6 is
H;
(C1-C6)haloalkyl;
a group —SO2R7, wherein R7 is (C1-C4)alkyl;
a group —C(O)R7 wherein R7 is (C1-C4)alkyl;
(C1-C10)alkyl optionally substituted by one or more (C3-C7) cycloalkyl groups or by a group —NR8R9 as below defined; or
(C3-C7)cycloalkyl;
a group —SR20 wherein R20 is
H;
(C1-C6)haloalkyl;
a group —C(O)RD wherein R7 is (C1-C4)alkyl;
(C1-C10)alkyl optionally substituted by one or more (C3-C7) cycloalkyl groups or by a group —NR8R9; or
(C3-C7)cycloalkyl;
a halogen atom;
CN;
NO2;
NR8R9 wherein R8 and R9 are different or the same and are independently selected from the group consisting of:
H;
(C1-C4)alkylene-NR13R14 wherein R13 and R14 are different or the same and are independently selected from the group consisting of:
H and (C1-C6)alkyl, which is optionally substituted with (C3-C7) cycloalkyl or (C3-C7)heterocycloalkyl; or they form with the nitrogen atom to which they are linked a saturated or partially saturated (C3-C7)heterocyclic ring;
(C1-C6)alkyl, optionally substituted with (C3-C7)cycloalkyl, (C3-C7)heterocycloalkyl, a group —OH or (C1-C6)alkoxyl;
a group —SO2R15, wherein R15 is selected in the group consisting of: (C1-C4)alkyl optionally substituted by (C3-C7)cycloalkyl or (C3-C7)heterocycloalkyl; (C3-C7)heterocycloalkyl; and phenyl optionally substituted by one or more (C1-C6)alkyl, halogen or a group —OH;
a group —C(O)R16, wherein R16 is selected in the group consisting of: (C1-C6)alkyl optionally substituted by (C3-C7)cycloalkyl or (C3-C7)heterocycloalkyl; (C3-C7)heterocycloalkyl; phenyl optionally substituted by one or more (C1-C6)alkyl, halogen or —OH; and a group —NH2;
a group —C(O)OR17, wherein R17 is selected in the group consisting of: (C1-C6)alkyl optionally substituted by (C3-C7)cycloalkyl or (C3-C7)heterocycloalkyl; (C3-C7)heterocycloalkyl; phenyl optionally substituted by one or more (C1-C6)alkyl, halogen or —OH; and a group —NH2;
or they form with the nitrogen atom to which they are linked a saturated or partially saturated heterocyclic ring, which is optionally substituted by one or more (C1-C6)alkyl or oxo groups;
(C1-C4)alkylene-NR8R9 as above defined;
COR10 wherein R10 is phenyl or (C1-C6)alkyl;
oxo;
—SO2R11 wherein R11 is (C1-C4)alkyl, —OH or —NR8R9 wherein R8 and R9 are as defined above;
—COOR12 wherein R12 is H, (C1-C4)alkyl or (C1-C4)alkylene-NR8R9 wherein R8 and R9 are as defined above; and
—CONR8R9 wherein R8 and R9 are as defined above;
wherein groups R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, and R20 may be the same or different at each occurrence, if present in more than one group;
an N-oxide derivative on the pyridine ring, or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1, which is represented by formula (IC):
Figure US20130005716A1-20130103-C00403
an N-oxide derivative on the pyridine ring, or a pharmaceutically acceptable salt thereof.
3. A compound according to claim 1, which is represented by formula (IF):
Figure US20130005716A1-20130103-C00404
Wherein:
Z is a bond,
A is a (C3-C7)heterocycloalkyl-ene group comprising a nitrogen atom which represents the connecting point to group K,
K is a group selected from the group consisting of:
Figure US20130005716A1-20130103-C00405
R4 is a phenyl group or a 5 or 6-membered heteroaryl group, each R4 being optionally substituted by one or more groups R5;
An N-oxide derivative on the pyridine ring, or a pharmaceutically acceptable salt thereof.
4. A pyridine N-oxide according to claim 1, which is represented by formula (IH):
Figure US20130005716A1-20130103-C00406
or a pharmaceutically acceptable salt thereof.
5. A compound according to claim 1, which is represented by formula (I)′:
Figure US20130005716A1-20130103-C00407
an N-oxide derivative on the pyridine ring, or a pharmaceutically acceptable salt thereof.
6. A pyridine N-oxide according to claim 1, which is represented by formula (IDa):
Figure US20130005716A1-20130103-C00408
or a pharmaceutically acceptable salt thereof.
7. A compound according to claim 1, which is selected from the group consisting of:
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(3-(cyclopropylmethoxy)-4-(methylsulfonamido)benzoyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(4-methoxy-3-(methylsulfonyloxy)benzoyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(3,4-dimethoxyphenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
4-((2S)-2-(3-(4-aminophenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(4-(methylsulfonamido)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(4-(N-(2-morpholinoethyl)methylsulfonamido)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
4-((S)-2-((R)-3-(4-aminophenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
4-((S)-2-((S)-3-(4-aminophenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
4-((S)-2-((S)-1-(4-aminophenylsulfonyl)pyrrolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(1-((4-(methoxycarbonyl)-5-methylfuran-2-yl)methyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(3-(dimethylcarbamoyl)-4-methoxyphenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((R or S)-4-(3-sulfamoylphenylsulfonyl)morpholine-2-carbonyloxy)ethyl)pyridine 1-oxide
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(2-oxo-2-(thiophen-2-yl)ethyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S or R)-3-(4-(dimethylcarbamoyl)benzyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S or R)-3-(4-(dimethylcarbamoyl)benzyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
4-((2S)-2-(3-(4-aminobenzoyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(4-(3-(dimethylcarbamoyl)phenylsulfonyl)thiomorpholine-3-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(4-(4-(N-methylsulfamoyl)phenylsulfonyl)thiomorpholine-3-carbonyloxy)ethyl)pyridine 1-oxide;
4-((2S)-2-(3-(3-amino-4-methoxyphenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
4-((S)-2-((R)-3-(4-aminophenylsulfonyl)thiazolidine-4-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
4-((2S)-2-(4-(4-aminophenylsulfonyl)morpholine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(3-(dimethylcarbamoyl)phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(4-(3-(dimethylcarbamoyl)phenylsulfonyl)morpholine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((R)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-4-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(1,3-dioxoisoindolin-5-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(4-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((R)-1-(3-(dimethylcarbamoyl)phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(3-sulfamoylphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
4-((2S)-2-(3-(3-carboxy-4-methoxyphenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(3-fluorophenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(2,4-dimethylphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(thiophen-2-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(3-(dimethylcarbamoyl)-4-methoxyphenyl sulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
(S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(2-(4-(3-(dimethylcarbamoyl)phenylsulfonyl)piperazin-1-yl)acetoxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(4-(4-methylpiperazine-1-carbonyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(3-chlorophenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(1-methyl-1H-imidazol-2-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(cyclopropylmethylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(pyridin-3-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(2,4-difluorophenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(2-chloro-4-fluorophenyl sulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(4-fluoro-2-methylphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(2-chlorophenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclohexyl sulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(thiophen-3-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(3-(dimethylcarbamoyl)phenylsulfonyl)piperidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((R)-1-(3-(dimethylcarbamoyl)phenylsulfonyl)piperidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(3-(cyclopropylmethoxy)-5-(N-(2-morpholinoethyl)methylsulfonamido)benzoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(3,4-dimethoxyphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
(S)-4-(2-(2-(4-(4-aminophenylsulfonyl)piperazin-1-yl)acetoxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(3-(dimethylcarbamoyl)-4-methoxyphenylsulfonyl)piperidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(6-morpholinopyridin-3-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(4-methoxy-3-(4-methylpiperazine-1-carbonyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(4-methoxy-3-(morpholine-4-carbonyl)phenyl sulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S or R)-3-(4-methoxy-3-(morpholinomethyl)benzoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(3-(N,N-dimethyl sulfamoyl)-4-methoxybenzoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
4-((S)-2-((S or R)-3-(3-carboxyphenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(4-(morpholinomethyl)benzoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(4-(phenylsulfonyl)morpholine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(3,5-dimethylisoxazol-4-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(thiazole-5-carbonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(3-((dimethylamino)methyl)benzoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(oxazole-5-carbonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(3-(4-methylpiperazine-1-carbonyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(1-methyl-1H-imidazol-2-ylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(5-(methoxycarbonyl)thiophen-2-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(pyridin-3-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(dimethylcarbamoyl)-4-methoxyphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(1-methyl-1H-imidazol-2-yl sulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-sulfamoylphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(4-(methylsulfonyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3,4-dimethoxyphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(5-((dimethylamino)methyl)thiophene-2-carbonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
4-((2S)-2-(3-(4-(2-aminoethyl)benzoyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(4-(N-methylsulfamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(furan-2-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(furan-3-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(N,N-dimethylsulfamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(3,4-dimethoxyphenylsulfonyl)piperidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(pyridin-3-ylsulfonyl)piperidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(4-(methoxycarbonyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(2-(methoxycarbonyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-4-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-methoxyphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(trifluoromethoxy)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(4-(1,1-dioxothiomorpholinobenzoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
4-((S)-2-((S)-3-(4-carbamoylbenzoyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(6-morpholinopyridin-3-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
4-((S)-2-((S or R)-3-(4-(aminomethyl)picolinoyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(2-methoxy-4-methylphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(2,4-dimethylthiazol-5-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-picolinoylthiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S or R)-3-(3-((2-morpholinoethoxy)carbonyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(4-methoxyphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(6-morpholinopyridin-3-ylsulfonyl)piperidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(4-nitrophenylsulfonyl)piperidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(3-(N,N-dimethylsulfamoyl)phenylsulfonyl)piperidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(phenylsulfonyl)piperidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(2,5-dimethoxyphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(1-methyl-1H-imidazol-2-ylsulfonyl)piperidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
4-((S)-2-((S)-3-(3-acetylphenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(4-(morpholinomethyl)benzoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide:
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(4-(1,1-dioxo thiomorpholinomethyl)benzoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
4-((S)-2-((S)-3-(3-(aminomethyl)benzoyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(oxazol-5-yl)benzoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
4-((S)-2-((S)-3-(3-aminophenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(4-(methylsulfonyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(4-methylpiperazine-1-carbonyephenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(3-(N-methylsulfamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(1-methyl-1H-imidazol-4-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(2-phenylacetyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-((S)-3-(2-cyclopropylacetyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(phenylsulfonyl)propanoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-morpholinopropanoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(4-methylpiperazin-1-yl)propanoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(3-(dimethylcarbamoyl)benzoyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
4-((S)-2-(2-((S)-1-benzoylpyrrolidin-2-yl)acetoxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(2-((S)-1-(3-(dimethylcarbamoyl)benzoyl)pyrrolidin-2-yl)acetoxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(2-(3-(dimethylcarbamoyl)phenyl)acetyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(2-(3-(dimethylcarbamoyl)phenyl)acetyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-((S)-3-(2-cyanophenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(2,3-dihydrobenzo[b][1,4]dioxin-6-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-((S)-3-(2-cyano-5-methylphenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(2,5-dimethylthiophen-3-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
4-((S)-2-((S)-3-(4-bromo-2-fluoro-5-methylphenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
4-((S)-2-((S)-3-(3-bromo-4-methylphenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
3,5-dichloro-4-((S)-2-((S)-3-(4-cyanophenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-((S)-3-(3-cyanophenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)pyridine 1-oxide;
4-((S)-2-((S)-3-(4-(1H-pyrazol-1-yl)phenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
3,5-dichloro-4-((S)-2-((S)-3-(3-cyano-4-fluorophenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(1-methyl-2-oxoindolin-5-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-((S)-3-(2-chloro-5-cyanophenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(5-methylbenzo[b]thiophen-2-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(4-(1-methyl-1H-pyrazol-3-yl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(4-(difluoromethoxy)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-((S)-3-(4-chloro-2-(trifluoromethyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(5-fluoro-2-methoxyphenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
4-((S)-2-((S)-3-(benzo[b]thiophen-2-ylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(2-oxo-2,3-dihydrobenzo[d]oxazol-6-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(4-(2-oxopyrrolidin-1-yl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
4-((S)-2-((S)-3-(1-acetyl-1,2,3,4-tetrahydroquinolin-6-ylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
4-((S)-2-((S)-3-(4-(2-acetamidoethyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(4-(2,2,2-trifluoroethoxy)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
4-(2-((S)-3-(benzylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(phenethylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
4-((S)-2-((S)-1-(benzylsulfonyl)pyrrolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((R)-3-(1-methyl-2-oxoindolin-5-ylsulfonyl)thiazolidine-4-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((R)-1-(phenylsulfonyl)piperidine-3-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(R)-1-(3-(dimethylcarbamoyl)phenylsulfonyl)piperidine-3-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(phenylsulfonyl)piperidine-3-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(3-(dimethylcarbamoyl)phenylsulfonyl)piperidine-3-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(R)-4-(phenylsulfonyl)morpholine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(R)-4-(3-(dimethylcarbamoyl)phenylsulfonyl)morpholine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-4-(phenylsulfonyl)morpholine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-4-(3-(dimethylcarbamoyl)phenylsulfonyl)morpholine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(2-((S)-1-(phenylsulfonyl)pyrrolidin-2-yl)acetoxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(2-((S)-1-(3-(dimethylcarbamoyl)phenylsulfonyl)pyrrolidin-2-yl)acetoxy)ethyl)pyridine 1-oxide;
4-((S)-2-(2-((S)-1-(benzylsulfonyl)pyrrolidin-2-yl)acetoxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(2-oxo-2-phenylethyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(2-oxo-2-phenylethyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
4-((S)-2-((S)-1-benzylpyrrolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(3-(dimethylcarbamoyl)benzyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(2-(3-(dimethylcarbamoyl)phenyl)-2-oxoethyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(2-(3-(dimethylcarbamoyl)phenyl)-2-oxoethyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(cyclopropylmethyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
4-((S)-2-((S)-3-benzylthiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(dimethylcarbamoyl)benzyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-phenethylthiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(2-((S)-1-(3-(dimethylcarbamoyl)benzyl)pyrrolidin-2-yl)acetoxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-ureidophenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(hydroxymethyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
4-((2S)-2-(2-(3-benzoylthiazolidin-2-yl)acetoxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(2-(3-(3-(dimethylcarbamoyl)benzoyl)thiazolidin-2-yl)acetoxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(2-(3-(phenylsulfonyl)thiazolidin-2-yl)acetoxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((2S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(2-(3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidin-2-yl)acetoxy)ethyl)pyridine 1-oxide;
(S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(1-(3-(dimethylcarbamoyl)phenylsulfonyl)azetidine-3-carbonyloxy)ethyl)pyridine 1-oxide;
(S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(1-(phenylsulfonyl)azetidine-3-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(3-(dimethylcarbamoyl)phenylsulfonyl)azetidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(phenylsulfonyl)azetidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(1-methyl-2-oxoindolin-5-ylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(2-morpholinoethylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(2-(4-methylpiperazin-1-yl)ethylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(2-(phenylsulfonyl)ethyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(2-phenylacetyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(dimethylcarbamoyl)benzylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(4-(difluoromethoxy)-3-methoxyphenyl)-2-((S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(4-(difluoromethoxy)-3-methoxyphenyl)-2-((S)-3-(phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopentyloxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopentyloxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S or R)-2-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-2-((S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(4-(difluoromethoxy)-3-methoxyphenyl)-2-((S)-1-(phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(4-(difluoromethoxy)-3-methoxyphenyl)-2-((S)-1-(3-(dimethylcarbamoyl)phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopentyloxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopentyloxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(3-(dimethylcarbamoyl)phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3,4-dimethoxyphenyl)-2-((S)-1-(phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3,4-dimethoxyphenyl)-2-((S)-1-(3-(dimethylcarbamoyl)phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-(2-(3-(cyclopentyloxy)-4-methoxyphenyl)-2-((S)-1-(phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-(2-(3-(cyclopentyloxy)-4-methoxyphenyl)-2-((S)-1-(3-(dimethylcarbamoyl)phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
(S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-methoxyphenyl)-2-(1-(phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
(S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-methoxyphenyl)-2-(1-(3-(dimethylcarbamoyl)phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S or R)-2-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-2-((S)-1-(3-(dimethylcarbamoyl)phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-(2-(4-methoxyspiro[benzo[d][1,3]dioxole-2,1′-cyclopentane]-'7-yl)-2-((S)-1-(phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-(2-((S)-1-(3-(dimethylcarbamoyl)phenylsulfonyl)pyrrolidine-2-carbonyloxy)-2-(4-methoxyspiro[benzo[d][1,3]dioxole-2,1′-cyclopentane]-7-yl)ethyl)pyridine 1-oxide;
3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-methoxyphenyl)-2-((S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-methoxyphenyl)-2-((S)-3-(phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-(2-(3-(cyclopentyloxy)-4-methoxyphenyl)-2-((S)-3-(phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-(2-(3-(cyclopentyloxy)-4-methoxyphenyl)-2-((S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3,4-dimethoxyphenyl)-2-((S)-3-(phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3,4-dimethoxyphenyl)-2-((S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-(2-(4-methoxyspiro[benzo[d][1,3]dioxole-2,1′-cyclopentane]-'7-yl)-2-((S)-3-(phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-(2-((S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)-2-(4-methoxyspiro[benzo[d][1,3]dioxole-2,1′-cyclopentane]-7-yl)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(3-(N,N-dimethylsulfamoyl)phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-methylisoxazolo[5,4-b]pyridin-5-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-5-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(1-methyl-5-(methylcarbamoyl)-1H-pyrrol-3-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(5-(pyrrolidine-1-carbonyl)-1H-pyrrol-3-ylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
(S)-((S)-1-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3,5-dichloropyridin-4-yl)ethyl) 3-(1-methyl-1H-imidazol-2-ylsulfonyl)thiazolidine-2-carboxylate;
4-((S)-2-((S)-3-(1H-1,2,4-triazol-5-ylsulfonyl)thiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
4-((S)-2-((S)-3-benzoylthiazolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(dimethylcarbamoyl)benzoyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((R)-1-(phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
4-((S)-2-((R)-1-benzoylpyrrolidine-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((R)-1-(3-(dimethylcarbamoyl)benzoyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((R)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((R)-1-(3-(dimethylcarbamoyl)phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((R)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(3-(dimethylcarbamoyl)phenylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
(S)-((S)-1-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3,5-dichloropyridin-4-yl)ethyl) 3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carboxylate;
3,5-dichloro-4-((R)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((R)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((R)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(4-(difluoromethoxy)-3-hydroxyphenyl)-2-((S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-ylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-1-(3-methylisoxazolo[5,4-b]pyridin-5-ylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((R)-3-(4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-ylsulfonyl)thiazolidine-4-carbonyloxy)ethyl)pyridine 1-oxide;
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((R)-3-(3-methylisoxazolo[5,4-b]pyridin-5-ylsulfonyl)thiazolidine-4-carbonyloxy)ethyl)pyridine 1-oxide; and
3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(methylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide;
or a pharmaceutically acceptable salt thereof.
8. A process for preparing a compound of formula (IDa) according to claim 6, comprising:
(1) reacting a compound of formula (XV) with a compound of formula (XIV), to obtain a compound of formula (XII):
Figure US20130005716A1-20130103-C00409
by: a) adding a compound of formula (XIV), 4-dimethylaminopyridine, and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) hydrochloride to a solution of a compound of formula (XV) in dimethylformamide, to obtain a mixture; b) stirring said mixture; c) pouring the mixture into cold water, to obtain a precipitate; and d) filtering the precipitate;
(2) converting said compound of formula (XII) to a compound of formula (XI):
Figure US20130005716A1-20130103-C00410
by: a) adding, with stirring, a solution of concentrated HCl in dry ethyl acetate (9 vol.) to a solution of said compound of formula (XII) in ethyl acetate at room temperature; b) stirring, to obtain a precipitated solid; c) filtering said precipitated solid; and optionally d) washing said precipitated solid with ethyl acetate; and
(3) reacting said compound of formula (XI) with a compound of formula (VII), to obtain said compound of formula (IDa):
Figure US20130005716A1-20130103-C00411
by: a) adding a solution of a compound of formula (VII) in pyridine to a refrigerated solution of said compound of formula (XI), in pyridine; b) stirring the resulting solution at room temperature; c) pouring the solution into aqueous HCl in excess, to obtain a precipitate; d) filtering said precipitated material and washing it with water or d′) extracting the aqueous phase with ethyl acetate, washing with HCl 1M, brine and evaporating the resulting organic phase; f) dissolving the compounds in ethanol (8 vol); g) vigorously stirring overnight at room temperature; and h) filtering the solid formed;
wherein R1, R2, R3, R4 and p in compounds of formulas (XV), (XIV), (XII), (XI), (VII) and (IDa) have meanings as per compounds of formula (I).
9. A combination of a compound, N-oxide, or pharmaceutically acceptable salt according to claim 1 with a second pharmaceutical active component selected from the group consisting of a beta2-agonist, a corticosteroid, and an antimuscarinic agent.
10. A pharmaceutical composition, comprising a compound, N-oxide, or pharmaceutically acceptable salt according to claim 1 and one or more pharmaceutically acceptable carriers and/or excipients.
11. A pharmaceutical composition, comprising a combination according to claim 9 and one or more pharmaceutically acceptable carriers and/or excipients.
12. A method for prevention and/or treatment of a disease of the respiratory tract characterized by airway obstruction, such as asthma or COPD, said method comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound, N-oxide, or pharmaceutically acceptable salt according to claim 1.
13. A method for prevention and/or treatment of allergic rhinitis, said method comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound, N-oxide, or pharmaceutically acceptable salt according to claim 1.
14. A method for prevention and/or treatment of atopic dermatisis, said method comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound, N-oxide, or pharmaceutically acceptable salt according to claim 1.
15. A device comprising a pharmaceutical composition according to claim 10.
16. A device comprising a pharmaceutical composition according to claim 11.
17. A kit comprising a pharmaceutical composition according to claim 10 and a device which is a single- or multi-dose dry powder inhaler, a metered dose inhaler, or a soft mist nebulizer.
18. A kit comprising a pharmaceutical composition according to claim 11 and a device which is a single- or multi-dose dry powder inhaler, a metered dose inhaler, or a soft mist nebulizer.
US13/488,818 2011-06-06 2012-06-05 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors Abandoned US20130005716A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/048,651 US20140057882A1 (en) 2011-06-06 2013-10-08 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
US14/863,915 US9931327B2 (en) 2011-06-06 2015-09-24 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11168853 2011-06-06
EP11168853.7 2011-06-06

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/048,651 Continuation US20140057882A1 (en) 2011-06-06 2013-10-08 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
US20130005716A1 true US20130005716A1 (en) 2013-01-03

Family

ID=46458441

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/488,818 Abandoned US20130005716A1 (en) 2011-06-06 2012-06-05 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
US14/048,651 Abandoned US20140057882A1 (en) 2011-06-06 2013-10-08 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
US14/863,915 Active US9931327B2 (en) 2011-06-06 2015-09-24 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors

Family Applications After (2)

Application Number Title Priority Date Filing Date
US14/048,651 Abandoned US20140057882A1 (en) 2011-06-06 2013-10-08 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
US14/863,915 Active US9931327B2 (en) 2011-06-06 2015-09-24 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors

Country Status (15)

Country Link
US (3) US20130005716A1 (en)
EP (1) EP2718267B1 (en)
JP (1) JP2014518203A (en)
KR (1) KR20140028049A (en)
CN (2) CN106946848B (en)
AR (1) AR086676A1 (en)
AU (1) AU2012266514A1 (en)
BR (1) BR112013028959A2 (en)
CA (1) CA2838435A1 (en)
MX (1) MX2013013557A (en)
RU (1) RU2626956C2 (en)
SG (1) SG195319A1 (en)
UA (1) UA111198C2 (en)
WO (1) WO2012168226A1 (en)
ZA (1) ZA201309150B (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8648204B2 (en) 2009-02-06 2014-02-11 Chiesi Farmaceutici S.P.A. 1-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors
US9000177B2 (en) 2007-08-08 2015-04-07 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
US9090606B2 (en) 2012-12-05 2015-07-28 Chiesi Farmaceutici S.P.A. Compounds
US9169245B2 (en) 2012-12-05 2015-10-27 Chiesi Farmaceutici S.P.A. Inhibitors of PDE4 enzyme and antagonists of muscarinic M3 receptor
US9199980B2 (en) 2012-12-05 2015-12-01 Chiesi Farmaceutici S.P.A. Compounds
US9265768B2 (en) 2011-09-26 2016-02-23 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
US9308200B2 (en) 2010-08-03 2016-04-12 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising a phosphodiesterase inhibitor
US9326976B2 (en) * 2014-06-05 2016-05-03 Chiesi Farmaceutici S.P.A. Carbamate derivatives
US9440954B2 (en) 2012-06-04 2016-09-13 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
US9944612B2 (en) 2012-12-05 2018-04-17 Chiesi Farmaceutici S.P.A. 1-phenyl-2-pyridinyl alkyl alcohol derivatives as phosphodiesterase inhibitors
US20180324916A1 (en) * 2017-05-03 2018-11-08 Silergy Semiconductor Technology (Hangzhou) Ltd Led driving circuit

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42048A (en) * 2015-05-07 2018-03-14 Chiesi Farm Spa AMINOESTERS DERIVATIVES
TW201710254A (en) * 2015-06-01 2017-03-16 吉斯藥品公司 Aminoester derivatives
AR104822A1 (en) * 2015-06-01 2017-08-16 Chiesi Farm Spa AMINOESTER DERIVATIVE
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
CN115466169B (en) * 2021-06-10 2024-03-26 中国医学科学院药物研究所 Substituted catechol ether compound and preparation method and application thereof
WO2023178378A1 (en) * 2022-03-21 2023-09-28 DMTC Limited Mip inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032163A1 (en) * 1999-11-03 2001-05-10 Astrazeneca Ab NEW COMBINATION COMPRISING A BETA 2 (β)2 ADRENO RECEPTOR AGONIST AND A LENKOTRIENE RECEPTOR ANTAGONIST
WO2009019909A1 (en) * 2007-08-08 2009-02-12 Nsk Ltd. Steering device with variable steering angle

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002465A1 (en) 1992-07-28 1994-02-03 Rhone-Poulenc Rorer Limited INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
US20050245750A1 (en) 2002-07-03 2005-11-03 Kyowa Hakko Kogyo Co., Ltd. Process for preparing 1,3-benzodioxole-2-spirocycloalkane derivative
JPWO2004096274A1 (en) 2003-03-31 2006-07-13 協和醗酵工業株式会社 Intra-airway administration
US20090274676A1 (en) 2003-07-31 2009-11-05 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
CN101123970A (en) * 2003-07-31 2008-02-13 埃匹吉尼斯医药有限公司 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
CN101123971A (en) 2003-07-31 2008-02-13 埃匹吉尼斯医药有限公司 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
GT200500284A (en) * 2004-10-15 2006-03-27 Aventis Pharma Inc PYRIMIDINS AS ANTAGONISTS OF PROSTAGLANDINA D2 RECEPTOR
ATE496029T1 (en) 2006-07-14 2011-02-15 Chiesi Farma Spa DERIVATIVES OF 1-PHENYL-2-PYRIDINYLALKYLENE ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS
EP2022783A1 (en) * 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2070913A1 (en) 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Ester derivatives as phosphodiesterase inhibitors
EP2110375A1 (en) 2008-04-14 2009-10-21 CHIESI FARMACEUTICI S.p.A. Phosphodiesterase-4 inhibitors belonging to the tertiary amine class
EP2216327A1 (en) * 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
CN103052378A (en) 2010-08-03 2013-04-17 奇斯药制品公司 Pharmaceutical formulation comprising phosphodiesterase inhibitor
ES2664175T3 (en) 2010-08-03 2018-04-18 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising a phosphodiesterase inhibitor
WO2013045280A1 (en) 2011-09-26 2013-04-04 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
EP2768822B1 (en) * 2011-10-21 2017-12-06 Chiesi Farmaceutici S.p.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
CN104334542A (en) 2012-06-04 2015-02-04 奇斯药制品公司 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
EP2928883B1 (en) * 2012-12-05 2018-02-14 Chiesi Farmaceutici S.p.A. Phenylethylpyridine derivatives as pde4-inhibitors and muscarinic receptor antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032163A1 (en) * 1999-11-03 2001-05-10 Astrazeneca Ab NEW COMBINATION COMPRISING A BETA 2 (β)2 ADRENO RECEPTOR AGONIST AND A LENKOTRIENE RECEPTOR ANTAGONIST
WO2009019909A1 (en) * 2007-08-08 2009-02-12 Nsk Ltd. Steering device with variable steering angle

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CAREY, FA. Organic Chemistry 6th Ed. McGraw Hill. 2006, chapter 1, p. 9. *
CAREY, FA. Organic Chemistry 6th Ed. McGraw Hill. 2006, p. 664, first paragraph. *
STEGLICH, W. et al. Esterification of Carboxylic Acids with Dicyclohexylcarbodiimide/4-dimethylaminopyridine: tert-butyl ethyl fumarate. Organic Syntheses, Coll. 1990, Vol. 7, page 93. *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9102619B2 (en) 2007-08-08 2015-08-11 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
US9000177B2 (en) 2007-08-08 2015-04-07 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
US8859778B2 (en) 2009-02-06 2014-10-14 Chiesi Farmaceutici S.P.A. 1-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors
US9056176B2 (en) 2009-02-06 2015-06-16 Chiesi Farmaceutici S.P.A. 1-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors
US8648204B2 (en) 2009-02-06 2014-02-11 Chiesi Farmaceutici S.P.A. 1-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors
US9308200B2 (en) 2010-08-03 2016-04-12 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising a phosphodiesterase inhibitor
US9265768B2 (en) 2011-09-26 2016-02-23 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
US9440954B2 (en) 2012-06-04 2016-09-13 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
US9169245B2 (en) 2012-12-05 2015-10-27 Chiesi Farmaceutici S.P.A. Inhibitors of PDE4 enzyme and antagonists of muscarinic M3 receptor
US9199980B2 (en) 2012-12-05 2015-12-01 Chiesi Farmaceutici S.P.A. Compounds
US9090606B2 (en) 2012-12-05 2015-07-28 Chiesi Farmaceutici S.P.A. Compounds
US9944612B2 (en) 2012-12-05 2018-04-17 Chiesi Farmaceutici S.P.A. 1-phenyl-2-pyridinyl alkyl alcohol derivatives as phosphodiesterase inhibitors
US9326976B2 (en) * 2014-06-05 2016-05-03 Chiesi Farmaceutici S.P.A. Carbamate derivatives
US20180324916A1 (en) * 2017-05-03 2018-11-08 Silergy Semiconductor Technology (Hangzhou) Ltd Led driving circuit

Also Published As

Publication number Publication date
CN106946848A (en) 2017-07-14
EP2718267A1 (en) 2014-04-16
CN106946848B (en) 2022-01-04
SG195319A1 (en) 2013-12-30
CN103562185A (en) 2014-02-05
US20160008338A1 (en) 2016-01-14
BR112013028959A2 (en) 2016-08-30
RU2626956C2 (en) 2017-08-02
EP2718267B1 (en) 2016-08-10
UA111198C2 (en) 2016-04-11
KR20140028049A (en) 2014-03-07
RU2013154117A (en) 2015-06-10
US20140057882A1 (en) 2014-02-27
MX2013013557A (en) 2013-12-16
US9931327B2 (en) 2018-04-03
JP2014518203A (en) 2014-07-28
WO2012168226A1 (en) 2012-12-13
AU2012266514A1 (en) 2014-01-09
AR086676A1 (en) 2014-01-15
ZA201309150B (en) 2015-03-25
CA2838435A1 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
US9931327B2 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
US9090606B2 (en) Compounds
US9199980B2 (en) Compounds
AU2012266378B2 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
US9024027B2 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
US10004728B2 (en) Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity
US9133185B2 (en) Heteroaryl derivatives
US9944612B2 (en) 1-phenyl-2-pyridinyl alkyl alcohol derivatives as phosphodiesterase inhibitors
CA2932486A1 (en) Benzhydryl derivatives for the treatment of respiratory diseases
EP3152204B1 (en) Carbamate derivatives which are both phosphodiesterase 4 (pde4) enzyme inhibitors and muscarinic m3 receptor antagonists
TW201302726A (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
NZ618727B2 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity

Legal Events

Date Code Title Description
AS Assignment

Owner name: CHIESI FARMACEUTICI S.P.A., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ARMANI, ELISABETTA;AMARI, GABRIELE;CARZANIGA, LAURA;AND OTHERS;REEL/FRAME:028936/0731

Effective date: 20120712

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION